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Abstract!
!
Glaucoma(is(the(second(leading(cause(of(blindness(worldwide.(Africa'region'has!
the$highest$burden!of#glaucoma!and$glaucoma(blindness."When%diagnosed%early%
and$appropriate$treatment$sustained,$blindness$from$glaucoma$is$avoidable.$!
!
The$Nigeria$national'blindness'and$visual$impairment)survey&(NBS),&with!>!",$%%&
people%aged%>!"#years#examined,#estimated#the#prevalence#of"blindness"as!!.#%%
("#%CI'(.*"!.#%).&!".$%&was&due&to&glaucoma,&the&leading&cause&of&irreversible&
blindness(and(functional(low(vision.!There%are%insufficient%population"based&
glaucoma(studies(in(Africa;!and$the$NBS$provided!the$largest$dataset$in$Africa!
from$which$data$on$glaucoma$could!be#derived.#!
!
In#this#study,#analysis#of!the$NBS$data!using&established&criteria&from&the&
International*Society*of*Geographical*and*Epidemiological*Ophthalmology!
showed!high$prevalence$of$glaucoma"($.&'%;"*$%CI#!.#$"!.#$%):!undiagnosed*
in#$%%;#and#open"angle&glaucoma&(OAG)!in#$%%."One"in"five%persons%with%
glaucoma(were!blind.'Increasing*age*and*higher*intraocular*pressure*were*
independent'risk'factors'for'OAG;!and$some$ethnic$groups$were!more%at%risk.%
Glaucoma'blindness(was$associated)with)socioeconomic(deprivation,(reflecting(
poor$access$to$care.$These%findings%underscored%the"high"level"of"need"for"optimal!
glaucoma(services.!
!
Information*about*glaucoma*management!obtained)from)!"#$practising*
ophthalmologists+in+Nigeria+highlighted(patient"related'challenges'of'late'
presentation!with%advanced%disease!and$poor$compliance$to$treatment;$and!
additional(constraints(due(to(inadequate)access)to)equipment)for)diagnosis)and)
treatment.(!
!
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In#the#qualitative#study,#we#sought#to#understand"access%to%glaucoma%care!and$
determine(why(people(with(glaucoma(are(presenting(late(for(treatment."We#
found&barriers&of&access&to&care&which&could&be&explained&as&evidence$of$
structural(inequalities!associated)with)coping)mechanisms)and)distinct)social)
suffering.!!
!
This%study%provided%data%required!to#develop#evidence"based&strategy(for(control'
of#glaucoma(blindness(by(improving)glaucoma(services'in'Nigeria.!These%data%
could&also&have&implications&to&other&Sub"Saharan&African&countries&with&similar&
socioeconomic&and&ecological&characteristics.&!
!
!  
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Chapter(1!
Glaucoma(clinical&care&and&community&perception!
!
!
 
Participants!in#the#community'departing$from%a"clinical"examination"site!
 
!
Introductory*material*about*glaucoma(classification,"clinical"care,!
knowledge!and$awareness$of$glaucoma!
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1.1! Definition(and(classification(of(glaucoma!
Glaucoma,)in)the)public)health)context,)is)an)optic)neuropathy)associated)with)
characteristic)structural)damage)to)the)optic)nerve)and)associated)visual&
dysfunction.!!These%are%seen%clinically%as%enlargement%of%the%optic%disc%cup%and%
loss$of$field$of$vision.$Glaucoma$can$be$classified$according$to$anterior$chamber$
angle&morphology&into&open"angle&glaucoma&(OAG)&or&angle"closure(glaucoma(
(ACG).!
!
The$diagnosis&of&glaucoma&in&prevalence&surveys&has&been&standardised&and&is!
based&on&the&following&three!levels%of%evidence,%according%to%the%International*
Society(of(Geographical(and(Epidemiological(Ophthalmology((ISGEO)!definitions)
of#glaucoma.!!
!
Level%&%evidence!entails(having(a(cup:disc(ratio((CDR)(>!".$th!percentile)or)CDR)
asymmetry(>!".$th!percentile)and)characteristic)visual)field)defect)detected)on)
the$threshold$pattern$deviation$plot;$or$on$the$suprathreshold$screening$result$
where%threshold%testing%was%indicated'but'not'done.!
!
Level%&%evidence!is#where#there#are#no#visual#field#test#results#and#the#CDR#or#
CDR$asymmetry$is$>!!.#th!percentile.*Included*at*this*level*of*evidence*is*expert*
opinion%adjudication%if%there%is%relative%afferent%papillary%defect%(RAPD)$or$raised$
intra"ocular'pressure'(IOP).''!
!
Level%&%diagnosis%is%made%where$the$disc$cannot$be$visualised#for#CDR#assessment#
but$the$visual$acuity$(VA)$is$<3/56$in$the$better$eye$and$the$IOP$>!!.#th!of#
normal'or'there'is'evidence'of'filtration'surgery.'Expert&opinion&adjudication&is&
also%included%at%level%.%diagnosis.! !
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! !
Figure'1a:!Optic&disc&with%a!normal'cup:disc'ratio!
!
!
!
!
Figure'1b:'Glaucomatous!optic&disc!
! !
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1.2! Clinical'presentation'and'risk'factors'for'glaucoma!
Glaucoma(causes(irreversible(blindness"due"to"loss"of"ganglion"cells"of"the"optic"
nerve.&There&have&been&a&few&hospital"based&studies!"!!that$have$helped$to$define$
pattern'of'glaucoma'morbidity'and'risk'factors'for'glaucoma'in'Nigeria.'In'an'
analysis'of#patients#presenting#to#the#hospital#with#glaucoma#in#south"western'
Nigeria!!!%#were#blind,#-.%#had#ACG#and#-4%#were#younger#than#:4#years#old.#
The$persons$with$ACG$were$more$likely$to$present$at$a$younger$age,$have$worse$
visual'acuities,'more'visual'field#defects#and#higher#IOP.!!Similarly,)in)northern)
Nigeria,!!".$%&of&glaucoma&patients&were&78&years&old&or!younger.!!The$
proportion'of'glaucoma'patients'presenting'with'blindness'was'up'to'56%'in'
these%studies.!"!!Older&patients&living&further&away&from&the&hospital&were&more&
likely&to&present&with&more&advanced/end"stage&disease.!!Other&socio"
demographic,risk,factors,associated,with,blindness,and,late,presentation,
included(lower(socio"economic'class,'being'less'educated'and'earning'lower'
monthly(income.!!Other&factors&associated&with&glaucoma&were&positive&family&
history,)increasing)IOP,)CDR$greater$than$,..!and$diabetes$mellitus.!!Increasing*
age$was$the$most$consistent$factor$associated$with$glaucoma.!
!
Generally,)possible)risk)factors"associated"with"glaucoma!"!"!are:!
!. Related'to'socio"demographic,attributes:!
a. Increasing*age!
b. Ethnicity(–!of#African#origin!
c. Male%sex!
d. Positive(family(history!
e. Occupation*–!lower&income&cadres!
f. Rural&residence!
!. Features(associated(with(incipient(disease:!
a. Larger&CDR!
b. Retinal(nerve(fibre(layer((RNFL)(atrophy!
c. Disc%haemorrhage!
d. Peri"papillary'atrophy'(PPA)!
!. Ocular'morphology/anatomical'features:!
a. High%refractive%error%(myopia%or%hyperopia)!
b. Increased"diameter"of"the"optic"nerve"head!
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c. Thinner'central'corneal'thickness'(CCT)!
!. Intra"ocular'pressure'(IOP)!
!. Pseudoexfoliation.syndrome!
!. Related'to'vascular'functions'and'systemic'conditions!
a. High%blood%pressure!
b. Diabetes(mellitus!
c. Sickle"cell$disease!
d. Reduced&ocular!perfusion*pressure*(Blood*pressure*minus*IOP)!
e. Increasing*body*mass*index*(BMI)!
!. Drugs:!
a. Corticosteroids!
!. Other&factors!
a. Infrequent)or)no)previous)eye)exam)!
b. Late%diagnosis!
c. Non"compliance*with*therapy!
!
1.3! Visual'fields'assessment'and'Frequency'Doubling'Technology$(FDT)$
perimetry!
To#make#the#diagnosis#of#glaucoma,#structural#abnormalities#of#the#optic#disc#
need$to$be$supported$by$evidence$of$functional$abnormality,$principally$visual$
field&defects.&There&is&a&need&for&early&detection&of&visual&field&loss&because!
structural(alteration(in(the(disc(and(nerve(fibre(layer(precedes(functional(
abnormality.!"!There%are%many%different%methods%and$instruments$that!can$be$
used%to%detect%visual%field%abnormalities,%the%“gold%standard”%being%standard%
automated(perimetry((SAP).(!
!
Another(instrument(uses(Frequency(Doubling(Technology((FDT)(and(it(has(been(
shown&to&have&high&sensitivity&and&specificity"in"the"detection"of"early"
glaucomatous*functional*loss.!"!FDT$machines$are$compact,$portable$and$a$quick$
method'for'visual'field'testing.'The'FDT'provides'rapid'screening'in#$%#to#()#
seconds'and'full"threshold)testing)in)-)to).)minutes.)It)has)been)demonstrated)to)
have%reasonable%sensitivity%and%specificity%in%detecting%eye%disease!"!and$high$
specificity)for)detecting)glaucomatous)visual)field#damage.!",$!%!The$threshold$C,-$
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test$provides$a$higher$sensitivity$than$the$screening$suprathreshold$C45"!"
strategy.!"!Clinical'validation'studies'of'the'FDT'using'the'Humphrey'Field'
Analyzer)(HFA))./"!"SITA"suggest"that"threshold"testing"using"the"FDT"is"
comparable*with*the*HFA*23"!"SITA"fast%test%pattern.!"!
!
!
Figure'1c:'Visual'field'testing'with'the'FDT!machine!
!
1.4! Clinical'management'of'glaucoma!
Studying)glaucoma)in)populations)has)increased)the)understanding)of)the)
fundamental*nature*of*the!disease&and&various&clinical&trials&have&informed&the&
clinical&diagnosis&and&treatment&of&glaucoma.!!"!"!
!
According)to)recommendation)of)the)UK’s)National)Institute)for)health)and)
Clinical'Excellence'(NICE)'guidelines,!"!the$diagnosis$of$glaucoma$in$clinical$
settings'would'include'slit'lamp'Goldmann'applanation'tonometry,'pachymetry'
to#measure#central#corneal#thickness,#gonioscopy#to#assess#anterior#chamber#
angle&features,&perimetry&using&the&standard&and&central&threshold&test&for&visual&
fields'and'optic'nerve'head'assessment'with'dilatation,'using'stereo'slit"lamp%
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biomicroscopy*with*a*condensing*lens#(Hruby#lens#or#+./,#+12,#+3/!Dioptres).!
The$diagnostic$protocol$outlined$is$similar$to$that$recommended$by$the$
International*Council*of*Ophthalmology*(ICO)!"!and$the$American$Academy$of$
Ophthalmology+(AAO).!",$%&!ICO$recommends$additional$documentation$of$optic$
disc%morphology%with%colour"stereo"photography)or)computer"based&image&
analysis.(!
!
According)to)the)NICE)guidelines,*the#treatment#recommended#as#first"line%is%a%
prostaglandin(analogue,"or"a"beta"blocker(in(moderately(elevated(IOP.(Surgery(
with%anti"metabolites*are*reserved*for*those*at*risk*of*vision*loss*despite*medical*
treatment.(!
!
Reduction*in*IOP*is*the*only%treatment&shown&to&be&effective&in&glaucoma.!",$!%,$!&,$
!"!Interventions)to)prevent)blindness)from)glaucoma)aim)at)lowering)IOP)to#
prevent'deterioration'of'vision;'and$include$surgical$(mostly$filtration$
procedures),(laser(and(medical(therapies.(Early(diagnosis(and(commencement(of(
treatment'is'an!important)factor)in)prevention)of)blindness)from)glaucoma.)A)
study&of&the&natural&history&of&OAG&in&the&Early&Manifest&Glaucoma&Trial&(EMGT)!
showed'that'many'of'the'untreated&patients&progressed&slowly&and&the&median&
rate%of%progression%from%a%full%field%to%blindness%was%34%years.!"!However,(a(
substantial)minority)progressed)rapidly)with)median)rate)of)progression)to)
blindness(in"#$"years."The$United$Kingdom$Glaucoma$Treatment$Study$(UKGTS),$
a"randomised,"triple"masked,(placebo"controlled)trial,)has)demonstrated)visual)
field&preservation&with&the&IOP"lowering)prostaglandin)analogue)eye)drops)
(latanoprost*+.++-%).!!!Latanoprost)is)the)most)commonly)used)anti"glaucoma(
medication*in*developed*countries.*!
!
While&highlighting&acceptable&surgical&outcomes&for&trabeculectomy&in&Nigeria,!""
!"!the#difficulties$and$challenges$in$diagnosis$and!treatment'of'glaucoma'in'West$
Africa'due'to'limited'equipment,'lack'of'treatment'options,'high'cost'of'
medications+and+lack+of+awareness+of+patients+have+been+elucidated.!""!!!
However,!recommendations,for,diagnosis,and,management,of,glaucoma,in,West,
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Africa'lack'evidence,!as#there#has#not#been#much#operational#research#or#clinical#
trials'to'determine'the'best'option'for'glaucoma'management'in'Nigeria.'Patients'
with%glaucoma%often%present&very&late&to&eye!care%facilities,%and%lack%of%awareness%
and$the$cost$of$treatment$are$likely$explanations.!"!!
!
1.5! Cost%of%glaucoma%treatment!
With%better%understanding%of%the%disease,%newer%medication%for%treatment&and&
new$diagnostic$technology$increase$the$cost$of$management.$Anecdotal$reports$
indicate(that(in(a(resource"limited'environment,'a'systematic'approach'is'
required'for'management'decisions'and'to'improve'treatment'outcomes.'
Prostaglandin+analogues+are$being$recommended$as$first"line%drugs%because%of%
their&IOP&lowering&efficacy&and&safety&profile.&Based&on&this&and&other&new&
medications,,the,cost,of,glaucoma,treatment,was,found,to,have,increased,by,
!!"%$in$the$Republic$of$Ireland.!"!There%is%also%an%increasing%linear%trend%in%
direct'cost'as'disease'severity'worsened,!"!such%that%managing%glaucoma%and%
delaying)the)progression)would)reduce)the)economic)burden)of)the)disease.)In)
real%out"of"pocket'terms,'Egyptian'patients'with'glaucoma'spent,'on'average,'
!"%$of$their$monthly!income'on'glaucoma'medications,!"!and$Nigerian$patients&
spent&at&least&)*%&of&their&monthly&income&on&glaucoma&medications.!"!On#the#
long"term,&this&is&not&affordable&and&it&poses&great&economic&challenges&on&the&
patients(thereby(leading(to(non"compliance*of*treatment.!
!
!
Figure'1d:'A"selection"of"glaucoma"medicines!available'in'Nigeria'(2012)!
Fatima Kyari PhD Thesis Page 24
1.6! Public'awareness'and'knowledge'of'glaucoma!
There%is%an%increasing%body%of%evidence'that!shows%that%in%Africa%there%is%limited%
awareness'of'glaucoma'among'patients'and'communities.'For'example,'in'a'study'
in#Nigeria#of#hospital#patients#with#glaucoma,#only#$%%#had#heard#of#the#disease#
before&their&diagnosis&though&01%&believed&it&to&be&a&serious&condition.!"!In#
Tanzania,'patients'did'not'understand'the'cause'and'chronicity'of'the'disease.!"!
Likewise,(among(an(urban(population(in(India!"!and$Ghana!"!there%was%low%level%
of#awareness#of#glaucoma.#Higher#levels#of#education,#increasing#age,#being#
female&and&positive&family&history&of&glaucoma&were&determinants&of&awareness.!"!!
Unlike'cataract,%glaucoma%did%not%have%a%local%name%in%most%of%the%communities%
studied.(Ophthalmologists(were(the(key(source(of(information(about(glaucoma(
for$%&%$of$patients$studied$in$an$Egyptian$hospital.!"!Forty!per!cent%did%not%know%
that$glaucoma$could$cause$blindness.$Even$among$Singapore$Chinese$patients$
suffering)from)acute)angle)closure,)glaucoma)awareness)was)low)(33.5%).!"!Lack%
of#awareness#was#associated#with#increasing#age,#lack#of#formal#education#and#
unemployment.+Indeed,+the+gradual+effects+of+glaucoma+on+vision+enabled+many+
patients(to(cope(with(the(diminishing(visual(ability(before(their(diagnosis(and$
they%had%assumed%these%were%part%of%normal%life.!"!Many%of%these%studies%
underscore)the)importance)of)providing!information)to)enhance)the)
understanding!of!glaucoma(especially)to!those&at&risk.!This%may%facilitate$earlier$
clinical&presentation&and&better&acceptance&of&treatment.&!
! !
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INTRODUCTION
Data from population-based surveys (PBS) indicate that glaucoma is the second leading cause of blindness, accounting 
for 8% of blindness among the 39 million people who are blind 
world-wide.1 In Africa, glaucoma accounts for 15% of blindness and it 
is the region with the highest prevalence of blindness relative to other 
regions world-wide2 (Adapted from Resnikoff, 2004)2 [Table 1]. 
In 2006, the number of individuals estimated to be bilaterally 
blind from glaucoma was projected to increase from 8.4 million 
in 2010 to 11.1 million by 2020.3 However, the numbers who 
are blind is just the tip of the iceberg as there are many more 
individuals with glaucoma who are at risk of blindness. In 2006, 
modeling the available data, it was estimated that 60.5 million 
Symposium-Glaucoma in Sub-Saharan Africa
ABSTRACT
Purpose: The purpose of this study is to review the epidemiology of different types of glaucoma 
relevant to Sub-Saharan Africa (SSA) and to discuss the evidence regarding the risk factors 
for onset and progression of glaucoma, including risk factors for glaucoma blindness.
Methods: Electronic databases (PubMed, MedLine, African Journals Online- AJOL) were 
searched using the full text, Medical Subject Headings (MeSH) terms, author(s) and title to 
identify publications since 1982 in the following areas: population-based glaucoma prevalence 
and incidence studies in SSA and in African-derived black populations outside Africa; 
population-based prevalence and incidence of blindness and visual impairment studies in 
SSA including rapid assessment methods, which elucidate the glaucoma-specific blindness 
prevalence; studies of risk factors for glaucoma; and publications that discussed public health 
approaches for the control of glaucoma in Africa.
Results: Studies highlighted that glaucoma in SSA is a public health problem and predominantly 
open-angle glaucoma. It is the second-leading cause of blindness, has a high prevalence, an early 
onset and progresses more rapidly than in Caucasians. These factors are further compounded by 
poor awareness and low knowledge about glaucoma even by persons affected by the condition.
Conclusion: Glaucoma care needs to be given high priority in Vision 2020 programs in Africa. 
Many questions remain unanswered and there is a need for further research in glaucoma in 
SSA in all aspects especially epidemiology and clinical care and outcomes involving randomized 
controlled trials. Genetic and genome-wide association studies may aid identification of high-risk 
groups. Social sciences and qualitative studies, health economics and health systems research 
will also enhance public health approaches for the prevention of blindness due to glaucoma.
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people world-wide would have glaucoma by 2010, increasing 
by 20 million by 2020. The Africa region also has the highest 
incidence and prevalence of glaucoma3 (Adapted from Quigley, 
2006)3 [Figure 1]. The prevalence of glaucoma is similar among 
the Caucasian populations of Europe,4 USA5,6 and Australia7,8 
being less than the prevalence in Latinos in the USA9 and people 
of Asian origin.10-17 The black populations of the Caribbean,18,19 
Africa20-23 and USA5 have the highest prevalence of open-angle 
glaucoma (OAG).24-26 Furthermore, there appear to be differences 
in the prevalence of glaucoma in different black populations in the 
Caribbean islands and within Africa,24 which may be attributed 
to genetic diversity as well as environmental and socio-economic 
factors.27,28
Who goes blind from glaucoma is influenced by the age of 
onset of glaucoma and the natural history29 as well as access 
to services,30-33 the quality of care provided34 and adherence 
to treatment and follow-up.32,33 There is some evidence that 
glaucoma has an earlier age of onset in blacks5,35 and has a 
more aggressive clinical course.34,36,37 In Africa, there are the 
additional factors of poor awareness,38-45 poor access to care, 
and less than optimal diagnosis and management.46-53 Socio-
economic deprivation exacerbates the situation, leading to 
very late presentation.54-59 Indeed, in Africa, glaucoma has been 
referred to as the “silent thief of sight.”60
Lately, there has been increased momentum about glaucoma care 
in Africa. At the World Glaucoma Association 1st Africa glaucoma 
summit in Ghana in 2010, a decision was made to strengthen 
and incorporate glaucoma management, training and education 
into existing programs.61 The Kampala resolution in 2012 called 
upon all those involved in glaucoma management “to highlight 
the importance of controlling vision loss from glaucoma as an 
integral part of eye healthcare and in health and safety policies.”62
The purpose of this review is to describe the epidemiology of 
the different types of glaucoma in Sub-Saharan Africa (SSA). 
The scope of the review encompasses published data on the 
prevalence and incidence of glaucoma and discusses the evidence 
regarding risk factors for the onset and progression of glaucoma, 
including risk factors for glaucoma blindness. The designation 
SSA refers to the geographical area of Africa that lies south of 
the Sahara desert including Sudan and comprises 48 countries63 
and this review also included studies of other black populations 
outside SSA.
Studying glaucoma in populations has public health implications 
Table 1: Blindness prevalence and glaucoma-specific blindness prevalence by WHO sub-regions 
WHO sub-region ,  Blindness prevalence 
estimate. All ages (%)
Proportion of blindness due to 
glaucoma (%)
Glaucoma-specific blindness prevalence
All ages (per 1000) Age 40+ years (%)
Afr-D 1.00 15 1.50 0.8
Afr-E 1.00 15 1.50 0.8
Sear-B 1.00 14 1.40 0.8
Emr-D 0.97 11 1.07 0.6
Emr-B 0.80 10 0.80 0.4
Eur-C 0.40 20 0.80 0.4
Wpr-B1 0.60 11 0.66 0.4
Eur-B1 0.40 15 0.60 0.3
Sear-D 0.60 9 0.54 0.3
Wpr-A 0.30 18 0.54 0.3
Eur-B2  0.30 16 0.48 0.3
Wpr-B2 0.80 6 0.48 0.3
Amr-B 0.30 15 0.45 0.3
Amr-D 0.50 8 0.40 0.2
Amr-A 0.20 18 0.36 0.2
Eur-A 0.20 18 0.36 0.2
Wpr-B3 0.30 6 0.18 0.1
World 0.57 12.3 0.70 0.4
αAfr: WHO African Region, Amr: WHO American Region, Emr: WHO Eastern Mediterranean Region, Eur: WHO European Region, Sear: WHO South-East Asian Region, Wpr: 
WHO Western Pacific Region, βA=Mortality stratum 0.1%, B or C = mortality stratum 0.15%, D or E = mortality stratum 0.2%, WHO: World Health Organization
Figure 1: Prevalence of glaucoma in population aged 40+ years (%) in 2010 by World 
Health Organization sub-regions (Labeled figures indicate percentage values for 
prevalence of primary open angle glaucoma)
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METHODS
Search methods
Electronic databases (PubMed, Medline, African Journals 
Online- AJOL) were searched using the full text, Medical Subject 
Headings (MeSH) terms, author(s) and title to identify the 
relevant publications. The search terms used were glaucoma, 
prevalence (in title), Africa (and names of each of the countries) 
open-angle, angle-closure, blindness, and visual impairment. 
The search was restricted to publications in the last three 
decades (from 1982 to 2012) and papers and/or abstracts 
available in English. The following publications were included: 
(1) population-based glaucoma prevalence surveys in SSA; (2)
population-based glaucoma prevalence surveys or incidence
studies in African-derived black populations living outside
Africa; (3) population-based prevalence surveys and/or incidence
studies of blindness and visual impairment studies in SSA,
including rapid assessment methods, which elucidate the cause-
specific blindness prevalence due to glaucoma; (4) PBS in
SSA and African-derived black populations, which reported
risk factors for glaucoma and/or glaucoma blindness; and (5)
publications that discussed public health approaches for the
control of glaucoma in Africa. Reference lists of cited articles
were searched for additional publications not identified by the
database searches.
PBS of blindness and visual impairment and rapid assessment 
of avoidable blindness (RAAB) surveys that did not have data 
on the proportion of visual impairment or blindness due to 
glaucoma were excluded. Hospital/facility-based studies were 
not included.
Strengthening the reporting of observational 
studies in epidemiology (STROBE) guidelines
Population-based glaucoma prevalence surveys in SSA and 
black populations living outside Africa were critically appraised 
using the STROBE guidelines.65,66 These guidelines are to 
assess the clarity of reporting in relation to completeness 
and accuracy, but are not designed to assess the quality of the 
research. The completeness and accuracy of the reports aided the 
interpretation and the generalizability of the results. The 22 key 
points enumerated on the STROBE checklist for cross-sectional 
studies were assigned one score each. Some of the key points 
appraised included: “presenting key elements of study design 
early in the paper; describing the setting, locations, and relevant 
as it allows identification of potential risk factors for the disease 
as well as the blinding consequences, enabling control strategies 
to be targeted to groups most at risk. These, together with 
clinical intervention studies, inform diagnostic and therapeutic 
approaches that can be applied to patients with glaucoma, hence 
contributing to the Kampala resolutions.
DEFINITIONS
Glaucoma is an optic neuropathy associated with characteristic 
structural damage to the optic nerve and associated visual 
dysfunction,64 which are seen clinically as enlargement of the 
optic disc cup and loss of field of vision. It is classified according 
to the anterior chamber angle morphology into OAG or angle-
closure glaucoma (ACG). The morphological classification is very 
important because the types have different characteristics and 
present in varying proportions in different populations. OAG 
and ACG have different natural histories and risk factors and 
require different management strategies,hence the importance 
of gonioscopy in the classification of glaucoma. A further 
classification is by etiology into primary or secondary glaucoma.
A standard definition and classification system for glaucoma was 
proposed in 1998 by the International Society of Geographical 
and Epidemiological Ophthalmology (ISGEO)64 principally for 
use in population-based prevalence. The definition considers 
glaucoma as a group of diseases defined by end-organ (optic 
nerve) structural damage and functional deficit. In the ISGEO 
classification, glaucoma is defined by three levels of evidence, 
regardless of angle morphology (from Foster, 2000)64 [Table 2]. 
The highest level of evidence is when both structural damage and 
functional deficit are seen; that is a large vertical cup:disc ratio 
(VCDR) and/or asymmetry between the two eyes. A large disc 
is defined by the distribution of cup:disc ratios in the normal 
population, an abnormally large disc being defined when it is 
≥97.5th percentile of the VCDRs of the normal population. The 
1st level evidence also requires characteristic defects in the visual 
fields (VF). The 2nd level requires greater structural damage of 
the optic disc (i.e., VCDR ≥ 99.5th percentile, or asymmetry) 
when VF testing is not possible. The 3rd level is where VCDRs 
cannot be assessed and VF testing is not possible and the 
diagnosis of glaucoma is based on other clinical parameters: 
most importantly, intraocular pressure (IOP), visual acuity of 
less than 3/60 on the Snellen’s chart and medical history (e.g., 
previous glaucoma surgery).
Table 2: ISGEO definition for glaucoma in prevalence surveys 
Level of evidence for the diagnosis of 
glaucoma
Parameter VA Medical history
VCDR VF  IOP
Level 1 ≥97.5th % Typical defect
Level 2 ≥99.5th % Not available
Level 3 Not available Not available ≥99.5th % <3/60 e.g., Surgery for glaucoma
ISGEO: International society of geographical and epidemiological ophthalmology, VCDR: Vertical cup:disc ratio, VF: Visual fields, IOP: Intraocular pressure, VA: Visual acuity
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well-described sampling strategy, and detailed descriptions of 
IOP measurement and VF assessment. Gonioscopy and optic 
disc examination methods were clearly described. Two of the 
surveys21,22 were analyzed using the ISGEO classification 64 and 
IOP was included as a diagnostic criterion only when optic 
discs could not be assessed and VFs were not obtainable. The 
prevalence estimates of all types of glaucoma were 4.5% (95% 
confidence interval [CI] 3.2–6.1%) and 5.3% (CI 3.9-7.1%) 
respectively. The other study in Mamre, South Africa67 also 
studied those aged 40 years and above. The prevalence estimate 
was similar (4.6%; CI not reported) but the methodology was 
less rigorous. The survey in Kongwa, Tanzania20 used three 
diagnostic criteria based on the optic disc and VF definitions. 
When definite field defects in association with compatible disc 
changes were used to define glaucoma, the prevalence of all 
types of glaucoma was 4.16% (CI 3.5-4.9%).
The other studies used different methods and had limitations, 
which may have affected the estimate of glaucoma. For example, 
a survey in south-eastern Nigeria69 used IOP as a major 
diagnostic criterion and disc assessment was performed by direct 
ophthalmoscopy through an undilated pupil. In this survey, the 
prevalence of glaucoma was 2.1% (CI not reported) in people 
30 years and older. In northern Nigeria,68 a survey of individuals 
aged 5 years and above reported the prevalence of glaucoma 
to be only 0.55% (CI 0.07-1.99%) in the 361 participants 
examined aged 35 years and above; and 1.02% (CI 0.12-3.64%) 
in the 196 participants aged 45 years and older. Glaucoma was 
defined based on typical glaucomatous disc appearance or IOP 
greater than 30 mmHg if the disc was not visualized. A further 
survey in southern Ghana,23 which used European glaucoma 
study guidelines, did not use stringent diagnostic criteria, 
and those with media opacities with no view of the disc were 
excluded. Another limitation was the sampling strategy, which 
was largely a volunteer sample and included family members of 
those with a positive family history of glaucoma. In this survey, 
the prevalence of OAG was 8.4% (CI 7.74-9.06%) in those 30 
years and older, which is likely to be an over estimate. A study 
reported from western Cameroon,71 which also used a voluntary 
sample, reported the prevalence of glaucoma to be 8.2% (CI 
not reported). Another study in Nigeria70 excluded persons 
with IOP greater than 21 mmHg and did not assess VFs. In this 
survey, the prevalence of glaucoma suspects was 2.7% (CI not 
given). Previous authors suggested in 2009 that a conservative 
estimate of the prevalence of glaucoma in Africa in people 40 
years and older be 4%.46
There have been four glaucoma surveys among black populations 
living outside Africa [Table 3]. In the Caribbean region, the 
prevalence of glaucoma in African-Caribbeans was 8.8% (CI not 
given) in those aged 30 years and above in St Lucia18 and 6.8% 
(CI 6.1-7.6%) in aged 40 years and above in Barbados.19 In 
African-Americans in Baltimore, USA5 the glaucoma prevalence 
dates, including periods of recruitment, exposure, follow-up, 
and data collection; mentioning the eligibility criteria, and the 
sources and methods of selection of participants; clarity on 
diagnostic criteria; describing all statistical methods, including 
those used to control for confounding; reporting numbers of 
individuals at each stage of the study—e.g., numbers potentially 
eligible, examined for eligibility, confirmed eligible, included in 
the study, completing follow-up, and analyzed; reporting other 
analyses carried out.” A numerical summary score was given 
to each of the publications and an arbitrary classification was 
applied. Papers that scored >75% were classified as good, those 
that scored 55-75% were classified as satisfactory and those that 
scored <55% were classified as incomplete.
RESULTS
Search results summary
PBS of glaucoma in SSA
A total of nine studies20-23,67-71 were identified and all were 
included [Table 3]. Using the STROBE guidelines,65,66 three 
were classified as good,20-22 one was satisfactory67 and five had 
incomplete reporting.23,68-71
PBS of glaucoma in African-derived populations living outside 
Africa
Four glaucoma prevalence studies5,18,19,72 [Table 3] and one 
glaucoma incidence study73 were included in the review. 
Using the STROBE guidelines, three surveys were classified 
as good.5,18,19
PBS of prevalence/incidence of blindness and visual 
impairment in SSA
Fifty-five publications were identified. Of these, 32 prevalence 
surveys74-105 [Table 4] and the only incidence study identified106 
were included in this review. Glaucoma was not clearly defined 
and/or was not mentioned as a specific cause of blindness in the 
other PBS of prevalence and RAAB publications.107-128 
Population-based studies that reported risk factors for 
glaucoma in SSA and African-derived populations
One report on risk for incident open-angle glaucoma129 and 10 
further publications that discuss risk factors for glaucoma were 
included in this review.130-139
Prevalence of glaucoma
There are few PBS data that provide prevalence estimates of 
any/all types of glaucoma in SSA20-23,67-69 [Table 3], and only 
four provided reliable estimates.20-22,67 Of these, three were 
undertaken in different districts in South Africa21,22,67 and one 
in the Kongwa region of Tanzania.20
The surveys in Kongwa, Tanzania,20 Hlabisa, South Africa21 
and Temba, South Africa22 conducted the study on people 
aged 40 years and above; had robust methodologies, with a 
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in those aged 40 years and above was 4.74% (CI 3.81-5.67%) 
among blacks, being four times higher than in whites (1.29%, CI 
0.80-1.78). A prevalence of 3.9% (CI not given) was reported 
in a cross-sectional study of a voluntary sample of African and 
Caribbean people aged 35 years and above living in London.72
The prevalence of glaucoma in the studied populations aged 40 
years and older in the Tanzania20 and South Africa21,22,67 surveys 
(range 4.2% to 5.3%) was comparable to the 4.2% prevalence 
in the African-American population of Baltimore,5 but much 
lower than the prevalence of 7.1% in the African-Caribbean 
population of Barbados.19 Although these surveys were not 
completely comparable as the definitions of glaucoma varied 
and the methodology was not uniform, a consistent pattern 
was revealed: that glaucoma is a public health problem in SSA.
Types of glaucoma
Where glaucoma was classified by angle morphology, OAG was 
approximately six times more prevalent than ACG in SSA20-23 
[Table 3]. The exception was a study in those of mixed South-
East Asian and western European origin in Mamre, South 
Africa.67 In this study, Salmon reported a prevalence of 2.3% 
for ACG and 1.5% for OAG. However, 12 participants (1.2%) 
had full VFs and were classified as having ACG on the basis of 
their angle configuration only, without evidence of functional 
deficit. If the ISGEO definition of functional visual deficit had 
been used the prevalence estimate for ACG would have been 
lower. Nonetheless, the findings indicate that in SSA, ACG 
is more prevalent in those of SE Asian origin than in blacks. 
Pseudoexfoliation, aphakic glaucoma, uveitic glaucoma, lens-
induced, and post-traumatic angle-recession glaucoma were 
Table 4: Glaucoma cause-specific blindness prevalence and proportion of blindness due to glaucoma as percentage of total blindness 
in SSA
Location/Country of 
study
Year Age 
(years)
Examined 
Sample
Blindness 
prevalence, 
all causes 
(%)
Proportion 
of blindness 
due to 
glaucoma (%)
Ranking of 
blindness 
due to 
glaucoma
Glaucoma 
blindness 
prevalence in study 
population (%)
Glaucoma 
blindness 
prevalence in 
40+ year olds 
Reference
South Africa 2003 40+ 839 5.60 32.0 2 1.79 1.79 [22]
Cameroon 2007 40+ 2215 4.10 29.0 1 1.19 1.19 [74]
South Africa 2002 40+ 1005 3.20 22.0 2 0.90 0.90 [14]
Nigeria, national 2009 40+ 13,599 4.20 16.7 2 0.70 0.70 [75]ø
Ethiopia 2003 40+ 2693 7.90 7.7 3 0.61 0.61 [76]
Ghana 2005 40+ 2298 2.80 20.6 2 0.58 0.58 [77]ø
Ghana 2012 40+ 5603 1.20 21.7 3 0.26 0.26 [78]ø
Eritrea 2011 50+ 3163 9.00 15.2 2 1.37 0.80 [79]
Liberia 2012 50+ 3,544 4.10 16.0 2 0.66 0.38 [80]
Malawi 2011 50+ 3430 3.30 15.8 2 0.52 0.30 [81]
Nigeria 2006 60+ 445 5.60 42.0 2 2.35 0.70 [82]
Nigeria 2005 30+ 480 10.40 6.0 4 0.62 1.02 [83]
Equitorial Guinea 2002 All 3218 3.20 13.3 4 0.43 2.36 [84]
Nigeria 2007 8 to 92 2201 1.20 33.3 2 0.40 1.54 [85]
Nigeria 2003 All 1964 1.22 20.8 3 0.25 0.25 [86]
South Africa 1993 All 6090 1.00 22.9 2 0.23 1.27 [87]
Ethiopia 1995 All 60,820 1.10 17.0 4 0.19 1.04 [88]
Nigeria 2004 All - 1.18 15.8 3 0.19 1.04 [89]
Malawi 1986 6+ 1574 1.27 - 3 0.19 0.90 [90]
Nigeria 2007 All 1248 1.10 14.3 2 0.16 0.87 [91]
Uganda 2002 13+ 4076 0.40 38.5 1 0.15 0.53 [92]
Cameroon 1996 All 10,647 1.20 12.0 2 0.14 0.80 [93]
Mali 1996 All 5871 1.70 8.1 3 0.14 0.77 [94]
Cape Verde 2006 All 3374 0.80 15.4 2 0.12 0.68 [95]
Nigeria 1996 All 2921 0.90 11.1 3 0.10 0.56 [96]
Benin 1995 All 7047 0.60 15.0 2 0.09 0.50 [97]
Ethiopia 1997 All 7423 0.85 9.5 3 0.08 0.45 [98]
Kenya 1990 All 13,803 0.70 - 3 0.06 0.33 [99]
Central African Republic 1997 All 6086 2.20 2.2 4 0.05 0.27 [100]
Togo 1989 All 11,081 0.82 6.0 3 0.05 0.27 [101]
Gambia 2000 5+ 13,046 0.42 9.0 3 0.04 0.18 [102]ø
South Africa 1988 All 18,962 0.57 6.0 4 0.03 0.19 [103]
Congo 1990 All 7041 0.30 9.0 2 0.03 0.15 [104]
Gambia 1989 All 8174 0.70 2.0 - 0.01 0.08 [105]
 40+ year-olds as 18% of the total population, 50+ year-olds as 10.5% of the total population, øVisual field examination done, SSA: Sub-Saharan Africa
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classified as secondary glaucoma,20-22,67 with the prevalence 
ranging from 0.49% in Kongwa, Tanzania20 to 2.0% in Temba, 
South Africa.22 Exfoliative glaucoma was responsible for 16% of 
all glaucoma in Temba22 and 21.6% of all glaucoma in Hlabisa 
in South Africa,21 but was not detected in Kongwa, Tanzania.20
The publications for the surveys in the African-derived populations 
living outside Africa were reports for OAG and did not give 
prevalence of other types of glaucoma except in Barbados where 
the prevalence of secondary glaucoma was 0.7%.19
Incidence of glaucoma
Incidence rates provide evidence of long-term risk of a disease 
and are important for planning services and for policy. The 
cumulative incidence is the number of new cases seen over the 
time of observation divided by the population at risk. There 
are no PBS that report observed incidence of glaucoma in 
SSA. In the African-descent population of Barbados, the 9-year 
incidence of definite OAG was 4.4% (CI 3.7-5.2%) or 0.5%/
year and showed an increased risk with age and in men.73
Awareness of glaucoma
A total of nine surveys reported whether or not participants with 
glaucoma knew they had the disease or if they were receiving 
treatment [Table 3]. In Kongwa, Tanzania,20 98.5% did not 
know they had the disease. Similarly, 90.2% in Hlabisa, South 
Africa21 and 87.1% (of those with Primary OAG) in Temba, 
South Africa22 were not aware they had the disease. In Mamre, 
South Africa,67 36 (78.3%) were newly diagnosed and another 
six out of the seven participants that were blind due to glaucoma 
were already receiving treatment. Ninety-three per cent in 
Akwapim-South23 and 85.7% in Enugu, Nigeria69 were newly 
diagnosed. Approximately, half in both racial groups (blacks and 
whites) in Baltimore5 as well as in Barbados19 did not know they 
had the disease.
Glaucoma blindness
Incidence of glaucoma blindness
In Uganda, the all-cause incidence of blindness was 9.9/1000 
person years, with glaucoma accounting for 3.6% of incident 
cases (i.e., 0.36/1000 person years).106 In the Barbados eye 
studies, OAG was the 2nd leading cause of incident blindness, 
accounting for 14.3% of the 9-year incidence (1%) i.e., 0.143% 
over 9 years.140
Proportion of people with glaucoma who are blind
The only SSA glaucoma prevalence surveys, which reported 
the proportion of participants with glaucoma who were blind 
were those conducted in Tanzania, South Africa and Ghana. The 
proportions were as follows: 14.1% in Kongwa, Tanzania,20 33% 
(of OAG) in Temba, South Africa,22 15.2% in Mamre, South 
Africa,67 and 9.5% in Akwapim-south, Ghana.23 In the Temba 
survey, 58% (32 of 55) of those with any type glaucoma were 
blind in at least one eye.22 In Hlabisa, South Africa study, 41% 
of eyes with OAG were blind.21
In the Baltimore eye survey, the proportion of participants with 
OAG who were blind was 5.3%.5,141
Glaucoma-specific blindness prevalence
Data on the glaucoma cause-specific blindness prevalence were 
available from the following sources: PBS of blindness and visual 
impairment, RAAB studies and World Health Organization 
(WHO) published data.
From the available data, the glaucoma-specific blindness 
prevalence was calculated for those aged ≥40 years, assumed 
to be 18% of the total population [Table 4]. In the seven 
surveys in which the studied populations were aged 40 years 
and older,21,22,74-78 the glaucoma-specific blindness prevalence 
ranged from 0.26% in Ghana78 to 1.79% in Temba, South 
Africa.22 In the recent RAAB studies conducted in Eritrea,79 
Liberia80 and Malawi,81 the glaucoma blindness prevalence in 
the study population of 50-year olds and above were 1.37%, 
0.66% and 0.52%, respectively. Glaucoma was the second 
or leading cause of blindness74,92 in the more recent surveys, 
but ranked third of fourth in older surveys, after cataract and 
corneal diseases. However, in all the surveys included in this 
review, only six had VF assessment as part of the examination 
protocol.75,77,78,102,109,126 In all the other surveys, glaucoma was 
diagnosed only as a cause of blindness and only included those 
who had lost central fixation in both eyes.
In Hlabisa, South Africa, the prevalence of blindness was 3.2% 
(CI 2.2-4.6%) in people aged 40 years and above, and 22% was 
due to glaucoma.21 In Temba, South Africa, the prevalence of 
blindness was 5.6% (CI 3.9-7.7%) in people 40 years and older 
and the proportion due to glaucoma was 32%.22
A recent nationally representative population based survey of 
blindness and visual impairment in Nigeria reported the all-
cause prevalence of blindness to be 4.2% (CI 3.8-4.6%)142 and 
the proportion of blindness due to glaucoma was 16.7% among 
those aged ≥40 years.75 The prevalence of blindness ranged 
from 3.3% (CI 2.4-4.5%) in the Delta ecological zone to 6.6% 
(CI 4.2-10.4%) in the northern Sahel ecological zone, and the 
proportion of blindness due to glaucoma varied from 13.2% 
in the Sudan Savannah to 23.5% in the Sahel ecological zones. 
The nationwide overall glaucoma-specific blindness prevalence 
was 0.7% (CI 0.55-0.88%)75 with a four-fold difference in the 
glaucoma-specific blindness prevalence which ranged from 
0.4% (CI 0.2-0.9) in the Delta to 1.6% (CI 0.6-3.8%) in the 
Sahel.143 A high prevalence of blindness in all ages was reported 
in Bioko, Equatorial Guinea (3.2%)84 and this was reflected as 
high prevalence estimate of glaucoma blindness of 2.36% in the 
40+ year-olds. A high prevalence of blindness (10.4% in people 
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30 years and older) was reported in a survey in leprosy villages in 
north-eastern Nigeria, where glaucoma ranked 4th as a cause of 
blindness, nevertheless, with a high glaucoma-specific blindness 
prevalence of 1.02% in the 40+ year-olds.83 This is in contrast 
to a survey undertaken decades ago in an area endemic for 
onchocerciasis in North-Eastern Nigeria where the prevalence 
of blindness was 11.8% in all ages and glaucoma did not feature 
as a cause as almost all blindness was due to onchocerciasis.128 
In the Baltimore eye survey,141 the overall prevalence of 
blindness was 1.21% and the proportion of blindness due to 
glaucoma was 14.1% among those aged 40 years and above. 
The glaucoma-specific blindness prevalence was 0.17%. 
Glaucoma blindness was compared between whites and blacks. 
In the blacks, glaucoma blindness was 0.37% and 6.6 times 
higher than the 0.06% glaucoma blindness prevalence in 
whites. Glaucoma blindness also occurred earlier in blacks with 
a prevalence of 0.29% in the age-group 50-59 years whereas 
none of the whites were blind due to glaucoma before the age 
of 60 years. In this population, glaucoma as well as cataract 
and diabetic retinopathy were more common as a cause of 
visual impairment in blacks while macular degeneration was 
more so in whites.144
Data on the prevalence and causes of blindness were published 
by WHO for the year 2002.2 Survey data available at the time 
were extrapolated to countries without data in order to derive 
global estimates. The glaucoma-specific blindness prevalence 
was calculated from these data, which are presented according 
to the 17 WHO sub-regions [Table 1]. The proportion of 
blindness in all ages due to glaucoma globally was 0.7/1000, 
ranging from 0.18/1000 in the Western Pacific sub-region B3 
to 1.5/1000 in both African sub-regions. Glaucoma blindness 
in Africa is, therefore, twice the global figure; and eight times 
higher than in the Western Pacific sub-region.
Risk factors
The study of risk factors gives information on who gets glaucoma 
(incidence studies), who has glaucoma (prevalence studies), 
who progresses and who goes blind due to glaucoma (risk of 
progression, prognostic factors). Risk factors for glaucoma 
incidence were reported from the Barbados eye study.129 Risk 
factors for glaucoma prevalence were reported in six of the 
PBS of glaucoma in SSA20-23,67,69 and in all four of the PBS 
of glaucoma in the African-derived populations.5,18,19,72 Ten 
other publications related to the Akwapim-South, Ghana 
survey,139 St Lucia survey,137 Barbados eye study,130 Baltimore 
eye survey,132,133,135,136 African descent and glaucoma evaluation 
study,134 a multicenter study138 and a PBS in African-Americans 
living in Canada131 reported risk factors for glaucoma.
Who is at risk of developing glaucoma?
Risk factors for incident OAG were increasing age, higher IOP, 
lower systolic blood pressure (BP) to IOP ratio (BP/IOP), lower 
mean diastolic ocular perfusion pressure (diastolic BP minus 
IOP), thinner central corneal thickness (CCT), and a positive 
family history.129 Racial variability of some of these risk factors 
at baseline has been demonstrated;130 with higher IOP131 and 
thinner CCT131,134 in African-derived groups.
Who has glaucoma?
Age was an important and consistent risk factor, with a 
higher prevalence of glaucoma associated with increasing 
age.5,19-23,69,72,130 The age-specific prevalence of OAG was higher 
with increasing age: From 1.7% (CI 1.1-2.5%) to 5.6% (CI 3.1-9.2) 
in Kongwa, Tanzania,20 from 1.2% (no CI reported) to 4.9% 
in Hlabisa, South Africa,21 and from 0.6% (no CI reported) to 
6.0% in Temba, South Africa,22 in the age-group 40-49 years 
and the age-group 70-79 years, respectively. Similarly, higher 
prevalence of OAG was reported from 1.4% (CI 0.8-2.2%) to 
14.8% (CI 12.5-17.4%) in Barbados;19 and from 1.23% (CI 
0.23-2.24%) to 9.15% (CI 5.83-12.48%) in blacks and from 
0.92% (CI 0.2-7.2%) to 2.89% (CI 1.44-4.34%) in whites in 
the Baltimore eye survey,5 in the age-groups 40-49 years and 
70-79 years, respectively.
Gender was not consistently associated with prevalent cases 
of glaucoma.5,23,69 However, some surveys reported a higher 
prevalence of OAG in men.19,21,22,67,130 Men were also more likely 
to have secondary glaucoma,22 especially following trauma.67 
ACG was more common in women.67
Higher IOP is another important factor associated with a higher 
prevalence of glaucoma,20,21,130,132 although IOP had a limited 
predictive value.21 Hypertension was not significantly associated 
with glaucoma prevalence.20,72,130 However, lower mean ocular 
perfusion pressure was associated with a higher prevalence in 
the surveys in African-derived populations of Barbados130 and 
Baltimore135 but, this was not reported in African-Caribbeans 
in London72 or in the only survey that this factor was studied 
in SSA.20 These factors associated with ocular blood flow i.e., 
systolic BP, diastolic BP and ocular perfusion pressure were 
stronger in older people.132,133,135
A positive family history of glaucoma was associated with higher 
prevalence of glaucoma.130,133
The higher prevalence of glaucoma in blacks compared to 
whites was consistently demonstrated in the surveys involving 
the two racial groups.5,19,72 Furthermore, those with darker skin 
and of African birth seemed to have a higher risk.72 However, 
in the two studies involving a number of ethnic groups in SSA, 
ethnicity was not associated with a variation in prevalence of 
glaucoma;22,23 but the sample sizes were relatively small and the 
studies were confined to limited geographical areas with few 
ethnic groups represented.
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Other risk factors for glaucoma include lower body mass index 
in men and history of cataract surgery.130
Who has glaucoma progression and who develops blindness 
due to glaucoma?
A survey in Ghana139 explored the risk factors associated with 
severe disease and surveys in Baltimore132 and St Lucia137 explored 
the risk factors for glaucoma progression and blindness. The 
Temba, South Africa survey22 was the only SSA survey that 
described the age of participants that were blind due to glaucoma. 
The risk of glaucoma blindness increased with increasing age. 
The average age of the blind glaucoma participants was higher 
(74.8 years) when compared to the average age (65.4 years) of 
the non-blind participants. In the Ghana study that combined 
population-based and facility-based samples, older age (more 
than 60 years) and IOP greater than 31 mmHg were associated 
with more severe disease and the absence of family history was 
associated with delay in seeking treatment.139 Increasing age was 
also associated with progression of the disease.136,137 Aggressive 
glaucoma therapy reduces the progression of VF loss that leads 
to bilateral blindness;136 and the proportion of patients with 
progressive VF loss is much higher in those untreated than in 
treated eyes.137 Glaucoma progression was more severe in blacks138 
and blindness occurred at an earlier age in blacks than in whites.141
DISCUSSION
World estimates on the prevalence of glaucoma and glaucoma 
blindness prevalence have been derived from projections and 
modeling from pooled data and surveys,3 and by extrapolating 
data from countries with data to those without,2 and more 
recently, using newly developed imputation methods based on 
country economic status.1 However, these approaches have given 
different estimates for glaucoma. One explanation for the WHO 
estimates of glaucoma blindness being lower than other estimates 
is that data were obtained from population based surveys of 
blindness, where VF are usually not included in the definition of 
blindness. Individuals with extensive VF loss, but with preserved 
central fixation in at least one eye would not, therefore, be 
included in the WHO estimates. Another reason may be that 
age-standardization is included in modeling estimates and this 
will take into account the steep decline in population after age 
40 years that is typical of developing country profile.
The number of high quality glaucoma surveys conducted in 
Africa is low and it is difficult to extrapolate the findings to 
wider populations as they were conducted in limited and defined 
geographical areas of large countries. These surveys were also 
often not directly comparable due to variation in the age of 
participants, and differences in the methods used to measure 
parameters of relevance to glaucoma and to define and classify 
the disease. Only two surveys used the ISGEO definition, which 
relates IOP and cup:disc ratios to population norms. This is 
important, given the recognized variation in the distribution of 
optic disc and cup size and IOP between populations.12-16,64,145-149 
There is only one small study of the incidence of glaucoma 
blindness in Africa,106 and no studies on the incidence of 
glaucoma. Longitudinal studies to address these questions will 
also give information on the natural history of the disease, as a 
high proportion of individuals diagnosed with glaucoma do not 
seek treatment even when this is recommended.
More reliable data are required from large scale, rigorous PBS 
in order to revise and refine the prevalence and magnitude 
estimates of glaucoma and glaucoma blindness for SSA. Ideally, 
the surveys should use the same age range, and the standard 
definitions and classification system, and use comparable 
methods of assessing VF, IOP and cup:disc ratios. The sample 
sizes should be large enough to allow analysis of risk factors 
for glaucoma in order to identify the population most at risk. 
Ideally, such surveys should also collect data on family history 
of glaucoma and socio-demographic data. Data on whether 
different ethnic groups in SSA are more at risk than others 
is currently lacking, as there are no published studies, which 
have included a large enough sample of different ethnic groups. 
The relatively small sample size of the reviewed surveys would 
limit the power of the studies to detect differences. Data from 
the Nigeria national survey150 are currently being analyzed and 
will provide data on risk factors including variations in ethnic 
groups. Again, this information would be of value for targeting 
control strategies.
The suggested prevalence of glaucoma in SSA of 4% in people 
40 years and older46 is a reasonable estimate as that is what 
these three “good” studies in SSA indicated.20-22 Since, this 
prevalence estimate was suggested in 2009 for Vision 2020 
planning purposes, there has been no additional high quality 
data to suggest that it needs to be changed.
The available evidence suggests that the prevalence of glaucoma is 
higher in SSA and in people of African descent who live outside 
Africa. A Bayesian meta-analysis that examined the relationship 
between OAG prevalence and age, gender, and racial group 
also showed that the pooled random effects prevalence of OAG 
was higher in the black populations (4.2%).26 Given the lack 
of evidence that environmental and behavioral risk factors are 
associated with glaucoma, these findings suggest a genetic basis for 
the greater susceptibility in blacks.28 The genetic basis of glaucoma 
is being increasingly recognised151,152 and genetic research and 
genome-wide association studies in Africa will possibly explain 
some of the variations and excess risk seen in black populations.
The most prevalent type of glaucoma in SSA is open-angle 
glaucoma. However, hospital-based studies tend to overestimate 
the proportion of ACG reporting a range of 6% to 18% of all 
glaucoma cases seen;54,153-157 and this may be related to the 
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health-seeking behavior in which the pain in acute ACG acts as 
a trigger for the need to obtain treatment.
The very low awareness of having the disease as reported in the 
PBS signifies that only a small fraction of people with glaucoma 
access healthcare, leaving a large majority untreated and with the 
potential blinding effects. Indeed, in those that access healthcare, 
up to 42% of glaucoma patients presented with advanced disease 
and bilateral blindness; and over half were blind in one eye.54-59
Glaucoma causes irreversible blindness due to loss of ganglion 
cells of the optic nerve leading to vision and VF loss. The 
proportion of people with glaucoma who are blind is higher 
in SSA than in any other region. The earlier age of onset of 
the disease in blacks has already been reported35 and this has 
been corroborated in the PBS in SSA20-22 and black populations 
where the prevalence of OAG in the age-group 40-49 years was 
much higher than in white populations of USA and Barbados.5,19 
Interestingly, a similar variation of the 40-49 years age-specific 
prevalence of 0.4% (CI 0.0-0.9%) and 3.1% (CI 0.4-5.8%) 
between the white and non-white groups, respectively, in 
Piraquara City, Brazil was reported.158 Comparatively, the 
40-49 years age-specific prevalence in Caucasian Australians was
0.2% (CI 0.0– 0.56%),8 and remarkably from as low as <0.2%
(no CI reported)159 and up to 1.5% (CI 0.4-2.5%)160 in
indigenous Australians. Glaucoma progression is also more
aggressive in blacks.36,37,138 Thus one of the plausible reasons
why blacks in Africa and African-derived populations have more
glaucoma blindness is that the early age of onset means they have
the disease for a longer time.
The Nigeria national survey on blindness and visual impairment 
is the largest PBS that has ever been carried out in Africa. 
The prevalence data by geo-ecological zones showed wide 
variation between the Sahel and the Delta ecological zones. The 
proportion of blindness due to glaucoma was also higher, with a 
4-fold difference in the prevalence of glaucoma blindness.143 The
only explanations are that the incidence of glaucoma blindness
is higher and/or the disease is more aggressive and/or access
to care is lower in the Sahel zone. Data on these factors are
currently being analyzed.
Further studies are needed to explore risk factors for glaucoma 
blindness, which will help to identify those most at risk for 
example by gender, socio-economic status (e.g., level of 
education), age, and ethnic group. Exploration of biomedical 
risk factors associated with disease progression (e.g., IOP and 
ocular perfusion pressure) will also provide guidelines for setting 
and monitoring target IOP following treatment.
The ranking of glaucoma as a major cause of blindness from lower 
ranks in older surveys to second leading cause in most recent 
surveys may be attributable to the increase in control efforts 
of corneal diseases, notably vitamin A deficiency and trachoma 
which became less in magnitude, and a decrease in onchocerciasis 
blindness. In addition, the classification and diagnosis of glaucoma 
had improved in more recent surveys. However, it is probable that 
figures for glaucoma prevalence and blindness are underestimations 
especially in populations with a high prevalence of cataracts. 
Cataract and corneal diseases are more easily diagnosed in surveys 
and may occlude the view of the optic disc for a definite diagnosis 
of glaucoma. Furthermore, in ranking of principal cause of 
blindness using the WHO format, cataract or corneal scar may 
take precedence being recorded preventable causes of blindness 
even in eyes with co-existing glaucoma.
A large number of the PBS from which data of glaucoma-specific 
blindness prevalence were derived did not have VF assessments. 
These data therefore underestimate glaucoma-specific blindness 
which, if using the WHO definition of blindness, should also 
include those with a central VF of less than 10 degrees in the 
better eye.161 The wide variation in glaucoma-specific blindness 
prevalence may be attributable to the sampling methodology 
and/or some studies done in areas where focal diseases were 
more prevalent. In addition, the definitions used for blindness 
as well as for glaucoma and the age of participants in the surveys 
varied. The age of the sample is very important since the disease 
is age-related. Even if definitions and measurements were 
standardized and the sample populations were all 40+ years, 
there could still be very different prevalence data because of the 
differences in the life expectancy and age structure of people 
aged 40 years and above between populations and regions. Age-
standardization between the surveys would have eliminated the 
differences due to confounding by differences in age structure 
of the populations.
A limitation of this review process is that age-standardization 
of these data was not possible. Another limitation is that there 
was a language restriction in the search strategy. If a publication 
and abstract were not in English they might have been missed. 
However, this would only apply to Francophone and Lusophone 
Africa.
Application of these studies to the control of 
glaucoma in SSA
These studies have highlighted that glaucoma is predominantly 
OAG and it is a public health problem in SSA. It has a high 
prevalence, an early onset and progresses more rapidly than 
in Caucasians; and it is a major cause of blindness. Thus case-
finding strategies need to be targeted at younger ages. Treatment 
needs to be more aggressive, life-long and with adequate follow-
up, and monitoring of patient-physician contact frequency.
Challenges for the control of glaucoma in African populations 
have been elucidated.46,47,50,52 The disease is most often diagnosed 
late and there is a poor response to treatment possibly due to 
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poor compliance or non-availability of any form of treatment. 
These factors are further compounded by poor awareness and 
low knowledge about glaucoma even by patients. Provider factors 
include poor facilities and equipment for glaucoma diagnosis 
and management,53 inadequate number of ophthalmologists162 
and support teams and limited treatment options (e.g., lasers 
and trabeculectomy with adjunctive antimetabolites).
In order to reduce morbidity from glaucoma, a public health 
approach is needed for control and particularly targeted to those 
at risk. Possible solutions have been proposed and some are being 
implemented.46,50,61,62,163 Approaches for control include: To 
increase public health education for awareness about glaucoma; 
to improve case-detection methods including opportunistic eye 
examinations; to encourage case-finding in first-degree relatives; 
to increase treatment options and availability of medications and 
surgery; to increase education and training for skilled glaucoma 
surgeons, patients’ counselors and other glaucoma care workers; 
and to strengthen infrastructure of eye care centers and other 
systems for glaucoma diagnosis, treatment, and counseling of 
patients. These should be incorporated into existing Vision 2020 
programs and blindness control strategies; and glaucoma care 
needs to be given high priority.
Further research
Despite the many challenges facing SSA, there is a need to 
streamline glaucoma control activities and provide evidence-
based care. The process to undertake such research can be 
scheduled systematically and tailored according to local needs 
and available pooled resources. In the longer term, results and 
output of the research will be beneficial.
Epidemiological research
More population-based research is needed to clarify the nature 
of glaucoma in many more populations in Africa, to determine 
reasons for its variation and to better define target risk groups.
Social sciences/qualitative research 
This is important in order to identify the factors and barriers 
to awareness and knowledge of blinding eye diseases; and 
compliance and adherence to treatment of glaucoma in SSA.
Clinical care and outcomes
Operational and clinical research for patient care is needed to 
define clinical guidelines (including issues of patient-physician 
contact frequency) and protocol of management for optimum 
glaucoma care. Monitoring of outcomes tools including patient 
reported outcome and experience measures164 and quality of life 
and visual function measures need to be developed. Randomized 
control trials are needed to define appropriate choices of 
treatment and provide evidence-base for best clinical care. 
Health systems research 
Studies that also provide evidence for policy makers and 
management to facilitate systems for the management of the 
disease are important.
Health economics research 
This will define issues such as cost-benefit of the different 
options of glaucoma treatment, the economic burden of the 
disease and health insurance coverage for glaucoma patients.
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Chapter(3!
Study%rationale,%research'questions,'study&aim$and$objectives!
!
!
!
!
Some%members&of&the&Nigeria&Blindness&Survey&team&at&Idanre&Hills,&SW&Nigeria!
!
!
Linking&material&summarising&rationale)of)the)study,"research"questions,"
and$study&aim&and&objectives!
!
! !
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Glaucoma(!!the$silent$thief$of$sight"
!
In#my#early#days#as#a#resident#ophthalmologist,(we(organised(a(glaucoma(
awareness'week.'As'part'of'the'activities'we'had'a'TV'programme.'First'thing'the'
following(morning,(Mr(CJ,(a(Judge(of(the(high(court,(came(to(our(hospital.(He(was(
well$educated$and$high$up$in$his$career.$Referring$to$the$TV!programme,"he"said"to"
the$Chief$Medical$Director$“your$doctors$made$me$to$come$here$today”.$He$had$
watched(the(TV(programme!in#which#a#colleague#advised#to#check#one’s#vision#by#
covering)one)eye)at)a)time.)Mr)CJ)had)lost)vision)in)his)left)eye)and)had)not!realised(
it#until#that#moment#he#watched#on#TV!and$checked$his$vision$by$covering$one$eye$
at#a#time."He"had!advanced!glaucoma.)Then,)it)struck)me)for)the)first)time,)that)
indeed,&glaucoma(silently(steals(away(eyesight(without(the(person(realising(it.!
!
Many"years%later,%while%on%the%Nigeria%national%blindness%and%visual%impairment%
survey'(thereafter'referred'to'as'Nigeria'Blindness'Survey),"we"saw"many"people"
with%glaucoma.%We%had%a%service%to%restore%vision%to%the%cataract%blind%that%we%
encountered,*but*we!could&not&do#so#much#for#the#glaucoma#persons#we#saw.#!
!
!
3.1! Rationale)of)the)study!
!
This%thesis%provides!the$baseline$epidemiological$data$on$glaucoma$prevalence$in$
Nigeria.(It(reports!the$association$between$potential$risk$factors$for$glaucoma$and$
glaucoma$blindness.$It$also%studied!issues%of%management%and%control%of%
glaucoma(blindness(from(the(physicians’(perspective,(and(in(the(context(of(
patients’)understanding)and)community/public)awareness)of)the)disease.)!
The$study$involved$three!main%components:!(!)"Assessing"the"level"of"need"for"
glaucoma(services;((!)"Identifying"available"services"and"the"constraints"involved;"
and$(!)"Understanding"access"to"glaucoma"care"by"the"population."!
!
This%thesis%includes%a%secondary%analysis'of'the'relevant'data'from"the$Nigeria$
Blindness(Survey!in#order#to#enable!assessment'of'the'level'of'need'for'glaucoma(
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services'and'identify#high"risk%groups.%The%analyses"of"the"Nigeria&Blindness'
Survey!data!would&further&clarify!ethnic,(geographical(and(socio"economic'
variations)in#the$disease$pattern$and$provide!baseline(data(for(planning(delivery(
of#care#to#glaucoma#patients#in#Nigeria#and#countries#with#similar#ecological#
characteristics)in)sub"Saharan&Africa.&The&Nigeria&Blindness'Survey!data$were!
also%analysed%to%identify%factors%associated%with%blindness%among%those%affected%
so#that#these#groups#can#have#specific#early&case"finding&eye&examinations&and&be&
offered&enhanced&health&education&when&they&attend&services.&These&data&were&
previously+not+available.!
!
The$second$section!of#the#thesis#outlines#the#barriers#of#giving#glaucoma#care.#
Identifying*how*glaucoma*is*currently*being#managed#in#Nigeria#identifies!how$
services'can'be'improved'and'areas'for'intervention,'including'training,'in'order'
to#define#clear,#safe#and#feasible!care"pathways(in(practice(patterns.(The(
information)about)cost)of)treatment)has)therapeutic)and)economic)implications.)
Such%analysis%in%Nigeria%would%be%useful%in%influencing%policy%on%glaucoma%care%
especially)in)terms)of)availability)and)cost)of)medication!and$treatment.!
!
The$third$section$sought$to$understand$why$people$with$glaucoma$present$late$
for$treatment.$Additionally,$understanding*what*patients*know*and*do*about*
glaucoma(and(public(awareness(for(the(disease(will(facilitate(health(education(
strategies%to%be%more%relevant%in%improving%awareness%of%glaucoma%in%the%
community)leading)to)better)access)to)care)and)control)of)visual)loss)and)
blindness(from(glaucoma.!
3.2! Research(questions!
!
!. How$many$people$have$glaucoma$in$Nigeria$and$what$are$the$risk$factors'
for$glaucoma$and$glaucoma$blindness$in$Nigeria?!
!
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!. How$are$physicians$in$Nigeria$diagnosing$and$treating$glaucoma$and$what$
constraints)do)they)face?!
!
!. Why$do$people$with$glaucoma$present$late$for$treatment?!
!
!. Why"do"people"with"glaucoma"present"late"and!what#do#the#public,#and#
patients(with(glaucoma(know,(do(and(think(about(the(disease?!
!
!
3.3! Aim!
!
The$overall$aim$of$the$glaucoma$in$Nigeria$study$is$to$determine$ways$in$which$to$
improve(service(delivery(for(glaucoma(care%in#Nigeria.#!
!
!
3.4! Objectives!
!
!. To#analyse'the'Nigeria'survey'data'to'estimate'the'prevalence'and'describe'
the$types$of$glaucoma$in$adults$aged%!"#years#and#above&in#Nigeria.!
!. To#determine#potential#risk#factors#for#glaucoma#as#well#as#risk#factors#
associated)with)blindness)among)those)affected.!
!. To#find#out#how#glaucoma#is#currently#being#diagnosed#and#managed#by#
ophthalmologists/ophthalmic-surgeons-in-Nigeria.!
!. To#determine#the#cost#of#care!for$glaucoma$patients$in$Nigeria.!
!. To#determine#why#people#with#glaucoma#present#late#for#treatment.!
!. To#identify(what(the(community(and(patients(with(glaucoma(know,(do(and(
think&about&the&condition.&!
!
! !
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Chapter(4!
Study&protocol,&description+of+data+collection+methods;"the"
Nigeria'national'blindness'and'visual'impairment'survey'and'
development*of*glaucoma*diagnosis&algorithm!
!
!
!
A"clinical"examination"room"set"up"in#the#community#for$the$Nigeria$Blindness$Survey!
!
!
Linking&material&detailing&the&study&design'and'protocol,"and"data"
collection(methods!
! !
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4.1! !Research(setting!
!
Nigeria!is#situated#along#the#western"coast"of"Africa"with"a"surface"area"of"
!"#,%&&'square'kilometres'within'latitude'8!N"and"&'!N"and"longitude"-!E"and"
!"!E.#Along#its#southern#border#is#an#344km#coastline#of#the#Atlantic#Ocean.#It#is#
divided%into%)%main%geographical%land%areas%by%the%rivers#Niger#and#Benue."!
!
Nigeria'became&amalgamated&as&a&nation"state!in#$%$&#and#became#independent#
from%British%rule%in%/012.%There%are%'()!identifiable*ethnic*groups!with!the$%$
main%ethnic%groups%being%Hausa%in%the%north,%Igbo%in%the%southeast%and%Yoruba%
in"the"southwest.!The$country$is$divided$into$six$administrative$geo"political#
zones&(GPZ),&-.&States%and%the%Federal%Capital%Territory%(FCT),%and%!!"!local%
government)areas)(LGA).!
!
The$%&&'$population$census$indicated$a$population!of#$%&#million#with#$..0%!
aged%&'%years%and%above.%With%an%average%annual%growth%rate%of%8%%the%
population)is)extrapolated)to)be)012)million)in)4505,)and)471)million)by)4595.)
The$literacy$level$is$...0%$and$the$infant$mortality$rate$is$!"!per$%&&&$live$births!
("#$%)."!
!
Nigeria'has!a"Revised"National"Health"Policy"launched"in"4556,"and"currently"
being&reviewed&(,-./)!with%an%overall%objective%“to%strengthen%the%national%health%
system&such&that&it&will&be&able&to&provide&effective,&efficient,&quality,&accessible&
and$affordable$health!services...”!Primary'health'care'(PHC)'is'regarded'as'the'
framework)to)achieve)improved)healthcare)for)the)population.!!However,(there$is$
no#specific#eye#health#policy#and#primary#eye#care#is#not#currently#embedded#in#
the$PHC$framework.$The$national$programme$for$the$prevention$of$blindness$
(NPPB)&coordinates&blindness&prevention&activities&and&eye&health&services&of&the&
national'Vision'*+*+'strategic)plan.&It&is&a&sub"unit%in%the%department%of%Public%
Health'at'the'Federal'Ministry'of'Health'(FMoH).!
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4.2! Funding,"collaborating"institutions"and"ethical"clearance!
!
This%PhD%study%was%supported%by%the#Fred#Hollows#Foundation,"Australia"
through'a'research'degree'grant'administered'by'the'London'School'of'Hygiene'
and$Tropical$Medicine$(LSHTM).!
!
Ethical(approval(was"obtained"from"the"Ethics"Committee"of"LSHTM"and"the"
Nigeria'National'Health'Research'and'Ethics'Committee'(NHREC)'(Appendix()).#
Informed)written)consent)was)obtained)from)participants)(Appendix()).#
Confidentiality,was,maintained,and,data,obtained,would,be"used"only"for"the"
purpose'of'this'study'and'possible'interventions'arising'from'it.'The'study'did'not'
interfere'with'any'treatment'the'patients'were'receiving'at'the'time'of'data'
collection.)Participants)and$other$attendees$at$the$community$sites$found&to"be"in"
need$of$further$management$were$referred$to$the$appropriate$facility.!
!
The$Nigeria$national'blindness'and'visual'impairment'survey'(thereafter'referred'
to#as#the#‘Nigeria'Blindness(Survey),"in"part,"forms"the"first&part!of#this#thesis!
(Epidemiology!of#glaucoma#in#Nigeria)."The$Nigeria$Blindness$Survey$was$a$
countrywide,survey,undertaken,by,the,International,Centre,for,Eye,Health,
(ICEH),(LSHTM(as(the(major(technical(partner.(Other(collaborating(institutions(
for$the$Nigeria$Blindness$Survey$were$Institute$of$Ophthalmology,$London,$UK;$
NPPB,"FMoH,!Abuja,'Nigeria;'National'Eye'Centre,'Kaduna,'Nigeria;'SightSavers'
International,+Country+office+in+Kaduna,+Nigeria+and+the+head+office+in+the+UK.+
There%was%additional%support%by%CBM,%Velux%Stiftung,%and%the%Federal,'State'and'
Local&Governments&of&Nigeria.!
!
The$qualitative$study#component#was#undertaken#in#two!selected'hospitals'and'
four%communities*around!these%hospitals%in%Abuja,%Federal%Capital%Territory%
(FCT)&and&Kaduna&State.!!
!
!
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4.3! Study&design!
!
The$overall"work"has"three"main"parts,!which%were%undertaken%separately.!
Part%&%describes%the%epidemiology%of%glaucoma%in%Nigeria;!part%&%examines%
glaucoma(care(provided(by#ophthalmologists;!and$part$($studies'access%to%
glaucoma(care(and(the$perception,$attitude$and!awareness'of'glaucoma'by'
patients(and(in(the(community.!These%three%components!influence(the(diagnosis(
and$treatment$of$glaucoma.!
!
Figure'4a:'Overview'of'the'study'design!
! !
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treatment!
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glaucoma!care!
Epidemiology!of!
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4.4! Part%1!–!Epidemiology+of+glaucoma+in+Nigeria!
Purpose:!!to#describe#the#epidemiology*of*glaucoma*in*Nigeria,*using*data*
collected'during'the'Nigeria'Blindness'Survey.!
!
4.4.1! The$Nigeria$national$blindness$and$visual$impairment!survey!
A"Nigeria'Blindness'Survey!was$conducted$across$Nigeria!from!!""#$to$!""'."
The$survey$was$prompted!by#the#World#Health#Organization,#as#data#on#
blindness(from(African(countries(was(limited."It"was$supported$by$the$
international(non"government)organisations'that!implement(prevention(of(
blindness(programmes"in"West"Africa"so"that"data"could"be"provided"for"priority"
setting'and'planning'eye#care!services.((The(methods(used(in(the(survey(have(
been$described$in$detail.!!Ethical!approval'for'the'study'was'obtained'from'the$
LSHTM&and&the&Federal&Government&of&Nigeria.&!
!
Multistage)stratified)cluster)random)sampling)with)probability)proportional)to)
size%procedures%were%used%to%select%a%nationally%representative%sample%of%56,89:%
persons'aged'>!"#years#in#+,"#clusters#across#Nigeria#(shown#in#Figure'(b)."More"
than%&',)**%people%were%examined.%Clinical%examination#sites#were#set#up#in#the#
community.!The$survey$was$undertaken$by$two$teams$(Team$A$and$Team$B)$
simultaneously,in,neighbouring,States,or,Local,Government,Areas,(LGAs).,Each,
team%comprised%one%community%ophthalmologist%as%team%leader,%one%clinical%
ophthalmologist,)one)optometrist,)two)ophthalmic)nurses,)four)enumerators,)two)
drivers'and'a'cook.'I'was'the'team'leader'and'community'ophthalmologist'for'
Team%A.%!
!
The$flow$of$participants$through$the$survey$methods$is$shown$in$Figure'(c.!(See$
Appendix():(Nigeria!Blindness(Survey(data(collection(form).!
All#the#participants#had#their#presenting#distance#visual#acuity#measured#(i.e.#
with%spectacles%if%usually%worn)%with%the%reduced%logMAR%E"chart&and&all&had&
FDT$visual$field$testing.$This$included$FDT$using$the$screening%test%initially%
Fatima Kyari PhD Thesis Page 57
which%was%then%run%at%C./%threshold,%when%indicated.%All%those%with%a%presenting%
visual'acuity'of'<!"#letters!(Snellen&equivalent&-//0)!in#one#or#both#eyes#had#a#
detailed'examination'which'included'Goldmann(applanation(tonometry,(Van(
Herrick’s)angle)grading,)gonioscopy)if)thought)to)have)glaucoma,)and)dilated)
fundus&examination&with&digital&fundus&imaging&of&the"optic"disc"and"posterior"
pole.&All#images#were#graded#at#the#Moorfields#Eye#Hospital#Reading#Centre,"
London!(MEHRC).)!
!
In#addition,&'"in"!"participants"also"had"the"full"examination"and"all"procedures"
regardless(of(their#visual#acuity,#to#provide#a#‘normative’!database'for'Nigerian'
eyes.%!
!
The$main$findings$of$the$Nigeria$Blindness$Survey$were$that$the$prevalence$of$
blindness(was"#.%%"(()%"CI",.-"–!!.#%)&among&those&aged&!1&years&and&above,!!
and$glaucoma$was$the$second$commonest$cause$of$blindness$(45.7%).!!There%was%
marked'regional'variation'in'the'prevalence'of'blindness'between'the'dry,'less"
densely'populated'north'of'the'country$(!.#%)"and"the"rainforest,"more"
urbanised*south*of*the*country*(!.#%).!
!
Figure'4b:!Map$of$Nigeria$showing$the$states!and$geo"political(zones(boundaries,"ecological(
zones&and&the&magnitude&of&blindness&(2008)&in&the&zones&!
!
!
!
!
!
!
!
!
!
Each%dot%represents%
the$location$of$one$of$
the$310$clusters(
included(in(the(survey!
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!Figure'4c:!Flow%chart$of!examination)protocol)for)the)Nigeria)Blindness)Survey!
!
Enumerators
Interviewer
Ophthalmic nurse
Ophthalmic nurse
Optometrist
Optometrist
Ophthalmologist 1
Ophthalmologist 1
Ophthalmologist 1
Ophthalmologist 2
Ophthalmologist 2
Ophthalmologist 1
Ophthalmologist 2
Interviewer
Ophthalmologist 2
More than 24 letters
in both eyes
Autorefraction, keratometry, axial 
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Cataract/couching 
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Slit lamp anterior segment 
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Discharged
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!!
!
Figures(4d(&(4e:!The$Nigeria$Blindness$Survey&was$undertaken$in$sites/clusters*in*all*terrains!
!
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!!
Figures(4f(and(4g:!A"clinical&examination&room#was!‘constructed’!in#this%church%area!in#the$
absence'of#a"suitable)building!in#this#community!
!
!
!
!
Figure'4h:!The!church%area!(Figure(4f)!turned'into'a'clinical!examination)room)for!the$Nigeria$
Blindness(Survey!
!
!
!
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The$data$collected!in#relation#to#glaucoma#are#shown#in#Table&!.#,"which!also%
shows!a"summary"of"which"participants"had"what"examination"according"to"the"
survey'protocol.!
Table&4.1:!Data$collected$in$relation$to$glaucoma$during$the$Nigeria$Blindness$Survey!
Subsets of participants examined 
Parameters 
Normal VA 
“Green cards” 
Normal VA  
“Green cards”  
with suspect discs 
(VCDR >0.6, VCDR 
asymmetry >0.2) 
1 in 7 (Normative) 
“Yellow cards” 
VA <24 letters 
“Red cards” 
FDT 
Screening Yes Yes Yes Yes 
Threshold If failed screening If failed screening If failed screening If failed screening 
Disc assessment 
Clinical on-field Direct funduscopy Direct funduscopy 
SLE Biomicroscopy 
+60D lens
SLE Biomicroscopy 
+60D lens
SLE Biomicroscopy 
+60D lens
Digital retinal 
photos 
(Dilated pupil) 
No Yes Yes Yes 
IOP 
GAT No Yes Yes Yes 
RAPD Yes Yes Yes Yes 
AC angle 
assessment 
Van Herrick’s Angle 
grading 
No Yes Yes Yes 
Gonioscopy 
(Volk’s one-mirror 
non-flanged lens) 
No Yes Yes 
If IOP > 20mmHg; 
VCDR >0.6;  
VCDR difference 
>0.2;
Van Herrick’s
grades 0,1,2
Yes 
If IOP > 20mmHg; 
VCDR >0.6;  
VCDR difference 
>0.2;
Van Herrick’s
grades 0,1,2
VA = visual acuity; VCDR = vertical cup:disc ratio; FDT = frequency doubling technology; SLE = slit-lamp 
examination; IOP = intraocular pressure; GAT = Goldmann applanation tonometry; RAPD = relative afferent 
pupillary defect; AC = anterior chamber.  
!
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!Figure'4i:'Registration+and+interview+of+enumerated+participants!
!
!
!
!
Figure'4j:'Visual'acuity'assessment!using&the&reduced&logMAR&E"chart!
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4.4.2! FDT$visual#field#interpretation!
Visual'field'testing'was'done'on'all'participants'except'where'they'were'unable'to'
do#the#test#for$a$variety$of!psychosocial*and*pathological*reasons.*Where!FDT$
readings)were)not$available,(the(reason(was(noted.(The$screening'test'was#initially#
done%and%then%threshold%test%done%where%indicated%according%to%the%survey%
protocol!!in#the#presence#of#clear#lens#and#clear&cornea!or#glaucomatous#disc#
changes((*(criteria:(VCDR;%VCDR%asymmetry;)optic&disc&notch)'and/or'IOP'>01'
mm"Hg"(as"agreed"by"the"survey'teams).!
!
An#algorithm#for#interpreting#the#visual#field#tests#results#and#identifying#
glaucomatous*field*defects*was*formulated.*The*grading*was*entered*into*
Microsoft)Excel!database,(which(was(merged(with(the(existing(glaucoma(
database.(The"screening"mode"and"the"grading"options"were"entered"separately"
for$the$right$eye$(RE)$and$left$eye$(LE).$!
!
!
!
Figure'4k:!FDT$visual$field$assessment!records'being&sorted!for$interpretation!and$grading!
!
!
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The$following$codes!were$used$for$visual'field'data!entry:!
!. FDT!
!. Done!
!. Not$done!
!
!. If#not#done,#indicate#why!
!. Uncooperative/!cannot%understand/!no"coordination/!alertness/!
unable'to'use'response&button!
!. Visual'axis'opacity'–!corneal(opacity!
!. Visual'axis'opacity'–!cataract!
!. Other&ocular&pathology!
!. Faulty'machine!
!. No#electricity!
!. No#reason#indicated!
!. Other&–!e.g.$home$visit!
!. Not$applicable$(i.e.$if$FDT$done)!
!
!. Screening(mode!
!. C!"–!!
!. C!"–!!
!. Not$applicable!
!
!. Screening(results((RE/LE)(!
!. Normal'!
!. Definitely)glaucoma!
!. Probably(glaucoma!
!. Possibly(glaucoma!
!. Not$likely$glaucoma!
!. Unreliable!
!. Unreadable/illegible+records+!
!. Missing!
!. Not$applicable$(also,$If$threshold$test$reading$available$and$
readable,(skip(and(mark(as(!)!
!
!. Threshold)mode!
!. Done!
!. Not$done$(for$those$that$failed$screening$and$should$have$done$a$
threshold)test)!
!. Not$applicable$(for$those!with%normal%screening%test%or%have%no%
FDTs%done)!
!
!. Threshold)results)(RE/LE)!
Interpreted(at(*(filter(levels(of(reliability(indices:(level(5,(level(7,(level(8(
(see$details!below)!
!. Normal'!
!. Definitely)glaucoma!
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!. Probably(glaucoma!
!. Possibly(glaucoma!
!. Not$likely$glaucoma!
!. Unreliable!
!. Unreadable/illegible,records,!
!. Missing!
!. Not$applicable!
!
!. Threshold)reliability)level!
!. No#errors#on#reliability#indices! !%!errors!
!. !!error$on$reliability$indices!! !"%!errors!
!. !!errors%on%reliability%indices! !!%!errors!
!
The$following$criteria$and$parameters(were(used(for(definitions(of(normal(result(
and$failed$screening.!
!)!Normal'screening'result'!
!. No#defects!
!. !!or#!!defects'at'p<!%!
!. !!defect&at&p<!.#%!(only&C!""!!has$this)!
!. !!or#no#false#positives!
!. !!or#no#fixation#errors!
!
!)!Failed'screening'test'–!(to#have#threshold#test)!
!. !!or#more#defects#at#p<!%!
!. !!or#more#defects#at#p<!.#%!(only&C!""!!has$this)!
! ! ! ! ! ! !
!)!Unreliable%screening%result!
All#visual#field#testing#equipment#depends#on#the#person#being#tested#having#
the$ability$to$hold$steady$and$on#central!fixation,!as#poor#fixation#can#lead#to#
unreliable)results.)Based)on)the)FDT)machine)recommendations,)the)
following(levels(of(reliability(indices(were(recorded(as(unreliable(and(
therefore,(the(FDT(result(was(not(graded:!
!. Fixation(errors(>!!/#!
!. False&positives">!!/#! ! ! *"!!%!failed'reliability'indices!
!. Brow/Lid)positions)at)lower)or)upper)edges!
!
Three%levels%of%reliability%were%acceptable%and%noted%in%the%grading%of%the%FDT%
threshold)results)(Nos.)!!to#!!below):!
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!)!Threshold)Level)!!reliability!! *"#%"No"errors"on"reliability"indices!
!. No#Fixation#errors#!
!. No#False#positives#!
!. Brow/Lid)positions)at)lower)or)upper)edges!
!
!)!Threshold)Level)!!reliability! ! *"!"%!errors%reliability%indices!
!. Fixation(errors(!!or#none!
!. False&positives&!!or#none!
!. Brow/Lid)positions)at)lower)or)upper%edges!
!
!)!Threshold)Level)!!reliability!! *"!!%!errors%on%reliability%indices!
!. Fixation(errors(!!or#less!
!. False&positives&!!or#less!
!. Brow/Lid)positions)at)lower)or)upper)edges!
!
!)!Unreadable/illegible,tracings,were,recorded,as,such,,and,were,therefore,,
not!graded.!
!. Cannot&see&margins&of&box!
!. Defects'seen'but'cannot'assess!
!. All#tracings#faded!
!
!)!Missing&results&were&noted&where!
!. FDT$sheet$could&not"be"found!but!FDT$marked$as$done!
!
!)!Grading(for(Abnormal(Results!
The$records$of$threshold$tests$were$assessed$for"defects"that"would"increase"
the$certainty$of$glaucoma$diagnosis.!
!
Age"matched(normal(probability(results(are(same(for(all(threshold(tests.!
!. Grading(was(on(the(defects(on(the(Pattern(Deviation(Probability((PDP)(
plot!
!. Compared)with)Total)Deviation)Probability"(TDP)"plot!
!
The!factors(considered(in(defining(defects(were(!
!. Positions'of'defects:'edge'or'not!
!. Depth&and&size&of&defects!
!. Clustering+of+defects:+adjacent+or+not!
!. Repeatability;+if+defect+is+at+same+location+on+TDP+and+PDP+plots!
!
!
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4.4.3! Disc%parameters%(images$and$clinical$assessment)!
To#determine#the#VCDR,"disc"assessment"was"by"direct"funduscopy"in"those"with"
normal'VA;'stereo"biomicroscope*funduscopy*with*+45D*aspheric*lens!and$
digital'image'reading'in'those%with%VA%<,/./%and%every%“."in"!”;$and$all$)$methods%
in#those#with#normal#VA#“green#cards”#with#suspect#discs#(see"Table&'.)).!
!
!
!
!
Figure'4l:!Slit"lamp%biomicroscope%funduscopy%with%+60D%aspheric%lens!
!
!
All#images#were#graded#at#the#MEHRC.#This#was#considered#the#gold#standard#
and$was!used%for%analysis."However,"in"participants"whose"retinal"images"were"
not$taken$or$were$ungradable,$the$clinical$records,$where$available,$were!used%for%
glaucoma(diagnosis.(To#corroborate#the#clinical#and#image#VCDR$readings,$the$
agreement(between(the(measurement(by(stereo"biomicroscope*funduscopy*and*
digital'image'analysis'was'determined'(see'Chapter'3)."!
!
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MEHRC&grading:&For&the&whole&dataset,&the&discs&were&classified&as&glaucomatous&
or#non"glaucomatous*based*on*the*0.2*VCDR*rule.*Some%large%cups%without%
glaucomatous*changes$were$classified$as$not$glaucomatous.$For$the$“)"in"!”#
normative*dataset,*all*images*were*extracted*and*re"read%to#indicate#the#specific#
VCDR$values.$The$VCDR$readings$on$this$data$subset$were!used%to%determine%the%
!".$th!and$%%.'th!percentile)values!VCDR!for$the$normal$population,$which$were!
used%in%the%glaucoma%diagnosis%for%Level%4%and%Level%5!evidence,"respectively.!
4.4.4! Intra"ocular'pressure'(IOP)!
The$IOP$was$measured$by!Goldmann(applanation(tonometry(for(participants(
with%VA<)/+,%in%either%eye,%the$“&"in"!”#normative#subset#and#those#with#normal#
VA#with#VCDR$>!.#.""!
!
The$normative$subset$was$used$to$determine$the$22.4th!percentile)IOP)value!for$
glaucoma(diagnosis(at(Level(1(and#for#where#expert#opinion#would!be#needed#to#
adjudicate)(Level)!b).$!
!
!
!
Figure'4m:!!Goldmann(applanation(tonometry(on(a(participant(at(the(Nigeria(Blindness(Survey!
!
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4.4.5! Glaucoma'diagnostic'algorithm!
To#make#the#diagnosis#of#glaucoma,#a#diagnostic#algorithm#(Figure'(n)"was"
developed'based'on'the'ISGEO'definition'and'classification(of(glaucoma(in(
prevalence)surveys.!!The$parameters$needed$include$the$appearance$and$size$of$
the$optic$discs/cup,$IOP,!and$whether$there$were#characteristic#defects#in#the#
visual'fields.'The$presence$of$features$suggestive$of$damage$due$to$the$disease,%
such%as%disc%haemorrhage%and%notching,%and%relative%afferent%pupillary%defect%
were$also$considered$in$glaucoma$diagnosis.$!
!
The$“&"in"!”#participants#who!had$full$ocular$examination$regardless$of$their$
presenting)VA)formed)the)normative)dataset)for)analyses'to'produce'the'normal'
percentile)values)for)the)parameters)required)for)the)diagnosis)of)glaucoma.)Of)
these,&participants&who!had$both$VCDR$grading$on$retinal$image$readings$and$
normal'visual'fields'in'both'eyes'were'regarded'as'the'normal'population#for#
calculation)of)the)VCDR$and$VCDR$asymmetry$percentile$values.$$Participants$
who!had$IOP$readings$and$normal$visual$fields$in$both$eyes$generated$the$
percentile)values)for)IOP)in)the)normal)population.)!
!
!
!
! !
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Figure'4n:!Glaucoma(diagnostic(algorithm!
!
VCDR%=%vertical%cup:disc%ratio;%VA%=%visual%acuity;%IOP%=%intraocular%pressure;%FDT%=%frequency%doubling%technology;%RAPD%=%relative'afferent'pupillary'defect.!
Level%3
Level%1
Level%2 Level%2b
IOP
RAPD
Type+of+glaucoma
ALL
Disc+graded+in+at+least+one+eye
Digital+photo+images
Pattern+threshold+FDT+fields+not+
done
Definite%glaucoma
Indicate+why+no+
VCDR/photos
VCDR+>0.6+and/or+asymmetry+>0.2,+
and/or+notch,+and/or+disc+haem+in+
one+or+both+eyes+
VCDR+>+97.5th+centile
Glaucoma+if+disc+is+cupped,+
VCDR+>99.5th+centile
Not+sure;+not+done;+poor+
reliability
Expert+opinion+to+adjudicate
Review+digital+fundus+images
4+or+more+defects+seen+at+P<5%
3+or+more+defects+at+P<2%
2+or+more+defects+at+P<1%
1+or+moredefects++at+P<0.5%
at+any+location,+in+any+hemifield
Yes%No%
Definite%glaucoma
VA+<3/60+
and
Gonioscopy
VCDR+<0.6+and+no+asymmetry,+
notch+or+haemorrhage+in+both+
eyes
Not%glaucoma
All+points+seen
or+1+or+2+nonVadjacent+defects+
at+P<0.5%,+or+1+at+P<0.2%
Also+FDT+fields+assessed+for+
Probably+glaucoma;+and+
Possibly+glaucoma
Not+glaucoma
on+medical+treatment+for+IOP
Otherwise+not+glaucoma
Expert+opinion+to+adjudicate
IOP+>99.5th+centile
or+evidence+of+surgery,+or
Pattern+threshold+FDT+fields+
available
or
SupraVthreshold+FDT+fields+
available
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4.4.6! Data$management!
Data$of$the$Nigeria&Blindness&Survey,"from%all%examination%sites,!relevant(to(
glaucoma(were!extracted.)Grading)of)the)retinal)images)were!entered&on&
Microsoft)Excel!at#MEHRC.#Data#cleaning#of#the#images#was#done#to#resolve#
conflicts)in)image)labelling.)Visual)field)interpretation)and$grading$results&were&
also!entered&in&Microsoft&Excel."These"datasets"were!merged&and!transferred)to)
STATA/IC'((.*!(Stata%Corp,%College%Station,%Texas,%USA)!using&stat&transfer&to&
form%a%single%database%that%was!used%for%the%analysis%of%the$Nigeria$Blindness$
Survey!data!using&this&software!and$its$subsequent$upgrades!(STATA%&'.)).""!
!
The$diagnosis$of$glaucoma$in$prevalence$surveys$according$to$the$ISGEO!
classification!!was!applied."The$glaucoma$defining$centile$values$for$the$4$ocular$
parameters((VCDR,(VCDR(asymmetry!and$IOP)$were$derived$from$a$normative$
subset&of&these&data.&The$data$were!analysed(to(estimate(the(prevalence(and(
magnitude*of*glaucoma*and*glaucoma*blindness*in*the*study*sample*and*
extrapolated*to*the*population.*The*types*of*glaucoma*were!determined(by"the"
gonioscopy)findings)as)open)angle)glaucoma((OAG)(or#angle"closure(glaucoma!
(ACG);"and"classified"by"the"absence"or"presence"of"an"underlying"cause"into"
primary'or'secondary'glaucoma,'respectively.''!
!
Risk%factors%for%OAG!and$for$blindness$among&adults"with"glaucoma"were!
determined(by(socio"demographic,characteristics,such,as,age,,sex,"ethnicity,"
geographical+location,+place&of&residence,&socio"economic'status,'and'literacy'
levels;&by&ocular/morphological&parameters&such&as&ocular&axial%length,"mean%
ocular%perfusion%pressure!and$IOP;$by#type#of#glaucoma;#and$by$systemic$
attributes)such)as)high)blood)pressure,)hyperglycaemia)and)body)mass)index.!!
!
4.4.7! Data$chapters)in)relation)to)this)aspect)of)the)study!
Chapter(5!"!Nigeria'normative'data'for'defining'glaucoma(in(prevalence(surveys!
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Chapter(6!"!A"population"based&survey&of&the&prevalence&and&types&of&glaucoma&in&
Nigeria:(The(Nigeria(National(Blindness(and(Visual(Impairment(Survey!
Chapter(7!"!Agreement(in(measurement(of(optic(cup"to"disc%ratio%with%stereo!
biomicroscope*funduscopy*and*digital*image*analysis.*Results*from*the*Nigeria*
National(Blindness(and(Visual(Impairment(Survey!
Chapter(8!"!Risk%factors%for%open"angle&glaucoma&in&Nigeria:&Results&from&the&
Nigeria'National'Blindness'and'Visual'Impairment'Survey!
Chapter(9!"!Ethnicity(and(deprivation(are(associated(with(blindness(among(adults(
with%primary%glaucoma%in%Nigeria.%Results%from%the%Nigeria%National%Blindness%
and$Visual$Impairment$Survey!
!
!
!
!
!
! !
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4.5! Part%2%–!Glaucoma'care!by#ophthalmologists!
Purpose:)to#describe#how#ophthalmologists#currently#manage#glaucoma,#and#the#
constraints)they)face!
!
This%component%of%the%thesis!examined!Nigerian(ophthalmologists’!practice(
patterns(for(glaucoma(management(including(their&knowledge&on&cost%of%therapy.%
It#determined!what%ophthalmologists%do%to%make%a%diagnosis%and%how%they%treat%
glaucoma.)Quantitative)data)was!obtained)from)practising$ophthalmologists$in$
Nigeria'who'were!given&self"administered*questionnaires*to*complete.*!
!
!
4.5.1! Questionnaires+completed)by)practising$ophthalmologists!
Participants*involved*and*methods*of*recruitment*were*in*the*following*order:!
!. The$databases$of$the$ophthalmological$society$of$Nigeria$(OSN),$tertiary$
institutions'and'the$postgraduate$ophthalmology$training$colleges$were$used$
to#recruit#the#participants.!
!. The$participants$were#all#practising$ophthalmologists/ophthalmic$surgeons$
qualified)by)either)the)fellowship)or)diploma)programmes.!
!. Self"administered*questionnaires*(Appendix(!)"for"collection"of"quantitative"
data$were$distributed$and$collected'at'the'annual'OSN'conference'held'in'
September(!"#"$and$by$personal$delivery$to$those$in$the$same$locality$as$I.$!
!. Subsequently,,questionnaires,were,distributed,and,returned,by,email.!
!. Some%ophthalmologists%completed%the%questions%through%telephone!interview(
conducted(by(the(research(assistant((MM).!
!
Information*about*the*survey*and*request*for*informed*consent*(Appendix(!a)"
were$distributed$together$with$the$questionnaire.$!
!
Data$collected!included:!
!. Personal/demographic1data1of1respondents!
!. Professional/training*background!
!. Place&of&practice,&type&of&eye&care&facility&and&subspecialty&training!
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!. Care%pathway%and%access%to%eye%care%facility%by%glaucoma%patients.%!
!. Equipment*for*glaucoma*diagnosis*and*treatment*–!available/functional.!
!. How$glaucoma$is$being!diagnosed.!
!. How$glaucoma$is$being$treated.!
!. The$types$and$number$of$glaucoma!surgeries'done'in'a"#"month&period!and$
compared)to)number)of)cataract)surgeries)done.!
!. The$frequency$of$glaucoma(surgical)treatment)offered)as)a)primary)option)and)
compared)to)medical#therapy.#!
!". Recommended(treatment(and(acceptance(rates(for(treatment(recommended.!
!!. The$availability$of$a$recommended$standard$protocol'of'glaucoma'care'in#the#
eye#care#facility.!
!". The$availability$of$patient$counselling!for$glaucoma$patients$(routine$or$on$
request)'in'the'facility.!
!". Follow"up#arrangement#and#request#for#first"degree%relatives%examination.!
!". The$cost$and$availability$of$glaucoma$medications.!
!". The$cost$of$glaucoma$surgery.!
!". Physicians’!challenges/fears:-training,-post"op#care,#uncertain#post"op#results,%
patient'acceptance'of'surgery,"etc.!
!
!
4.5.2! Data$management!
Data$collected$for$ophthalmologists’!practice(pattern(were(entered(in(Microsoft(
Excel&'()),&transferred)to,)and)analysed)with)STATA)!".$%(Stata%Corp,%College%
Station,(Texas,(USA)."Simple"descriptive'analysis'was$undertaken!along&a&
systems"oriented(approach(to(determine(the(pattern(of(practice(of(
ophthalmologists+for+glaucoma+care.!
!
4.5.3! Data$and$linking$chapters)in)relation)to)this)aspect)of)the)study!
Chapter(10!"!Ophthalmologists’-practice-patterns'and'challenges'in'achieving'
optimal(management(for(glaucoma(in(Nigeria:(Results(from(a(nationwide(survey!
Chapter(11!"!Managing&a&patient&with&open"angle&glaucoma:&a&case&study!
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4.6! Part%3%–!Access$to$glaucoma$care$and$community!awareness,(
knowledge!and$attitude!regarding(glaucoma!!
Purpose:)To#determine#why$people$with$glaucoma$present$late$for$treatment!and$
what%the$community$and$patients!with%glaucoma!know,!do!and$think!about&
glaucoma!
!
Qualitative)methods)were!used%to%identify%the%level%of%public%awareness&and&
patients’)knowledge,)attitudes)and)beliefs)about)glaucoma.)This%component%of%
the$study$sought$to$determine:!
!. Community/patients’.perceptions.and.awareness.of.glaucoma.!
!. Care"seeking'behaviour'of'participants'in'terms'of'what'they'do'when'they'
have"symptoms"of"eye"disease/blindness"particularly"glaucoma.!
!. What!triggers'patients'to'seek'treatment'for'glaucoma/visual'
impairment/blindness.!
!. The$factors$that$delay$presentation$at$the$appropriate$health$facility.!
4.6.1! Participant)recruitment)and)data)collection(methods!
The$qualitative$study$involved!various(methods:!
!. Focus&group&discussions&(FGDs)!with%participants!in#four%selected!
communities."This"included!their&positive&experiences,&as&well&as&the&barriers&
they%experienced%to%accessing%eye#health&care.!
!. In"depth&interviews&(IDIs)"with"blind"persons"in"the"community"who!had$not$
accessed&treatment&or&had!not$had$successful$treatment;$preferably$glaucoma$
cases.&This&took!a"narrative"approach;"e.g.$“tell%me%about%your%blindness…”!
!. Direct!observations+(DOs)"of!blind&persons&in&the&community.&This&involved!
observing$blind$persons$to$note!how$their$day"to"day$lives$are$affected.!
!. Exit%interviews%(EIs)&for$glaucoma(patients(seen(by(ophthalmologists!in#the#
two!participating)hospitals.)They)were!asked&to&narrate&their#experience#of#
their&hospital&visit&and&what&they&felt&about&the&diagnosis&and&treatment.&!
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Purposive*sampling*method*was!employed(to(select(four%communities%and%
participants)for)the)FGDs)and)IDIs."Two"communities"were"selected"in"the"same"
State%as%each%of!two$selected$hospitals.$Selection$was$based$on$rural/urban&
residence,)and)practical)and)logistical)consideration)for)the)research)team)in)
terms&of&ease&of&access&and&language&of&communication.&Language&spoken%was%a%
key$consideration!so#that#the#discussions$could!be#conducted/moderated#without#
the$need$for$an$interpreter;$in$order$to$be$as$close$to$the$data$as$possible.!
!
For$the!FGDs!in#the#community,"!"#to#!&#participants#in#a#group#were!invited'and'
informed)of)the)date,)time)and$place$of$the$meeting."Participants)invited!were:$
the$community$leader,$community$health"worker!(if$any),$and$visually$impaired$
and$normal$sighted$residents$of$the$community.!
!
For$the$IDI,$visually$impaired$and$blind$participants$in$the$community$were$
selected,(some(of(who(had(DO.!!
!
Patients(in(the(care(system(were!recruited(from(the$two$selected!participating)
hospitals!for$EIs.!A"designated"focal"person"in"the"hospitals"selected"the"
participants)for)the)EIs.!The$inclusion$criteria$were:$$glaucoma$patient$aged$56$
years&and&above,&undergoing(treatment(and(having(just(seen(a(doctor(in(the(
clinic.!
!
The$data$collection$instruments$used%were#!
• Information*sheets!
• Consent'forms!
• Introductory*information!
• Data$collection$forms$for$demographics$of$participants!
• Topic&guide!
• Note"taking'forms:'labelling&of&participants&!
• Probe&for&questions!
• Voice"recorder!
• Camera!
• Check"list!
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!
Figure'4o:'A"participant"expressing"her"views"in"a"focus"group"discussion!
!
!
!
!
Figure'4p:'Focus&group&discussion&involving&men&aged&25&years&and&above!
!
! !
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4.6.2! Topic&guide!
The$development(of(the(topic(guide(was"based"on"the"conceptual*framework!that$
knowledge,*attitude*and*understanding*would*influence*early*diagnosis*and*
treatment'of'glaucoma.'The'topic'guide!included!a"series"of"questions"that"would"
bring&out&the&potential$factors.%The$three!components)of)disease)perception)and)
awareness'(knowledge,+attitude+and+practice)+were!explored.!The$probing$
followed'issues'that'arose#in#the#discussions:!
• Explore(knowledge(and(practice(!
• Explore(perception(of(glaucoma(risk:(is(it(serious,(treatable,(can(it(resolve(
on#its#own!
• Determine(the(concept/understanding(of(blindness:(at(what(stage(of(vision(
to#call#someone#blind;#known#causes#!
• Perception*of*health*facility*process!
• Perception*of*eye*examination*and*diagnosis!
• Perception*of*treatment*of*eye#diseases,#particularly#glaucoma,#and#
surgery!
• Knowledge)of)eye)health)education)and)awareness)carried)out!
• Triggers'that'lead'to'seeking'treatment!
!
Themes&and&guide%questions!
Knowledge:*!!
• Is#the#disease#recognised?!Have%you%heard%about%the%disease%before!your%
diagnosis?!
• Do#local#names#exist?#For#cataract#or#glaucoma!
• Knowledge&about&the&concept&of&IOP!
• Knowledge)about)the)familial)tendency.!Do#you#know#about#risks#for#family#
members!
• Knowledge)about)the!disease&onset&and&bilaterality!
• Is#the#condition#known#to"be"a"cause"of"visual"impairment"and"blindness?!
!
Attitudes:! !
• Where%to%find%care.!
• Is#the#condition#considered#serious?#!
!
!
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Practice:! !
• Are$there$traditional$medicines$for$it?!
• Use$of$eye$drops;$instillation;$its$purpose$and$importance!
• Surgery'–!types,'acceptance$and$purpose!
• Do#they#access#available#care?!
• Timing&of&presentation&to&an&eye&care&facility&!
• What%are%the%triggers%for%seeking%medical%care?!
!
Perception*of*risks:*!
• Is#glaucoma#serious?!
• Is#it#treatable?!
• Can$it$resolve$on$its$own?!
• Do#you#consider#it#as#a#cause%of%blindness?!
!
Concept(and(understanding(of(blindness:!
• At#what#stage#of#vision#loss#do#you#consider#someone#to#be#blind?!
• Known%causes%of%blindness!
• Diminishing(vision(part(of(ageing!
!
Perception*of*health*facility*processes:!
• How/where(to(access(care!
• Who!is#to#give#treatment!
• Triggers'to'seeking'treatment!
• Possible(causes(of(delay(in(seeking(treatment!
!
Perception*of*eye*exam*and*diagnosis:!
• What%makes%you%go%for%an%eye%exam!
!
Perception*of*treatment*of*eye*diseases:!
• Especially*glaucoma*and*surgery!
• What%can%be!cured&–!can$vision$be$restored$in$glaucoma!
• Purpose(of(surgery!
• When%to%have%eye%surgery!
!
Knowledge)of)eye)health)education:!
• Know%any%awareness%programme%being%carried%out!
• Radio&and&other&media!
• At#hospital(waiting(lounge!
• In#the#community!
• Key$source$of$information'about'glaucoma!
!
Cost:! ! !
• How$much$spent!
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• Direct'cost'–!medicines,)surgery!
• Indirect)costs!
• Opportunity*cost!
!
For$IDIs!and$EIs,"we#added#the#following:!
Experience)and)expectations)in)hospital!
Interventions*tried*before*coming*to*hospital!
What%do%they%do%when%they%have%visual%symptoms?!
Positive(experiences!
Barriers'they'experience'to'accessing'healthcare!
Narrative:)“tell)me)about)your)disease/visual)impairment/blindness…”!
Do#you#know#about#risk#for#family#members?!
Have%you%asked%any%first"degree%relative%to"go"for"eye"examination?!If#not,#why#
not?!
!
For$DOs,"our"checklist"of"observations"included:!
How#they#interact#with#their#family#and#members#of#the#community;#!
How#members#of#the#community#or#anyone#that#visited#approached)and)related)
with%them;!!
How#independent"they"are"in"terms"of"mobility;!
How$they!use$day"to"day$gadgets$such$as$mobile$phones$and$telling$the$time$on$
their&watches.!
!
!
!
! !
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!Figure'4q:'A!participant(sobbing(as(she(gives(her(account(of(living(with(glaucoma(!
!
!
!!
!
Figure'4r:'A"directly!observed!participant$in$his$home$answering$a$phone&call&! !
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4.6.3! Data$collection$process!
For$the$FGDs,"IDIs"and"DOs"in"the"community,"we#obtained#permission)from%the%
community)leader."The$community"based&health&workers&(fieldwork&assistants)&
identified'the'communities%and%participants%and%a%suitable%venue%for%the%
discussions.)Participants)were)invited)on)the)day)of)the)interviews.)Information)
(Appendices!!b"or"%c;"as"indicated)"were"given,"read"and"explained;"and"informed"
consent'was'obtained'(Appendix()).#The$participants(for(the(IDI(and$DO$were!
identified'at'the'time'of'the'initial'visit'to'the'community,'a'day'before'the'data'
were!collected.(However,(they(were!informed)only)at)the)time)the)interviews)took$
place.'The'IDI'and'DO!took$place$in$the$participant’s!usual"environment,"mostly'
their&home&in&the&morning.&!
!
For$the$patients’$exit$interviews,"the"permission"to#conduct#interviews#was!
obtained)from)the)hospital)authorities.)On)the)day)of)the)interviews,"the"focal!
doctor&in#the#hospital#selected!patients(based(on!the$inclusion$criteria.$They$were!
invited'for'the'discussion'and'information'(see#Appendix()d)"regarding"the"study"
was!given&and&written&informed&consent&obtained!from%them!(Appendix(!).#The#
meetings!took!place&in&a&quiet&meeting&room&in&or&around&the&clinic$area.$$!
FGDs!lasted#about!!"hour"'("minutes:"introductions/ice"breaking)*+)minutes;)
discussion()*(minutes,(rounding(up/summary(5*(minutes(and(contact(summary(
!"#minutes.#On#arrival,#participants#were!welcomed;"the$group$was!seated&in&a&
circle&and&demographic'information'taken.'Each'was!given&a&label&for&
identification*and*note"taking'purposes."For$all$interviews,$participants)were!
assured'that'they'could&stop&the&discussion&at#any#time!if#they#did!not$wish$to$
participate"and"that"the"tape"recorder"would!be#switched#off.#The#recording!was$
then%begun"and"the"facilitator"followed!the$topic$guide$to$develop$the$discussion.$!
!
The$meetings!included!introductions,*information*about*FGD/IDI/EI,"obtaining"
informed)consent,)ice"breaking)activities)for)a)few)minutes,#topic#guide#
discussions,)closing)remarks)and)debriefing.)All#discussions#were#audio"recorded.!
!
A"checklist"of"some$key$elements$of$the$interviews$were:!
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Introduction!
• General'purpose'of'the$study!
• Aim$of$interview/discussion!
• Expected(duration!of#interview!
• Who$is$involved!
• Cooperation*is*important!
• Information(to(be(collected!
• How$information$will$be$of$benefit!
• Any$questions$can$be$asked!
• Consent'obtained!
!
Warm%up!
• Demographics:.Tell.us.about.your.name,.age,.work.you.do!
• Know%any%persons%with%difficulty%in%seeing%or#with#eye#disease?!
• What%is%remarkable%about%them?!
!
Closing(remarks!
• Is#there#anything#you#think#is#important#that#we#have#not#talked#
about?!
• Summarise!
• Thank&participants!
• Provide(extra(information(and(key(contacts(to(participants!
!
! !
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!!
Figure'4s:'In"depth&interview(with(a(participant(in(her(home(!!
!
!
!
Figure'4t:'Conducting*an*exit*interview*with*a*patient*in*the*hospital!
!
!
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4.6.4! Recruitment*and*training*of*field*assistants!
Recruitment*and*training*of*field*assistants&were!undertaken)before)the)
commencement'of"data"collection."The"following"field!assistants!were$involved(in(
the$qualitative$study:"a"research"assistant"who"also"facilitated"some"interviews,"
two!senior'community)ophthalmic)nurses!experienced)in)community)public)
health&awareness&and&education,&a&medical&social&welfare&officer&involved&in&
counselling*for*glaucoma*patients!and$two!community"based&rehabilitation&
officers."!
!
Training'of#field#assistants!addressed!overview'of'the'study,'aim'and'objectives,'
procedures,*participant*recruitment*and*interview/discussion*techniques*and*
possible(challenges(and(how(to(overcome(them.(It(also(addressed!issues%on%
standardisation)of)data)collection,)quality)control)of)data)collected)and)skill)
acquisition*for*qualitative*methodology.!
!
!
4.6.5! Data$management!
Identification&of&study&participants,&data&collection&and&data&entry&were$done!by#
the$study&personnel&only.&Data&was!accessible(only(to(study(personnel."They"had!
access%to%only%the%data%that%they%were%involved%in%collecting%at%the%time%of%the%
interviews."The"data"collected'were!entered&into&an&anonymous&database&with&
study&numbers&as&identifiers.&The&original&data&collection&forms&and&voice&data&
recordings*of*the$interviews$would!be#archived#for#-.#years!("#$"%–!!"!!).!
!
Audio"recorded!data!were!translated)(where)applicable),!transcribed+and+entered+
into%NVivo.%Data%obtained%from%one%FGD%was!regarded&as&one&set&of&data&even&
though&a&number&of&people&gave#varying#responses.#Responses#of#interest#were!
quantified*and*patterns!of#views#identified.#!
!
The$data!were$analysed!using&the&directed&approach&to&qualitative&content&
analysis'to'extend'the'theoretical'framework'of'the'glaucoma'care'pathway.'The'
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three%main%themes%were%knowing%glaucoma,%reaching%a%diagnosis%of%glaucoma%
and$accessing$continued$care.!Additional)codes)were!applied'to'identify'lived'
realities(and(coping(mechanisms.(!
!
In"terms"of"interpretation,"we"looked"at"what"would"explain"these"themes"and"
identified'structural'violence!,#$!that$could$be$causing$people$to$be$in$the$
situation(of(lack(of(access(to(care.!!
"
"
Categories*coded*at*NVivo*nodes!"
There%were%'!main%themes:!
!. Knowing'glaucoma!
!. Reaching)a)diagnosis)of)glaucoma!
!. Accessing(continued(care!
Some%categories%straddle"between"the"three!concepts.!
!
‘Knowing(glaucoma’!categories:!
!. Misconceptions*on!causation)of)eye)disease$–!e.g.$in$bilateral$disease,$
treatment'of'*st!eye#affects#the#*nd!eye#with#the#same#disease.!
!. General'lack'of'knowledge'and'information'about'the'disease'–!little%
knowledge)on)causes)of)eye)disease!
!. Lack%of%access%to%information!
!. General'lack'of'awareness"of"the"disease!
!. Use$of$alternate$nonmedical$care!
!
!‘Reaching*a*diagnosis’!categories:!
!. Why$aren’t$people$coming$for$care,$for$treatment!
!. Wait%for%funding!
!. Physical)access)to)healthcare)–!how$the$blind$and$visually$impaired$get$
to#treatment;"distance"to"appropriate(healthcare(facility!
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!. Trust&issues&for&the&health&system&–!e.g.$frequent$tests$not$understood$
by#patient!
!". Cost%of%finding%care%–!Hopping'and'hoping!
!!. Waiting'for'patients'to'come'to'the'hospital'!
!
‘Accessing)continued)care’)categories!
!". Cost%of%purchasing!care%"!Medicines(and(surgery!
!". Debt%–!contributes+to+structural+violence!
!". Hierarchical)characteristics)of)the)doctor"patient'relationship,'one"way$
communication!–!e.g.$no$courage$to$ask$for$explanation!
!". Unrealistic+biomedical+instructions!–!not$aware$to$use$medicines'for'a'
long%time%and%didn’t%follow"up#so#didn’t#continue#with#medicines!
!". Clinicians(and(the(difficult(situation(they(live(in,(enormous(
responsibilities;"and"expectations"from"others!
!". Doctors'still'don’t'know'the'best'way'to'communicate'–!(best&to&have"
trained(personnel(do(this)!
!". How$to$support$the$doctors$better$to$practice$better$–!e.g.$resource$
allocation!
!". Doctors'overworked'and'too'busy'to'explain'to'patients!
!". Hospital)visit)experience)"!language'barrier'(speak'English)(at(hospitals!
!". Constraints)in)the!health&system!
!!. Fear%of%the%effect%of%vision%loss!
!". Coping'mechanisms'–!ability'to'accept'consequences'based'on'
information)provided!
!". When%people%do%understand%that%all%we%can%do%is%to%stop%progression.%
Glaucoma(vision(loss(is(irreversible.!
!
Other&codes!
!". Physical#fatigue!
!". Financial'stress!
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!". Burden'on'the'family!
!". Unwillingness)and)not)being)able)to)talk)about)their)disease!"!What%
can$be$talked$about,$what$cannot$–!e.g.$says$she$doesn’t$want$to$talk$
about&it!
!". Relationships,–!with%siblings,%neighbours!
!". Emotional)component!–!e.g.$kept$crying!
!". Self"blame;'have'to'make'own'effort;'language'barrier'(speak'english)'
at#hospitals;#poor#follow"up!
!
The$%&!categories*coded*at*NVivo*nodes*were*reduced*to*the*following*essential*
points'for!interpretation)and)discussion:!
!
Knowing'glaucoma!
!. Known%symptoms!
!. Few$ocular$symptoms$–!mostly'general,'not'specific!!
!. Triggers'to'seeking'care'!
!. Visual'symptoms'not'noticed'until'late!
!. Visual'field'deficits(–!linked'to'disease'on'hindsight!
!. As#a#cause#of#blindness#–!“silent(thief”(quote!
!. General'lack'of'knowledge'and'information'about'eye'diseases'and'glaucoma!
a. Poor$access$to$information!
• Where%obtained%–!mostly'only'radio!
• How$information$obtained!
• Inadequate)information!
• What%is%needed!
!
Reaching)a)diagnosis)and)continued)care!
!. Cost%of%care!
b. Finding&care&"!hopping"and"hoping!
c. Purchasing"care"–!meds,&surgery&etc.,!and$debts,!amount'spent!
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d. Waiting'for'patients'to'come'to'hospital!
!. Hospital)visit)experience!
a. Physical)access)to)healthcare)"!how$the$blind$and$visually$impaired$get$to$
treatment!
b. Language'barrier'"!speak&English$in$hospitals!
c. Information*on*diagnosis*and*treatment!
d. Accepting)treatment'options'as'advised!
e. Unrealistic"biomedical"instructions;"and"compliance*to*treatment!"!e.g.$not$
aware%to%use%medicines%for%a%long%time%and%didn’t%follow"up#so#didn’t#
continue(with(medicines!
f. Dr/healthcare*worker"patient'relationship!
• Hierarchical!characteristics)of)doctor"patient'relationship'–!e.g$one"
way$communication,$no$courage$to$ask$for$explanation!
• Clinicians!and$the$difficult$situation$they$live$in$–!enormous(social(
responsibilities,&expectations&from&others!
• Doctors!still%don’t%know%the%best%way%to%communicate%or%doctors%
overworked(and(too(busy(to(explain(to(patients(–!best%to%have%trained%
personnel(to(do(this((quotes(of(when(done)!
• How!to#support#the#doctors#to#practice#better#–!e.g.$resource$
allocation,)provision)of)equipment!
g. Trust&issues&and&constraints&in&the&health&system!
• E.g.#felt#as#being#held,#not#being#cured#and#still#not#being#referred#to#
appropriate(place(of(care!
!". Treatment(of(glaucoma(!!
a. Making'choices:"Influenced(by:(severity,'age,'relatives!
b. Difficulty)in)appreciating)the)threat)of)future)sight)loss)without)treatment!
c. Agency'–!ability'to'make'autonomous'decisions!
d. Unable'to'make'informed'choice'of'treatment'and'continued'care,!e.g.#
advice'they'could'not'accept!
e. Misconceptions"of"causation"of"eye"disease"–!e.g.$in$bilateral$disease,$
treatment'of'*st'eye'affects'the'/nd'eye'with'the'same'disease.'!
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f. Use$of$traditional)eye)medication)(TEM)!
!
Lived&realities&and&coping&mechanisms!
!!. Fear%of%sight%loss!
a. Fear%of%the%effect%of%vision%loss!
b. Emotional)component)–!e.g.$kept$crying!
c. Unwillingness)and)not)being)able)to)talk)about)their)disease)"!What%can%
be#talked#about,#what#cannot#–!e.g.$says$she$doesn’t$want$to$talk$about$it!
!". Loss$of$economic/social$productivity!
a. Employment/retirement-and-work!
b. Inequality)and)being)left)out)in#socialisation!
c. Self"esteem%–!feeling'of'failure,'indignity'and'loss'of'value'to'
family/community!
d. Relationships,with,family,and,neighbours!
e. Physical)fatigue!
!". Financial'stress!
a. Looked&after!
b. Wait%for%funding!
!". Coping'mechanisms!
a. Faith;!Family'support!
b. Ability'to'accept'consequences'based'on'information'provided!
c. When%people%understand%that%all%we%can%do%is%to%stop%progression.%
Glaucoma(vision(loss(is(irreversible.(Gradual(loss(of(vision(–!coming'to'
terms&with&it?!
d. Family'–!burden'on'family;"family"care!
e. For$carers:$benefits$of$assisting$"!Improves)bonding,)Improves)self"esteem,&
Altruism,*Feel*good!
f. Relationships!
g. Self"blame;'have'to'make'own'effort;'poor'follow"up!
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!". Other%issues!
a. Why$aren’t$people$coming$for$care,$for$treatment?!
b. They%do%not%feel/know%it%is%their%right%to%access%care!
c. No#bargaining#power!
d. Biological(citizenship(–!e.g.$glaucoma$patient$association!
!
!
4.6.6! Data$chapters)in)relation)to)this)aspect)of)the)study!
"
Chapter(12!"!So#let#me#find#my#way,#whatever#it#will#cost#me,#rather#than#leaving&
myself'in'darkness:'A'perception'and'behaviour'study'on'glaucoma'care!
!
!
!
!
!
!
! !
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Nigeria Normative Data for Defining Glaucoma
in Prevalence Surveys*
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ABSTRACT
Purpose: To determine normative values for defining glaucoma in cross-sectional surveys in Nigerian adults.
Methods: Multistage stratified cluster random sampling with probability-proportional-to-size procedures to
select a nationally representative sample of 15,027 persons aged !40 years in 305 clusters across Nigeria.
Systematic sampling of 1 in 7 participants gave 1759 who were examined in detail to construct a normative
database. The normative subset was used to determine values for vertical cup/disc ratio (VCDR) and
intraocular pressure (IOP) for glaucoma diagnosis according to the International Society of Geographical and
Epidemiological Ophthalmology (ISGEO) criteria. Examinations included visual field testing by frequency
doubling technology (FDT), Goldmann applanation tonometry, and optic disc image grading by Moorfields Eye
Hospital Reading Centre.
Results: In the normative dataset, 1057/1759 persons (60.1%) had normal FDTs, and constituted the
hypernormal. Of these, 851 had VCDR and 973 had IOP measurements taken in both eyes. For category 1
(structural and functional evidence of glaucoma), the 97.5th percentile VCDR was 0.7. For category 2 (advanced
structural damage with unproven visual field loss), the 99.5th percentile VCDR was 0.75. In addition,
asymmetry in VCDR was 0.1 difference at the 97.5th percentile and 0.2 difference at the 99.5th percentile.
Category 3 criteria were used when the optic disc was not visible and field testing not possible; 99.5th percentile
IOP is one criterion (28mmHg).
Conclusion: While these results do not differentiate between open-angle and angle-closure mechanisms, they can
be applied to determine the prevalence of glaucoma in Nigeria and sub-Saharan African countries with similar
sociodemographic characteristics.
Keywords: Epidemiology, glaucoma, ISGEO, Nigeria, prevalence
*This paper was presented, in part, as a poster at the World Ophthalmology Conference (WOC), Abu Dhabi, February 2012.
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INTRODUCTION
The number of people with glaucoma worldwide
was estimated to be 60.5 million in 2010.1 With an
estimated 8.4 million people blind due to glaucoma in
2010 and projected to increase to 11.1 million in 2020,
it is the second leading cause of blindness. The
Nigerian national blindness and visual impairment
survey (thereafter referred to as the Nigeria blindness
survey) reported a prevalence of blindness of 4.2% in
adults aged 40 years and over,2 with glaucoma being
the second cause, accounting for 16.7% of blindness.3
Over 180,000 Nigerian adults are estimated to be blind
from glaucoma.
Glaucoma is an optic neuropathy associated with
characteristic structural damage to the optic nerve
and visual dysfunction.4 These are seen clinically as
enlargement of the optic disc cup and loss of visual
field, respectively. In order to provide a practical
framework for classification of glaucoma in preva-
lence surveys and also to enable valid comparisons
of results between populations, the International
Society for Geographical and Epidemiological
Ophthalmology (ISGEO) standardized the criteria
for classification of glaucoma in prevalence surveys.4
The defining features in this classification are
described according to three levels of evidence,
regardless of angle morphology (Table 1). The highest
level of evidence is when both structural damage and
functional deficits are detected, i.e. a large vertical
cup/disc ratio (VCDR) and/or asymmetry between
both eyes. An abnormally large VCDR is defined as
!97.5th percentile of the VCDRs of the normal
population in association with characteristic defects
in visual fields. Second level evidence is used when
visual field testing is not possible, and the diagnosis of
glaucoma at this level requires the presence of greater
structural damage of the optic disc, i.e. VCDR !99.5th
percentile of VCDRs in the normal population. The
third level is where VCDRs cannot be assessed and
visual field testing is not possible, then the diagnosis
of glaucoma is based on other clinical parameters in
combination; most importantly, intraocular pressure
(IOP) !99.5th percentile of the IOPs in the normal
population, loss of visual acuity attributed to glau-
coma, relative afferent papillary defect and med-
ical history (e.g. previous glaucoma surgery).
Gonioscopy is included in the ISGEO classification
to classify the type of glaucoma according to the
mechanism of damage,4 and is not required for the
three levels of evidence for defining glaucoma of all
types, as described above.
It is recognized that there is variation in the
distribution of optic disc size, VCDR and IOP between
populations,4–37 but there are no data for these values
for the normal population in Nigeria. In addition, the
Nigeria blindness survey showed that there were
considerable differences in the prevalence and causes
of blindness between the six geo-political zones as
well as between ecological areas.2,3,38 The prevalence
of blindness among those aged 40 years and over
ranged from 3.3% (95% confidence interval, CI,
2.4–4.5%) in the southern Delta area to 6.6% (95% CI
4.2–10.4%) in the northern Sahel. The proportion of
blindness due to glaucoma varied from 13.2% in the
Sudan Savannah to 23.5% in the Sahel.38 The overall
glaucoma-specific blindness prevalence was 0.7%
(95% CI 0.55–0.88%)3 with a 4-fold difference between
the ecological areas that have the lowest and highest
prevalence, i.e. 0.4% (95% CI 0.2–0.9%) in the Delta
and 1.6% (95% CI 0.6–3.8%) in the Sahel.38 These
findings may reflect variation in the incidence or
aggressiveness of the disease and/or variation in
access to eye care services.
There have only been two, relatively small, popu-
lation-based surveys designed to estimate the preva-
lence of glaucoma in Nigeria,39,40 but neither used
standardized criteria to define or classify the condi-
tion. The provision of normative data for Nigeria will
allow data from subsequent glaucoma prevalence
surveys to be compared with other surveys which
have used the ISGEO classification, and to elucidate
trends over time in response to interventions. The
data will also be useful for glaucoma prevalence
surveys in other West African countries that have not
reported normal values for the defining criteria, and
that have similar ecological, sociodemographic and
ethnic characteristics.
This paper describes the methods used to derive
the normative data for defining glaucoma using
population-based data obtained during the Nigeria
blindness survey, and reports the distribution of
VCDR and IOP for defining glaucoma in prevalence
surveys. These values are not intended for use for the
TABLE 1. International Society of Geographical and Epidemiological Ophthalmology (ISGEO) definitions for glaucoma in prevalence
surveys (from Foster et al.).4
Parameter
Level of evidence for the
diagnosis of glaucoma
Vertical cup/
disc ratio Visual fields Intraocular pressure Visual acuity Medical history
Category 1 !97.5th percentile Typical defect
Category 2 !99.5th percentile Not available
Category 3 Not available Not available !99.5th percentile 53/60 e.g. surgery for glaucoma
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diagnosis of glaucoma in a clinical setting. The
findings have been applied to the whole Nigeria
blindness survey dataset to derive glaucoma preva-
lence estimates and to explore geographical, socio-
demographic and ethnic differences, the results of
which are the subject of a separate report.
MATERIALS AND METHODS
Study Design
The Nigeria survey was designed to estimate the
prevalence and determine the causes of blindness
and visual impairment. A nationally representative
sample of 15,027 persons aged 40 years and over was
selected in 305 clusters across the 36 states and the
Federal Capital Territory of Nigeria by multistage
stratified cluster random sampling with probability-
proportional-to-size procedures. Data were collected
over a 30-month period between January 2005 and
June 2007 by two clinical teams, each comprising
two qualified ophthalmologists, an optometrist, two
ophthalmic nurses, interviewers and enumerators.
A detailed protocol for all methods was developed
and used in training and for reference. Training on
clinical assessment was on standardizing method
and recording according to the survey protocol and
included VA measurement, lens grading, applanation
tonometry and optic cup/disc ratio measurement.
Quality assurance included on-the-spot supervision
by the team leader, daily review of completed ques-
tionnaires and data collected, frequent visits to the
field by the Project Manager and Project
Epidemiologist, inter-observer agreement studies,
retraining of all team members before starting the
survey in each zone, and double data entry by two
trained data entry personnel.
Informed consent was obtained from all partici-
pants and community leaders. The study adhered to
the tenets of the Declaration of Helsinki and ethics
approval was obtained from the Ethics Committee of
the London School of Hygiene & Tropical Medicine
and the Federal Ministry of Health, Nigeria.
A subsample was used to derive the normative
dataset. The subsample was identified by systematic-
ally sampling every seventh participant recruited into
the study, regardless of ocular findings. These indi-
viduals were identified at the registration point by the
interviewer and verified by the team leader. They
underwent exactly the same rigorous examination
procedures as those with visual impairment, as
detailed below.
Clinical Assessment
The rationale, objectives and detailed methodology
of the Nigeria survey have already been described
in detail.41 A summary of the clinical assessments,
with particular reference to data relevant to deriving
the distribution and percentile values of VCDR and
IOP are described below. Temporary examination sites
were set up in the clusters and all enumerated
individuals were invited for examination. All partici-
pants (N= 13,591) had their personal and demo-
graphic details recorded. Presenting and best
corrected visual acuities were measured using a
reduced logarithm of the minimum angle of reso-
lution (logMAR) tumbling-E chart42,43 and categor-
ized using World Health Organization (WHO)
definitions of blindness and visual impairment44
with a further category for near normal/mild visual
impairment (56/12 to 6/18).
Visual field assessment
All participants had visual field testing, after explan-
ation and demonstration, with a Humphrey
Frequency Doubling Technology (FDT) visual field
analyzer (Carl Zeiss Meditec AG, Jena, Germany). The
purpose of the FDT screening test was to identify
those without definite or suspected visual field
defects (hypernormals). All were screened using the
suprathreshold screening mode (C20-1 or C20-5).
Prior to conducting the test, images of the test
screen and depictions of the flickering of the light
seen were used to explain the test. Each eye was
tested separately, right then left eye, without correc-
tion. The screening test was stopped and restarted or
repeated if there were two or three false positives
and/or two or more fixation errors. If a participant
could not be tested a reason was given, e.g. did not
understand the test.
Printouts of all FDT tests were obtained immedi-
ately following the test, and data were subsequently
extracted and entered into a database. Perimetry
results were interpreted using a detailed algorithm
(devised and adapted45–47 by PGS and FK) to define
which screened individuals had an abnormal test. The
screening test result was considered reliable if there
was only one fixation error and/or one false positive
(i.e. 433% failed reliability indices).46 The visual
field test was also considered unreliable if there
were brow/lid positions at lower or upper edges.
A screening test was considered normal if it was
reliable (i.e. !33% failed reliability indices) and there
were no visual field defects; or if there were less than
three defects at p51%; or less than two defects
at p50.5%.
Intraocular pressure measurement
Detailed eye examinations included slit-lamp exam-
ination (Zeiss SL 115 Classic Slit Lamp, Carl Zeiss
Meditec AG, Jena, Germany), assessment for relative
afferent pupillary defect and Van Herick’s (VH) angle
grading. IOP measurement by Goldmann applanation
tonometry was performed after instilling topical
100 F. Kyari et al.
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anesthesia and fluorescein dye (Minims Lidocaine
Hydrochloride 4% and Fluorescein Sodium 0.25%,
Bausch & Lomb Ltd, UK). A single reading of IOP was
measured by the ophthalmologist and recorded to the
nearest 1mmHg. Calibration of the tonometer was
verified daily using standard procedures as recom-
mended by the manufacturers. Eyes with significant
corneal surface pathology, phthisis or participants
unable to fixate were excluded. Central corneal
thickness was not assessed.
Gonioscopy and Van Herick’s anterior chamber
angle estimation
All participants who had a slit-lamp examination also
underwent VH anterior chamber angle estimation.
Gonioscopy (Volk’s 1-mirror non-flanged lens) was
performed if IOP was !20mmHg, or VCDR !0.6 or
VCDR asymmetry !0.2, or VH grades were 0, 1, or 2.
Gonioscopy and VH grades were used to determine
the type of glaucoma by mechanism/angle morph-
ology; findings are reported in a separate paper,
and are not the focus of this study.
Optic disc size estimation
Detailed posterior segment examination included
dilated optic disc and retinal examination with a 60
diopter (D) aspheric condensing lens (Volk Optical,
Inc., Mentor, OH, USA) and binocular indirect oph-
thalmoscopy (All-pupil binocular indirect ophthalmo-
scope; Keeler Ltd., Windsor, UK) with a 20D lens. Lens
opacities were graded using the WHO grading
system.48 Participants also had digital retinal photog-
raphy (Zeiss Visucam Lite Desk Top Fundus Camera,
Carl Zeiss Meditec AG, Jena, Germany) focused on a
mid-point showing the optic nerve head and macular
region through a dilated pupil which displays the
fundus of the eye at a field angle of 45" showing both
disc and macula in the observed field. Reasons for not
obtaining images were recorded.
Images were graded independently by Moorfields
Eye Hospital Reading Centre using their standard
protocol. Images were viewed ‘‘full screen’’ on either
a 2400 Eizo S2433W monitor calibrated using a
Datacolor Spyder2 calibrator or on a 2400 widescreen
Dell 2407WFP LCD monitor calibrated using a
GretagMacbeth Eye-One Display 2 calibrator. After
determining image quality and clarity, the scleral rim
was identified and the boundaries of the disc and the
cup were identified using monocular clues such as
vascular change in direction. These varied with image
quality. Disc pallor gave few clues and was not used.
One successful measurement was performed per eye,
along the vertical meridian, in Adobe Photoshop
(version 7) using the measurement tool, resulting in a
cup and a disc diameter value in pixels, along the
same plane, the division of the two values producing
the VCDR which was recorded to the nearest 0.05.
Primary grading was performed by the first reader
and inconclusive cases were adjudicated by a second
reader.
Magnification of the eye-camera system was
determined as described by Bengtsson and
Krakau.49 Parameters included in the formula were
axial length measured by A-scan biometry, refractive
index of the camera lens (1.336) and a derived
camera constant (0.0083) for Zeiss camera magnifi-
cation (0.5).50 A correction factor for indentation
biometry (0.25mm) was also applied.51 The equation
assumed that variations in the distance from the
apex of the cornea to the posterior principal point of
the eye were small, and also assumed that the
fundus camera and the ultrasound probe were
correctly positioned in relation to the participant’s
eye. The magnification was applied to the observed
vertical disc measurement in pixels and adjusted to
obtain estimates of the vertical disc diameter (VDD)
in millimeters (adapted from Bartling and
colleagues).50
A few participants eligible for detailed examination
were unable to attend the examination site, and so
were examined in their home. In these individuals
some investigations were not possible.
Data Analysis
All analyses were undertaken using Stata (Stata/IC
13.0; Stata Corp, College Station, TX, USA).
A descriptive analysis of the normative dataset
(n=1759) was undertaken. Missing values were
excluded. Participants who passed the FDT screening
test in both eyes and who did not have visual function
abnormalities from other pathology were termed the
hypernormal subset. In this subset the popula-
tion distribution for those with bilateral optic disc
grading and bilateral IOP measurements was used
to derive the percentile values for VCDR, VCDR
asymmetry and IOP. VCDR asymmetry was the
absolute value difference of VCDR between both
eyes (range 0–1.0). The distribution of these param-
eters in the whole normative dataset was also
determined so as to make comparisons with those in
the hypernormal subset.
The strength of the relationship between VCDR
and VDD and axial length, and between VDD and
axial length was quantified by Pearson’s correlation
coefficient and linear regression analysis.
The 97.5th and/or 99.5th percentile values for
VCDR and IOP in hypernormal persons were ana-
lyzed by sociodemographic variables (i.e. age, sex,
ethnic group) and place of residence (rural/urban,
geo-political zone). Ethnic groups represented by
!100 participants were analyzed separately (i.e.
Fulani, Hausa, Ibo, Yoruba). Smaller ethnic groups
(5100 participants) were grouped together as ‘‘others’’
and analyzed collectively.
Nigeria Normative Data for Glaucoma Surveys 101
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RESULTS
In the ISGEO classification, visual field findings are
used to separate category 1 from category 2 evidence.
The first step in defining normative values was,
therefore, an analysis of the FDT data.
The normative dataset consisted of 1759 partici-
pants. FDT testing was conducted in 2889 eyes of 1493
participants (84.9%). Of these, 1396 (79.4%) had both
eyes tested; 51 participants (2.9%) had right eyes only
tested and 46 (2.6%) had left eye data only. FDT
testing could not be done in both eyes of 266
participants (15.1%). Thus FDT testing was not
undertaken in 629 eyes of 363 participants (Table 2),
the main reasons being poor understanding and
inability to use the handheld button (198 eyes; 5.6%).
About half of the eyes without visual field results had
significant ocular pathology and could not be tested
(Table 3).
A total of 1366 (77.7%) of the participants had
VCDR image grading at Moorfields Eye Hospital
Reading Centre in at least one eye, 1244 (70.7%) of
whom had grading for both eyes. Of these, 369
participants (21.0% of 1759) had no fundus photos
in both eyes, in about half (187) this was because of
a faulty camera and/or generator.
The Hypernormal Subset
In the 1396 participants with FDT results in both eyes,
1057 individuals (60.1% of 1759) had normal visual
fields in both eyes and formed the hypernormal
subset (Figure 1).
Percentile distributions for vertical cup/disc ratios
A total of 1101 participants (62.6%) had both VCDR
grading and FDT testing in both eyes, 851 of whom
(48.4% of 1759) had normal visual fields in both eyes.
This subset was used to derive the percentile values
for VCDR and VCDR asymmetry (Figure 1).
Overall, there was 99.7% inter-observer agreement
for VCDR grading on photos. Regarding quality of the
photographs, 72% of images were graded good/
adequate for disc field definition for disc assessment.
The 97.5th and 99.5th percentile values for VCDR in
the hypernormal subset were 0.7 and 0.75 respectively
(Table 4). The 97.5th percentile value (0.7) was
consistent across all age groups, sexes, places of
residence and ethnic groups except in the Fulani and
those living in the north-east geo-political zone where
the value was 0.6. The 99.5th percentile value (0.75)
was more variable, ranging from 0.7–0.85 (Table 5).
In comparison, if all eyes regardless of visual field
findings were included, the 97.5th and 99.5th percent-
ile values for VCDR in the normative dataset would
be 0.75 and 0.95, respectively (Table 4).
Vertical disc diameter was normally distributed
and the estimated mean VDD was 1.29mm (standard
deviation 0.14mm) with a minimum of 0.85mm and
maximum 1.86mm. The Pearson’s correlation coeffi-
cient was 0.36, thus there was a moderate positive
linear relationship between VCDR and VDD. The
gradient of the linear regression line was 0.40 (95% CI
0.34–0.46). There was also a moderate positive linear
relationship between VDD and axial length. Thus,
longer eyes had larger disc diameters. However,
VCDR was not related to axial length.
TABLE 3. Distribution of participants (and eyes) on the basis of FDT testing, Nigeria.
Reason Persons, n Eyes, n % of eyes
Had FDT testing in both eyes with normal results 1057 2114 60.1
Could be tested in both eyes but failed FDT screening test 339 678 19.3
Could not be tested in other eye 97 97 2.8
Could not be tested in either eye 266
Poor coordination of handheld button 198 5.6
Corneal opacity 59 1.7
Cataract 153 4.3
Other ocular pathology 146 4.1
Faulty machine 7 0.2
No electricity/generator 2 0.1
No reason stated 32 0.9
Other, e.g. home visit examination 32 0.9
Total 1759 3518 100
FDT, frequency doubling technology.
TABLE 2. Number of participants who had FDT visual field
screening results, Nigeria.
FDT results Participants, n % Eyes, n
In both eyes 1396 79.4% 2792
In one eye only 97 5.5% 97
Other eye not tested – – 97
Neither eye 266 15.1% 532
Total 1759 100% 3518
FDT, frequency doubling technology.
102 F. Kyari et al.
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TABLE 4. Percentile distributions for VCDR, VCDR asymmetry and IOP in the normative dataset and in the
hypernormal subset (normal FDT in both eyes), Nigeria.
Parameter
All eyes of participants
with parameter measured
(N= 1759)
By left and right eyes with
normal FDT in both eyes
(N= 1057)
VCDR RE LE All eyes RE LE All eyes
N 1308 1302 2610 851 851 1702
0.5th 0.1 0.1 0.1 0.1 0.1 0.1
2.5th 0.1 0.1 0.1 0.1 0.1 0.1
Median 0.4 0.4 0.4 0.4 0.4 0.4
97.5th 0.75 0.75 0.75 0.7 0.7 0.7
99.5th 0.95 0.9 0.95 0.75 0.75 0.75
VCDR asymmetry Persons Persons
n 1244 851
0.5th 0.0 0.0
2.5th 0.0 0.0
Median 0.0 0.0
97.5th 0.1 0.1
99.5th 0.3 0.2
IOP, mmHg RE LE All eyes RE LE All eyes
n 1577 1575 3152 973 973 1946
0.5th 7 7 7 8 8 8
2.5th 9 9 9 9 9 9
Median 14 14 14 14 14 14
97.5th 24 24 24 20 20 20
99.5th 36 34 34 28 28 28
VCDR, vertical cup/disc ratio; IOP, intraocular pressure; FDT, frequency doubling technology; RE, right eye;
LE, left eye.
The shaded numbers denote the 97.5th and 99.5th percentile values which are relevant for the classification
of glaucoma in prevalence surveys.
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FIGURE 1. Parameters measured in participants recruited to the normative dataset for glaucoma in Nigeria (FDT, frequency doubling
technology; VCDR, vertical cup/disc ratio; IOP, intraocular pressure; BE, both eyes; OE, one eye).
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Percentile distributions for vertical cup/disc ratio
asymmetry
The 97.5th and 99.5th percentile values for VCDR
asymmetry in the hypernormal subset were 0.1 and
0.2, respectively. In comparison, if all persons regard-
less of visual field results were considered, the 97.5th
and 99.5th percentile values for VCDR asymmetry in
the total study population would be 0.1 and 0.3,
respectively (Table 4).
Percentile distributions for intraocular pressure
Data were available on IOP for 3152 eyes of 1595
participants (90.7%) in at least one eye, of whom 1557
(88.5%) had IOP measurement in both eyes. A total of
1284 participants (73.0%) had both IOP measured and
FDT testing in both eyes, of whom 973 (55.3% of 1759)
had normal visual fields in both eyes. This subset was
used to derive the percentile values in the population
distribution of IOP (see Figure 1).
The 99.5th percentile value for IOP was 28mmHg.
This is the cut-off value for category 3 diagnosis of
glaucoma according to the ISGEO criteria. In com-
parison, if all eyes were included regardless of visual
field results, the 99.5th percentile value for IOP in the
total study population would be 34mmHg (Table 4).
The 99.5th percentile value for IOP in the hypernor-
mal population varied considerably by age and ethnic
group (range for both 0.7–0.85).
DISCUSSION
We have described the methods used in the first
nation-wide study in Sub-Saharan Africa to derive
percentile values for defining glaucoma in popula-
tion-based surveys. These values are for population-
based studies only and not values for diagnosing
glaucoma in clinical settings. Additionally, as the
results of gonioscopy to determine anterior chamber
angle morphology have not been included, this paper
cannot differentiate open-angle glaucoma and angle-
closure glaucoma. Other morphological features of the
optic disc area such as disc hemorrhage, retinal nerve
fiber layer defects and peripapillary atrophy con-
sidered in the clinical diagnosis of glaucoma have not
been included in the ISGEO criteria. The hypernormal
population was defined by persons with normal
suprathreshold visual fields in both eyes. In this
TABLE 5. Percentile values for vertical cup/disc ratio and intraocular pressure by sociodemographic variables and location of
residence, Nigeria.
Whole
study dataa
Normative
dataset
Hypernormal
subset
Vertical cup/disc ratio Intraocular pressure, mmHg
n (%) n (%) n (%)
Both eyes
n (%)
97.5th
percentile
99.5th
percentile
Both eyes
n (%)
99.5th
percentile
Sociodemographic factor
Age group, years
40–49 4889 (36.0) 613 (34.9) 446 (42.2) 373 (43.8) 0.7 0.75 416 (42.8) 22
50–59 3577 (26.3) 464 (26.4) 324 (30.7) 248 (29.1) 0.7 0.75 296 (30.4) 28
60–69 2773 (20.4) 368 (20.9) 198 (18.7) 170 (20.0) 0.7 0.85 185 (19.0) 34
70–79 1653 (12.2) 229 (13.0) 73 (6.9) 50 (5.9) 0.7 0.7 64 (6.6) 26
80+ 699 (5.1) 85 (4.8) 16 (1.5) 10 (1.2) 0.7 0.7 12 (1.2) 17
Sex
Female 7345 (54.0) 939 (53.4) 533 (50.4) 435 (51.2) 0.7 0.75 489 (50.3) 28
Male 6246 (46.0) 820 (46.6) 524 (49.6) 416 (48.9) 0.7 0.75 484 (49.7) 23
Ethnic group
Fulani 840 (6.2) 108 (6.1) 49 (4.6) 48 (5.6) 0.6 0.75 46 (4.7) 20
Hausa 3375 (24.9) 429 (24.4) 258 (24.4) 218 (25.6) 0.7 0.7 244 (25.1) 28
Ibo 1918 (14.1) 248 (14.1) 128 (12.1) 102 (12.0) 0.7 0.7 120 (12.3) 22
Yoruba 2669 (19.6) 351 (20.0) 226 (21.4) 175 (20.6) 0.7 0.85 193 (19.9) 35
Others 4731 (34.8) 614 (34.9) 391 (37.0) 304 (35.7) 0.7 0.75 370 (38.0) 23
Not indicated 58 (0.4) 9 (0.5) 5 (0.5) 4 (0.5) – – 0 –
Location
Place of residence
Rural 10,540 (77.6) 1371 (77.9) 809 (76.5) 654 (76.9) 0.7 0.75 737 (75.8) 28
Urban 3051 (22.4) 388 (22.1) 248 (23.5) 197 (23.1) 0.7 0.75 236 (24.2) 34
Geopolitical zone
North east 1727 (12.7) 270 (15.4) 110 (10.4) 100 (11.7) 0.6 0.75 102 (10.5) 21
South east 1662 (12.3) 211 (12.0) 96 (9.1) 79 (9.3) 0.7 0.7 92 (9.5) 22
South south 1852 (13.6) 241 (13.7) 160 (15.1) 140 (16.5) 0.7 0.7 156 (16.0) 20
North west 3593 (26.4) 402 (22.8) 260 (24.6) 236 (27.7) 0.7 0.75 245 (25.2) 28
South west 2728 (20.1) 362 (20.6) 242 (22.9) 184 (21.6) 0.7 0.85 196 (20.1) 35
North central 2029 (14.9) 273 (15.5) 189 (17.9) 112 (13.2) 0.7 0.75 182 (18.7) 24
Total 13,591 (100) 1759 (100) 1057 (100) 851 (100) 973 (100)
aEight excluded due to missing data.
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group, any visual dysfunction from other ocular
pathologies, and not just glaucoma, would be
excluded. The values are of relevance to Nigeria as
well as other countries in Sub-Saharan Africa that have
similar sociodemographic and ecological profiles to
Nigeria. Even though there were differences demon-
strated in the values by geo-political zone and in the
Fulani and Yoruba ethnic groups, it is still pertinent
that the national values be used even in localized
surveys in defined geographical areas in Nigeria.
Other glaucoma studies of normative values in
Africa,5–7 Asia,10–17,26–28 Australia,35 Europe36 and
South America37 report a VCDR of 0.7 to be the
97.5th VCDR for level 1 evidence but there is wide
variation in the values for other parameters (Table 6).
Some of these studies9,12,26,27,29–31 used values derived
from previous studies in the region. Interestingly,
even in this study, there was some variability in the
VCDR between ethnic groups. There is a need for
more rigorous population-based data from African
countries where glaucoma is often the second most
frequent cause of blindness after cataract.52
It is noteworthy that longer eyes did not necessarily
have larger VCDRs. However, as predicted VCDR
increased with increasing VDD, VCDR was moder-
ately disc-size dependent. Thus, assessment of VCDR
and a diagnosis of glaucoma must be interpreted
taking account of disc size, particularly in the absence
of visual field testing which provides a definite
glaucoma diagnosis.
One of the limitations of this study is that the ‘‘gold
standard’’ Humphrey field analyzer was not used as
TABLE 6. Distribution of cup/disc ratio and intraocular pressure derived from the ISGEO categorization in different populations.
Cup/disc ratio
Cup/disc ratio
asymmetry
Intraocular
pressure, mmHg
Study populations Year
97.5th
percentile
99.5th
percentile
97.5th
percentile
99.5th
percentile
99.5th
percentile Reference
African countries
Nigeria (current study) 2013 0.7 0.75 0.1 0.2 28 –
Kongwa,Tanzania 2000 0.7 0.7 0.2 0.3 30 4,5
Hlabisa, South Africa 2002 0.7 0.9 0.2 0.3 30 6
Temba, South Africa 2003 0.7 0.9 0.2 0.3 30 7
Tema, Ghana 2013 0.73 0.85 – – 34 8
Asian countries
India
West Bengal 2005 0.6 0.6 0.1 0.2 24 9
Chennai 2008 0.7 0.8 – 0.2 30 10,11
Andra Pradesh 2010 0.7 0.8 – – 24R/30U 12
China
Guangzhou 2006 0.7 0.8 0.2 0.3 24 13
Beijing 2010 0.7 0.8 0.2 0.3 – 14
Inner Mongolia 2011 0.7 0.8 0.2 0.3 23.1 15
Handan 2011 0.7 0.8 0.2 0.3 23.7 16,17
Harbin 2011 0.5 0.6 0.1 0.3 25 18,19
Yunnan 2012 0.7 0.9 0.1 0.3 21 20
Other Asia
Hovsgol, Mongolia 1996 0.71 0.82 0.2 0.3 – 4,21
Chinese, Singapore 2000 0.71 0.82 0.21 0.32 21 4,22
Malay, Singapore 2008 – – 0.2 0.23 26.5 23
Indian, Singapore 2013 0.60 0.62 0.13 0.20 24 24
Bangkok, Thailand 2003 0.72 0.86 0.21 0.29 22 25
Tajimi, Japan 2004 0.7 0.9 0.2 0.3 23 26,27
Dhaka, Bangladesh* 2004 0.7 0.85 0.15 0.3 32 28
Meiktila, Myanmar 2007 0.65 0.8 0.3 – 25 29
Kandy, Sri Lanka 2009 0.6 0.75 – – 24 30,31
Sangju, Korea 2011 0.6 0.9 – – 19 32
Bhaktapur, Nepal 2012 0.6 0.8 0.1 0.2 20 33
Yazd, Iran 2013 0.6 0.7 0.2 0.2 22 34
Australia
Central Australia
(indigenous Australians)
2012 0.7 0.8 – – 24 35
Europe
Reykjavik, Iceland 2003 0.7 0.8 0.2 0.3 – 36
South America
Piraquara, Brazil 2007 0.7 0.9 0.2 0.3 30 37
*Percentile values include participants without visual field testing. R, rural; U, urban; ISGEO, International Society of Geographical
and Epidemiological Ophthalmology.
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all equipment had to be portable. Nevertheless, FDT
perimetry in a population-based glaucoma screening
study has been shown to be reliably performed and
with high specificity.53 Additionally, in our study, two
screening modes were used (C20-1 or C20-5). This
arose from a difference in calibration of the FDT
machine for one of the two teams. Nonetheless, we
normalized the criteria when defining the normal
visual field. It is acknowledged that another limitation
of this study is that only a single reading for IOP was
taken. However, for multiple readings to be mean-
ingful, there has to be some time interval between
readings which was not practicable in the context of
this large survey. The role of IOP in the diagnosis of
glaucoma has been contentious and this is reflected in
the ISGEO classification where IOP data are used
when disc and visual field data are not available. In
this study 99.5th percentile values varied considerably
by sociodemographic variables, with the value
28mmHg being higher than most of the studies in
Asia, but more consistent with other studies from
Africa4–36 (Table 6). Some of the variability may reflect
the relatively small sample sizes in some subgroups.
Central corneal thickness was not measured but it is
not a defining parameter in the ISGEO classification.
However, central corneal thickness measurement is
important because corneal thickness may mask the
accurate measurement of IOP, which may be under-
estimated in persons with thinner central corneal
thicknesses as documented in an African-derived
population.54 The use of monocular disc photographs
with a mid-point disc-macular field image is a
limitation. As the images were not centered on the
disc, this may have impacted on disc markings and
the results may not be directly comparable to those in
other studies that used a different focus point.
However, monocular clues were used to assess the
disc rim and cup, measurements were taken object-
ively and the reading was standardized. Measuring
the true size of the optic disc relies on many imaging
properties such as camera and eye magnification
factors, and the distance and position in relation to the
participant’s eye. Some of these were very difficult or
not possible to determine in our study. Thus, the
stated VDD were estimates and cannot be compared
to VDD observed in other studies. However, since the
measurements in all participants were subject to
the same constant in deriving estimates, the values
of VDD in relation to VCDR remain valid. More
studies to determine actual disc size in this population
are required.
There is a statistical limitation inherent in the
ISGEO classification by using the convention that55%
of normal VCDR is considered significant deviation.
However, as VCDR is not normally distributed, in the
definition of glaucoma, 2.5% (97.5th percentile) is
regarded as the upper limit of normal. In addition, the
use of VCDR asymmetry as a second parameter
improves the definition of glaucoma.4 Furthermore,
the use of visual fields as another parameter to
ascertain abnormality considers visual function in
the definition. This scheme identifies the more severe
cases of glaucoma and provides the minimum esti-
mate of glaucoma prevalence. In defining glaucoma in
population-based surveys, it is important to include a
group that may not meet the three levels of evidence
by the ISGEO criteria but have other defining features
such as relative afferent pupillary defect indicative of
severe functional deficit in the absence of visual field
tests and large VCDR !99.5th percentile. It is also
important to note that other parameters should be
considered for category 3 diagnosis, when optic disc
and visual field assessment are not possible in
subjects who have IOP less than the 99.5th percentile
(28mmHg in this report), otherwise the misdiagnosis
of these individuals would underestimate the preva-
lence of glaucoma in the population.
This study has strengths: It was population-based,
nation-wide and had a high response rate (90.5%). It
had a robust sampling and methodology, with good
quality control measures and all participants were
examined by ophthalmologists who had additional
training for the survey protocol. The normative
database was derived by systematic sampling and
so was representative of the study population as well
as the whole population.
In conclusion, this study gives Nigeria normal
standardized sets of values for diagnosis of glaucoma
in prevalence surveys without having to extrapolate
from other populations. These have been applied to
derive glaucoma prevalence estimates in Nigeria. The
values will also be useful for comparison between
studies and in monitoring glaucoma prevalence in
response to interventions, with implications on popu-
lation cohort studies and glaucoma studies of people
of African descent.
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Abstract
Background: Glaucoma is the leading cause of irreversible blindness worldwide. There tends to be a lower reporting
of glaucoma in Africa compared to other blinding conditions in global burden data. Research findings of glaucoma in
Nigeria will significantly increase our understanding of glaucoma in Nigeria, in people of the West African diaspora and
similar population groups. We determined the prevalence and types of glaucoma in Nigeria from the Nigeria National
Blindness and Visual Impairment cross-sectional Survey of adults aged ≥40 years.
Methods: Multistage stratified cluster random sampling with probability-proportional-to-size procedures were used to
select a nationally representative sample of 15,027 persons aged ≥40 years. Participants had logMAR visual acuity
measurement, FDT visual function testing, autorefraction, A-scan biometry and optic disc assessment. Participants
with visual acuity of worse than 6/12 or suspicious optic discs had detailed examination including Goldmann
applanation tonometry, gonioscopy and fundus photography. Disc images were graded by Moorfields Eye
Hospital Reading Centre. Glaucoma was defined using International Society of Geographical and Epidemiological
Ophthalmology criteria; and classified into primary open-angle or primary angle-closure or secondary glaucoma.
Diagnosis of glaucoma was based on ISGEO classification. The type of glaucoma was determined by gonioscopy.
Results: A total of 13,591 participants in 305 clusters were examined (response rate 90.4 %). Optic disc grading
was available for 25,289 (93 %) eyes of 13,081 (96 %) participants. There were 682 participants with glaucoma; a
prevalence of 5.02 % (95 % CI 4.60–5.47). Among those with definite primary glaucoma that had gonioscopy
(n = 243), open-angle glaucoma was more common (86 %) than angle-closure glaucoma (14 %). 8 % of glaucoma
was secondary with the commonest causes being couching (38 %), trauma (21 %) and uveitis (19 %). Only 5.6 %
(38/682) of participants with glaucoma knew they had the condition. One in every 5 persons with glaucoma
(136;20 %) was blind i.e., visual acuity worse than 3/60.
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Conclusion: Nigeria has a high prevalence of glaucoma which is largely open-angle glaucoma. A high proportion
of those affected are blind. Secondary glaucoma was mostly as a consequence of procedures for cataract. Public
health control strategies and high quality glaucoma care service will be required to reduce morbidity and
blindness from glaucoma.
Keywords: Prevalence, Glaucoma, Epidemiology, Nigeria, Open-angle glaucoma, Angle-closure glaucoma
Background
Glaucoma is the second leading cause of blindness world-
wide and the leading cause of irreversible blindness, ac-
counting for 8 % of all blindness, affecting an estimated
3.12 million blind people [1]. A review of relevant
population-based surveys of glaucoma, and of blindness
and visual impairment in sub-Saharan Africa indicate that
glaucoma affects about 4 % of adults aged 40 years and
above and accounts for 15 % of blindness [2–4]. Africa is
the region with the highest incidence and prevalence of
glaucoma, most of which is open-angle glaucoma (OAG)
[5, 6], and OAG is more prevalent in the black popula-
tions of Africa and Africa-derived populations [7]. Reports
also suggest that the most difficult problematic OAG that
there is in terms of severity of disease, difficulty in treating
it and as a cause of blindness comes from West Africa
[2, 3, 8]. Additionally, there tends to be a lower report-
ing of glaucoma in Africa compared to other blinding
conditions in global burden data because surveys in Af-
rica may have had limited diagnostic capacity for glau-
coma [9]. The Nigeria national blindness and visual
impairment survey (hereafter referred to as the Nigeria
Blindness Survey), in which over 13,500 people aged
40 years and above were examined, is a population-
based survey that substantially addresses glaucoma
prevalence and risk factors. The Nigeria Blindness Sur-
vey reported the prevalence of blindness to be 4.2 % (95 %
confidence interval 3.8–4.6 %) [10], 16.7 % being due to
glaucoma [11]. Glaucoma was the leading cause of irre-
versible blindness [11] and functional low vision [12].
A standard definition and classification system for
glaucoma in prevalence surveys proposed by the Inter-
national Society of Geographical and Epidemiological
Ophthalmology (ISGEO) [13] allows comparison of
glaucoma prevalence surveys, further highlighting the
variation between populations. Whereas angle-closure
glaucoma is more frequent among east Asian popula-
tions [6, 14], the black populations of USA [15] the
Caribbean [16, 17], and Africa [6, 18–22] have the
highest prevalence of open-angle glaucoma with up to
90 % of those affected being unaware that they have
the condition [18, 21, 22].
In this study, data from the Nigeria Blindness Survey
were analyzed using ISGEO criteria to determine the
prevalence and types of glaucoma, to provide data for
advocacy, policy and to plan services for glaucoma. How-
ever, the ISGEO classification system is not for clinical
diagnosis or for assessment for treatment of glaucoma.
The percentile values for the vertical cup:disc ratio
(VCDR), VCDR asymmetry and intraocular pressure
(IOP) to define glaucoma were derived from this study
population. Possible risk factors for glaucoma in the popu-
lation are presented in another paper.
Nigeria is the 7th most-populous country in the world
and had a total population of 128 million at the time of the
national survey (January 2005 to June 2007). Nigeria has 6
main administrative/geo-political zones (GPZ): north-east
(NE), south-east (SE), south-south (SS), north-west (NW),
south-west (SW) and north-central (NC). Two-thirds
(63 %) of the population live in rural areas. Nigeria has
more than 250 ethnic groups, who live in different
areas in the country each with their own language/dia-
lects, customs and practices. The largest ethnic groups
are the Hausa and Fulani in the north, Ibo in the south-east
and Yoruba in the south-west. Despite recent economic de-
velopment, adult literacy levels remain low (51 %), and
54 % of the population live below the poverty line on less
than a dollar a day [23].
There are insufficient population-based glaucoma stud-
ies in Africa to represent the entire continent in global
glaucoma prevalence estimates [6]. From the few high-
quality surveys, it is difficult to extrapolate the findings to
wider populations as they were conducted in limited and
defined geographical areas of large countries [3]. This is
the largest truly population-based study of glaucoma in
Africa. Estimating the magnitude of glaucoma in Nigeria
is important because it sheds light on inter-ethnic and
regional variations of OAG prevalence in the black
populations of Africa, Caribbean and USA. It will also
provide a baseline for planning delivery of care to glau-
coma patients in Nigeria and in countries with similar
socio-demographic and ecological characteristics in
sub-Saharan Africa.
Methods
Details of all the methods used in the Nigeria Blindness
Survey have been published [24] as well as data on the
prevalence [10] and causes of visual impairment, blind-
ness [11] and low vision [12].
Kyari et al. BMC Ophthalmology  (2015) 15:176 Page 2 of 15
Fatima Kyari PhD Thesis Page 111
Ethics
Ethical approval was obtained from the Ethics Committee
of the London School of Hygiene & Tropical Medicine
and the Federal Ministry of Health, Nigeria. Oral informed
consent was obtained from community leaders, heads of
households and all participants. The study adhered to the
tenets of the declaration of Helsinki. Persons with medical
or eye conditions needing further assessment and treat-
ment were referred to the nearest healthcare facility. Cata-
ract blind participants were offered surgery after the
survey had been completed in each zone.
Sample size calculation and sampling strategy
The sample size calculation was based on the following:
target population (22.6 million); expected prevalence of
blindness in persons 40 years and older (5 %); desired
precision (0.5 %); design effect due to clustered sampling
(2); 95 % confidence level; and 85 % response rate. The
sample size was 15,375 after allowing for non-response
in 310 clusters of 50 participants each. With assumed
glaucoma prevalence of 5 % [3], this sample size would
also give a precise estimate of the prevalence of glau-
coma and allow risk factors for OAG to be analysed.
Multi-stage sampling using probability in proportion
to size was used to select a nationally representative
sample. In each cluster the center of the village/ward
was identified and the direction of enumeration deter-
mined by spinning a bottle. Individuals aged 40 years
and above who had lived in the household for at least
the preceding 3 months were enumerated until 50 indi-
viduals had been identified. Examination took place over
two days in a temporary clinic set up in the community.
Those unable to leave their homes (e.g., due to disability)
were examined at home.
Clinical teams and quality control
Data were collected by two clinical teams each comprising
of two ophthalmologists, one optometrist, two ophthalmic
nurses, four enumerators and one interviewer. Quality as-
surance included field supervision by the team leader, daily
review of data collection forms, frequent visits by the Pro-
ject Manager (MR) and Project Epidemiologist (GVSM),
inter-observer agreement studies, retraining of all team
members before visiting each zone, and double data entry
by two trained data entry personnel. Three of the four
ophthalmologists and both optometrists comprising the
clinical teams remained unchanged but different nurses
were recruited for each zone in order to address lan-
guage and cultural variations. A detailed protocol of all
the methods was used in training and for reference.
Data collection and clinical assessment
Clinical assessment in relation to glaucoma is described
below. The examination flow is shown in Fig. 1.
All participants
All participants had their personal and socio-demographic
data recorded including their self-reported ethnic group
as well as medical and ocular history, including a history
of glaucoma. Height, weight and blood pressure (Omron)
were measured. Presenting and best-corrected distant
visual acuities (VA) were measured by an ophthalmic
nurse with a reduced logMAR E-chart [25]. All partici-
pants also had automated refraction, frequency doubling
technology (FDT) visual field testing (see below), A-scan
biometry by the optometrist and a basic eye examination
by the first ophthalmologist.
Detailed examination
The following participants underwent detailed eye examin-
ation by the second ophthalmologist [10, 24]: those with a
presenting VA <6/12 in one or both eyes; VCDR ≥0.6 in
one or both eyes or VCDR asymmetry of ≥0.2, or any ret-
inal abnormality seen on non-dilated direct ophthalmos-
copy. In addition, 1-in-7 participants also had the detailed
examination regardless of their VA, with random blood glu-
cose testing, to provide a ‘normative’ database. Detailed eye
examination included slit-lamp examination (Zeiss SL 115
Classic Slit Lamp, Carl Zeiss Meditec AG Jena Germany),
Van Herick’s (VH) anterior chamber (AC) angle depth esti-
mation [26], assessment for relative afferent pupil defect
(RAPD), applanation tonometry (Goldmann), lens opacity
grading using the World Health Organization (WHO)
classification, fundus and optic disc examination with
60D aspheric condensing lens (Volk) and binocular in-
direct ophthalmoscopy (BIO; Keeler all-pupil) with a
20D lens, and digital fundus imaging with Zeiss Visucam
Lite Desk Top Fundus Camera (Carl Zeiss Meditec AG
Jena Germany) focused on mid-point between the optic
nerve head and the macular region through a dilated
pupil. All images were graded independently at the Moor-
fields Eye Hospital Reading Centre (MEHRC). Gonioscopy
(Volk’s 1-mirror non-flanged lens) was performed if the
IOP was ≥20 mmHg, or VCDR ≥0.6, or VCDR asymmetry
≥0.2, or VH grades 0, 1, 2. Central corneal thickness was
not assessed.
Visual field testing
Visual field testing was performed with a Humphrey
FDT visual field analyzer (Carl Zeiss Meditec AG Jena
Germany). The FDT perimeter is a robust, portable, self-
contained unit that weighs less than 10 kg and has a self-
calibration procedure. It is generally inexpensive, easy to
understand and quick to perform the test [27]: it takes
about 45 s to complete a normal screening test and about
45 s for a normal threshold test. These features informed
the choice of the FDT perimeter and were advantages
considering the logistics of a large population-based sur-
vey of this kind where examinations were carried out in
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temporary examination centers set up in the community.
FDT utilizes a vertical sine wave grating of low spatial fre-
quency (0.25 c/deg) with counterphase flickering at a high
temporal frequency (25 Hz) [28]. All participants were
screened using the suprathreshold (C20-5 or C20-1)
screening mode after explaining the test and running a
demonstration. Each eye was tested separately without
correction. The reliability indices considered were fixation
error and false positive. The screening test was stopped
and restarted or repeated if considered unreliable i.e.,
there were two or three false positives and/or two or more
fixation errors. Clinically abnormal tests were not re-
peated. A threshold test was done if there were ≥3 field
defects at p <1 % or ≥2 field defects at p <0.5 %. If a par-
ticipant could not be tested or could not see the FDT flick-
ering black and white patterns, s/he was classified as
having no FDT test and a reason was given e.g., cataract;
or did not understand the test. Print-outs of all FDT tests
were obtained immediately and data were extracted and
entered into a database. Perimetry results were interpreted
using a detailed specific algorithm (devised and adapted
[27] by PGS and FK) to identify abnormal visual fields and
to classify defects as glaucomatous or non-glaucomatous.
The criteria used are outlined in Table 1. The FDT result
was interpreted by a 1st reader (PM) and validated by a
2nd (FK); any discrepancy was adjudicated (PGS). Screen-
ing reliability was defined as ≤1 fixation error and/or ≤1
false positive (i.e., <33 % failed reliability indices) and
threshold reliability was defined as ≤2 fixation errors, ≤2
false positives (i.e., ≤33 % errors on reliability indices).
Tests were also considered unreliable if there were brow/
lid positions showing as uniformly dense artefact along
the upper or lower edges of the FDT result chart. Unreli-
able results were not included.
Threshold test results were used to diagnose glaucoma
if available, otherwise screening results were used. Grading
used defects on the Pattern Deviation Probability (PDP)
plot compared with the Total Deviation Probability (TDP)
plot. Screening tests were considered normal if reliable
without defects, or there were ≤2 defects at p <1 %; or ≤1
defect at p <0.5 %. Threshold tests were normal if there
were no defects at p <0.5 % and p <1 %, or ≤1 defect at p
<2 %, or ≤2 non-adjacent defects at p <0.5 %. Factors con-
sidered in categorizing defects as definitely, probably or
possibly glaucomatous were position, depth and size, clus-
tering (i.e., adjacent or not) and position; and repeatability
(i.e., defect in same location on PDP and TDP plots).
We could determine repeatability in participants that
had both screening and threshold tests. Defects were
not likely glaucomatous if 1) there was a highly shaded
Fig. 1 Examination flow chart for study participants in the Nigeria national survey of blindness and visual impairment. VA = visual acuity;
BNB = believed not blind; BB = believed blind, VCDR = vertical cup:disc ratio. Basic eye examination: (n=7194)- Pen-torch anterior segment
examination, non-dilated direct ophthalmoscopy. Detailed eye examination: (n=6397) - Slit-lamp examination, WHO lens grading, Van Herick's anterior
chamber angle depth estimation, applanation tonometry, gonioscopy if indicated, dilated ophthalmoscopy, digital retinal photography
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TDP with normal PDP plot – this diffuse loss could be
due to cataract, for example; 2) TDP was normal or
better than the PDP plot or 3) there were vertical me-
ridian defects. However, for diffuse defects, other com-
pelling evidence for glaucoma classification were used
(see later).
Van Herick’s anterior chamber angle estimation and
gonioscopy
The VH AC angle estimation was performed at the slit-
lamp. The relationship between the corneal slit image and
AC depth was graded 0 to 4 [26]. Grades 0, 1 and 2 were
grouped as angle closure or likely to close angles; and
grades 3 and 4 as open angles. The iridocorneal angle was
assessed by gonioscopy without corneal compression and
graded as either open angle or closed angle. The anterior
chamber angle was classified as open when Schwalbe’s
line could be seen; and as closed when it could not be
seen. In eyes with glaucoma, the correlation between
VH grades and gonioscopy was assessed with the kappa
statistic.
IOP measurement
Intraocular pressures were measured by Goldmann
applanation tonometry using standard methods and re-
corded to the nearest 1 mmHg. Tonometers were
checked for calibration daily according to the manufac-
turer’s recommendation. Eyes with significant corneal
surface pathology, phthisis or participants unable to fix-
ate were excluded.
Optic disc assessment
Cup-disc ratios were assessed clinically by direct oph-
thalmoscopy for all participants during the basic exam-
ination, and after pupil dilation in those having the
detailed examination using slit lamp biomicroscopy with
a 60D lens. Clinical grading was used in analysis for
participants that did not have photo VCDR grading.
Methods for clinical VCDR grading by the ophthalmolo-
gists were standardized during training using standard sets
of optic disc photographs and comparing the clinical grad-
ing with the VCDR measured on the retinal photo of the
participant being observed.
Digital fundus images were graded independently by
MEHRC using their standard protocol. Images were viewed
"full screen" on either a 24-in. Eizo S2433W monitor or on
a 24-in. widescreen Dell 2407WFP LCD monitor. The
former was calibrated using a Datacolor Spyder2 calibrator
and the latter was calibrated using a GretagMacbeth Eye-
One Display2 calibrator. After determining image quality
and clarity, the scleral rim was identified and the boundar-
ies of the disc and cup identified using monocular clues
such as vascular change in direction. Disc pallor gave few
clues and was not used. The VCDR was then quantified.
One successful measurement was performed per eye, along
the vertical meridian, in Adobe Photoshop (version 7) using
the measurement tool, resulting in a cup and a disc diam-
eter value in proprietary units, the division of the two
values producing the VCDR which was recorded to the
nearest 0.05. Primary grading was performed by the 1st
reader (FS) and inconclusive cases, e.g., tilted discs, blurred
images, generalized disc pallor, were adjudicated by a 2nd
reader (TP) immediately. If a VCDR measurement could
not be obtained, this was stated.
Inter-observer agreement for clinical VCDR measure-
ment between ophthalmologists was assessed with the
kappa statistic; each participant had two observations with
the second examiner blinded to the result obtained by the
first examiner. Inter-observer agreement for VCDR grad-
ing on photos was also assessed. The Bland-Altman
method was applied to assess agreement between the
two methods of measurement i.e., by biomicroscope
funduscopy (clinical VCDR) and digital image analysis
(image VCDR).
Table 1 Definition of glaucomatous visual field defects for level 1 evidence of glaucoma
FDT test defects Visual fields
Normal Definitely glaucoma Probably glaucoma Possibly glaucoma Unlikely glaucomaa
P <5 % 2 or less non-adjacent 4 3 2 adjacent
P <2 % 1 3 2 1
P <1 % 0 2 1 non-edge
P <0.5 % 0 1 1 non-edge
Comments At any location in any
hemi-field
At one hemi-field At one hemi-field If TDP plot is better than
PDP plot
Participants with glaucoma Total
Number of participantsb 268 (100 %) 252 (94 %) 6 (2.2 %) 9 (3.4 %) 1 (0.4 %)
Number of eyes 310 (100 %) 283 (91.3 %) 9 (2.9 %) 13 (4.2 %) 5 (1.6 %)
TDP total deviation probability, PDP pattern deviation probability
aOther evidence of glaucoma noted in those classified as glaucoma
bIn participants with bilateral glaucoma, the eye with the highest level of evidence is used to classify that person
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Glaucoma diagnostic algorithm
Glaucoma was classified according to the ISGEO criteria,
using percentile distributions of VCDR, VCDR asymmetry
and IOP in normal Nigerians, derived from the normative
dataset (n = 1759) of this study population [29] (Table 2).
The diagnosis of glaucoma started with VCDR findings
(Fig. 2). Category 1 required structural and functional evi-
dence i.e., 97.5th percentile of the VCDR (≥0.7) or VCDR
asymmetry (≥0.1) in our normal population and visual
field loss typical of glaucoma. Category 2 required ad-
vanced structural damage i.e., 99.5th percentile VCDR
(≥0.75) or VCDR asymmetry (≥0.2) in the absence of
Table 2 International Society of Geographical and Epidemiological Ophthalmology (ISGEO) definitions for glaucoma used in analysis
(Adapted From Foster, 2002) [13]
VCDR or VCDR asymmetry
Level of evidence Image reading
analysis
Clinical records
analysis
Visual fields Intraocular pressure Visual
acuity
Medical history
Other features
Category 1 ≥97.5th percentile: ≥97.5th percentile: Typical defect
VCDR 0.7 0.6
VCDR asymmetry 0.1 0.2
Category 2 ≥99.5th percentile: ≥99.5th percentile: Not available
VCDR 0.75 0.7
VCDR asymmetry 0.2 0.3
Category 2b ≤97.5th percentile: 0.7 ≤97.5th percentile: 0.6 ±Typical defect ≥99.5th percentile: 28 mmHg RAPD, Corneal edema
Category 3 Not available Not available ≥99.5th percentile: 28 mmHg <20/400 Surgery for glaucoma
VCDR vertical cup:disc ratio, RAPD relative afferent pupillary defect
Fig. 2 Glaucoma diagnostic algorithm and number of glaucoma participants in each category
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visual field evidence i.e., when a useful visual field result
was not possible or available. Category 3 applied when the
optic disc was not seen and visual field testing was not
possible, and used: a) blindness (VA <3/60) with the 99.5th
percentile IOP (≥28 mmHg), or b) diagnosed with/being
treated for glaucoma. An additional level of evidence (level
2b) was added where the optic disc was visualized but the
VCDR was <99.5th percentile and visual fields were not
available or if visual fields were interpreted as “unlikely
glaucoma” but there were other compelling evidence such
as RAPD, high IOP and/or corneal edema. Other glau-
comatous optic nerve head features such as localized nar-
rowing of the rim, optic disc hemorrhages, and retinal
nerve fiber layer defects are not included in the ISGEO
classification, and so individuals with these signs only (i.e.,
no visual field defects; IOP within the normal range for
the study population) would not have been classified as
having glaucoma. These cases were adjudicated by glau-
coma specialists (RW and WN). A person was said to have
glaucoma if there was glaucoma in one or both eyes.
Type of glaucoma
Glaucoma was classified as primary and secondary
glaucoma. Primary glaucoma was classified as primary
open-angle glaucoma (POAG) or primary angle-closure
glaucoma (PACG) according to angle morphology viewed
by gonioscopy. Glaucoma was classified as secondary where
there was an underlying cause such as AC angle neovascu-
larization, exfoliation, pigment dispersion, trauma, surgical
procedure, couching or uveitis. The type was unclassified in
eyes that did not have gonioscopy.
Data analysis and statistical methods
Visual acuities were categorized using the WHO classifi-
cation of blindness and visual impairment with addition
of a category for mild visual impairment (worse than 6/
12 but up to 6/18). The classification uses presenting VA
in the better seeing eye. Age was categorized in 10-year
groups. Any ability to read and write was classified as
literate. Ethnic groups represented by ≥200 participants
were analyzed separately (i.e., Hausa, Yoruba, Igbo, Fu-
lani, Kanuri, Nupe, Ijaw, Ibibio, Tiv and Urhobo). Ethnic
groups with <200 participants were grouped as “Others”
and analyzed collectively. Settlements with a population
of ≤20,000 were classified as rural.
The percentile VCDR values used for classification of
glaucoma in this study were derived from the photo
VCDR grades of the ‘normative’ data. The percentile
values for the distribution of the clinical VCDR records
are included in Table 2 for comparison.
Statistical analysis was performed using Stata (Stata/IC
13.0; Stata Corp, College Station, TX). A descriptive analysis
of the study population was undertaken. Univariate analysis
was performed to describe socio-demographic characteris-
tics (age, gender, ethnic group, literacy and rural/urban
place of residence). The age/sex-specific prevalence of glau-
coma with 95 % confidence intervals (CI) was calculated
taking account of additional variation introduced by the
stratified cluster sampling design. Missing values were indi-
cated and excluded in the analysis.
Results
A total of 15,027 adults aged ≥40 years were enumerated
in 310 clusters, 13,591 (90 %) of whom were examined in
305 clusters. 6,397 participants had detailed eye examin-
ation, 3814 (59.6 %) of whom had images for VCDR as-
sessment in both eyes and 817 (12.8 %) in one eye. Where
there was no disc image (2624 eyes of 1329 [20.8 %]
participants), clinical VCDR grade was used (Table 3).
Reasons why there were no disc images are stated in
Table 4. Photos were ungradable if no optic disc features
could be assessed due to blur or wrong field definition.
Clinical VCDR grades were also used in participants
undergoing the basic eye examination only. In the whole
study sample, a total of 25,289 (93 %) eyes of 13,081 (96 %)
participants had photographic or clinical VCDR grades;
510 (4 %) participants did not have VCDR graded in both
eyes (Fig. 2).
Table 3 Summary of completeness of data for participants undergoing full examination (N = 6397)
Eye level data Person level data
Right eye Left eye All eyes One/both eyes Both eyes
N % N % N % N % N %
Total 6397 6397 12,794 6397 6397
Examination
Van Herick’s 5830 91.1 5821 91.0 11,651 91.1 5967 93.3 5684 88.9
Intra-ocular pressure 5496 85.9 5478 85.6 10,974 85.8 5638 88.1 5336 83.4
Disc grading
Photo 4203 65.7 4242 66.3 8445 66.0 4631 72.4 3814 59.6
Clinical 1320 20.6 1304 20.4 2624 20.5 1329 20.8 993 15.5
None 874 13.7 851 13.3 1725 13.5 – – 437 6.8
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The kappa for inter-observer agreement on ophthal-
mologists’ clinical measurement of VCDR within 0.1 was
κ = 0.86 (almost perfect agreement) and classifying ≥0.6
or <0.6 was κ = 0.47 (moderate agreement). Overall, the
inter-observer agreement between graders for the image
VCDR grading at MEHRC was 99.7 %. The Bland-Altman
limits of agreement between the clinical and the image
VCDR measurements for 95 % of eyes were lower limit of
−0.2 to upper limit of 0.3; and 93 % eyes had a difference
of ≤0.25 between the two methods of VCDR measure-
ment. In participants undergoing detailed eye examination
(n = 6397), 93 % and 88 % had VH AC depth estimation
and IOP measurement in at least one eye, respectively
(Table 3). With 94 % agreement, the kappa for correlation
of gonioscopy (closed/open) Vs VH AC (grades 0–2/3–4)
in 397 eyes with glaucoma was κ = 0.70 (substantial
agreement).
As shown in Fig. 2, 770 participants had VCDR ≥ 0.7 in
one or both eyes and a further 3768 had VCDR asym-
metry ≥ 0.1, thus a total of 4995 eyes in 4538 participants
required visual field analysis (for level 1 evidence) which
were available for 3016 (60.4 %) eyes of 2725 (60.1 %) per-
sons. Glaucoma was diagnosed in 63 % (485/770) par-
ticipants with VCDR ≥0.7/0.75, and in 4.1 % (156/3768)
participants with VCDR asymmetry. Other participants
were assessed for level 2b and level 3 evidence. The
diagnosis of glaucoma was made in a total of 950 eyes
of 682 participants - by photo VCDR in 352 (51.6 %),
clinical VCDR in 294 (43.1 %) and the disc was not
seen in 36 (5.3 %). Thus, glaucoma diagnosis was made
by level 1 evidence in 268 (39.3 %), level 2 evidence in
373 (54.7 %), level 2b in 5 (0.7 %) and level 3 in 36
(5.3 %) participants (Table 5).
Prevalence and types of glaucoma
The prevalence of glaucoma of all types was 5.02 % (95 %
CI 4.60–5.47 %). The prevalence increased with increasing
age and was higher in males, those who were not literate
and the Igbo ethnic group (Table 6). These differences
were statistically significant. The age-specific prevalence
and the magnitude of glaucoma in Nigeria derived by dir-
ect standardization with the 2012 Nigeria population are
shown in Table 7. There are estimated to be 1.2 million
Nigerians aged ≥40 years with glaucoma.
Among the 243 participants with primary glaucoma
classified according to pathophysiology based on AC
angle morphology by gonioscopy, 208 (86 %) were classi-
fied as POAG and 35 (14 %) as PACG (Table 8). PACG
was more common in women but the difference was not
statistically significant (p = 0.08). There were no differ-
ences in age, ethnic distribution or rural/urban place of
residence between the two groups. Additionally, there
was no statistically significant difference in awareness of
having glaucoma (p = 0.55): 1 in 8 of those with POAG
and 1 in 12 of those with PACG knew they had the dis-
ease. IOPs were higher in PACG than POAG: the mean
IOP was 34 mmHg, standard deviation (SD) 13 in PACG
and 27 mmHg, SD 11 in POAG (p <0.001).
Table 4 Reasons why there was no photo disc grading in
4349 (34 %) eyes among those who had full examination
(n = 12,794 eyes)
Reason Right eye Left eye All eyes %
Eye disease
Cataract 552 469 1021 24 %
Corneal opacity 304 295 599 14 %
Other ocular pathology 166 192 358 8 %
1978 46 %
Participants factors
Uncooperative 27 31 58 1 %
Other e.g., home visit 31 27 58 1 %
116 2 %
Technical reasons
Faulty camera 471 472 943 22 %
No electricity 144 144 288 7 %
1231 28 %
Other
No reason stated 271 312 583 14 %
Ungradable photosa 228 213 441 10 %
1024 24 %
Total 2194 2155 4349 100 %
aPhotos were taken but VCDR could not be assessed because of blurred image
due to media opacity or poor positioning of the participant
Table 5 Classification of participants with glaucoma by levels of
evidence (as described in Table 2)
Participants with glaucoma
Level of evidence Number of participants Number of eyes
Category 1
VCDR 155 (22.7 %) 197 (20.8 %)
VCDR asymmetry 113 (16.6 %) 113 (11.9 %)
Total 268 (39.3 %) 310 (32.7 %)
Category 2
VCDR 330 (48.4 %) 511 (53.8 %)
VCDR asymmetry 43 (6.3 %) 43 (4.5 %)
Total 373 (54.7 %) 554 (58.3 %)
Category 2b 5 (0.7 %) 10 (1.0 %)
Category 3 36 (5.3 %) 76 (8.0 %)
Total glaucoma 682 (100 %) 950 (100.0 %)
VCDR vertical cup:disc ratio
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Other findings
Only 5.6 % (38/682) of all participants with glaucoma
knew they had the condition. The commonest causes of
secondary glaucoma (n = 53 participants) were couching
(an ancient, traditional non-medical manipulation of the
crystalline lens; 38 %), trauma (21 %), uveitis (19 %) and
following intracapsular cataract surgery (17 %). Over a
third of the eyes with glaucoma (365; 38 %) had a present-
ing VA worse than 3/60; and 1 in every 5 persons with
glaucoma (136; 20 %) was blind (VA worse than 3/60 in
the better eye). In 68 % of the 136 blind with glaucoma,
the main cause of blindness was attributable to glaucoma.
Among the 40–49 year-group with glaucoma, 13 % were
blind, and this age-specific proportion of blindness among
glaucoma participants increased with age to 30 % in the
80+ years age-group.
Figure 3 shows the distribution of IOP in all eyes: the
mean IOP was 14 mmHg, SD 4 in the non-glaucomatous
eyes compared to 23 mmHg, SD 12 in the glaucoma eyes.
The difference in the mean values was statistically signifi-
cant (p <0.001). The modal IOP was 12 mmHg in both
groups. There were three different peaks at 12, 28 and
Table 6 Socio-demographic characteristics of participants with glaucoma in the study population
Total Participants with glaucoma
N N % 95 % CI
Total 13,591 (100 %) 682 5.02 4.60–5.47
Socio-demographic factors
Age group (years) 40–49 4889 93 1.90 1.55–2.33
50–59 3577 130 3.63 3.03–4.36
60–69 2773 178 6.42 5.50–7.48
70–79 1653 178 10.77 9.24–12.52
80+ 699 103 14.74 12.31–17.54
p <0.001
Gender Female 7345 328 4.47 3.98–5.00
Male 6246 354 5.67 5.05–5.47
p = 0.002
Ethnic groupa Hausa 3375 130 3.85 3.00–4.93
Yoruba 2669 156 5.84 4.94–6.90
Igbo 1918 149 7.77 6.57–9.16
Fulani 840 30 3.57 2.53–5.01
Kanuri 353 18 5.10 3.40–7.58
Tiv 342 11 3.22 2.29–4.51
Ijaw 251 15 5.98 4.46–7.96
Urhobo 245 7 2.86 1.50–5.37
Ibibio 212 12 5.66 2.35–13.03
Nupe 211 11 5.21 3.41–7.88
Others 3117 139 4.46 3.72–5.33
p <0.001
Literacy Literate 5925 248 4.19 3.60–4.86
Illiterate 7666 434 5.66 5.14-6.23
p = 0.001
Place of residence Rural 10,540 520 4.93 4.46–5.46
Urban 3051 162 5.31 4.47–6.30
p = 0.473
Visual status Not blind 13,022 546 4.19 3.83–4.59
Blind 569 136 23.90 20.24–27.99
p <0.001
CI = confidence interval
a58 missing values excluded
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50 mmHg in the IOP distribution of the eyes with glau-
coma. About half (56 %) of the eyes with glaucoma had
IOP ≤22 mmHg. Conversely, 4 % had IOP >21 mmHg but
did not have glaucoma.
Discussion
The Nigeria Blindness Survey was the largest, national
population-based survey of eye disease in an ethnically di-
verse, indigenous black African population, giving precise
estimates of the prevalence of glaucoma. The sample was
nationally representative by age, gender, ethnicity, rural/
urban residence and socioeconomic status [24], with a
high response rate and the results are generalizable to the
whole country and also to people of the West African
diaspora around the world whose predecessors were vic-
tims of the slave trade e.g., African Caribbean and African
American people. Though now genetically mixed to vary-
ing extent, our study population is likely to have the same
genetic determinants of the glaucoma seen in those popu-
lations. Additional strengths are the standardized protocol,
the same clinicians and equipment were used throughout
the study, and photographic VCDR grading was performed
by the MEHRC, an independent, internationally recognized
reading center. Furthermore, the centile values for VCDR
and IOP distribution in the population used to define glau-
coma were derived from the same study population.
The survey indicates that 1.1 to 1.4 million adults in
Nigeria have glaucoma, most of whom are not aware that
they have the disease. One in every 20 Nigerians aged
40 years and above has glaucoma, and one in five being
blind. There are approximately 8500 people aged 40 years
and above with glaucoma per million population. The
high prevalence and high rate of blindness confirm glau-
coma to be of public health importance and should be-
come a priority among healthcare planners and policy
makers, emphasizing the need for glaucoma care pathways
for early detection and treatment to prevent blindness. In
Nigeria, 8 % of glaucoma was secondary, with over half
of these following procedures for cataract, particularly
couching, which is still widely practiced in Nigeria despite
very poor visual outcomes [30]. This underscores the need
for high quality, affordable and accessible cataract surgical
services. The findings have public health implications for
other countries in sub-Saharan Africa which share similar
socio-demographic characteristics.
The prevalence of glaucoma in Nigeria is similar to that
in Temba, South Africa [20], slightly higher than in South
African Zulus [19] and in Kongwa, Tanzania [18] but lower
than in Tema, Ghana [21] and Akinyele, SW Nigeria [22].
Although these surveys were undertaken in localized pop-
ulations, there seems to be an emerging pattern with the
prevalence being higher in West Africa than in South
Africa which in turn is higher than in East Africa. The
Ghana study [21] had a high proportion of Level 1 diagno-
sis (87.2 %) compared with our study (39.3 %) as in Nigeria
there were high rates of cataract and other pathology
which precluded visual field assessment. As Level 2 re-
quires evidence of more advanced structural damage our
estimates for Nigeria are, therefore, minimum estimates.
The prevalence of glaucoma in Nigeria is lower than that
of POAG reported from Barbados (6.7 %, 95 % CI 6.3–7.8)
[17], being similar to black populations in the United
States of America (USA) [15] but slightly higher than in
Asian populations [31–38] and much higher than white
populations in the USA [15, 39], Australia [40] and Europe
Table 7 Age-standardized glaucoma prevalence rates
Study sample Prevalence of glaucoma Magnitude of glaucoma
Crude rate Age-adjusted ratea Estimated numbers
N % N % % 95 % CI
Age group (years)
40–49 4889 35.97 93 1.90 1.51 1.96–2.94 166,308
50–59 3577 26.32 130 3.63 3.69 2.98–4.29 232,792
60–69 2773 20.40 178 6.42 8.85 3.99–5.43 318,689
70–79 1653 12.16 178 10.77 16.85 5.91–8.00 321,820
80+ 699 5.14 103 14.74 12.32 14.72–20.98 181,807
Total 13,591 100 682 5.02 5.02 4.60–5.47 1,221,416
CI confidence interval
aStandardized with the 2012 Nigeria population
Table 8 Proportion of the different types of glaucoma in the
Nigeria National Survey of Blindness and Visual Impairment
Proportion of glaucoma
Glaucoma type N %
All glaucomaa 682 100.0
POAG 208 30.5
PACG 35 5.1
Secondary glaucoma 53 7.8
Unclassifiedb 386 56.6
POAG primary open angle glaucoma, PACG primary angle-closure glaucoma
aAll glaucoma prevalence is 5.02 % (95 % CI 4.60–5.47 %)
bNo data on gonioscopy, thus not classified by anterior chamber angle morphology
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[41–44]. The prevalence of glaucoma in Nigeria is also
higher than in Brazil [45], Iran [46], indigenous popula-
tions in Australia [47] and Qatar [48]. Regional/racial vari-
ations in prevalence have been attributed to genetic and
possible environmental differences [49, 50]. Susceptibility
gene loci significantly associated with POAG and genes
involved in IOP regulation have been studied in some
African populations [51, 52]. In Nigeria, the Igbo, a rather
homogenous ethnic group, had the highest prevalence of
glaucoma which may also reflect genetic susceptibility.
The relatively high age-specific prevalence of glau-
coma in 40–49 year olds in Nigeria and the high pro-
portion of glaucoma blindness suggest severity at an
earlier age [15, 17, 21, 22] and more aggressive course [53]
in Blacks than in Caucasians [41, 42, 44] and some Asian
populations [33, 34] over and above lack of diagnosis and
treatment since the high proportions of undiagnosed glau-
coma are relatively similar (Table 9). However, this could
also be the natural history signifying poor access to treat-
ment. Additionally, because of the earlier age of onset and
longer years with untreated glaucoma, the risk of going
blind would be much greater. The racial/regional dispar-
ity in disease severity may be attributed to additional
factors such as inflammation [54, 55] and the different
peaks of IOP in eyes with glaucoma may indicate gen-
etic susceptibility at varying levels of IOP. However,
these interpretations are speculative and warrant fur-
ther research.
The classification of glaucoma by pathophysiological
mechanism based on angle morphology is important be-
cause POAG and PACG have different natural histories
and different management strategies. In Nigeria POAG
was the commonest type of glaucoma, as reported in
other black populations [3, 15–22, 45].
It is acknowledged that communities in Nigeria, where
prior diagnosis of glaucoma is low, have extremely little
knowledge about glaucoma. Questions were, therefore,
not asked on whether first-degree relatives had glaucoma
as participants would be highly unlikely to know. In
addition, the ISGEO classification does not take first-
degree relatives into account.
It is noteworthy that at least half of the glaucoma eyes
had an IOP less than the mean +2SD IOP (22 mmHg) of
non-glaucoma participants. The important implication is
that IOP is unable to differentiate between those with
glaucoma and those without glaucoma.
A limitation of this study is that the ‘gold standard’
Humphrey field analyzer was not used as, unlike the port-
able FDT perimeter, it would not have been feasible to
transport it to all examination centers especially in the ter-
rain and environment of the survey. Nevertheless, we had
an acceptable and reproducible test of visual function
based on the central 20° field of vision. Another limitation
was that pachymetry was not done. The data would have
added more information on corneal thickness in relation
to glaucoma. Interestingly, in the Barbados Eye Studies,
corneal thickness tended to be thinner in the black partici-
pants than in the white participants but was not correlated
to IOP [56]. However, as corneal thickness decreased,
there was a higher likelihood of incident OAG [57]. Also,
not all participants had dilated disc assessment or photo-
graphic disc grading as this was not possible given the
large sample size of the study. The fundus camera pro-
duced non-stereoscopic images and monocular clues were
used to determine optic disc and cup boundaries. Though
this may have led to misclassification, most of the cases
classified as glaucoma in this survey were “barn-door”.
Even though there is a tendency for non-stereoscopic
Fig. 3 Distribution of IOP in glaucoma and non-glaucomatous eyes
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assessments to yield slightly varied optic disc parameters
[58, 59], these differences were inconsistent and the agree-
ment between stereoscopic and non-stereoscopic VCDR
assessment were generally extremely good and repeatable
[58]. A further limitation was that the fundus camera was
not calibrated for disc size so VCDRs could not be ad-
justed for disc size. Technical difficulties in the field (faulty
camera or generator) meant that disc images were not ob-
tained in 616 participants when needed. High humidity
damaged the mirror coating of gonioscopy lenses so that
some eligible participants did not have gonioscopy per-
formed and VH AC angle estimation was used instead.
Hence, the proportions for angle-closure glaucoma and
open-angle glaucoma were obtained only from partici-
pants that had gonioscopy. Additionally, lack of indenta-
tion gonioscopy, use of a one-mirror gonioscopy lens, and
defining open-angle glaucoma as a visible Schwalbe’s line
may have led to some misclassification of the type of glau-
coma. The survey protocol indicated detailed eye exam-
ination of those with VCDR asymmetry of ≥0.2 whereas
the asymmetry required for Level 1 diagnosis in later
analysis was found to be 0.1. In individuals with VCDR
asymmetry between 0.1 and 0.2, the diagnosis of glau-
coma was based on the presence of glaucomatous visual
fields. The ISGEO classification system is designed to
identify moderate, severe glaucoma and those blind
from glaucoma and therefore glaucoma ‘suspects’ and
those with early disease may not have been captured.
Our estimate is, therefore, a minimal estimate.
One survey team inadvertently used the C-20-1 FDT
screening mode in 141 clusters. The C-20-1 mode has
greater specificity and is less likely to misclassify a normal
field. The C-20-5 has higher sensitivity at detecting early
defects at the expense of lower specificity. To overcome
Table 9 Prevalence of Glaucoma in some population-based studies for age ≥40 years
Study population Examined
(response rate %)
Prevalence of glaucoma Undiagnosed
glaucoma (%)
Proportion
blind (%)
Reference
n All glaucoma %
(95 % CI)
40–49 years age-specific
Nigeria, National 13,951 (90) 682 5.0 (4.6–5.5) 1.9 (1.6–2.3) 94 20 This study
Africa
Kongwa, Tanzania 3247 (89) 135 4.2 (3.5–4.9) 1.7 (1.1–2.5) 98 14 [18]
Hlabisa, South Africa 1005 (90) 41 4.5 (3.2–6.1) 1.2 (0.2–3.4) 90 [19]
Temba, South Africa 839 (75) 55 5.3 (3.9–7.1) 1.1b 87 [20]
Tema, Ghana 5603 (82) 32 6.5 (5.8–7.1) 3.2 (2.7–4.1) 97 3 [21]
Akinyele, Nigeria 811 (90) 59 7.3 (5.5–9.1) 4.6 (2.1–7.1) 90 6 [22]
Asia
Qatar 3149 (97) 67 1.7 (1.7–1.8) 1.45 b 51 6 [48]
Yazd, Iran 1990 (86) 87 4.4 (3.3–5.4) 1.6 (0.8–2.4) 90 [46]
Chinese, Singapore 1232 (72) 45 3.2 (2.3–4.1)a 1.1 (0.2–4.8) 62 [31]
Chinese, Singapore 3353 (73) 134 3.2 (2.7–3.9)a 0.7 b 85 10 [38]
Malay, Singapore 3280 (79) 150 3.4 (3.3–3.5)a 2.2 b 92 10 [36]
Indian, Singapore 3400 (76) 78 1.9 (1.5–2.5)a 1.3 b 72 10 [35]
Beijing, China 4439 (83) 158 3.7 (3.1–4.2) 2.2 (1.5–3.0) - 2 [37]
Kailu, China 5197 (87) 169 2.9 (2.0–3.8)a 2.0 (1.3–2.7) 66 7 [32]
Bhaktapur, Nepal 3991 (83) 75 1.8 (1.7–1.9)a 0.3 b 96 2 [33]
Central India 4711 (80) 122 3.5 (2.8–4.1) 1.0 (0.5–1.6) – 1 [34]
Australia
Indigenous, Australia 1061 (64) 26 2.2 (1.6–3.6) 1.5 (0.4–2.5) 81 12 [47]
Europe
Ponza, Italy 1034 (84) 39 3.8b 0 (0.0–1.7) – [42]
Egna-Neumarkt, Italy 4297 (74) 121 2.9b approx 0.5 b – [41]
Wroclaw, Poland 4853 (83) 79 1.6 (1.3–2.0) 0.4 (0.1–1.1) 71 [44]
CI confidence interval
aAdjusted rates
b95 % confidence interval not reported
– no data
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the difference visual fields were classified according to the
probability of pattern deviation and were equalized for the
2 screening modes.
Having described the high prevalence and distribution
of glaucoma in this comprehensive and representative
study, we are obliged to recommend a strategy for the
prevention blindness and visual impairment from glau-
coma in Nigeria and more widely in West Africa. The
clinical care of glaucoma in Nigeria remains challenging
and we suggest a top-down approach [60].
Conclusion
This nationally representative survey in Nigeria indicates
a high prevalence of glaucoma, with ethnic variation, se-
verity at an earlier age and high rates of blindness. The
latter is likely to reflect an aggressive natural history as
well as lack of awareness of the condition and low levels
of treatment. Most glaucoma in Nigeria is POAG with a
high proportion of secondary glaucoma being the conse-
quence of procedures for cataract. The findings shed
light on the more severe and prevalent disease seen in
black communities of the West African diaspora around
the world and quantify the enormous challenge of pre-
venting blindness from glaucoma in West Africa and in
people of this ethnic origin. Public health control strat-
egies with high quality integrated glaucoma care services
will be required to reduce morbidity and blindness.
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Chapter(7!
Agreement(in(measurement(of(optic(cup"to"disc%ratio%with%
stereo&biomicroscope)funduscopy)and)digital)image)analysis!
Results'from'the'Nigeria'National'Blindness'and'Visual'Impairment'Survey!
!
!
Digital'fundus'photography!
!
!
Research(paper(investigating!the$agreement$between$clinical&and&digital'
photo%VCDR%measurements!in#a#subset#of#participants#who#had#both#
methods(of(assessment!
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Abstract!!
Purpose:!
To#determine#agreement#of#estimations#of#vertical#cup"to"disc%ratios%(VCDR)%
between&clinical&stereo"biomicroscopic)funduscopy!and$digital$fundus$images$
analysis.!
Methods:!
Systematic*sampling*of*1"in"!"from"a"sample"of",-,/0,"participants"aged">!"#years#
gave%a%subsample%who%were%examined%in%detail.%VCDR%was%estimated%clinically%by!
!"D$aspheric%lens!biomicroscopic)funduscopy)(c"VCDR)&and&by&fundus&images&
(i"VCDR)&graded&at&Moorfields&Eye&Hospital&Reading&Centre.&Spearman’s$
correlation*coefficient,*paired*t"test$and$Bland"Altman'method'to'assess'limits'of'
agreement!(LOA)!between&the&two&methods&were&applied.!
Results:!
Of!!"#$%participants%in%the%subsample,%!"!!participants!("#%)#who$had$normal'
FDT$visual'fields'and'data$for$i"VCDR%and$c"VCDR%in#both#eyes!(n=!"#"!eyes)!
were$analysed.!By!absolute)difference)of!VCDR!values!for!each%eye,%between%the%
two$methods,!!"%$eyes$(n=+,-,)"differed&by&<!.#.$Mean$i"VCDR%was%).+!!,"
standard'deviation'(SD)'0.2!!;!and!mean%c"VCDR%!.!"!,"SD"%.'!!."i"VCDRs&were&
significantly+larger&by&a"mean"difference"of!!.!!"!SD#$.&'&#("#%%confidence%
interval)[+,%CI])!.!##"!.!##;"p<#.##%).!The!!"%$LOA!assessed%by!the$Bland"
Altman'method!were!lower&limit&"!.!"#!("#%CI!"!.!"#;""!.!"#)"and"upper"limit"
!.!"!!("#%CI'(.!"#;"#.!"!).#The$interval$of$the$./%$LOA!narrowed(with(higher(
VCDRs.!
Conclusion:!
Digital'image'analysis'and$clinical$assessment$are$two$distinct$methods%of%
measurement)for)VCDR;)with!larger!i"VCDRs!in#this#survey."Applying'i"VCDR%
cut"off!values'to!c"VCDR!measurements!in#the$Nigeria$Blindness$Survey!might!
have%underestimated!glaucoma(prevalence.!It#is#recommended#that#all#
participants!in#glaucoma(surveys!have%VCDR%by%digital'image'measurement.!
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Introduction!
!
Glaucoma(is(the(leading(cause(of(irreversible(blindness.(It(is#projected)to)affect&up&
to#$%!million!people!by#the#year#)*)*!!and$%%%.'$million$in$,-.-.!!In#population"
based&surveys,&evidence&of&structural&optic&disc&damage&is&an&essential&element&in!
identifying)individuals)who)may)have)glaucoma.)The)optic)vertical)cup"to"disc%
ratio&(VCDR)&is&one&of&the&ways&of&determining&optic&disc&structural&damage.&&!
!
For$the#Nigeria#National#Blindness#and#Visual#Impairment#Survey#(hereafter#
referred%to%as%the%Nigeria%Blindness'Survey)!!glaucoma'classification'was'
according)to)the)ISGEO)criteria.!!The$glaucoma"defining'VCDR%values'for'the'
!".$th!(".$)&and$%%.'th!(".$%)'percentiles!in#the#study#population!!were$applied,$
reporting)a)glaucoma)prevalence)of)1.34%)(71%CI):.;3"!.#$)&among&adults&aged&
!""years&old!and$above.!!The$i"VCDR%grading%by%Moorfields%Eye%Hospital%
Reading(Centre((MEHRC)(was(considered(the(gold(standard;(it(was(objective,(
quantified*with*a*scale*and*adjudicated.!According)to)the)survey)protocol,)
participants)who)had)good)visual)acuity)of)4/6)or)better)in)both)eyes)would)not)
have%fundus%photography%except!if#they#were#among#the#/"in"!"subsample"or"if"
they%had%disc%abnormalities%suggestive%of%glaucoma%detected%by%direct%
ophthalmoscopy.,Also,&fundus&photography&was&not&obtained&for&all&participants.&
Thus,&these%i"VCDR%cut"off#values#were!also!applied'to'clinically'graded'VCDR%of%
participants)who)did)not)have)digital)fundus)photography)with)optic)disc)
imaging.!!
!
In#this#report,#data#from#the#Nigeria#Blindness#Survey#were#analysed#to#determine#
the$agreement$in$measurement$of$i"VCDR%and%c"VCDR%among%adults%aged%>!"#
years&in&a"subset&of&participants&who&had&both&methods&of&assessment&i.e.&the&4"
in"!"subsample."Determining)the$agreement$between$the$two$VCDR%
measurement)methods)will!potentially!inform'VCDR%measurement%in%subsequent(
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glaucoma(prevalence(surveys.#It#will!also!enable&better%interpretation)of)the)
results'obtained'by!applying(the(i"VCDR%defining%percentile$values$to$the$whole$
dataset&for&glaucoma&classification&in&the&National&Blindness&Survey.&!
!
!
Methods!
!
Details(of(all(the(methods(used(in(the(Nigeria(Blindness(Survey,!!a"report"on"the"
defining'values'for'glaucoma'in'prevalence'surveys'in'Nigeria!!as#well#as#the#
prevalence)and)types)of)glaucoma)in)Nigeria)have%been%published.!!!
!
Study&design,&data&collection&and&clinical&assessment!
The$sample$size$calculation$and$sampling$strategy$for$the$Nigeria'Blindness'
Survey'gave%a%nationally%representative%sample%of%12,452%persons%aged%78%years%
and$above$in$*+,$clusters$across$the$country.$Multi"stage&sampling&using&
probability"proportional"to"size%methods%were%used%to%select%the%study%
population.*A*further*systematic*sampling"of"%"in"!"participants"registered"at"the"
examination)centre)was)done.)All)participants)were)invited)to)a)temporary)clinic"
type%set%up%for%examination.%Data%were%collected%by%two%teams,%each%comprising%
of#two#ophthalmologists,#one#optometrist#and#two#ophthalmic'nurses.'The'
ophthalmologists+received+further+training+in+survey+protocols+and+standardising+
VCDR%measurement.%!
!
Systematic*sampling*of*1"in"!"from"a"sample"of",-,/0,"participants"aged">!"#years#
gave%a%subsample%who%were%examined%in%detail,"including"visual"field"assessment"
with%a%Humphrey%FDT%visual%field%analyzer%(Carl%Zeiss%Meditec%AG%Jena%
Germany)."!
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The$first$ophthalmologist$performed$undilated$direct$funduscopy.$Detailed$eye$
examination)performed)by)the)second)ophthalmologist)included(slit"lamp%
biomicroscopy*(Zeiss*SL*001*Classic*Slit*Lamp,*Carl*Zeiss*Meditec*AG*Jena*
Germany))and)dilated'retinal'examination'and'optic'disc'assessment'using'!"D$
aspheric)condensing)lens)(Volk).)VCDR)was)estimated)clinically)(c"VCDR)&by&
determining!the$rim$of$the$optic$disc$and$estimating$the$cup$size$in$the$vertical$
meridian(and(calculating(the(spatial(ratio(between(the(optic(cup(and(the(optic(
disc.!!
!
Participants*also*had*digital*retinal*photography*(Zeiss*Visucam*Lite*Desk*Top*
Fundus&Camera,&Carl!Zeiss%Meditec%AG%Jena%Germany)%through%a%dilated%pupil%
focused(mid"point&between&the&macular&and&optic&nerve&head&displaying&a&field&of&
!"#degrees#showing#both#the#macula#and#the#optic#disc#in#the#observed#field.#
Images'were'graded'independently'by'the'Moorfields)Eye)Hospital)Reading)
Centre&(MEHRC).&Images&were&viewed&"full&screen"&on&either&a&>?"inch%Eizo%
S"#$$W&monitor&calibrated&using&a&Datacolor&Spyder"&calibrator&or&on&a&"#"inch%
widescreen)Dell),-./WFP)LCD)monitor)calibrated)using)a)Gretag)Macbeth)Eye"
One$Display$,$calibrator.!After&determining&image&quality&and&clarity,&the&scleral&
rim$was$identified$and$the$boundaries$of$the$disc$and$the$cup$were$identified.$
One$successful$measurement$was$performed$per$eye,$along$the$vertical$meridian,$
in#Adobe#Photoshop%(version%,)%using%the%measurement%tool,%resulting%in%a%cup%
and$a$disc$diameter$value$in$pixels,$along$the$same$plane,$the$division$of$the$two$
values'producing'the'i"VCDR%which%was%recorded%to%the%nearest%2.24.%Primary%
grading'was'performed'by'the'3st!reader%(FS),%and%a%,nd!reader%(NP)%and%
inconclusive*cases*were*adjudicated*by*a*3rd!reader%(TP).%!
!
Inter"observer'agreement'assessments'were'conducted'for'ophthalmologists'on'
c"VCDR%measurement%during%the%training%sessions%and%at%intervals%during%
fieldwork."There#was#one#clinical!ophthalmologist!in#each#of#the#two#teams!
throughout'the'survey.!For$i"VCDR%grading,%inter"observer'agreement'between'
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the$%st!and$%nd!readers&was&assessed.!Kappa$statistics$for$inter"observer'error'were'
calculated.!
!
Ethics"
Ethical(approval(was(obtained(from(the(Ethics(Committee(of(the(London(School(
of#Hygiene#and#Tropical#Medicine#(LSHTM),#UK#and#the#Nigeria#National#Health#
Research(and(Ethics(Committee((NHREC).(Oral%informed)consent)was)obtained)
from%participants.!The$study!adhered&to&the&tenets&of&the&declaration&of&Helsinki.&
Persons'with'medical'or'eye'conditions'needing'further'assessment'and'
treatment'were'referred'to'the'nearest'healthcare'facility.!
!
Data$analysis!
Statistical(analysis(was(performed(using(Stata/IC(8!."#(Stata$Corp,$College$
Station,(TX).(Included(in(the(analysis(were(both(eyes(of#the#'('!participants)in"
whom"both"eyes!had$VCDR$grading'by'the'two'methods'(slit"lamp%
biomicroscopic!funduscopy*with*/0D*aspheric*lens*and*digital*fundus*
photography)image)analysis),)normal!FDT!visual'fields'and'no'detected'ocular'
pathology.*!
!
For$kappa$analysis,$ophthalmologists’$clinical$measurement$of$VCDR$within$<.>$
in#one#session#was#assessed;"and"image%grading%within&'.)&obtained)by)the)two)
primary'readers'was'assessed.!
!
Frequency)distribution)of)the)absolute)difference)between)the)VCDR)values)in)
each%eye%was%determined.%The$frequency$distributions!of#c"VCDR%and%i"VCDR%
were!determined(and(compared;"and$the$Shapiro"Wilk%test%of%normality%was%
applied.(The(association(between(the(two(methods(of(measurement(was(
calculated!and$expressed!as#the#Spearman’s#rank"order%correlation%coefficient.%
Fatima Kyari PhD Thesis Page 133
8"
"
Paired't"test$was$applied$for$comparison$of$means$to$investigate$the#presence#of#
any$systematic!(fixed)(bias."!
!
Bland"Altman'method'to'assess'!"%$limits&of&agreement&(LOA)&between&the&two&
methods(was(applied.!"!!To#assess#agreement#on#the#Bland"Altman'plot,"the"y"
axis%was%the%difference%between%the%two%measurement%methods!(i"VCDR%minus%
c"VCDR),"i.e."the"amount"of"disagreement,"plotted"against"the"x"axis,&the&mean&of&
the$two$measurements.$The$LOA!were$the$mean$differences$+!!"standard"
deviation)of)the)differences.)The$%&%$confidence$intervals$for$the$upper$and$
lower&LOA!were$calculated.$The$difference$between$the$two$measurement!
methods!was$regressed$on$the$average$of$the$two$measurements$and$the$slope$of$
least"squares'regression(with!the$regression"based&'(%&LOA!were$determined.$
The$slope$of$the$least$squares$regression!line%was%tested%if%it%significantly%differed%
from%zero,"to"investigate"the"presence"of"any"proportional"bias."The"adjusted(R"
squared(was(calculated!by#linear#regression#analysis."!
!
The$Bland"Altman'method'was'also'applied'to'the'data'where'c"VCDR%was%>!.#$
and$a$quadratic$regression$line$was$determined.!
!
!
Results!
!
The#kappa#for#inter"observer'agreement'for$ophthalmologists’,clinical,
measurement)of)VCDR)within)3.5)was)κ=#.%&'(almost(perfect(agreement),"
calculated(for(one(assessment(session!for$%&$eyes.!For$the$image$VCDR$grading$at$
MEHRC,'the'overall!inter"observer'agreement'between'two$graders'for$%&'$eyes$
was$%%.'%!and$the$kappa$for$<!.#$difference$between$graders$was$κ=#.%#&
(moderate)agreement)."!
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Both!eyes$of$'('$participants!(n=$%&%)!were$included$in!the$analysis.$All$eyes$had$
data$for$VCDR$obtained$by$the$two$methods$of$measurement.!The$clinical$
estimates'recorded&a&zero&(*)&VCDR&in&23&eyes&(3.7%);&and&were$recorded$in$*.,$
difference(steps."The#image#grading#was#recorded#in#/./1#steps#in#4/5#eyes#(8.!%)#
(Figure'().!
!
Frequency)distribution)of)the)absolute)difference)of)VCDR)values)for)each)eye,)
between"the"two"methods"showed"that",-%"eyes!(n=$%&')"differed"by"<!.#,%and%
!"%$eyes$(n=+,-,)"differed"by"<!.#.!!
!
The$Shapiro"Wilk!test$for$normality$of$data$showed$that$the$i"VCDR%had%a%high%
value&of&W&(+.--.)&but&p<#.##%.!Thus%the$distribution$of$values$for!i"VCDR%in#
this%sample%did%not%follow%a%normal%distribution.%The%distribution%of%values!for$c"
VCDR!followed'a'normal'distribution!(W=##$,&p=#.%#).!
!
The$Spearman’s!rank"order!correlation*coefficient*showed*a*strong*positive*
correlation*between*i"VCDR%and%c"VCDR%which%was"statistically"significant"
(rs=".$%,'p<".""*).!
!
The$mean$VCDR$differed$significantly$between$the$i"VCDR,!!.#!!!standard'
deviation)(SD))..0!!!and$the$c"VCDR,!!.!"!!SD#$.!!!."The$difference$in$the$
means!was!!.!#$!("#%CI'(.(##'–!!.!##),"SD"%.'(',!p<#.##%&and&suggestive(of!a"
systematic)(fixed))bias.!Where%the%c"VCDR%was!>!.#!(n=$%)'the$difference$in$the$
two$means$was$!.!##$(&'%CI!!.!!#"!.!#$),'SD'!.*!*;'p=!.!..!!
!
The$Bland"Altman'plot'in'Figure'0'shows'agreement'between'the'two'methods'of'
estimating)VCDR)where)the)difference)between)the)two)measurement)methods)
was$plotted$against$the$average$of$the$two$measurements,$which$is$assumed$to$be$
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the$best$estimate$of$the$true$value.'The'line'of'no'difference'(a;"solid"green"line)"
indicates)where)there)is)no)difference)between)the)two)methods)of)measurement)
at#this#level.#Most#of#the#points#are#above#this#line,#indicating#that#measurements#
of#i"VCDR%were%higher%than%c"VCDR%with%an#average#discrepancy#bias#of#1.13!,"
indicated(as(a(solid&red&line%(b).%The$%&%$LOA$are$indicated$by$the$two$solid$
horizontal*black*lines*(c)*which*demarcate*the*upper*LOA*:.<:!!("#%CI'(.*"!!to#
!.#$!)"and"the"lower"LOA""!.#$!!("#%CI'"!.#$!!to#"!.#$!).#Figure$%$also$shows$the$
least&squares&regression&line!indicated(by(the(red(dash(line((d)(with(regression"
based&'(%&LOA&(e;#dash"!dot%lines).%The$trend$in$the$plot$showed$that$the$
interval)between)the)upper)and)lower)LOA)narrowed)with)higher)VCDR)values)
showing(fewer(data(points(and(indicating(that(the(differences"between"the"two!
measurements)became!smaller'for'higher!average&VCDR%values.%The!least&squares!
linear'regression(line!(d;$red$dash$line)$significantly$differed$from$zero$(p<7.779),$
indicating(the!existence(of(proportional(bias.(The$existence$of$proportional$bias$
implies'that'the'two"methods"of"VCDR"measurement"did!not$agree$equally$
through'the'range'of'measurements.'!
!
Further,(in(eyes(with(c"VCDR>!.#$(n=())$the$quadratic$model$(Figure'(),#
appeared!to#fit#the#data#better#than#a#linear#model#with#the#quadratic#regression#
line%(d;%red%dash%line)%trending%towards%the%line%of%no%difference%(a;%solid%green%
line)&as&the&average&VCDRs&increase.!
!
!
Discussion!
!
In#investigating#the#difference#between#the#two#methods#of#measurement#of#
VCDR%by%clinical%slit"lamp%biomicroscopic#funduscopy!with%!"D$aspheric$lens!
and$by$digital$fundus$photography$image$grading,!the#use#of#Bland"Altman'
method'of'assessment!"!!determines)how)closely)the)two)methods)agreed."The$
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discrepancy+between+the+two+methods+was+clinically+substantial+and!showed!that$
they"were"two"distinct"methods"of"measurement"of"VCDR"with!a"statistically"
significant!average&discrepancy!of#$.$&'."With%higher%c"VCDRs,'the'average'
discrepancy+was+less+(/./11).+This+may+mean%that$when$the$disc$changes$are$
obvious,(the(detection(and(measure(would(be(easier(and(more(similar!for$both$
methods.)Digital&image&analysis&gave&larger&VCDRs&than&clinical&assessment.'We#
acknowledge+this+difference,+thus$the$application$of$image$VCDRs&glaucoma"
defining'percentile'values'to'the!whole!Nigeria'Blindness'Survey'data'might'have'
underestimated+the+prevalence+of+glaucoma+in+the+population.+!!
!
The$advantages$of$using$digital%image%grading%of%the%VCDR%were%that%the%disc%
images,(under(the(survey(conditions,(could(be(captured(and(kept(as(records,(
which%could%be%reviewed%objectively%and%quantified%with%a%scale.%The%images%
could&also&be&used&for&follow"up.$However,$the$disadvantages'were'that'the'
fundus&camera&did&not&take&stereoscopic&images&so&monocular&clues&were&used&to&
determine(cup(and(disc(boundaries;(and(the(angle(of(projection(might(affect(the(
spatial'measurement'of'disc'parameters.'Whereas'with'the'56D!aspheric!lens,&
stereoscopic)images)were)viewed)and)assessed)but)a)measurement)graticule)was)
not$used;$and$the$disc$assessments$were$not$documented$with$hand"drawings)on)
a"template,"thus"it"would"be"difficult"to"review"afterwards"or"adjudicate.!!!!
!
The$Bland"Altman'method'to'assess'LOA!has$been$applied$to$various$methods$of$
measuring*VCDR*and*the*results*vary.*Jayasundera!"!and$Durmus,!!!in#their#
respective)studies,)found)poor)agreement)between)stereoscopic)photographs,)
clinical&assessment,&HRT&and&digital&stereoscopic&optic&disc&camera&which&was&
worse&for&small&discs&and&smaller&cups.!"!The$Rotterdam$study$also$showed$that$
semi"automated(VCDR(measurements(were(larger(than(ophthalmoscopic(
estimates'with'a'moderate'correlation.!"!Perera%compared%clinical%measurement%
of#VCDR#(mean#-./-+!.#$)&using&an&eyepiece&graticule&with&HRT&(mean&
!.#$+!.#$)&and&with&OCT&(mean&!.4!+!.#$)&and&found&lack&of&agreement&
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(p<$.$$&),)with)OCT)tending)to)overestimate)VCDR)and)HRT)tending)to)
underestimate+values.!"!!
!
Limitations)of)this)study)are)that)it)was)a)retrospective)analysis!and$a$graticule$
was$not$incorporated$in$the$clinical$VCDR$measurement.$A$8.89mm$graticule$
might&have&increased&the&accuracy&of&clinical&measurement&and&also&improved&
inter"observer'agreement.!"!Regarding$image$quality,$lack$of$centration$of$the$
optic&disc&in&the&image&could&have&contributed&to&differences&due&to&
magnification*and*positioning.*An*algorithm*for*measurement*which*takes*into*
account'the'magnification'factor'and'the'actual'size'in'micrometre"of"one"pixel"
used%directly%on%the%images%with%the%participant%still%available%for%re"examination)
has$been$found$to$be$useful$in$both$population"based&measurement&and&clinical&
practice.!"!
!
Based&on&the&differences%between%the%two%methods,%the%use%of!optic&disc&
imaging/photography-with-digital'image'analysis'for'measurement'of'VCDR!is#
recommended!in#glaucoma#prevalence#survey!for$all$participants."This"will"
provide(uniformity(and(objective(evaluation(of(VCDR(and(comparable(glaucoma(
prevalence)estimates.!
! !
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Figure'(.'The'frequency'distribution'of'values'for'image'VCDR'and'clinical'VCDR!
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Figure'(.'Bland"Altman'plot'comparing'VCDR'measured'by'clinical'slit"lamp%
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Figure'(.'Bland"Altman'plot'comparing'VCDR'measured'by'clinical'slit"lamp%
biomicroscopy*funduscopy*and*by*fundus*photography*image*grading*if*c"VCDR%
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Figure'3.!Bland,Altman'plot'comparing'VCDR'measured'by'clinical&slit,lamp%
biomicroscopy*funduscopy*and*by*fundus*photography*image*grading*if*c,VCDR>0.6"
!
Lines&shown&indicate:"
a) __________!Solid&green&line&is&the&line&of&no&difference&at&zero.&"
b) __________!Solid&red&line&is&the&mean&difference&(0.022)"
c) __________!Solid&horizontal&black&lines&demarcate&the&"
!!!!!!!!!!!!!!!!!!!!!!!upper%limit%of%agreement%(Mean%+%2SD)%0.224;%and%"
!!!!!!!!!!!!!!!!!!!!!!!lower&limit&of&agreement&(Mean&–!2SD)%,0.180"
d) ,,,,,,,,,,,,,,!Red$dash$line$is$the$quadratic$regression$for$the$difference"
!!!!!!!!!!!!!!!!!!!!!!!!!!between!the$two$measurements$on$the$average$of$the$two$"
!!!!!!!!!!!!!!!!!!!!!!!!!!measurements."
"
c,VCDR%=%clinical%vertical%cup:disc%ratio;%LOA%=%limit%of%agreement;%MD%=%mean%
difference;)SD)=)standard)deviation."
!
!
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Risk factors for open-angle glaucoma in
Nigeria: results from the Nigeria National
Blindness and Visual Impairment Survey
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Abstract
Background: The glaucoma-specific blindness prevalence in Nigeria (0.7 %, 95 % CI 0.6–0.9 %) among those aged
≥40 years is one of the highest ever reported. This study determined the risk factors for open-angle glaucoma
(OAG) in adults examined in the Nigeria National Blindness and Visual Impairment Survey.
Methods: A nationally representative sample of 13,591 people aged ≥40 years in 305 clusters in Nigeria were examined
(response rate 90.4 %) between January 2005 to June 2007. Everyone had logMAR visual acuity measurement, Frequency
Doubling Technology (FDT) visual field testing, autorefraction, A-scan biometry and optic disc assessment. Full ocular
examination (n = 6397), included Goldmann applanation tonometry. Values for defining glaucoma using International
Society of Geographical and Epidemiological Ophthalmology criteria were derived from the study population.
Disc images were graded by Moorfields Eye Hospital Reading Centre. Socio-demographic factors (age, gender,
ethnicity, literacy and place of residence), ocular parameters (intraocular pressure [IOP], axial length and mean
ocular perfusion pressure [MOPP]) and systemic parameters (blood pressure, blood glucose and body mass index
[BMI]) were assessed for association with OAG.
Results: Thirteen thousand eighty-one (96 %) of 13,591 participants had vertical cup:disc ratio measured in at least one
eye. 682 eyes of 462 participants were classified as OAG, with 12,738 controls. In univariate analyses the following were
associated with OAG: increasing age, male gender, Igbo and Yoruba ethnic groups, illiteracy, longer axial length, higher
IOP, lower MOPP, greater severity of hypertension and low BMI (underweight). In multivariate analysis, increasing age
(odds ratio [OR] 1.04, 95 % CI 1.03–1.05), higher IOP (OR 1.22, 95 % CI 1.18–1.25) and Igbo ethnicity (OR 1.73,
95 % CI 1.18–2.56) were independent risk factors for OAG.
Conclusion: Case detection strategies for OAG should be improved for those aged ≥40 years and for ethnic groups
most at risk as a public health intervention.
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Background
In 2013 it was estimated that there were 64.3 million
people aged 40–80 years with glaucoma worldwide, pro-
jected to increase to 76.0 million by the year 2020 and
111.8 million in 2040 [1]. Open-angle glaucoma (OAG)
is the most prevalent type of glaucoma in Africa [1–6]
and a leading cause of blindness and visual impairment
[2, 7]. The glaucoma-specific blindness prevalence in
Nigeria (0.7 %, 95 % confidence interval [CI] 0.6–0.9 %)
among those aged 40 years and above is one of the highest
ever reported [8], and glaucoma is the second-leading
cause of blindness after cataract [8]. The all glaucoma
prevalence in Nigeria in this age-group was 5.02 % (95 %
CI 4.60–5.47 %), with 86 % being OAG based on gonio-
scopy. An estimated 1.2 million adults in Nigeria had
glaucoma in 2012 [9].
There are some similarities in the epidemiology of
OAG in sub-Saharan African and Caribbean popula-
tions. An interesting aspect of the Barbadian history is
that a significant portion of the population was derived
from the Bight of Biafra (also known as Bight of Bonny)
in southeastern Nigeria; and about 44 % of enslaved
Africans taken to Barbados during the 18th century were
said to be mainly of Igbo origin [10]. Studies of risk
factors for OAG in sub-Saharan Africa and African-
derived black populations have reported that increasing
age [3–6, 11–13] and higher intra-ocular pressures
(IOP) [3, 4, 12, 14] are consistent and important risk fac-
tors. Although not always observed, men have a higher
prevalence of glaucoma [4, 5, 12, 15]. A consistent find-
ing is a higher prevalence of OAG in blacks compared
to whites in populations where the two racial groups
were studied [11, 13, 15]. The prevalence of glaucoma
was higher in those with darker skin and of African birth
[13], which suggest possible influence of environmental
factors and inter-ethnic variation in the prevalence and
risk of OAG within black populations, mediated by gen-
etic factors. A higher prevalence of OAG in the urban
population of Chennai compared to the rural population
suggest a possible influence of lifestyle differences and
non-communicable diseases such as hypertension and
diabetes which are also more prevalent in the urban
population [16]. Very few studies have explored other
socio-demographic and systemic risk factors.
The Nigeria National Blindness and Visual Impair-
ment Survey (hereafter referred to as the Nigeria Blind-
ness Survey) is one of the largest population-based
survey ever undertaken in Africa [17]. The present paper
analysed data from the Nigeria Blindness Survey to ex-
plore risk factors for OAG among adults aged ≥40 years.
Factors other than age and IOP were assessed. Identify-
ing population groups most at risk, such as ethnic
groups, will aid in planning appropriate control strat-
egies and enhance the development of care-pathways to
prevent visual loss from glaucoma. It is envisaged that
these results will also be relevant to other countries in
sub-Saharan Africa and for African-derived black
populations.
Methods
Details of all the methods used in the Nigeria Blindness
Survey have been published [17] as well as data on the
prevalence [7] and causes of visual impairment and
blindness [8] and the prevalence and types of glaucoma
in Nigeria [9].
Study design
The sample size calculation and sampling strategy for
the Nigeria Blindness Survey gave a nationally represen-
tative sample of 15,375 persons aged 40 years and above
in 310 clusters across the country. The sample size was
also adequate for precise estimates of glaucoma preva-
lence and was adequately powered for risk factor ana-
lysis for OAG.
Multi-stage sampling using probability proportional to
size methods was used to select the study population.
Clinical data were collected by two teams, each compris-
ing two ophthalmologists, one optometrist and two
ophthalmic nurses.
Data collection
All participants were invited to a temporary clinic for
examination. Relevant personal and demographic details
and examination findings were recorded.
The examination flow chart (Fig. 1; adapted [17]) indi-
cates the data collected by the team members. All partic-
ipants had presenting and best-corrected visual acuity
(VA) measured with a reduced logMAR tumbling E-
chart, automated refraction and keratometry (Takagi
ARKM-100, Takagi Seiko, Japan), frequency doubling
technology (FDT) visual function testing (Carl Zeiss
Meditec AG Jena Germany) and ultrasound A-scan
biometry (Bioline Biometer OPTIKON 2000 S.p.A
Roma, Italy). All participants had basic eye examination
performed by the first ophthalmologist, and detailed
ocular examination was performed by the second oph-
thalmologist: in those with VA of worse than 20/40 in
one or both eyes; vertical cup:disc ratio (VCDR) ≥0.6 in
one or both eyes or VCDR asymmetry of ≥0.2, or any
retinal abnormality seen on undilated fundoscopy [17].
In addition, a subsample of 1-in-7 participants who also
had the detailed examination regardless of their VA had
a random blood glucose (RBG) test (OneTouch Ultra
blood glucose meter, LifeScan UK).
Risk factors assessment and classification
There were five socio-demographic ‘person’ factors (age,
gender, ethnic group, literacy and place of residence), six
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biophysical ‘person’ factors (presence of hypertension,
severity of hypertension, systolic blood pressure [SBP],
diastolic blood pressure [DBP], RBG and body mass
index [BMI]); and three ‘ocular’ factors (axial length,
IOP and mean ocular perfusion pressure [MOPP]). Age
was analysed as a continuous variable and gender as
a binary variable. Participants were asked about their
ability to read and/or write and their ethnic group.
Literacy was classified as ability to read and write or
not at all and analysed as a binary variable. The geo-
graphical origins of some of the major ethnic groups
are shown in Fig. 2. The Ibibio and Ijaw are from the
southern Niger delta region, the Igbos and Urhobos
are from the southeastern equatorial region and the
Hausa, Fulani and Kanuri are from the northern
savannah region. Ethnic groups with ≥200 participants
(Hausa, Yoruba, Igbo, Fulani, Kanuri, Tiv, Ijaw,
Urhobo, Ibibio and Nupe) were categorised and ana-
lysed separately, and the smaller ethnic groups were
combined into an ‘others’ category. Urban place of
residence was defined as a settlement of more than
20,000 people.
Fig. 1 The Nigeria Blindness Survey examination flow chart
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Blood pressure (BP) was recorded three times with BP
Omron wrist instrument (Omron Healthcare Ltd, Milton
Keynes, England) after resting for at least 10 min [18].
Average values were used for analysis. Hypertension was
defined as BP ≥140/90 mmHg and severity was
categorised using World Health Organization (WHO)
categories: stage 1 for systolic/diastolic BP of ≥140/
90 mmHg, stage 2 ≥ 160/100 mmHg and stage 3 ≥ 180/
110 mmHg [19]. SBP and DBP were analysed as con-
tinuous variables. RBG was grouped as less than
11.1 mmol/L or ≥11.1 mmol/L [20]. Height was mea-
sured to the nearest tenth of a centimeter and weight
was measured to the nearest 100 g using standard equip-
ment. BMI was calculated by dividing body weight (kg)
by height (m) squared and categorised according to the
international classification for adults i.e., underweight
(<18.5 kg/m2), normal (18.5–24.9 kg/m2), overweight
(25.0–29.9 kg/m2) and obese (≥30.0 kg/m2) [21].
Axial length was measured by contact ultrasound A-
scan biometry. IOP was measured using one Goldmann
applanation tonometer in each of the two teams by the
second ophthalmologist, using standard methods. To ex-
plore the association of vascular perfusion and OAG,
the MOPP was calculated as 2/3[DBP +
1/3 (SBP-DBP)-
IOP] [22]. Axial length, IOP and MOPP were analysed
as continuous variables.
A person was classified as having glaucoma if one or
both eyes had glaucoma. The diagnosis of glaucoma was
based on the International Society for Geographical and
Epidemiological Ophthalmology (ISGEO) criteria with
defining values obtained from a subsample of this study
population [23]: VCDR ≥0.7 or VCDR asymmetry ≥0.1
Fig. 2 Geographical origins of ethnic groups and their open-angle glaucoma prevalence. Adapted from Map of the ethno-linguistic groups of
Nigeria. Source: University of Texas Libraries; obtained from https://commons.wikimedia.org/wiki/File:Nigeria_linguistic_1979.jpg
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(97.5th percentile) with evidence of glaucomatous visual
function deficit; or VCDR ≥0.75 or VCDR asymmetry
≥0.2 (99.5th percentile) when visual fields results were
not available; or IOP ≥28 mmHg (99.5th percentile) ± VA
worse than 20/400 or known glaucoma on treatment; or
if there was relative afferent pupillary defect (RAPD) as-
sociated with high IOP and/or corneal edema. The Van
Herick’s anterior chamber (AC) angle estimation was
performed on the slit-lamp with a narrow slit of light
projected on the peripheral cornea, and was based on
the relationship between the corneal slit image on the
corneal surface and the AC depth. Grades 3 and 4 infer
open angles and angle-closure is unlikely. The validity of
the Van Herick’s method for the estimation of the AC
angle to correctly identify grades 3–4 as being open an-
gles was assessed in comparison to identification of open
angles by gonioscopy. Eyes with glaucoma were classified
as OAG based on open-angles seen on gonioscopy or
Van Herick’s grades 3–4 in those who did not have
gonioscopy.
Data for all participants classified as OAG were com-
pared to those of the control group in analysis. Socio-
demographic, ocular and biophysical factors were analysed
for associations with OAG. The control group consisted
of all other participants without OAG after excluding
glaucoma eyes that did not have gonioscopy or Van Her-
ick’s test findings and those with other types of glaucoma,
and phthisical eyes. The algorithm for selection of OAG
cases and the control group is shown in Fig. 1.
Statistical analysis was performed using Stata/IC 13.0
(Stata Corp, College Station, TX).
We examined the association between OAG and each
risk factor separately and report odds ratios with 95 %
confidence intervals (CI). We used logistic regression to
assess the independent effect of each risk factor on OAG
and report adjusted odds ratios and 95 % CI intervals.
BMI was also adjusted for gender. The following vari-
ables were included in the multivariable model: age, gen-
der, ethnic group, literacy, rural/urban residence, BP,
BMI, ocular axial length, IOP and MOPP. For ocular
factors, the analysis took account of within-person
correlation using robust standard errors. Possible extra
variation introduced by the cluster sampling strategy
was also considered but it did not impact the results.
Results
A summary of completeness of data for the Nigeria
Blindness Survey has been reported: for participants
undergoing full examination (6397), 88 % had IOP meas-
urement with Goldmann applanation tonometer in at
least one eye [9]. In the Nigeria Blindness Survey, 950/
27,182 (3.50 %) eyes of 682/13,591 (5.02 %) participants
had glaucoma according to the ISGEO criteria, of which
320 eyes of 208 persons were classified as OAG by
gonioscopy. 375 eyes had Van Herick’s AC angle estima-
tion but did not undergo gonioscopy. In eyes with both
values, Grades 3 and 4 Van Herick’s AC angle estimation
had a 99.1 % sensitivity and 93 % positive predictive
value in identifying open angles by gonioscopy. Thus, an
additional 362 eyes of 254 persons were included as
OAG cases as they had grades 3 or 4 Van Herick’s
estimation. Hence, 462 persons (682 eyes with OAG)
were included in the analysis as OAG while 12,738 per-
sons were classified as controls (without OAG) and 391
participants were excluded (Fig. 3).
The OAG group was older and more likely to be male
(Table 1). The mean age ± standard deviation (SD) of par-
ticipants with OAG was significantly higher than that of
controls (66.2 ± 12.3 years Vs 55.4 ± 12.1 years, p <0.001).
Men with OAG were significantly older (mean age
67.6 years ±12.7) than women with OAG (mean age
64.8 years ±11.8; p = 0.02). The OAG group also had a
higher proportion of participants that were of the Yoruba
or Igbo ethnic group, illiterate and with hypertension and
low BMI (underweight). After adjusting BMI for gender,
the odds of OAG was higher in underweight women (OR
1.84, 95%CI 1.27–2.68; p = 0.001) but not after adjusting
for age or for age and IOP. The mean ± SD IOP was
higher in eyes with OAG (22 ± 11 mmHg) than in eyes
without OAG (14 ± 4 mmHg, p <0.001). Similarly, the
mean ocular axial length was longer in eyes with OAG
(22.8 ± 1.09 mm) than in those without OAG (22.6 ±
0.97 mm, p = 0.001).
In univariate analysis, increasing age was positively as-
sociated with OAG (Odds ratio [OR] 1.06, 95 % CI
1.06–1.07; p <0.001), as was being male (OR 1.29, 95 %
CI 1.06–1.57; p = 0.01) (Table 2). There was 6 % higher
odds of OAG with each increasing year of age. The
following factors were also positively associated with
OAG: Igbo and Yoruba ethnic groups, being illiterate,
any hypertension and greater severity of hypertension,
low BMI (underweight), longer ocular axial length,
higher IOP and lower MOPP (Table 2). When adjusted
for myopia, axial length remained significantly associated
with OAG (OR 1.13, 95 % CI 1.02–1.25; p = 0.03). In
multivariate logistic regression analyses, increasing age,
higher IOP and Igbo ethnic group were identified as in-
dependent risk factors for OAG. The ethnic group-
specific prevalence of OAG for the analysed ethnic
groups are shown in Fig. 2. The Urhobo had the lowest
odds of OAG (OR 0.69, 95 % CI 0.24–1.97), while the
Kanuri (OR 1.81, 95 % CI 0.90–3.63; p = 0.10) and Igbo
(OR 1.73, 95 % CI 1.18–2.56; p = 0.01), the highest. The
Igbo ethnic group had a 73 % higher odds of OAG
than the Hausa (reference group) (Table 2); and when
adjusted for gender, Igbo men were 2.5 times more
likely to have OAG than Hausa men (OR 2.54, 95 %
CI 1,50–4.30; p = 0.001).
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Systemic hypertension (BP ≥ 140/90 mmHg) was
also associated with OAG, with moderate and severe
hypertension having stronger and significant associ-
ation with OAG in univariate analysis. After adjusting
for age, IOP and other potential risk factors in a mul-
tivariable model, mildly elevated BP (stage 1) was
protective of OAG compared to participants without
hypertension but this was not statistically significant
(OR 0.87, p = 0.52). There was a strong association
between lower MOPP and OAG (p <0.001) in univari-
ate analysis which did not persist after adjusting for
age, IOP and other factors.
In univariate analysis, lower BMI was associated
with 60 % greater odds of OAG (p = 0.001) and the
odds decreased with increasing BMI. However, in the
adjusted model, BMI was not statistically significant.
Discussion
We report results of the first cross-sectional study of
risk factors for OAG in sub-Saharan Africa in a large
population-based, nationally representative survey in
Nigeria. We did not explore the risk factors for angle-
closure glaucoma, as the numbers were too few. Older
age and higher IOP were independent risk factors for
OAG. Additionally, an important and new finding was
that the Igbo ethnicity was an independent risk factor
associated with OAG, especially in men.
Significant inter-racial variation between White, Asian
and Black populations has been described [11, 13, 15, 24]
with the prevalence and risks of OAG being higher in
Blacks. However, studies in smaller population groups
in sub-Saharan Africa have not identified differences
in risks of OAG by ethnic group within black popula-
tions [5, 25]. Under-powered sample sizes may be a
reason why they could not detect ethnic differences
in those studies. The Nigeria Blindness Survey had
relatively large numbers of the main ethnic groups,
giving adequate power to detect significant associa-
tions and differences within the black population.
One of the potential reasons for the ethnic
differences we observed may be the differential sus-
ceptibility due to larger optic discs. As reported in
the normative data for the classification of glaucoma
in prevalence surveys in Nigeria, the 97.5th percentile
VCDR for the Igbo was 0.7 compared to 0.6 for the
Fulani. Interestingly, the 99.5th percentile for IOP was
Fig. 3 Algorithm for selection of open-angle glaucoma cases and control
Kyari et al. BMC Ophthalmology  (2016) 16:78 Page 6 of 12
Fatima Kyari PhD Thesis Page 152
Table 1 Distribution of participants with and without open-angle glaucoma by socio-demographic, biophysical and ocular
characteristics
Without OAG
[control]
OAG
[cases]
Total participants N = 12,946 n = 12,738 (96.5 %) n = 462 (3.5 %)
n % n %
Socio-demographic factors
Age group (years)
40 – 49 4760 37.4 45 9.7
50 – 59 3415 26.8 75 16.2
60 – 69 2550 20.0 124 26.9
70 – 79 1439 11.3 141 30.5
80+ 574 4.5 77 16.7
Age (years) Mean ± SD 55.4 ± 12.1 66.2 ± 12.3 p < 0.001
Gender
Female 6940 54.5 221 47.8
Male 5798 45.5 241 52.2
Ethnic groupa
Hausa 3191 25.2 78 16.9
Yoruba 2478 19.5 95 20.6
Igbo 1752 13.8 114 24.7
Fulani 801 6.3 20 4.3
Kanuri 326 2.6 13 2.8
Tiv 328 2.6 10 2.2
Ijaw 234 1.8 11 2.4
Urhobo 231 1.8 5 1.1
Ibibio 199 1.6 7 1.5
Nupe 198 1.6 8 1.8
Others 2946 23.2 100 21.7
Literacy
Literate 5618 44.1 159 34.4
Illiterate 7120 55.9 303 65.6
Place of residence
Rural 9883 77.6 354 76.6
Urban 2855 22.4 108 23.4
Biophysical factors
Blood pressure (mmHg)a
Normal 9343 73.8 308 67.2
Hypertension ≥140/90 mmHg 3315 26.2 150 32.8
Random blood glucose (mmol/L)a
Normal 1551 97.1 98 96.1
Diabetes ≥11.1 mmol/L 47 2.9 4 3.9
Body mass indexa
Normal 18.5–24.9 kg/m2 7672 61.1 276 60.6
Underweight <18.5 kg/m2 1365 10.9 74 16.3
Overweight 25.0–29.9 kg/m2 2464 19.6 75 16.5
Obese ≥30.0 kg/m2 1060 8.4 30 6.6
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lower for the Igbo (22 mmHg) than for the Hausa
(28 mmHg) [23] and this may imply that the Igbos
have thinner corneas. However, a major limitation in
interpreting this difference is the absence of pach-
ymetry to measure central corneal thickness in the
Nigeria Blindness Survey, which would have enabled
corrected IOP estimates for comparison. Optic disc
parameters are important in OAG with respect to at-
tenuation of structural support, axonal protection and
metabolic support provided by astrocytes [26]. These
quantitative parameters are heritable traits [27, 28],
thus genetic variation is another plausible reason for
the ethnic differential risk. Genome-wide association
studies (GWAS) in the African Caribbean population
of Barbados, which has a high prevalence of OAG
(6.8 %, 95 % CI 6.1–7.7 % in Blacks ≥40 years old)
[15], confirmed two mechanisms of gene interaction
with OAG: the absence of protective genes, and the
presence of predisposing alleles increased the risk for
OAG [29, 30]. Although the demographics of
Barbados have been dynamic, and there are other
socio-demographic and lifestyle factors that influence
disease incidence [31] and progression [12, 32], the
historical link between the Igbos and Barbadians
lends credence to the genetic basis for the ethnic dif-
ferences in risk of OAG seen in Nigeria.
Another interesting observation in our study was the
strong association between low BMI (underweight) and
OAG, albeit only in univariate analysis: presumably be-
cause of age, as older persons have lower BMI especially
when of poor socioeconomic status. Higher BMI has
been reported to be protective for OAG in Barbados
[12] and Rotterdam [33]. Systemic inflammatory process
[34] are possible linking factors which may also result in
weight loss from general debilitation.
Our study did not find significant difference in risk
for OAG in urban compared to rural population as
seen in urban South India where the prevalence of
OAG was more than doubled than in the rural popu-
lation [16]; and possible associations with hyperten-
sion or diabetes were not statistically significant.
All studies have shown increasing age to be a risk fac-
tor for OAG [12, 31, 32, 35–43]. Indeed, in the Barbados
Eye Study a 4 % increase in the relative risk of OAG
per year was reported [31], and comparable to 6 %
higher odds of OAG per year in this study. Increasing
mitochondrial dysfunction in retinal ganglion cells
and increased vulnerability of the optic nerve to
neurodegeneration from oxidative stress serve as pos-
sible links between ageing and increased risk for
OAG [44, 45].
This study also demonstrated that higher IOP has
an independent association with OAG, as in numer-
ous other studies. Higher IOP was an independent
risk factor for glaucoma despite a large number of
eyes having IOPs lower than the ‘upper limit of nor-
mal’ i.e. mean (+2SD) [40]. In the National Blindness
Survey, 56 % of glaucoma eyes had IOP <22 mmHg;
the mean IOP in glaucoma eyes was 23 (SD12)
mmHg and the mean IOP in non-glaucoma eyes was
14 (SD4) mmHg [9]. This underscores the role of
IOP as a tool for monitoring response to treatment
rather than as a diagnostic factor.
Men had higher odds of OAG but only in univariate
analysis. An increased risk of OAG in men has been
reported in previous prevalence studies in Barbados,
United States [12, 32] and Singapore [43], and in a
Bayesian meta-analysis, men were more likely to have
POAG than women (OR 1.36, 95 % CI 1.23–1.52) [1].
Further incidence studies are needed to clarify gender
differences in risks of OAG.
Some studies have addressed associations between
ocular perfusion factors (IOP, BP and MOPP) and OAG
which suggest that vascular insufficiency is an important
factor in OAG [31, 38, 46], as was in our study, higher
BP and lower MOPP were significantly associated with
higher odds of OAG.
Longer ocular axial length has been associated with
OAG [37, 47]. In the Nigeria Blindness Survey axial
length was longer in OAG eyes and was significantly
associated with OAG, but this was not an independ-
ent risk factor after adjusting for age, IOP and other
variables. In our study we assessed axial length rather
than myopia as a potential risk factor because there
was a high prevalence of nuclear lens opacities
(8.8 %, 95 % CI 7.5–10.1) [48] which would increase
Table 1 Distribution of participants with and without open-angle glaucoma by socio-demographic, biophysical and ocular
characteristics (Continued)
Ocular factorsb
Total eyes N = 26,316 (100 %) 25,634 (97.4 %) 682 (2.6 %)
Axial length (mm) Mean ± SD 22.63 ± 0.97 22.76 ± 1.09 p = 0.001
IOP (mmHg) Mean ± SD 14 ± 4 22 ± 11 p < 0.001
IOP intraocular pressure, OAG open-angle glaucoma, SD standard deviation
amissing values excluded; bocular factors distribution by eyes
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Table 2 Open-angle glaucoma and association with potential risk factors
All eyes OAG Univariate analysis Multivariate analysis
n (%) n (%) OR 95 % CI p-value OR 95 % CI p-value
26,316 (100 %) 682 (2.6 %)
Socio-demographic factors
Age (years) (Min 40) Reference Reference
Increasing age (Max 100) 1.06 1.06–1.07 <0.001 1.04 1.03–1.05 <0.001
Gender Female 328 (2.3) Reference Reference
Male 354 (2.9) 1.29 1.06–1.57 0.01 1.23 0.94–1.61 0.13
Ethnic group Hausa 113 (1.7) Reference Reference
Yoruba 150 (2.9) 1.71 1.24–2.36 0.001 1.10 0.75–1.63 0.62
Igbo 167 (4.5) 2.70 1.98–3.68 <0.001 1.73 1.18–2.56 0.01
Fulani 31 (1.9) 1.09 0.65–1.85 0.73 1.18 0.65–2.19 0.58
Kanuri 20 (2.9) 1.72 0.92–3.23 0.09 1.81 0.90–3.63 0.10
Tiv 15 (2.2) 1.30 0.64–2.62 0.47 1.03 0.42–2.52 0.96
Ijaw 14 (2.9) 1.69 0.86–3.35 0.13 1.51 0.50–4.60 0.47
Urhobo 7 (1.5) 0.85 0.32–2.23 0.74 0.69 0.24–1.97 0.48
Ibibio 10 (2.4) 1.43 0.62–3.27 0.40 1.29 0.58–2.89 0.53
Nupe 9 (2.2) 1.29 0.59–2.79 0.52 1.25 0.58–2.67 0.57
Others 144 (2.4) 1.38 1.01–1.90 0.05 1.13 0.75–1.70 0.57
Literacy Literate 235 (2.0) Reference Reference
Illiterate 447 (3.0) 1.50 1.22–1.84 <0.001 1.06 0.79–1.42 0.70
Place of residence Rural 527 (2.6) Reference Reference
Urban 155 (2.6) 1.02 0.81–1.28 0.88 1.14 0.85–1.54 0.38
Biophysical factors
Hypertension Normal 454 (2.4) Reference NI
Hypertension 223 (3.2) 1.38 1.12–1.70 0.002
Blood pressure Normal 454 (2.4) Reference Reference
(severity of stage 1 mild 110 (2.7) 1.15 0.88–1.51 0.31 0.87 0.57–1.33 0.52
hypertension) stage 2 moderate 68 (3.7) 1.61 1.16–2.24 0.01 1.05 0.58–1.90 0.87
stage 3 severe 45 (4.4) 1.91 1.27–2.88 0.002 1.05 0.45–2.45 0.90
Systolic BP (Min 60) Reference NI
(Max 259) 1.01 1.01–1.02 <0.001
Diastolic BP (Min 35) Reference NI
(Max 157) 1.01 1.00–1.02 0.002
RBGa Normal 141 (4.3) Reference NI
Diabetes 4 (4.1) 0.94 0.33–2.67 0.91
Body mass index Normal 406 (2.6) Reference Reference
(Categories) Underweight 116 (4.0) 1.60 1.21–2.10 0.001 1.29 0.91–1.83 0.16
Overweight 111 (2.2) 0.85 0.65–1.12 0.26 0.82 0.58–1.17 0.27
Obese 42 (1.9) 0.75 0.50–1.12 0.16 1.18 0.71–1.96 0.52
Ocular factors
Axial length (mm) (Min 18.4) Reference Reference
(Max 30.0) 1.14 1.03–1.26 0.01 0.99 0.89–1.10 0.88
I OP (mmHg) (Min 5) Reference Reference
(Max 50) 1.21 1.18–1.23 <0.001 1.22 1.18–1.25 <0.001
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the risk of index myopia; and a relatively low preva-
lence of myopia ≤0.5D (after excluding persons with
lens opacity, 9.4 %, 95 % CI 8.7–10.2) [49].
A strength of the Nigeria Blindness Survey is that it
was nationally representative and had a large sample
size with adequate power to detect statistical associa-
tions. A range of ethnic groups was represented in
large enough numbers to allow comparison of risk
between the largest ethnic groups in Nigeria. As part
of the study protocol, not all participants had gonio-
scopy done and we did not record the presence of
pseudoexfoliation (PXE). Hence, PXE was not
assessed as a risk factor for OAG. In addition, some
eligible participants did not have gonioscopy per-
formed due to damage to the mirrors on the gonio-
scopy lenses by high humidity; and did not have Van
Herick’s AC angle estimation due to structural ocular
pathology. Another limitation was that IOP was mea-
sured once and it was not interpreted using central
corneal thickness, which was not measured. Addition-
ally, visual field analysis was by FDT and participants
classified as glaucoma did not undergo Humphrey
visual field analysis (HFA). We were also not able to
obtain information on duration of hypertension,
history of cardiovascular disease or use of antihyper-
tensive medication. However, this may not have a sig-
nificant impact as only 14 % of participants reported
being hypertensive [18]. Additionally, we did not ob-
tain information on family history of glaucoma which
would not have been reliable in this context. Indeed,
only 5.6 % of those identified with OAG knew they
had the condition [9].
This is the first time that an association of OAG has
been observed with some ethnic groups. It is imperative
that this finding be replicated in further studies as it
may be a chance finding. While cultural or other prac-
tices might underlie the differences, or failure to fully
adjust for confounders, given the relative lack of envir-
onmental factors identified to date for OAG, these ob-
servations suggest the need for a molecular genetics
study of glaucoma in Nigeria. This might be included
within a follow-up study on the cohort of the Nigeria
Blindness Survey to explore the natural history and in-
cidence of glaucoma, and the influence of immuno-
logical markers of inflammation.
Conclusion
This study gives us risk factors data on OAG and con-
firms that OAG is a public health problem in people
≥40 years. As a public health strategy, opportunistic eye
examination, case detection and examination for OAG
need to be performed on all people aged ≥40 years and
the ethnic groups most at risk.
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Chapter(9!
Ethnicity(and(deprivation(are(associated(with(blindness(among(
adults'with'primary'glaucoma'in'Nigeria'!
Results'from'the'Nigeria'National'Blindness'and'Visual'Impairment*Survey!
!
!
Participants*arriving*for*a*focus*group*discussion*in*the*community!
!
!
!
Research(paper(determining!the$risk$factors$associated$with$glaucoma$
blindness!
!
! !
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Abstract("
!
Purpose:"We#explored"the!risk%factors%for%glaucoma%blindness%among%adults%aged%
>!"#years#with#primary#glaucoma(in(Nigeria.!
!
Participants*and*methods:"!",$%!&participants&aged%>!"#years#were$examined$in$the$
Nigeria'National'Blindness'and'Visual'Impairment'Survey;"!"#$(!.#$%,'(!CI'
!.#$"!.#$%)#had!glaucoma(by!ISGEO’s(criteria.!This!was$a$case"control'study'
(n=!"#$eyes$of$*+"$persons):!glaucoma(blind(were!cases%and%glaucoma%not"blind!
were!controls.!Education*level*and*occupation*were*used*to*determine*
socioeconomic(status%scores,!which%were%divided%into%three%tertiles%(affluent,%
medium&and&deprived)."We#assessed$socio"demographic,-biophysical-and-ocular-
factors(by#logistic#regression#analysis#for#association#with#glaucoma(blindness.!
Multinomial*regression*analysis*was*also*performed*with*non"glaucoma(as(the(
reference&category.!
!
Results:!!!"/$%"&(!(."%;&",%CI#$%.'"!!.#%)&persons&were&blind&in&both&eyes,&
leaving()*+(as(controls.(There%was%inter"ethnic'variation'in'odds$of$blindness;"age,"
male%sex,"socio"economic'status,'prior'diagnosis'of'glaucoma,'hypertension,,
intra"ocular'pressure#and#lens#opacity#were!associated)with)glaucoma)blindness.)
Axial%length,%mean%ocular%perfusion%pressure%and%angle"closure(glaucoma(were(
associated)with)blind)glaucoma(eyes.%In%multivariate%analysis,%Igbo!ethnicity!
(OR$.&',!!"%CI#$.&'"!.!")!had$higher$risk$as$was$being$male$(OR3.56,$85%CI#
!.#$"!".$%),(and(unmarried((OR".45,(%6%CI#$.&'"!.#$).#Deprivation!(OR!.#$,&
!"%CI#$.&&"!.#$),'prior'glaucoma'diagnosis'(OR8.98,!!"%CI#$.&'"!"."$)&and&
higher&intraocular&pressure!(OR$.&',)*+%CI#$.&'"!.!#)%were"also"independent"risk"
factors(for(glaucoma(blindness.!
!
Conclusion:!Approximately-.-in-!"people"with%primary%glaucoma%were$blind."Male%
sex,"ethnicity!and$deprivation+were$strongly)associated)with)blindness.)Services)
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for$glaucoma$need$to#improve#in#Nigeria,(focusing$on$poor$communities$and$
men.!
!
Key$words:"glaucoma!blindness;)ethnicity;!deprivation;,risk,factors;,population"
based;!Nigeria.!!
!
Running&head!–!Blindness(among(adults(with(glaucoma(in(Nigeria!
! !
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Introduction*!
!
Glaucoma(is(the(leading(cause(of#irreversible#blindness#worldwide.!!Although(
there%are%very%few%population"based&blindness!prevalence)surveys)in)Africa,!!data$
suggest&that&the$prevalence$of$glaucoma$blindness$in$Africa$is$the$highest$in$the$
world.!,"!!In#sub"Saharan&Africa,&the&proportion&of&people&with&glaucoma&
identified'in'population"based&surveys&who&are&blind&is&alarming."In"Ghana"
("##$)&$#%&of&participants&aged&5#&years&and&above&with&glaucoma&were&blind.!!
Among&participants&aged&01&years&and&above,&the&proportion&of&people&with&
glaucoma(who(were(blind(was(23%(in(Kongwa,(Tanzania((2::;),!!!"%$in$Mamre,$
South&Africa&(.//0),!!and$%%%$in$Temba,&South&Africa&(2334).!!Glaucoma(occurs(
all#over#the#world,!!but$risks$for$glaucoma$blindness$vary.!","!!!Early&diagnosis&and&
treatment'delay'vision'loss'and'prevent'blindness'from'glaucoma!"!as#the#rate#of#
progression)of)optic)nerve)damage)is)slowed)by)treatment.!","!"!Recent&advances&in&
technology*for*diagnosing*glaucoma,*greater*therapeutic*options,*and*treatment*
monitoring(have(decreased(the(probability(of(glaucoma&blindness&in&patients&in&
the$care$system$in$industrialized$countries.!"!Conversely,+without+treatment+there+
is#a#very#high#rate#of#progression#of#visual#field#loss.!"!Who$goes$blind$from$
glaucoma(is(influenced(by(biomedical(factors(such(as(age(at(onset,(duration(of(
disease&and&rate&of&progression%of%glaucoma.!","!"!In#many#low#income'settings'
aggravating(factors(relating(to(the(health(care(system(include(low(provision(of(
glaucoma(services(and(access(to(services,!""!"!poor$quality$of$care,!"!and$
inadequate)compliance)with)treatment)and)follow"up,!","!"!the$latter$being$
compounded)by)low)levels)of)education.!!!Few$studies$of$risk$factors$for$
glaucoma(blindness(have(been(undertaken(in(Africa(where(glaucoma(has(an(
earlier&age&of&onset&and&a&more&aggressive&course.&Services&for&glaucoma&are&also&
inadequate)and)acceptance)and)compliance)with)treatment)are)low.)!
!
The!increase(in(susceptibility(of(retinal(ganglion(cells(to(premature(death(may(be(
mediated'by'genetic'factors'which'may'also'interact'with'environmental'
factors.!"!Family'studies'and'genome"wide%association%studies%(GWAS)%for%open"
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angle&glaucoma&(OAG)&have&demonstrated&genotype"phenotype(correlations(of(
heritable)ocular)features)such)as"central"corneal"thickness"(CCT),!"!optic&disc!
size,&vertical&cup:disc&ratio&(VCDR)!"!and$intraocular*pressure*(IOP).!"!However,(
only%one%molecular%genetics%study%of%glaucoma%has%been%undertaken%to%date%in%
Africa'and'the'investigators'did'not'observe'significant'association'with'any'of'
the$previously$reported$genes$and$loci$in$OAG$cases$in$the$Ghana$study$
population.!"!Determining)variation)in)the)susceptibility)to)and)severity)of)
glaucoma"among"different"ethnic"groups!who$share$common$ancestry,$is$a$first$
step%in%assessing%the%role%of%genetic%factors%in%the%pathogenesis%of%OAG%in%Africa.%
In#an#earlier#study#arising#from#the#Nigeria#National#Blindness#and#Visual#
Impairment*Survey*(hereafter*referred*to*as*the*Nigeria*Blindness&Survey)&-.%!of#
glaucoma!was$undiagnosed$and$untreated,$and$the$crude&prevalence)was)
significantly+higher&in&the$Igbo$ethnic$group$(0.00%;$45%CI!!.#$"!.#$).!"!In#this#
paper%we%present%findings%on%risk%factors%for%blindness,%including%ethnic%groups,%
among&those&identified&with&glaucoma&during&the&Nigeria&Blindness&Survey.!
!
The$Nigeria$Blindness$Survey$was$the$largest$population"based&blindness&survey#
ever$undertaken$in$Africa,$providing$data$on$the$major$blinding$diseases,!"!
including(glaucoma(which(was(the(second(commonest(cause((23.5%).!"!The$
prevalence)of)blindness)in)adults)aged)>!"#years#was#!.+%#(./%CI$%.'"!.#)!"!and$
the$glaucoma"specific'blindness'prevalence'was'0.2%'(56%CI$%.'"!.#).!"!
Systematic)sample)of)."in"!"participants"provided"normative*values!"!for$defining$
glaucoma!using&the&International&Society&of&Geographic&and&Epidemiology&
Ophthalmology+(ISGEO)+levels+of+evidence.!!!The#prevalence#of#glaucoma#of#all#
types&was&).+,%&(/)%CI$%.'("!.#$),#one"fifth%of%whom%were%blind%in%both%eyes.!"!!
!
!
Materials)and)Methods!
!
Details(of(the(methods(used(in(the(Nigeria(Blindness(Survey,!"!normative*values*
for$diagnosing$glaucoma!"!and$the$prevalence$and$types$of$glaucoma$in$Nigeria!"!
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have%been%published;!and$data$on$risk$factors$for$OAG!have%been%accepted!for$
publication."A"summary"of"the"clinical"assessments,"with"particular"reference"to"
classification*of*glaucoma*and*how$potential$risk$factors$for$glaucoma$blindness$
were$measured$and$categorised,"are"described!here.!
!
Ethics!
Ethical(approval(was(obtained(from(the(Ethics(Committee(of(the(London(School(
of#Hygiene#&!Tropical)Medicine)and)the)Federal)Ministry)of)Health,)Nigeria.)
Informed)consent)was)obtained)from)community)leaders,)heads)of)households)
and$all$participants.$The$study$adhered$to$the$tenets$of$the$declaration$of$
Helsinki.)Persons)with)medical)or)eye)conditions&including&glaucoma&needing&
further'assessment'and'treatment'were'referred'to'the'nearest'healthcare'facility.'!
!
Study&design&and&study&population!
The$study$design$for$the$analysis'of'risk%factors%for%glaucoma%blindness!was$a$
case"control'study:'people%with%glaucoma%that%were!blind&in&both&eyes&(visual&
acuity'[VA]'worse'than'3/56'in'the'better'eye)'were'classified'as'cases;'and'people'
with%glaucoma%but%not%blind%were%classified%as%controls.%For$analysis$of$risk$of$
blindness(in(eyes(with(glaucoma,(the$cases$were$glaucoma(eyes!that$were$blind$
(VA$worse!than%&/())%and%the%controls%were%glaucoma!eyes!that$were$not$blind.$
The$analysed$sample$consisted$of!persons'classified'as'glaucoma!and$with$no$
identified'features'suggesting'secondary'glaucoma'(Figure!!).$A$person$was$
classified)as)having)glaucoma)if)the)condition)was)present)in)one)or)both)eyes.)
The$sample$size$calculated$for$the$Nigeria$Blindness$Survey$was$;<,>?<$persons$
aged%>!"#years#in#+,"#clusters.!"!
!
Data$collection$and$clinical$assessment!
Participants!were$invited$to$a$temporary$examination$site$set$up$within$the$
community.*All*were*interviewed*to*obtain*relevant*personal*and*socio"
demographic,data.,Evidence,of,glaucoma,surgery,,presence,of,cataract,and,
evidence!of#cataract#surgery#were#noted."Some"investigations)were)not#possible#in#
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participants)who)could&not&come&to&the&examination&center&and&who&were&
examined(in(their(home.(!
!
Glaucoma(classification!
Glaucoma(was(classified(according(to(the(ISGEO(criteria,(using(percentile(
distributions*of*VCDR,*VCDR*asymmetry(and(IOP(in(normal!Nigerians,*derived*
from%the%normative%subset$(n=()*+)$of!this%study%population.!"!The$diagnosis$of$
glaucoma(started#with#VCDR#findings."Level!!"classification*required!structural(
and$functional$evidence$i.e.$/0.1th!percentile)of)the)VCDR)(>!.#)%or%VCDR%
asymmetry((>!.#)%in%our%normal%population%and%visual%field%loss%typical%of%
glaucoma.)Level!!"required"advanced"structural"damage"i.e."33.4th!percentile)
VCDR%(>!.#$)&or&VCDR&asymmetry&(>!.#)%in%the%absence%of%visual%field%evidence."
Level!!"applied"when"the"optic"disc"was#not#seen#and#visual#field#testing#was#not#
possible,)and)used:)a))blindness)(VA<45/755))with)the);;.=th!percentile)IOP)
(>!"mmHg),(or(b)(diagnosed(with/being(treated(for(glaucoma.(An(additional(
level$of$evidence$(level$,b)$was$added$where$the$optic$disc$was#visualized#but#the#
VCDR%was%<**.,th!percentile)and)there)were)no)visual)fields)available,)but)there)
was$other$compelling$evidence$such$as$RAPD,$high$IOP$and/or$corneal$edema.$
These%cases%were%adjudicated%by%glaucoma%specialists%(RW%and%WN).%A%person%
was!said%to%have%glaucoma%if%there%was%glaucoma%in%one%or%both%eyes.%!
!
Visual'acuity'measurement'and'definition'of'blindness!
Presenting)VA!was$assessed$by$a$trained$ophthalmic$nurse$using$a$reduced$
logMAR'tumbling"E"chart!","!"!at#$#meters.#If#the#participant#could#not#see#any#
letters&at&(&meters,&testing&was&repeated&at&1&meter.&Participants&unable&to&see&any&
letters&at&(&meter&were&assessed&for&counting&fingers,&hand&movement&or&
perception)of)light)(PL))or)no)PL)(NPL).)Visual)acuities)were)categorized#using#
World&Health&Organization&(WHO)&definitions&of&blindness&and&visual&
impairment)(VI)!"!where%blindness%at%the"person"level"is"defined"as"VA"worse"
than%!/#$!in#the#better#eye.#An#eye#was#classified#as#blind#if#the#VA#was#worse&
than%&/()!in#the#affected#eye.#!
!
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Determining)the)cause)of)blindness!
All#participants#with#a#VA#worse&than&+/-.!in#one#or#both#eyes#were#examined#by#
the$experienced$ophthalmologist.$All$disorders$that$may$have$contributed$to$
visual'loss'in'each'eye'were'determined'from'a'list'of'disorders.'The'
principal/main*cause*was*then*selected*for*each*eye*and*then$for$the$person$in$
the$order$of$most$preventable$cause$first$(e.g.$corneal$opacity)$then$most$
treatable'(e.g.'refractive'errors,'cataract)'and'then'other'avoidable'causes'(e.g.'
glaucoma).!Causes&of&blindness&were&determined&using&the&World&Health&
Organization’s)algorithm)for)use)in)surveys,)which)emphasizes)treatable)and)
preventable*causes.*In*the*Nigeria*survey,*glaucoma*was*only*assigned*as*the*
cause&if,&in&the&view&of&the&examiner,&other&more&readily&treatable&causes,&such&as&
clinically'significant'cataract%were%not%present.%!For$example,$in$a$blind$person$
with%clinically%significant%cataract%and%glaucoma,%the%main%cause%of%blindness%
would&be&cataract.&!
!
In#this#paper,#glaucoma(blindness!refers%to%a%person%with%glaucoma%in%one%or%both%
eyes$and$with$a$VA"of"worse"than"-//0"in"the"better"eye."A"blind&glaucoma&eye!has$
glaucoma(with(VA(worse(than(3/56(in(the(affected(eye.!
!
Risk%factors%assessment%and%classification!
Variables)were)analysed#as#continuous#(age,#axial#length,#IOP#and#mean%ocular%
perfusion*pressure&[MOPP])"or"binary"(sex,"marital"status,"literacy,"place"of"
residence,)history)of)glaucoma,)presence)of)hypertension,)random'blood'glucose'
level$[RBG],"lens"opacity,"type"of"glaucoma"and"history"of!glaucoma(surgery);(or(
categorised#into#groups#(ethnicity,'socio"economic'status'[SES],"geo"political(
zone%[GPZ],"severity"of"hypertension"and"body%mass%index%[BMI]).!
!!
Participants*were*asked*about*their*ethnicity,*marital*status,*ability*to*read*
and/or'write,'education'level'and'occupation.'Ethnic'groups!represented(by(>!""#
participants)were)analysed#separately#(Fulani,(Hausa,(Ibibio,(Ibo,(Ijaw,(Kanuri,#
Nupe,&Tiv,&Urhobo&and&Yoruba).#Marital#status#was$classified$as$married$and$
unmarried)(single,)divorced)or)widowed)."Being&literate&was&any&ability&to&read&
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and/or'write,'otherwise'the'participant'was'classified'as'illiterate.'Proxies'were'
used%to%determine%household%SES.%Occupations%were%ranked%from%zero%(not%
employed))to)seven!(professional)-and-the-highest-level"of"school#attended#were#
from%zero%(no%schooling)%to%four!(tertiary(education).(The(sum(of(these(scores(
were$calculated$for$each$individual$and$the$mean$of$sum$of$these$ranks$within$
the$household$was$assigned$as$the$SES$score$for$each$individual$in$order$to$take$
into%account%of%heterogeneity%and%household%size.%The%SES%scores%were%further%
divided%into%)%equal%tertiles%as%deprived,%medium%and%affluent.%Rural%place%of%
residence(was(defined(as(a(settlement(with(a(population(of(<!","""$residents,$
and$GPZ$are$the$,$administrative)zones)in)Nigeria)–!North&Central,&North&East,&
North&West,&South&East,&South&South&and&South&West.""!
!
Blood%pressure%(BP)$was$measured$with$the$Omron$wrist$instrument$(Omron$
Healthcare)Ltd,)Milton)Keynes,)England).)The#average!of#three#readings#was!used%
in#analysis.#Hypertension+was+defined+as+BP>!"#/%!mmHg%and%severity%was%
categorised#using#WHO#categories:#stage!!"for"systolic/diastolic"BP>!"#/%#&
mmHg,%stage%*%>!"#/!##%mmHg%and%stage%/%>!"#/!!#%mmHg.!"!BMI$was$
calculated(by(dividing(body(weight((kg)(by(height&(m)&squared&and&categorised!
according)to)the)international)classification)i.e.)underweight)(<56.7)kg/m!),#
normal'()*.,–!".$%kg/m!),#overweight#(./.1–!"."kg/m!)"and"obese"(>!"."$
kg/m!).!"!Every&'"in"!"participants"and"all"participants"suspected"to"have"diabetic"
retinopathy+on+examination+had+RBG+tested+with+One"touch&ultra&blood&glucose&
meter%(LifeScan,*UK),#and#grouped(as(normal((<!!.!#mmol/L)#or#raised#
(>!!.!mmol/L).!"!
!
Ocular'axial%length%was%measured%by%ultrasound%A"scan%biometry%(Bioline'
Biometer(OPTIKON(/000(S.p.A(Roma,(Italy)(and(IOP$was$measured$by$
Goldmann(applanation(tonometry(using(standard(methods.(To#explore#the#
association(of(vascular(perfusion(and(glaucoma(blindness,(MOPP(was(calculated(
from%diastolic%BP%(DBP),%systolic%BP%(SBP)%and%IOP%as%!/![DBP+!/!!(SBP"DBP)"
IOP].!"!Lens%grading%was%performed&using&the&Mehra"Minassian!"!and!the$WHO$
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grading'systems.!"!Lens%opacity%was%classified%as%positive%if%it%was%visually%
disabling)and)VA<!/#$%in%the%affected%eye.!
!
The$type$of$glaucoma$was$determined$by$gonioscopy$without$corneal$
compression*performed*with*Volk’s'("mirror%non"flanged(lens(and(Van$Herick’s$
(VH)%method%for%the%estimation%of%the%anterior%chamber%(AC)%angle.!"!Grades'('
and$%$VH$AC$angle$estimation$had$a$33.5%$sensitivity$and$39%$positive$predictive$
value&in&identifying&open&angles&by&gonioscopy!(risk%factors%for%OAG,%paper!
submitted)for)publication).!Thus%glaucoma%eyes%in%which%Schwalbe’s!line%could%
be#seen,#or#had#grades#-#or#.#by#VH#estimation#if#gonioscopy#was#not#done,#were#
classified)as)OAG."Glaucoma"eyes"in"which"Schwalbe’s"line"could"not"be"seen,"or"
had$grades$),$+$or$-$by$VH$estimation$if$gonioscopy$was$not$done,$were$classified$
as!angle"closure(glaucoma((ACG).(The(eyes(were(unclassified(if(there(was(no(
gonioscopy)or)VH)estimation)of)the)AC)angle.)Participants*were*asked*about*
history(of(ocular(surgery(and(examined(for(evidence(of(glaucoma(surgery(such(as(
bleb$and$peripheral$iridectomy.%!
!
Statistical(analysis!
Socio"demographic,-biophysical-and-ocular-factors-were-analyzed#for#associations#
with%glaucoma(blindness(after(identifying(participants(with(primary(glaucoma(
who$were$blind$or$not$blind$(Figure$1).$Statistical(analysis(was(performed(using(
Stata/IC'().+'(Stata'Corp,'College'Station,'TX).'!
!
We#examined#the#association#between#glaucoma#blindness#and#each#risk#factor#
separately)and)report)odds)ratios)(OR))with)45%)confidence)intervals.)We)also)
assessed%associations%between%blind%glaucoma%eyes%and%each%of%the%six%ocular%
factors.)We)used)logistic!regression(to(assess(the(independent(effect(of(each(risk(
factor'on'glaucoma'blindness'and'blind'glaucoma'eyes'and'report'adjusted'odds'
ratios'and'*+%'confidence'intervals.'Likelihood)ratio)tests)and)joint)Wald)tests)
were$performed$to$check$the$fit$of$the$model&and&the&effect&of&levels&of&categorical&
variables)and$those$with$missing$data."We"assessed"the"variance"inflation"factor"
(VIF)!for$the$covariates."Collinear'variables'were'not'included'in'the'same'
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multiple(logistic(regression(model.(The$following$covariates!were$included$and$
adjusted(for(in(the(main%multivariable+model!for$glaucoma$blindness:"age,"sex,"
ethnicity,)marital)status,)literacy,)SES,)rural/urban)residence,)history)of)glaucoma,)
BP,$BMI,$axial$length,%IOP,"lens"opacity"and"history"of"glaucoma#surgery.!The$
association(of(MOPP(was(explored(in(a(model(without(BP(and#IOP.#Associations#
for$GPZ$and$type$of$glaucoma$were$explored$in$separate'models.!All!eyes!were$
analyzed!to#take#into#account#bilateral#cases!and$ocular'variables'for'within"
person'correlation)clustered)for)pairs)of)eyes,)with%robust%standard%errors.%!
To#determine#associations#for#a#glaucoma#eye#being#blind,#all#ocular#variables#
were$included$in$the$multivariate$model.$!
!
To#explore#the#magnitude#and#direction#of#the#relative#risk#ratios#(RRR)$of"the"
two$glaucoma$outcomes$(not"blind&and&blind)&compared)to!the$non"glaucoma(
group,'we'performed'multinomial'logistic'regression'analysis'with'the'non"
glaucoma(subset(as(the(reference$category.$The$variables)age"group,'sex,'ethnic'
group,'marital'status,'literacy,'SES'and'place'of'residence'were'included'in'the'
model.'We#tested#the#overall#effect#of#each!of#the#covariates#and$levels$of$ethnic'
group!and$SES!on#predicting#the#two#glaucoma#outcomes."The$marginal$
predicted(probability*plot*of*glaucoma*blindness*by*age"group&with&sex&and&with&
SES#were#produced.#P"values'<).)+'were'considered'as'statistically'significant.!
Missing&values&were&excluded.!
!
!
Results"
!
In#the#study#sample,#01,232#participants#did#not#have!glaucoma:)**,,-*)(/0.2%))
had$both$optic$discs$assessed$and$classified$as$non"glaucoma((Figure(.).(For(eyes(
that$VCDR$could$not$be$assessed!(n=$%&$'eyes,',..%),"there"was"no"level"."
evidence!for$glaucoma."In#this#analysis#of#risk#factors#for#glaucoma#blindness#678#
eyes$of$'()$participants&were&included&(Figure&2):&!!"#had!glaucoma((*+.-%;!
!"%CI,!!".!"!!.#)"and!blind&in&both&eyes&(cases);!and$%&'$controls."A"further"*+,"
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participants)with)glaucoma)had)monocular)blindness.)Nearly!half%of%those!with%
glaucoma(("#$;&'(%)&were$therefore$blind$in$at#least#one#eye.#Glaucoma(was(the#
main%cause%of%blindness%in%both%eyes%of%23/556%persons%(:3.<%)%and%in%one%eye%of!
!"#persons.!Thus%glaucoma'was$the!main%cause%of%blindness%in%at%least%one%eye!of#
!"/""!$(&'.)%)."Other"main%causes&of&blindness$were$cataract,$optic$atrophy$and$
macular'degeneration."The"main"cause"of"blindness"at"the"person"level"in"the"667"
participants)was)glaucoma)in)01)("#%)&and&cataract&in&./&(.0%)(Table&').#Of#the#
!"#$eyes$with$glaucoma$included$in$the$analysis$there$were$a$total$of$787$(7:.7%)$
blind&eyes&with&glaucoma&in&345&participants.!
!
Glaucoma(blind(persons(were(older((mean(age(45.7(years/SD(<=.=)(than(the$non"
blind$(mean$age$*+.-years/SD)*+.-;)p=-.---*)(Table)6).#The#number!blind&
increased)with)increasing)age)up)to)the)age"group&'("!"#years.#!
!
There%was%a%higher%proportion%of%unmarried$glaucoma$blind$participants!than%
married.(Stratified(by(sex,"among"the"+,"unmarried)glaucoma)blind,)00)(23.2%))
were$women$(p<+.++-).!
!
A"history"of"prior"glaucoma"diagnosis"was"positive!in#$%/'()#('.,%)#participants;#
!".!%%known%to%have%glaucoma%were%blind%compared%with%9.!%#of#undiagnosed#
cases%(Table%*).!
!
The$likelihood$ratio$tests$on$categorical$covariates:$ethnic$group$across$all$levels$
(p=$.$$&),)BP!groups'(p=*.**,)'and'SES!(p<$.$$&)(indicate(that(these(variables(
create&a&statistically&significant&improvement&in&the&fit&of&the&main%multivariable%
model;'whereas'for!BMI$categories$(p=#.%&)!and$type$of$glaucoma$(p=#.%&)."For"
the$joint$Wald%test%(ethnic,%BP,"BMI)"p"value&is&!.!!#.!
!
Risk%factors%associated%with%glaucoma%blindness!
Ethnicity(and(GPZ(were(not(predictors(of(SES.(In(univariate(analysis,(people(with(
glaucoma(blindness'were'more'likely'to'be'older,'male'and'in'deprived'
households.)They)were)also)more)likely)to)be#known#glaucoma(and(have(
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hypertension,,and,the,odds,of,blindness,increased,with,increasing'severity'of'
hypertension!(Table'().'The$Igbo,$Hausa,$Fulani$and$Ijaw$ethnic$groups$had$
significantly+higher+odds+of+glaucoma+blindness+than+the+reference+ethnic+group"
(Yoruba)!(Table'()."Higher"IOP"(OR!="!.#$;!!"%CI!!.#$"!.#$;"p<%.%%')"and"
presence'of'visually'disabling'lens'opacity!(vdLO)!(OR!="!.#!;!!"%CI#$.&'"!.#$;"
p<#.##%)"also"increased"the"odds"of"glaucoma"blindness"(Table"2).!
!
In#multivariate'analysis,'being'male,"living&in&a&deprived&household!(see$Table$)),"
severe%hypertension!(see$Table$))$and$higher$IOP!(see$Table$))!remained(
independent'risk'factors'for'glaucoma'blindness.'Being'poor/deprived'had'three"
and"half!times&higher&odds&of&glaucoma&blindness%(OR!="!.!";"#$%CI#$.&'"!.#$;&
p=#.##%)"than"affluent"participants!(Table'()."A"prior"diagnosis"of"glaucoma"had"
a"significantly(higher(odds(of#glaucoma#blindness#(OR!="!.#$;!!"%CI#$."#"!".$%;'
p=#.##%)'(Table'.).#Being#unmarried#was#also#an#independent#risk#factor#with#
higher"odds"of"being"blind"(OR!="!.#$;!!"%CI#$.&'"!.#$;"p=%.%')."The"Igbo%and%
Fulani'ethnic'groups'had'higher'odds'for'glaucoma'blindness'(Table#$).!
!
Risk%factors%associated%with%blind%glaucoma%eyes!
About&half"of"the"eyes"with"glaucoma"and!vdLO!were$blind$(+,-//01;$/3.-%),$and$
almost'two"thirds'of'eyes'with'ACG'were#blind#(*+/--;#!".!%)(Table,!).#There#
was$evidence$of$glaucoma$surgery$in$34/674$(9.;7%)$participants$of$whom"eight!
had$surgery$in$both$eyes$(total$23/567$eyes);$all$of$which$were$trabeculectomy.$
There%was%no%significant%difference%in%blindness%status%in%eyes%that%had%
undergone'trabeculectomy.'!
!
In#univariate#analysis,#longer#axial#length,#higher#IOP,#lower#MOPP,#vdLO!and$
ACG$were$significantly$associated$with$blind&glaucoma&eyes."However,"when"
adjusted(for(age,(sex,"ethnicity,"marital"status,"SES,"location"and"other"factors(in(
the$multivariable!model,'only'higher'IOP$(OR!="!.#$;!!"%CI&!.#$"!.!#)"and$vdLO$
(OR!="!.#$;!!"%CI&'.)*"!.!!)$remained!independent'risk'factors."There"was"no"
statistically(significant(association(between(trabeculectomy(and(glaucoma(
blindness(or(blind&glaucoma&eyes.!
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!
Relative(risk(of(the(two(glaucoma(outcomes((not"blind&and&blind)&compared)to)non"
glaucoma!!
!
RRR>#$signifies$that$there$is$an$increase$in$the$outcome$(not"blind&or&blind)&when&
compared)to)the)reference)group,)non"glaucoma;!given&that&the&other&variables&in&
the$model$are$held$constant.!Table&'!shows%the%frequency%distribution%and%the%
RRR"of"the"covariates"for"the"two"outcomes"of"glaucoma."The"factors"that"
increased!the$outcome$for$glaucoma$are$shown.!
!
Glaucoma&not"blind&relative%to%non"glaucoma!
Increasing*age*was*the*only*independent*factor*that*had*an*increased*relative(risk!
for$glaucoma$not"blind&compared&to&non"glaucoma;)from)RRR)-./0!("#%CI!!.#$"
!.#$)!in#the#'("!"#years#age"group#to#&.&(#((*%CI!!.#$"!.#!)#in#the#)*+#year"
olds%(Table%+).!!
!
Glaucoma(blind(relative(to(non"glaucoma!
Older!age"groups'were'more'likely'to'have'glaucoma'blindness,"with"a"RRR"
increasing)from)-.!"#(!"%CI!!.##"!.##)%in%the%!+"!"#years&age"group&to&().)+&
("#%CI!!.#$"!".$%)'in'the'-"+'year"olds.&!
!
The$Igbo$ethnic$group$had$a$non"statistically(significant(increase(in(relative(risk(
for$glaucoma$not"blind&(RRR"="#.#%;!!"%CI!!.#$"!.#$;&p=).*!)"but"were"more"likely"
to#be#glaucoma#blind#by#a#factor#of#2.45#(!"%CI!!.!""!.!";$p<".""$).#Males&were&
more%likely"than"females"to"be"glaucoma"blind"compared"to"non"glaucoma(with(
an#expected#increase$by$a$factor$of$,...$(01%CI!!.#$"!.#$).!
!
Deprivation+did+not+increase+the+outcome%of%glaucoma%not"blind&(RRR!="#.%&;!
!"%CI!!.#$"!.#!).%However,%for%people#with#glaucoma,#the$deprived$were#more#
likely&than&the&affluent&to&be&blind&with&glaucoma&by&a&factor!of#$.$&#(()%CI!
!.#$"!.#$).&The$overall$effect$of$SES$was"statistically"significant."More"specifically,"
we#tested#the#effect#of#deprivation#in#predicting#glaucoma#not"blind"and"
glaucoma(blind(and"this"showed"that"the"effects"were#statistically#different#from#
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each%other,"i.e."the"deprived"were"not"at#higher#risk!than%the%affluent%to%have%
glaucoma(but(were(more(likely(to(be(blind(with(it."The"Igbo,"Hausa"and"Fulani"
ethnic'groups$also$showed$different$effects$in#outcome#of#glaucoma#(Table#1).#!
!
Figure'('shows'the'marginal'predicted'probabilities'of'glaucoma'blindness'by'
increasing)age!and$by$SES."For"a"'("!"#year"old$male,$the$average$marginal(
probability&of&being&glaucoma&blind&was"about"(.*%"compared"to"!%#for#a#female#
of#the#same#age#group.!
!
Compared)to)the!affluent,)deprivation)increased!the$average$marginal$probability$
of#glaucoma#blindness#by#approximately().+%(in(the(younger(age(group,!to#$%#in#
!""!"#year#age"group!and$over$)%$in$the$./+$ages.!
!
!
Discussion!
!
To#our#knowledge,#this#is#the#first#population"based&study&of&risk&factors&for&
blindness(among(individuals(with(glaucoma(in(a(black(population(in(Sub"Saharan&
Africa.(In(this(study(the(vast(majority(of(participants"with"glaucoma"had"
undiagnosed*and*untreated*disease*(./%)*at*the*time*of*the*survey,*and*so*the*
findings'largely'reflect'the'natural'history'of'untreated'glaucoma.'!
A"set"of"post"estimation)statistical)analysis!tools%that%would%aid%the%
understanding,,interpretation,and,presentation,of,the,relationship,between,the,
assessed%risk%factors%were%used.%Being&of!Igbo!ethnicity!was$an$independent$risk$
factor'for'glaucoma'blindness.&The$Fulani,$Ijaw$and$Tiv$ethnic$groups$had$odds$
ratios'with'very'wide'confidence'intervals'hence'we'cannot'draw'meaningful'
conclusions(on(these.!Those&with&higher&IOP&and!vdLO,&being&male&and&those!
living&in&deprived&households!also%had$increased)odds)of)blindness.)!
!
Although(there(are(over(-./(languages(spoken(in(Nigeria,(each(ethnic(group(has(
similar'ancestry'and'may'be'of'common'genetic'stock.'As'ethnic'group'did'not'
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correlate(with(socio"economic'status,'ethnic'differences'in'risk'of'glaucoma'
blindness(suggest(that(there%may%be%genetic%similarities%that!lead%to%more%
aggressive(disease(in(some(ethnic(groups,(in(terms(of(higher(IOP(or(greater(
susceptibility+of+the+optic+nerve+head+to+glaucoma,+or+gene"environment)
interactions.+In+the+Nigeria+Blindness+Survey,+about+half"($%%)"of"the"eyes"with"
glaucoma(had(IOP(<!!mmHg%(mean%IOP+!SD),!"!and$there$was$variation$in$
optic&disc&parameters&as&well&as&IOP&among&some&ethnic&groups.!"!These%data%are%
being&explored&to&assess&whether&different(ethnic(groups(are(at(increased(risk(of(
normal'tension'glaucoma,'which'may'reflect'genetic'susceptibility'to'structural'
optic&nerve&damage!(as$in$the$Japanese$population,$for$example),!!!or#have#
differing(frequencies(of(genetic'variants'such'as'CDKN/BAS!associated)with)
normal'tension'glaucoma.!"!
!
Most%of%earlier%studies%have#been#retrospective,#facility"based&studies&of&glaucoma&
patients(in(the(care!system,'showing'that'severity'of'glaucoma'at'diagnosis'and'
poor$control$of$IOP$were$key$risk$factors$for$progression$to$blindness.!""!"!They%
buttress'the'paradigm'that'glaucoma'visual'loss'could'be'prevented'by'earlier'
diagnosis(and(consistent(and(adequate(treatment(with(IOP(lowering(as(the(
cornerstone.)Hospital)reviews)in)Nigeria)and)sub"Saharan&Africa&also&highlight&
factors(that!limit%glaucoma'patients’'ability'to'access'or'maintain'treatment,'thus'
worsening)their)visual)prognosis.!""!"!One$population"based&study&reported&older&
age$as$the$only$factor$associated$with$progression/severity$of$glaucoma$in$
untreated(individuals(who(were(re"examined(after(,-(years(of(the(initial(survey.!"!!
In#our"study"a"staggering"-"in"!!people%with%glaucoma%were%already%blind%
suggesting(that(services(for(glaucoma(are(either(not(available(or(poorly(accessible.(
This#is#in#contrast#to#data#from#a"glaucoma"clinic"in"Scotland,"where"glaucoma"
blindness(was(uncommon.!"!In#Norwich,#Ang!and$Eke’s#review#of#treated#
glaucoma(patients(reported(1.1%(blind,(none(of(whom(was(certified(due(to(
glaucoma.!"!However,(in(Sweden(glaucoma(patients(had(a(lifetime(risk(of(
glaucoma(blindness"of"%&%.!"!These%studies!did#not#include#those#undiagnosed#in#
the$population$and$may$have$overestimated$the$risk$of$glaucoma$blindness.$!
!
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In#our#study,!not$all$blindness$was$due$to$glaucoma$and$at$least$12%$could$have$
been$prevented(by(cataract(surgery.(Highlighting(this(and(other(causes(
underscores)the)need)for)providing)non"glaucoma(interventions.(The$low$cataract$
surgical)coverage)in)this)population!"!compounds)the)problem.)Hence)there)is)a)
need$for$integrated$comprehensive$eye$care$services$and$high$quality$cataract$
surgery'in'patients'with'glaucoma.'!
!
A"surprising"finding"was"that"men"were"at"a"considerably"higher"risk"of"glaucoma"
blindness.)This)is)likely&to&reflect&the&significantly&higher&prevalence&of&glaucoma&
in#men#(".$%%;()"%CI(".,""!.#$)&than%women%(!.!#%;&'(%CI$%.'("!.##;%
p=#.##%)!"!and$also$an$indication$of$general'lack"of"availability"or"access"to"
glaucoma(services.(Being(unmarried(was(also(an(independent(risk(factor(for(
glaucoma(blindness,(particularly(among(women.(This(finding(probably(reflects(
disempowerment,of,unmarried&women&whose&health&needs&are&not&prioritized&by&
other&family&members&or&the&community.&In&our&study,&those&living&in&deprived&
households(were(also(at(a(considerably(higher$risk$of$glaucoma$blindness$and$
poor$old$people$were$most$affected.$As#in#most!studies'and'reviews'of'poverty'
and$blindness,$socio"economic'status'tends'to'influence'health"seeking'behavior,'
awareness'and'healthcare'access.!""!!!Rural/urban)and)GPZ)location"were"not"
independent'risk'factors'in'this'study,'suggesting'that'services'for'glaucoma'are'
equally&poor&across&the&country.&As"in"the"St"Lucia"study,!"!increasing)age)was)
associated)with#glaucoma#blindness,#but#the#association(was(not(significant(in(
multivariate*analysis.*This*may*signify*that*glaucoma*occurs*at*an*earlier*age*in*
Nigeria'with'blindness(occurring(across(all(age(groups,(as(duration(of(disease(is(
an#important#risk#factor#for#blindness.!","!"!Blindness(occurring(at(an(earlier(age(
has$also$been$reported$in#the#black#population#of#Baltimore.!"!
!
A"prior"diagnosis"of"glaucoma(was(independently&associated&with&blindness.&
Many$facility"based&studies$in$Africa$show$that$a$high$proportion$of$newly$
diagnosed)glaucoma)patients)present)with)very)advanced)disease;!","!""!","!"!and$
diagnosed)cases)were)more)severely)affected)than)non"diagnosed)cases)in)the)
population.!"!This%underscores%the%need%for%an%integrated%approach%for%earlier%
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case"finding!in#the#community,#and#the#need#for#services#that#are#acceptable#and#
affordable.*!
!
There%are%some%limitations%in%this%study.%The%definition%of%blindness%by%VA!alone&
would&underestimate&the&total&numbers&blind&from&glaucoma.&Including&visual&
fields'in'the'definition'of'blindness'might'have'increased'the'estimates'of'
blindness(by(up(to(./%.!"!SES!was$determined$by$proxy$factors$i.e.$education$and$
occupation)rather)than)using)asset)scores)or)other)measures)as)this)was)not)
feasible(within(the$constraints$of$the$survey.$Data$on$the$duration$of$glaucoma!or#
of#blindness#were$not$collected,!as#these#data#would#be#subjective#and#unreliable.#!
!
The$combination$of!high$prevalence$of$glaucoma,$socioeconomic$deprivation$and$
lack%of%access%to%services%means%that%in%Nigeria%glaucoma%is%often%a%blinding%
condition.(The(finding(that(some(ethnic(groups(are$at$increased$risk$of$glaucoma$
and$of$glaucoma$blindness$warrants$further$investigation$from$a$molecular$
genetics(perspective(which(may$further$our$understanding$of$the$pathogenesis$of$
glaucoma(in(African(populations(and(among(those(of(African(ancestry(who$live!
elsewhere.(!
!
!
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Figure'1.!Selection)of)Cases)and)Controls$for$Analysis$of$Risk$Factors$for$Glaucoma$Blindness$and$Classification$of$Glaucoma$Eyes$by$Levels$of$
Evidence!#
!
Enumerated
15027
Respondents Non-response
13599 1428
Level 1
VCDR> 0.7
or asym>0.1 Analysed Excluded (no VA)
13591 8
303 eyes (90% response rate)
Level 2
VCDR> 0.75 Glaucoma Not glaucoma Disc graded in BE
or asym>0.2 682 (5.02%) 12909 11,651 90.30%
520 eyes Disc graded in OE
Primary glaucoma Secondary glaucoma 765 5.90%
Level 2b 629 persons 53
RAPD/Other 890 eyes Disc not graded in BE
evidence 493 3.80%
5 eyes Blind Not blind
(Cases) 119 (Controls) 510
Level 3
VA<20/400
IOP>28mmHg Cases 114 Controls 497
On treatment
62 eyes
Blind = VA<20/400 in the better eye
VA = visual acuity; BE = both eyes; OE = one eye; VCDR = verical cup:disc ratio; asym = VCDR asymmetry; RAPD = relative afferent pupillary defect; 
IOP = intraocular pressure. * = multinomial regression logistic sample includes primary and secondary glaucoma, 61 persons have missing data
Multiple logistic regression analysis sample (n=611)
Glaucoma blind 136 Glaucoma not blind 542 Not glaucoma 12,852
Multinomial logistic regression analysis sample (n=13,530)*
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Figure'2.!Marginal(Predicted(Probabilities(of(Glaucoma(Blindness(by(Age$Group&With&Sex$
and$With$Socioeconomic$Status$#
!
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Table&1.#Main#Causes#of#Blindness#in#Participants#With#Primary#Glaucoma##
#
Main%cause%of%blindness! Number! %!
Glaucoma! !"! !".$!
Cataract! !"! !".$!
Optic&atrophy! !! !.#!
Macular'degeneration! !! !.#!
Other!posterior(segment(disease! !! !.#!
Corneal(opacity! !! !.#!
Uncorrected)aphakia! !! !.#!
Refractive*error! !! !.#!
Anterior(uveitis! !! !.#!
Unexplained*! !! !.#!
Total! !!"! !""."!
#
!
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Table&2.#Distribution#Of#Glaucoma#Participants#With#and#Without#Blindness#By#Socio$
Demographic#And#Biophysical#Factors#(Total#=629)#
Variable& & Not$blind$n$(%)&
510$(81.1%)&
Blind&n&(%)&
119#(18.9%)&
Socio$demographic,factors# # & &
Age$group$(years)# !!!!!40#–!49# 78#(15.3)# 11"(9.2)#
# !!!!!50#–!59# 105$(20.6)# 14#(11.8)#
# !!!!!60#–!69# 133#(26.1)# 29#(24.4)#
# !!!!!70#–!79# 125$(24.5)# 37#(31.1)#
# !!!!!80+# 69#(13.5)# 28#(23.5)#
# !!!!!Mean+SD# 63.4+13.0# 68.5+13.3#
Sex# !!!!!Female# 268$(52.5)# 43#(36.1)#
# !!!!!Male# 242#(47.5)# 76#(63.9)#
Ethnic'group# !!!!!Yoruba# 132$(26.1)# 15#(12.6)#
# !!!!!Igbo# 112#(22.1)# 30#(25.2)#
# !!!!!Hausa# 86#(17.0)# 24#(20.2)#
# !!!!!Fulani# 16#(3.2)# 10#(8.4)#
# !!!!!Kanuri# 12#(2.4)# 4"(3.3)#
# !!!!!Ijaw# 10#(1.9)# 5"(4.2)#
# !!!!!Ibibio# 9"(1.8)# 2"(1.7)#
# !!!!!Nupe# 8"(1.6)# 2"(1.7)#
# !!!!!Tiv# 8"(1.6)# 3"(2.5)#
# !!!!!Urhobo# 7!(1.4)# 0"(0.0)#
# !!!!!Others# 106$(20.9)# 24#(20.2)#
Marital'status# !!!!!Married# 355#(69.6)# 76#(63.9)#
# !!!!!Unmarried# 155#(30.4)# 43#(36.1)#
Literacy)))# !!!!!Literate# 182$(35.7)# 41#(34.5)#
# !!!!!Non$literate# 328$(64.3)# 78#(65.5)#
Socio$economic'status# !!!!!Affluent# 138$(27.1)# 17#(14.3)#
# !!!!!Medium# 192$(37.6)# 20#(16.8)#
# !!!!!Deprived# 180$(35.3)# 82#(68.9)#
Place&of&residence# !!!!!Urban&&# 116#(22.7)# 30#(25.2)#
# !!!!!Rural&# 394$(77.3)# 89#(74.8)#
Geo$political(zone# !!!!!South&south# 85#(16.7)# 15#(12.6)#
# !!!!!North&east# 39#(7.6)# 15#(12.6)#
# !!!!!South&west# 129$(25.3)# 18#(15.1)#
# !!!!!North&central# 70#(13.7)# 19#(16.0)#
# !!!!!South&east# 103$(20.2)# 24#(20.2)#
# !!!!!North&west# 84#(16.5)# 28#(23.5)#
History(of(glaucomaα# !!!!!Not$known$glaucoma# 490$(96.1)# 101#(84.9)#
# !!!!!Known%glaucoma# 20#(3.9)# 18#(15.1)#
Biophysical+factors# # # #
Blood%pressure%(mmHg)%%%%<140/90# !!!!!Normal'# 374$(73.6)# 65#(55.6)#
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!>140/90# !!!!!Hypertension+# 134$(26.4)# 52#(44.4)#
Random'blood'glucose''!!!!!!<11.1# !!!!!Normal'# 84#(96.5)# 21#(95.5)#
(mmol/L)(((((((((((((((((((((((((((((>11.1# !!!!!Diabetes(# 3"(3.5)# 1"(4.5)#
Body%mass%index%(kg/m2)"""18.5$24.9# !!!!!Normal''''# 303#(60.5)# 71#(61.2)#
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!<18.5# !!!!!Underweight# 76#(15.2)# 21#(18.1)#
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!25.0$29.9# !!!!!Overweight# 81#(16.1)# 21#(18.1)#
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!>30.0# !!!!!Obese# 41#(8.2)# 3"(2.6)#
Glaucoma(surgery# !!!!!Trabeculectomy# 12#(2.4)# 7"(5.9)#
# !!!!!No#surgery# 498$(97.6)# 112#(94.1)#
Type%of%glaucoma# !!!!!OAG# 360$(91.8)# 102$(91.9)#
# !!!!!ACG# 32#(8.2)# 9"(8.1)#
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Table&3.#Univariate#and#Multivariate#Analysis#of#Risk#Factors#for#Blindness#Among#Participants#With#Glaucoma:#SocioCDemographic#Factors#
# n&(%)&
[95%CI]&
Univariate&analysis& Multivariate&analysis& &
& Odds#Ratio# 95%CI# pCvalue# # Odds#Ratio# 95%CI# pCvalue# VIF#
Blind&persons& 119#(18.9)[15.9C22.4]# # # # # # # # #
Age#(years)# (Min#40)# # 1.00# # # # 1.00# # # 1.46#
# Increasing#age# # 1.03# 1.01C1.05# <0.001# # 0.99# 0.96C1.02# 0.48# #
Sex# Female# 43#(13.8)# 1.00# Reference# # # 1.00# Reference# # 1.95#
# Male# 76#(23.9)# 1.96# 1.30C2.96# 0.001# # 4.59# 1.73C12.16# 0.002# #
Ethnic#group# Yoruba# 15#(10.2)# 1.00# Reference# # # 1.00# Reference# # 1.06#
# Igbo# 30#(21.1)# 2.36# 1.21C4.60# 0.01# # 2.79# 1.03C7.57# 0.04# #
# Hausa# 24#(21.8)# 2.46# 1.22C4.95# 0.01# # 2.69# 0.89C8.14# 0.08# #
# Fulani# 10#(38.5)# 5.50# 2.12C14.28# <0.001# # 9.75# 2.91C32.67# <0.001# #
# Kanuri# 4#(25.0)# 2.93# 0.84C10.26# 0.09# # 2.83# 0.62C13.00# 0.18# #
# Ijaw# 5#(33.3)# 4.40# 1.33C14.61# 0.02# # 15.02# 1.17C193.69# 0.04# #
# Ibibio# 2#(18.2)# 1.96# 0.39C9.92# 0.42# # 2.43# 0.29C20.36# 0.41# #
# Nupe# 2#(20.0)# 2.20# 0.43C11.34# 0.35# # 3.22# 0.41C25.02# 0.26# #
# Tiv# 3#(27.3)# 3.30# 0.79C13.81# 0.10# # 7.92# 1.65C37.99# 0.01# #
# Others# 24#(18.5)# 1.99# 1.00C3.99# 0.52# # 4.01# 1.41C11.43# 0.01# #
Marital#status# Married# 76#(17.6)# 1.00# Reference# # # 1.00# Reference# # 1.57#
# Unmarried# 43#(21.7)# 1.30# 0.85C1.97# 0.23# # 2.50# 1.03C6.07# 0.04# #
#Literacy# Literate# 41#(18.4)# 1.00# Reference# # # 1.00# Reference# # 1.43#
# NonCliterate# 78#(19.2)# 1.06# 0.69C1.61# 0.80# # 1.03# 0.49C2.19# 0.08# #
Socioeconomic## Affluent# 17#(11.0)# 1.00# Reference# # # 1.00# Reference# # 1.20#
Status# Medium# 20#(9.4)# 0.85# 0.43C1.67# 0.63# # 0.50# 0.17C1.49# 0.21# #
# Deprived# 82#(31.3)# 3.70# 2.10C6.53# <0.001# # 3.57# 1.46C8.72# 0.005# #
#Residence# Urban# 30#(20.6)# 1.00# Reference# # # 1.00# Reference# # 1.08#
# Rural# 89#(18.4)# 0.87# 0.55C1.39# 0.57# # 1.48# 0.65C3.37# 0.36# #
Geopolitical#zone# NorthCeast# 15#(27.8)# 2.18# 0.97C4.90# 0.06# # 2.18# 0.59C7.97# 0.24# #
# NorthCwest# 28#(25.0)# 1.89# 0.94C3.79# 0.07# # 1.60# 0.53C4.86# 0.40# #
# NorthCcentral# 19#(21.4)# 1.54# 0.73C3.25# 0.26# # 1.07# 0.38C3.01# 0.90# #
# SouthCsouth# 15#(15.0)# # Reference# # # 1.0# Reference# # #
# SouthCeast# 24#(18.9)# 1.32# 0.65C2.68# 0.44# # 0.87# 0.30C2.56# 0.80# #
# SouthCwest# 18#(12.2)# 0.79# 0.38C1.66# 0.53# # 0.54# 0.17C1.67# 0.28# #
History#of#glaucoma# Not#known# 101#(17.1)# 1.00# Reference# # # 1.00# # # 1.32#
# Known#glaucoma# 18#(47.4)# 4.37# 2.23C8.55# <0.001# # 5.89# 1.79C19.40# 0.004# #
VIF#=#variance#inflation#factor#for#covariates#in#the#main#multiple#logistic#regression#model;#mean#VIF#=#1.28#
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Table&4.#Univariate#and#multivariate#analysis#of#risk#factors#for#blindness#amongst#participants#with#glaucoma:#Biophysical#factors#
& n&(%)&
[95%CI]&
Univariate&analysis& & Multivariate&analysis& &
& Odds#
Ratio#
95%CI# pC
value#
# Odds#
Ratio#
95%CI# pCvalue# VIF#
Hypertension#mmHg# # # # # # # # # # #
#<140/90# Normal# 65#(14.8)# 1.00# Reference# # # NI# # # #
>140/90# Hypertension## 52#(28.0)# 2.23# 1.47C3.38# <0.001# # # # # #
Blood##pressure#
mmHg#
(severity)# # # # # # # # # #
<140/90# Normal# 65#(14.8)# 1.00# Reference# # # 1.00# # # 1.03#
>140/90#–#160/100# stage#1#mild# 24#(25.0# 1.92# 1.13C3.27# 0.02# # 2.29# 1.02C5.14# 0.04# #
>160/90#–#180/110# stage#2#
moderate#
15#(27.8)# 2.21# 1.15C4.25# 0.02# # 1.59# 0.64C3.93# 0.32# #
>180/100# stage#3#severe# 13#(36.1)# 3.25# 1.57C6.75# 0.002# # 3.53# 1.25C9.98# 0.02# #
Random#blood#
glucose#
mmol/L# # # # # # # # # #
<11.1# Normal## 21#(20.0)# 1.00# Reference# # # NI# # # #
>11.1### Diabetes## 1#(25.0)# 1.33# 0.13C13.62# 0.81# # # # # #
Body#mass#index#
kg/m2#
(Categories)# # # # # # # # # #
18.5C24.9# Normal# 71#(19.0)# 1.00# Reference# # # 1.00# # # 1.08#
<18.5### Underweight# 21#(21.7)# 1.18# 0.68C2.04# 0.56# # 0.73# 0.34C1.54# 0.40# #
25.0C29.9# Overweight# 21#(20.6)# 1.11# 0.64C1.91# 0.72# # 0.90# 0.40C2.01# 0.80# #
>30.0# Obese## 3#(6.8)# 0.31# 0.09C1.04# 0.06# # 0.49# 0.09C2.62# 0.41# #
NI#=#not#included#in#multivariable#models.#
& &
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Table&5.#Univariate#and#multivariate#analysis#of#risk#factors#for#blindness#amongst#participants#with#glaucoma:#Ocular#factors#
& n&(%)&
[95%CI]&
Univariate&analysis& & Multivariate&analysis& &
& Odds#
Ratio#
95%CI# pC
value#
# Odds#
Ratio#
95%CI# pCvalue# VIF#
Axial#length#(mm)# (Min#18)# C# 1.00# # # # 1.00# # # 1.19#
# (Max#30)# C# 1.15# 0.92C1.43# 0.22# # 0.79# 0.56C1.11# 0.18# #
IOP#(mmHg)# (Min#5)# C# 1.00# # # # 1.00# # # 1.09#
(higher)# (Max#50)# C# 1.06# 1.04C1.08# <0.001# # 1.07# 1.04C1.09# <0.001# #
MOPP#(mmHg)# (Min#6)# C# 1.00# # # # 1.00# # # #
# (Max#115)# C# 0.99# 0.97C1.00# 0.10# # 0.99# 0.97C1.00# 0.14# #
Lens#opacity# Clear#lens# 31#(9.9)# 1.00# # # # 1.00# # # 1.22#
# Lens#opacity# 88#(27.9)# 2.72# 1.89C3.91# <0.001# # 1.36# 0.78C2.35# 0.28# #
Type#of#glaucoma# OAG# 102#(22.1)# 1.00# # # # 1.00# # # #
# ACG# 9#(22.0)# 1.38# 0.69C2.77# 0.36# # 0.63# 0.21C1.92# 0.42# #
Glaucoma#surgery# No#surgery# 112#(18.4)# 1.00# # # # 1.00# # # 1.23#
& Trabeculectomy## 7#(36.8)# 1.45# 0.55C3.96# 0.44# # 0.41# 0.09C1.83# 0.25# #
IOP#=#intraocular#pressure;#MOPP#=#mean#ocular#perfusion#pressure;#OAG#=#openCangle#glaucoma;#ACG#=#angleCclosure#glaucoma.#
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Table&6.##Association#of#Ocular#Factors#with#Glaucoma#Blind#Eyes#
# For&blind&eyes&
& Univariate&analysis& Multivariate&analysis&
# # # Odds#Ratio# 95%CI# pCvalue# # Odds#Ratio# 95%CI# pCvalue#
Eyes#with#glaucoma#
N#=#890#eyes#(100%)#
Not#blind##
567#
(63.7%)#
Blind&#
323#
(36.3%)#
# # # # # # #
Ocular#factors*# # # # # # # # # #
Axial&length#(mm)#Mean+SD# 22.68+0.87# 22.89+1.28# # # # # # # #
####(Min#19.32)# Min#20.42# Min#19.45# 1.00# # # # Reference## # #
####(Max#29.92)# Max#25.14# Max#29.92# 1.21# 1.05C1.40# 0.01# # 1.03# 0.81C1.32# 0.80#
IOP#(mmHg)#Mean+SD# 20+9# 28+13# # # # # # # #
####(Min#5)# # # 1.00# # # # Reference## # #
####(Max#50)# # # 1.08# 1.06C1.09# <0.001# # 1.09# 1.05C1.13# <0.001#
MOPP#(mmHg)#Mean+SD# 50+15# 44+17# # # # # # # #
####(Min#6)# # # 1.00# # # # Reference## # #
####(Max#98)# # # 0.98# 1.06C1.09# <0.001# # 1.00# 0.98C1.04# 0.77#
Lens&opacity& & & & & & & & & &
####Clear#lens# 358#(75.4)# 117#(24.6)# 1.00# # # # Reference# # #
####Lens#opacity# 209#(50.4)# 206#(49.6)# 3.02# 2.27C4.01# <0.001# # 2.13# 1.36C3.33# 0.001#
Type&of&glaucoma@& & & & & & & & & &
####OAG# 423#(62.0)# 259#(38.0)# 1.00# # # # Reference# # #
####ACG# 24#(36.4)# 42#(63.6)# 2.86# 1.69C4.83# <0.001# # 1.25# 0.59C2.67# 0.56#
Glaucoma&surgery@& & & & & & & & & &
####No#surgery# 553#(64.1)# 310#(35.9)# 1.00# # # # Reference## # #
####Trabeculectomy## 14#(51.9)# 13#(48.2)# 1.66# 0.77C3.57# 0.20# # 0.71# 0.20C2.52# 0.60#
# # # # # # # # # #
*analysis#adjusted#for#within#person#correlation;#SD#=#standard#deviation;#IOP#=#intraocular#pressure;#MOPP#=#mean#ocular#perfusion#
pressure;#@#=#missing#data#excluded;#OAG#=#openCangle#glaucoma;#ACG#=#angleCclosure#glaucoma.##
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Table&7.#Relative#Risk#Ratios#of#the#Glaucoma#Outcomes#(Glaucoma#NotCblind#and#Glaucoma#Blind)#Compared#to#the#NonCglaucoma#Group##
& Frequency&distribution&(%)& Relative&Risk&Ratio&(RRR)& Effect#on#
predicting#
glaucoma#
outcome.#
p<0.05#if#the#
effect#is#
different#on#
the#2#
outcomes#
NonCglaucoma#
N#(%)#
Glaucoma#
not#blind#
N#(%)#
Glaucoma#
blind#
N#(%)#
Glaucoma#notCblind# # Glaucoma#blind#
RRR# 95%CI# pCvalue# # RRR# 95%CI# pCvalue#
Total& 12909#(94.98)# 546#(4.02)# 136#(1.00)# # # # # # # #
SocioT
demographic&
factor&
# # # # # # # # # #
AgeCgroup#(years)# # # # # # # # # # # #
####50C59# 3447#(96.37)# 112#(3.13)# 18#(0.50)# 1.85# 1.37C248# <0.001# # 1.77# 0.85C3.70# 0.13# #
####60C69# 2595#(93.58)# 147#(5.30)# 31#(1.12)# 3.13# 2.34C4.20# <0.001# # 3.51# 1.77C6.99# <0.001# #
####70C79# 1475#(89.23)# 134#(8.11)# 44#(2.66)# 5.10# 3.73C6.99# <0.001# # 7.43# 3.75C14.71# <0.001# #
####80+# 596#(85.26)# 72#(10.30)# 31#(4.43)# 6.69# 4.63C9.67# <0.001# # 10.08# 4.85C20.93# <0.001# #
# # # # # # # # # # # #
Male# 5892#(94.33)# 267#(4.27)# 87#(1.39)# 1.15# 0.92C1.42# 0.23# # 3.00# 1.87C4.83# <0.001# #
# # # # # # # # # # # #
Ethnic#groups# # # # # # # # # # # #
####Igbo# 1769#(92.23)# 116#(6.05)# 33#(1.72)# 1.18# 0.91C1.54# 0.21# # 3.71# 2.01C6.85# <0.001# <0.001#
####Hausa# 3245#(96.15)# 97#(2.87)# 33#(0.98)# 0.62# 0.48C0.81# 0.001# # 1.94# 1.05C3.56# 0.03# <0.001#
####Fulani# 810#(96.43)# 18#(2.14)# 12#(1.43)# 0.47# 0.29C0.78# 0.003# # 2.39# 1.11C5.14# 0.03# <0.001#
####Ibibio# 200#(94.34)# 10#(4.72)# 2#(0.94)# 1.14# 0.59C2.23# 0.70# # 2.30# 0.51C10.47# 0.28# 0.40#
# # # # # # # # # # # #
Unmarried# 2619#(92.51)# 164#(5.79)# 48#(1.70)# 1.05# 0.82C1.33# 0.71# # 1.85# 1.14C3.00# 0.01# #
# # # # # # # # # # # #
Deprived# 4191#(93.44)# 199#(4.44)# 95#(2.12)# 0.94# 0.73C1.21# 0.63# # 4.42# 2.50C7.80# <0.001# <0.001#
# # # # # # # # # # # #
#
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ABSTRACT
Purpose of the study: Glaucoma, a chronic non-
communicable disease, and leading cause of
irreversible blindness worldwide is a public health
problem in Nigeria, with a prevalence of 5.02% in
people aged ≥40 years. The purpose of this nationwide
survey was to assess Nigerian ophthalmologists’
practice patterns and their constraints in managing
glaucoma.
Study design: Ophthalmologists were sent a
semistructured questionnaire on how they manage
glaucoma, their training in glaucoma care, where they
practice, their access to equipment for diagnosis and
treatment, whether they use protocols and the challenges
they face in managing patients with glaucoma.
Results: 153/250 ophthalmologists in 80 centres
completed questionnaires. Although 79% felt their
training was excellent or good, 46% needed more
training in glaucoma diagnosis and surgery. All had
ophthalmoscopes, 93% had access to applanation
tonometers, 81% to visual field analysers and 29% to
laser machines (in 19 centres). 3 ophthalmologists had
only ophthalmoscopes and schiøtz tonometers. For 85%,
a glaucomatous optic disc was the most important
feature that would prompt glaucoma work-up. Only 56%
routinely performed gonioscopy and 61% used slit-lamp
stereoscopic biomicroscopy for disc assessment.
Trabeculectomy (with/without antimetabolites) was the
only glaucoma surgery performed with one mention of
canaloplasty. Poor compliance with medical treatment
(78%) and low acceptance of surgery (71%) were their
greatest challenges.
Conclusions: This study indicates that a systems-
oriented approach is required to enhance
ophthalmologist’s capability for glaucoma care.
Strategies to improve glaucoma management include
strengthening poorly equipped centres including
provision of lasers and training, and improving patients’
awareness and education on glaucoma.
INTRODUCTION
Glaucoma, a chronic non-communicable
disease that leads to progressive damage to
the optic disc with loss of visual ﬁeld, is the
leading cause of irreversible blindness world-
wide. Blindness from glaucoma is avoidable
with early diagnosis and appropriate sus-
tained life-long treatment. The number of
people (aged 40–80 years) with glaucoma
will increase to 111.8 million by 2040, dispro-
portionately affecting people in Africa.1 The
Nigeria National Blindness and Visual
Impairment Survey showed a high preva-
lence of glaucoma (5.02%, 95% CI 4.60% to
5.47%) among adults ≥40 years. One in 5
persons with glaucoma was blind and only 1
in 20 had been diagnosed with glaucoma
prior to the survey, suggesting poor knowl-
edge of glaucoma and poor access to services
for glaucoma care.2
People still go blind from glaucoma in
Africa as it is frequently undiagnosed, inad-
equately treated with poor compliance to
treatment regimens;3 due to limited equip-
ment and treatment options, the high cost of
care and lack of awareness among patients.4–8
Up to 42% of patients with glaucoma attend-
ing hospitals in Nigeria are already blind at
Strengths and limitations of this study
▪ This study is the first of its kind, giving insight
into available skills, distribution, productivity and
training of ophthalmologists in glaucoma care in
Nigeria.
▪ Ophthalmologists from across the country and
different healthcare sectors were represented.
▪ It was difficult to obtain a comprehensive list of
all practising ophthalmologists as some are
qualified overseas and not all are registered with
the Ophthalmological Society of Nigeria (OSN).
▪ If non-responding ophthalmologists had less
access to equipment for diagnosis and treat-
ment, then the equipment available and surgical
output may have been overestimated.
▪ Another limitation is that the study relied on
recall by the respondents.
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the time of diagnosis,9–15 and middle-income earners
spend up to 50% of their monthly income on medical
therapy for glaucoma which equates to total monthly
income among low-income earners.16
In order to prevent blindness from glaucoma in
Africa, recent advances in technology for diagnosing
glaucoma need to be embraced, together with thera-
peutic options that are effective, affordable and accept-
able, combined with ongoing monitoring which can
decrease the risk of blindness.17
The term physician’s practice pattern describes the
pattern of practice by doctors to diagnose and formulate
a plan of care, in this case by ophthalmologists for glau-
coma, within their scope of professional practice.18 It is
deﬁned as patterns of practice related to diagnosis and
treatment as especially inﬂuenced by the cost of the
service requested and provided.19 Benchmarking prac-
tice patterns according to recommended guidelines has
important implications for quality of care.
The UK’s guidelines (the National Institute for Health
and Care Excellence, NICE) recommend that glaucoma
be diagnosed using applanation tonometry to measure
intraocular pressure (IOP), measurement of central
corneal thickness, assessment of anterior chamber
angle, visual ﬁelds analysis and optic nerve head (ONH)
assessment with dilation, using slit-lamp biomicroscopy
with a condensing lens (Hruby lens or+60/78/90 diop-
tres).20 The NICE diagnostic protocol is similar to
recommendations by the International Council of
Ophthalmology (ICO)21 and the American Academy of
Ophthalmology (AAO).22 ICO also recommends docu-
mentation of ONH morphology and retinal nerve ﬁbre
assessment with colour stereophotography or computer-
based image analysis.
NICE recommend a prostaglandin analogue (PGA) or
a β-blocker as ﬁrst-line topical treatment. Surgery with
antimetabolites is reserved for those at risk of vision loss
despite medical treatment. However, in Africa, one-off
procedures such as surgery or laser treatment are recom-
mended due to low compliance with topical medication
and the ongoing out-of-pocket expenditure this
entails.9 16 The economic burden on the patient is inﬂu-
enced by the lifetime nature of the treatment as well as
the cost of medications.
This study was undertaken to explore current practice
patterns of glaucoma care by ophthalmologists in
Nigeria and to identify what glaucoma treatments are
available and how much they cost. The paper describes
management of glaucoma only in patients who come to
health facilities where there is an ophthalmologist. We
discuss ophthalmologists’ practice patterns using the
systems thinking concept to try to understand how care
provision can be inﬂuenced by linkages and interactions
between the six components of the health system.23 The
information obtained will be disseminated to ophthal-
mologists and also used for advocacy to hospital man-
agers and policymakers. The systems thinking approach
provides new opportunities to understand processes and
enable shared development of interventions24 by these
groups to improve services for glaucoma care.
METHODS
Between September 2010 and July 2012, information
sheets for consent to participate and semistructured
questionnaires with a space for comments were delivered
to ∼250 Nigerian ophthalmologists listed in the data-
bases of the Ophthalmological Society of Nigeria (OSN)
and the West African College of Surgeons (WACS).
Distribution was to all ophthalmologists participating at
the 2010 OSN conference and subsequently by email
and phone interviews for initial non-responders and also
those not attending the 2010 OSN conference. These
avenues for data collection were used for convenient
access to ophthalmologists. There were no ﬁnancial
incentives to participate, which was encouraged by
reminder emails and telephone calls. Conﬁdentiality
and anonymity of responses were maintained.
Information was obtained regarding providers’ patterns
of care provision. Ophthalmologists were asked about
their training/professional background, facility/hospital
of practice, availability of functional equipment, and their
protocol for glaucoma diagnosis and treatment. Data
were collected at individual level as some ophthalmolo-
gists worked in more than one facility. They were asked
what they considered to be optimum treatment under
ideal circumstances, and how they managed their last 10
patients with glaucoma. They were asked to provide infor-
mation on the number of glaucoma surgeries and cata-
ract surgeries they perform in an average 3-month
period, to estimate the ratio of glaucoma-to-cataract sur-
geries, and to recall surgical complications in relation
to use of antimetabolites. Other questions covered
systems-related issues such as the cost and availability of
glaucoma medication and surgery in their facility, and
challenges they faced in glaucoma management.
Descriptive analysis was undertaken using Stata V.14.0
(Stata Corp, College Station, Texas, USA). The distribu-
tion of ophthalmologists by healthcare geopolitical
zones and states was determined but the ﬁndings are
reported nationally. Missing data were excluded.
Ethical approval was obtained from the London
School of Hygiene and Tropical Medicine and the
Federal Ministry of Health, Nigeria.
RESULTS
A total of 153/250 ophthalmologists from 80 centres
returned questionnaires (61% response rate). Out of
these, 72 (47%) were completed by respondents at the
2010 OSN conference, while the rest were completed
and returned by email or by phone.
Demographic details and training background of
ophthalmologists
Respondents were aged 34–68 years (median 46 years),
43% were female and the highest number (48; 32%)
2 Kyari F, et al. BMJ Open 2016;6:e012230. doi:10.1136/bmjopen-2016-012230
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practised in the south-west (SW) zone where Lagos is
situated (ﬁgure 1). All ophthalmologists were based in
cities, with 50% in Lagos, Abuja, Kaduna and Ibadan,
which also have training institutions.
A high proportion (87%) of respondents had fellow-
ship training in ophthalmology. The number of years
since qualiﬁcation was 1–38 years. Training in glaucoma
management was reported as good (62%), fair (18%)
and excellent (17%). Thirty-eight per cent had under-
gone subspecialty training, being higher among those
who qualiﬁed more than 16 years ago. Ten (7%) had
subspecialty training in glaucoma.
The majority of respondents (97%) engaged in con-
tinuous medical education (CME) with 87/118 (74%)
and 116/138 (84%) attending three or more courses or
conferences, respectively, in the previous 3 years. Other
sources of CME were online educational resources and
medical journals.
Ophthalmology practice
Ophthalmologists practised in government hospitals
(63%), private practice (28%), non-governmental/
mission hospitals (6%) and military hospitals (3%).
About half (75/145; 52%) practised in teaching/tertiary
institutions and 33/145 (23%) in state government
hospitals. Half (75/150; 50%) said their hospitals ran
subspecialty clinics, the most frequent being for glau-
coma, paediatric ophthalmology, vitreoretina, oculoplas-
tics, cornea and neuro-ophthalmology.
Most patients (95%) accessed services via walk-in
clinics and from community-based outreach screening
(73%). Most ophthalmologists (71%) reported that their
hospital did not have a written protocol for glaucoma
care.
Equipment
Equipment that was available/functional/used in glau-
coma management is indicated in table 1. Three
ophthalmologists had access to only ophthalmoscopes
and schiøtz tonometers.
Service delivery of glaucoma care
Examination and diagnosis
Ophthalmologists saw 3–200 new patients with glaucoma
over a 3-month period, with an average of 43 per doctor
(SD 37). The most important clinical feature that would
prompt a glaucoma work-up was suspicious ONH
morphology (85% of respondents) and 7% indicated
IOP.
Figure 1 Map of Nigeria showing the magnitude of blindness and distribution of responding ophthalmologists in the six
geopolitical zones. NC, north-central; NE, north-east; NW, north-west; SE, south-east; SS, south-south; SW, south-west.
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When asked how they examined patients with glau-
coma, 96% performed cup:disc ratio assessment, 94%
measured IOP, 88% assessed visual ﬁelds and only 56%
performed gonioscopy on all patients. Fewer than 20%
routinely performed ONH imaging or assessed corneal
thickness. For ONH assessment, most ophthalmologists
used a direct ophthalmoscope, 61% used slit-lamp bio-
microscopy, 14% used a fundus camera and 11% also
used optical coherence tomography.
Glaucoma surgery
Among those providing data on their last 10 patients
with glaucoma, 54% patients were offered glaucoma
surgery, 35% accepted it and 28% actually underwent
surgery (ie, approximately half of those offered surgery
underwent the procedure). Of the 124 respondents pro-
viding data for an average 3-month period, 60 (48%)
performed 5 or fewer glaucoma surgeries and 12 (10%)
performed ≥15. There was a wide variation in the
number of glaucoma surgeries compared with cataract
operations. Overall, ∼1000 glaucoma surgeries were per-
formed in 3 months compared with ∼6500 cataract
operations, giving an average ratio of 1:6.5. However,
80% of ophthalmologists had a ratio of at least 1:10.
Trabeculectomy, with/without antimetabolites or
releasable sutures, was the only surgery performed for
glaucoma in the preceding 3 months, apart from one
canaloplasty. Antimetabolites were used by 88% of sur-
geons. Only 44% of hospital pharmacies provided
antimetabolites and some ophthalmologists obtained
these agents privately albeit with difﬁculty.
The main complications following the last 10 trabecu-
lectomies with antimetabolites were ocular hypotony,
cystic blebs, thinned/leaking blebs and shallow anterior
chambers. Only 24 (18%) reported that they had
audited their last 10–50 glaucoma surgeries.
Regarding follow-up, 68% of respondents did not have
a standard written follow-up plan: 70% would give an
appointment and hope the patient attended; 20% sent
reminders by text, phone or email to non-attenders, or
home visits were made. First-degree relatives were
requested to attend for glaucoma ‘all the time’ by 60%
of respondents, and ‘sometimes’ by 34%.
Implications of health financing
Cost of glaucoma treatment
In total, 113/136 (83%) of respondents knew the cost of
the medications available in their facility which ranged
from 1000 to 50 000 Nigerian Naira (NGN) (approxi-
mately £4–£200) for 1 month’s supply, depending on the
type/brand). All pharmacological groups of antiglau-
coma medication were available and 97% had both
β-blockers and PGAs to prescribe. The cost of surgery
ranged from NGN2000 to 190 000 (approximately £8–
£760) which was sometimes provided free by non-
governmental organisations.
Choice of treatment
Ophthalmologists were asked what treatment they would
offer patients with glaucoma if all equipment and treat-
ment options were available to them, and if cost was not
a barrier. Over half (54%) chose surgery, mostly trabecu-
lectomy with/without antimetabolites which inhibit scar-
ring, while 41% preferred medical therapy with PGAs.
Two doctors preferred laser treatment—trabeculoplasty
and selective laser trabeculoplasty (SLT). However, most
ophthalmologists would modify their choice, or offer a
combination of treatment based on risks and beneﬁts,
taking account of disease severity at diagnosis (84%),
acceptability (75%), availability (54%) and cost (53%).
Other considerations included age, access to care and
follow-up, compliance to treatment, family history of
glaucoma and coexisting conditions.
Challenges in glaucoma care
The challenges in glaucoma care cited by respondents
can be categorised into provider-related, patient-related
and health systems-related. Provider-related challenges
included fear of surgical complications, their inability to
offer a cure or improve patients’ vision and the uncer-
tainty of postoperative outcomes. Difﬁculties in post-
operative care were also reported. Patient-related
challenges included poor compliance with medical treat-
ment, low acceptance of glaucoma surgery, poor aware-
ness and understanding of glaucoma, poor access to
care, late presentation, and poor compliance with
follow-up. Health systems-related challenges included lack
Table 1 Equipment available and used for glaucoma
diagnosis and care
Equipment
Available
n (%)
Used
n (%)
Remarks per
cent is of
N=146
Ophthalmoscope 152 (99) 142 (93)
Applanation
tonometer
142 (93) 127 (83)
Schiøtz tonometer 107 (70) 39 (25)
Other tonometer 76 (50) 53 (35) Non-contact
air puff
Gonioscope 130 (85) 101 (66)
Slit-lamp lens 136 (89) 113 (74)
Binocular indirect
ophthalmoscope
133 (87) 89 (58)
Visual field
analyser
123 (80) 104 (68)
Fundus camera 70 (46) 50 (33)
Ultrasound scan 88 (58) 58 (38)
Optical coherence
tomography
41 (27) 30 (20) In 14 centres
Scanning laser
ophthalmoscope
5 (3) 2 (1) In 1 centre
Laser 44 (29) 23 (15) In 19 centres
Pachymeter 7 (5) 4 (3) 1 each in 7
centres
HRT II 1 (1) 0 (0)
HRT, Heidelberg retina tomography.
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of equipment and medication, cost of treatment and a
need for more training in early glaucoma diagnosis and
in glaucoma surgery.
The ophthalmologists made other comments, high-
lighting their needs and challenges and how they are
being addressed.
Provider-related:
Glaucoma is such a big burden and the challenges posed
by its management are enormous in our setting. The
uptake of surgery…is low but with the advent of SLT
[laser treatment], a lot more are taking up SLT as
adjunct in our centre and so far we are recording suc-
cesses with regards to IOP control.
There is the need for refractive correction before and
after surgical intervention.
Another important practice I observe is to request the
presence of spouse/next-of-kin in the pre-op counselling
sessions. I am never in a hurry to proceed to surgery.
Patient-related:
Most of our patients present very late and expect
treatment.
(There are) issues of patients understanding of disease
progression despite surgery.
We have a Glaucoma Patient Club/Association…
Health systems-related:
We need to look at acceptable ways for screening and
case-ﬁnding in the communities rather than waiting for
them to come with advanced, late stage disease.
Treatment options are limited: drugs—by cost and avail-
ability; laser and surgery—by availability and expertise.
Ophthalmologists highlighted their need for further
training:
Major challenges are (few) opportunities for training
and retraining in glaucoma management.
All practising ophthalmologists should be trained on how
to manage glaucoma well.
Lack of equipment and maintenance were of concern:
We don’t have an operating microscope for trabeculect-
omy and no perimeter to assess functional damage and
progression.
Our major constraint is non-availability of both diagnostic
and surgical equipment and instruments.
Essential equipment like ﬁeld analyser & OCT require
technical support that is not available in the country.
There is a need for an articulated national protocol for
diagnosis and treatment of glaucoma.
DISCUSSION
This study, which describes ophthalmologists’ practice
patterns in relation to glaucoma in Nigeria, is the ﬁrst of
its kind, giving insight into available skills, distribution,
productivity and training of ophthalmologists in glau-
coma care in Nigeria.
This paper focuses on the human resources for glau-
coma care from the perspective of the ophthalmologist.
Other allied eye health personnel and the team for glau-
coma care were not addressed in this survey. In 2011,
Nigeria had an estimated 3.2 ophthalmologists per million
population which is just below the
ophthalmologist-to-population ratio of 4 per million
recommended by VISION2020, which will not be achieved
by 2020 without additional intervention.25 However, the
overall ﬁgure of 3.2 per million masks maldistribution of
ophthalmologists within the country, as the north-east is
less well served than the SW, and more needs to be done
to encourage ophthalmologists to work in the north. The
southern city of Lagos has a large number of ophthalmol-
ogists, but there is a shortage of allied eye health person-
nel who play an important role in glaucoma care.26
Training in leadership and management is essential as
it would support glaucoma services at the hospital.27
Given the high prevalence of glaucoma blindness, there
is a need for competency-based training for early detec-
tion, and surgical and laser treatment of glaucoma, so
that all ophthalmologists in Nigeria can manage the con-
dition at secondary and tertiary levels, which would
enable glaucoma specialists to focus on more complex
cases at the tertiary level. In Africa, there is increasing
momentum to improve glaucoma care, encapsulated
by the resolution of a meeting in Kampala, Uganda,
in 2012.28 Nigeria now has a glaucoma society (Nigeria
Glaucoma Society, NGS), and there are subspecialty
training initiatives for glaucoma in the region, such as
that in Ghana. Clinical fellowships are also offered by
ICO and the Commonwealth Eye Health Consortium.
However, current training has not yet translated into
written protocols, their use and challenges. The NGS
needs to develop national glaucoma guidelines appropri-
ate to the local context, which include minimal essential
diagnostic examination procedures and recommenda-
tions on primary treatment.
In this study, training in ophthalmology was reported
as excellent by 17% and good by 62%. However, it is
noteworthy that there was no speciﬁc or detailed infor-
mation on training. It may seem contradictory that there
was request for more training in glaucoma care by some
respondents. Young ophthalmologists need to be encour-
aged to develop competencies in glaucoma early in their
careers, with self-audit being an integral component of
the training. Prospective monitoring is also essential and
can gauge surgical competencies and outcomes.
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Ophthalmologists in our study reported high levels of
CME. Free online access to journals, such as that pro-
vided by the WHO HINARI programme, ONE Network
and African Journals Online (AJOL) platforms, is
immensely useful as most training institutions or hospi-
tals do not prioritise journal subscriptions.
In our study, service delivery in relation to the man-
agement of glaucoma fell short of NICE, ICO and AAO
recommendations in several respects, in part due to lack
of equipment but also because of late presentation,
where visual ﬁeld assessment is not possible, for
example, and low adherence to medical and surgical
treatment and follow-up. Similar challenges have been
reported in Botswana.29
Advocacy will be required with the government to
strengthen infrastructure and provide appropriate equip-
ment (with maintenance) in all eye care centres across
the country. In this study, ophthalmologists reported
that laser was a more acceptable form of treatment than
trabeculectomy, and equipment and skills in laser treat-
ment need to be expanded.
Surgery was the treatment of choice in this study, but
only about half of patients offered surgery underwent
the procedure. Several authors have recommended
surgery as ﬁrst-line treatment for glaucoma in Africa,
including in Port-Harcourt where all consecutive patients
with glaucoma enrolled in a study were on medical
therapy as all had refused surgery. Medical treatment
was too expensive for many patients, leading to non-
compliance and loss to follow-up.16 Research is needed
on interventions which improve acceptance of surgery,
and a randomised control trial of motivational interview-
ing adapted for glaucoma is currently being undertaken
in Nigeria, in which patients are supported to overcome
obstacles to accepting surgery or laser.30 Studies are also
required on different forms of laser treatment in Africa.
Micropulse diode laser trabeculoplasty has been used
with adjunctive effect,31 and a prospective, observational
study of trans-scleral cyclodiode laser photocoagulation
as ﬁrst-line or second-line treatment for patients with
advanced glaucoma is ongoing, to assess the effective-
ness of these modes of laser treatment which are accept-
able and easier to deliver than trabeculoplasty (Abdull
MM, personal communication 2015).
Medical therapy with PGAs was the second commonest
treatment choice in our study, which were available but
expensive. In a hospital study in Benin, there was no sig-
niﬁcant difference between cost of medication compared
with surgical treatment over a 3-year period up to 2008,32
but this was before PGAs became widely available.
Indeed, the clinical outcomes and cost-effectiveness of
newer medications versus surgery with antimetabolites is
not known.33 Another trial is taking place in Tanzania, in
which SLT is being compared with timolol (Heiko P, per-
sonal communication 2015). Audit of outcomes of treat-
ment in black ethnic groups will enable evidence-based
choices to be made. Other factors which may improve
compliance with medical therapy include policies on
marketing, non-branding and cost, and inclusion of
PGAs in health insurance schemes.
There was wide variation in the number of glaucoma
surgeries reported. The highest number (150 in
3 months) were performed in a high-volume centre
where most patients have advanced disease and compli-
ance with medical therapy and follow-up is poor. In this
centre, glaucoma surgery is offered to all patients at
diagnosis, and performed almost immediately at a highly
subsidised cost (respondent, personal communication
2015). The reduced cost seemed to be an important
factor contributing to the high volume. Glaucoma
surgery needs to be included in universal health cover-
age and health insurance schemes.
In our study, poor follow-up was a problem. Robust
health information systems are important in patient ﬂow
and follow-up. Indeed, a hospital study in Benin showed
that ≥70% of patients with glaucoma either failed to reat-
tend after diagnosis, or within 9 months. Poor follow-up
was associated with worse stage of glaucoma, poorer
visual acuity and age.34 Follow-up may be improved by
patient counselling and education, reminders by text,
email, phone and community follow-up, and by improv-
ing the hospital visit experience for patients.
Patient-related factors contribute to the main chal-
lenges of glaucoma care. An important reason for late
presentation by patients with glaucoma is lack of aware-
ness about glaucoma.15 It would be useful to develop a
health education pamphlet for the local context, suit-
able for all including those who are not literate.27 There
is also a need to develop primary-level and community-
based case-ﬁnding strategies to improve opportunities
for early intervention.35
A strength of the study is that ophthalmologists from
across the country and different healthcare sectors were
represented. A limitation of this study was that it was dif-
ﬁcult to obtain a comprehensive list of all practising
ophthalmologists as some qualiﬁed overseas and not all
are registered with the OSN. If non-responding ophthal-
mologists had less access to equipment for diagnosis and
treatment, then the equipment available and surgical
output may have been overestimated. Another limitation
is that the study relied on recall. The eye care team was
not addressed in this study.
Further areas of operational research would be the
development and investigation of glaucoma care teams
involving primary eye care workers for early case detection
in the community and other allied eye health personnel
for refraction and vision care, counselling, health educa-
tion and follow-up of glaucoma suspects and patients with
glaucoma. This study could also form the baseline to
assess the impact on practice patterns following the intro-
duction and dissemination of clinical guidelines.
CONCLUSION
This study indicates that a health systems-oriented
approach is required to overcome the major obstacles to
providing optimal glaucoma care. Strategies include
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leadership by the NGS to develop national guidelines
and benchmark for service delivery of glaucoma care;
infrastructural strengthening for diagnostic and thera-
peutic/surgical equipment with provision of lasers and
training; and medicines. Strategies to improve glaucoma
management also include development of healthcare
ﬁnancing strategies through universal health coverage
and health insurance schemes; operational/implementa-
tion research to develop methods for early diagnosis and
robust referral/feedback systems and patients’ health
information systems.
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?????????????????
Mr AA is a 48-year-old 
shop attendant who 
presented at the eye 
unit of a teaching 
hospital with a history of 
gradual, painless vision 
loss. His presenting 
(unaided) visual acuity was counting 
fingers at 1 metre in the right eye and 
6/60 in the left eye. Both corneas were 
clear, and the pupils had a slow reaction 
to light. There was a right relative afferent 
pupillary defect (RAPD). The right eye had 
a nuclear sclerotic cataract which 
precluded a good view of the optic nerve 
head, and a vertical cup:disc ratio (VCDR) 
of about 0.9, barely visible through the 
dilated pupil with the binocular indirect 
ophthalmoscope. The left eye VCDR was 
0.8. Intraocular pressure (IOP) was 
32 mmHg (right eye) and 30 mmHg 
(left eye) by applanation tonometry. 
Gonioscopy showed open angles in 
both eyes. Visual field tests (standard 
automated perimetry [SAP]) could not 
be carried out.
????????????????????
??????? ?????
Most of the panellists mentioned the 
importance of talking to Mr AA about 
glaucoma and what his treatment options 
were. Some mentioned asking a nurse 
counsellor to talk to the patient.
The next important issue to be 
addressed was the setting of a target IOP 
in the lower teens, and discussing this 
target with the patient.
There was general agreement that the 
initial control of IOP should be by medical 
treatment, while preparing for surgery 
on the right eye. First choice was a 
combination of a beta-blocker and a 
prostaglandin analogue (PGA). A second 
option was a combination of a beta-
blocker and an alpha-agonist. The panel 
mentioned the need to bear in mind the 
cost and availability of the drugs.
All panellists agreed that the right eye 
should be treated first, and firmly recom-
mended a combined procedure: cataract 
with posterior chamber intraocular 
lens (PCIOL), and trabeculectomy with 
adjunctive antimetabolite therapy. The 
reasons were both clinical and patient 
related:
“A trabeculectomy alone may give better 
IOP control, but will likely worsen vision 
and, depending on the techniques 
available and how the bleb turns out, 
going back to take out the cataract could 
create inflammation and/or directly 
compromise the bleb and worsen IOP 
control.“
“Cataract surgery alone is out of the 
picture, since a serious IOP spike could 
wipe out remaining visual field and 
adequate IOP control is not likely to be 
achieved.”
“The patient will better understand the 
benefit of surgery [and therefore be more 
likely to attend further appointments] if 
he can be offered some visual 
improvement.”
Depending on the centre and available 
facilities, the suggested approaches for 
surgery on the right eye were:
??phacoemulsification with PCIOL and 
trabeculectomy
??small incision cataract surgery (SICS) 
with PCIOL and trabeculectomy at a 
separate site 
??extra-capsular cataract extraction 
(ECCE) with PCIOL and trabeculectomy.
Adjunct therapy could be with:
??beta irradiation applied with a strontium 
plaque
??mitomycin C (MMC)
??5-fluorouracil (5FU).
Adjunct therapy is to prevent bleb 
scarring, however, there is little evidence 
that MMC or 5FU make any difference in 
combined procedures. 
There is some evidence to support 
using separate sites rather than the same 
site in combined phacoemulsification and 
trabeculectomy surgery. 
The choice of treatment for the left eye 
was not so uniform across the panel. Having 
initiated medical treatment for IOP control, 
a top choice was to perform a trabeculectomy 
with adjunct 5FU or MMC. However, some 
panellists said they would only offer 
surgery if there was inadequate IOP 
control with medications; others would 
also offer laser treatment as an option.
Both eyes would also have refraction, 
and the patient would be given spectacles 
if needed. 
?????????????????????????
?????????
“Patients are becoming more informed 
and are likely to seek more information 
and ask for more choices, regardless of 
their literacy or socioeconomic levels. 
Therefore, counselling needs to be more 
comprehensive, to include the biological 
situation of the eye and whole body, the 
patient’s psychological perceptions, their 
social and economic situation, as well as 
their religious beliefs.”
“The role of counsellors cannot be overem-
phasised, as they will take more time to 
explain to the patient the pros and cons 
of staying away or declining surgery.”
“The nurse counsellor could keep a 
register with the patient’s mobile phone 
number. She could sms (text) or phone 
him if he defaults on follow-up.”
“When the mode of treatment is certain 
and options are limited, like in the case of 
the right eye, then be firm to recommend 
that to the patient.”
??????????
Managing a patient with open-angle 
glaucoma: a case study
????????? ???????
Ophthalmologist: Ophthalmology 
Department, Abubakar Tafawa Balewa 
University Teaching Hospital, Bauchi, 
Nigeria.
???? ???????
Ophthalmologist: Department of 
Ophthalmology, College of Health 
Sciences, University of Abuja, Nigeria.
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End-stage glaucoma: disc-cupping
????????????????
????????????????????
?????????
Head of Ophthalmology, Aga Khan 
University Hospital, Kenya.
???????? ????
Professor of Ophthalmology, 
University of Alberta.
??????? ??????
Consultant Ophthalmologist,
College of Medicine, Lagos 
University Teaching Hospital,
Lagos, Nigeria.
??????????
Professor of Ophthalmology, 
University of Cape Town; CBM Eye 
Medical Advisor.
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“In the absence of a visual field test 
machine, assessment can be done very 
simply, by confrontation visual field 
testing, with a red pin or fingers [see page 
68]. Some people have abnormally large 
discs, which may seem to indicate 
pathology, but have normal visual fields.”
“If it is not possible to visualise the disc, 
for example because of cataract, be 
guided by the patient’s 
IOP and by the results of 
visual field tests, however 
basic.”
“It is important to carefully 
assess for RAPD because 
the disease is asymmetric. 
In the absence of any 
other formal function test (such as visual 
fields) RAPD is a very useful clinical sign in 
glaucoma, because it provides objective 
evidence of functional loss [see page 58].” 
?????????????? ?????????
After the panelists outlined their 
management plan for Mr AA, they were 
given the full case and details of the 
management that was actually under-
taken in his presenting hospital.
Mr AA was diagnosed with glaucoma 
and cataract at his initial presentation. At 
that time he was told he had advanced 
eye disease and needed to have surgery 
to preserve his vision. He asked whether 
the operation would make him see better. 
He was frankly informed that it would only 
preserve the vision he had at that time in 
the left eye; and that, if the cataract was 
causing much of the poor vision in the 
right eye, his vision in that eye would 
improve after cataract surgery. 
Medical treatment with eye drops 
(xalatan and timolol) was recommended, 
and Mr AA was given one month to make 
a decision about surgery. He was told to 
get the prescribed medications in the 
meantime and to start using them.
Mr AA did not return until six months 
later. He said that he had bought one 
bottle each of the eye drops, but could 
not buy more because they were 
expensive. He decided not to come back 
to the clinic because he was sure the 
doctor would be angry with him. At that 
stage he decided to see a traditional 
healer on the recommendation of a close 
family friend. 
When this did not work, Mr AA went to 
a different eye clinic near his home where 
he was told he had cataract and needed 
to go to hospital for surgery. This brought 
him back to the same eye unit, where 
visual fi eld assessment by confrontation 
was attempted. 
This showed substantial loss of his 
peripheral visual fi eld: Mr AA was only 
able to see fi ngers when they were 
presented in the centre of his visual axis.
Mr AA was informed that his vision had 
deteriorated further since the last time he 
was seen, and that if this continued he 
would lose vision permanently in both 
eyes. He was offered combined cataract 
surgery and trabeculectomy in the right 
eye, and trabeculectomy only in the left 
eye. The right eye would be 
operated on fi rst. 
Surgery, rather than 
medical treatment, was 
offered because it was 
clear from past experience 
that he would not be able 
to afford to use the more 
effective eye drops on a regular basis: 
surgery would be a one-time procedure 
which would be cheaper for him in the 
long run. 
The decision to offer combined 
trabeculectomy and cataract surgery was 
made based on the patient’s record of 
defaulting on follow-up. Removal of the 
cataract from the right eye would provide 
him with some improvement in vision as 
well as IOP control, which would hopefully 
motivate him to present for trabeculectomy 
in the left eye at a later time.
Mr AA agreed that he would have the 
operation this time, but said he wanted 
time to talk to his family about how they 
could make the money available. As he 
could not afford xalatan, he was then 
asked to use only timolol until the surgery 
date. Pilocarpine, even though less costly, 
was not an option for him as cataract 
surgery was being planned. 
Mr AA was given two weeks to make a 
decision and return.
He returned after three weeks, 
explaining that the person accompanying 
him had been away. However, he came 
prepared to have surgery and was 
admitted for surgery immediately so as 
not to lose him. 
The standard surgery usually offered at 
the hospital is manual small-incision 
sutureless cataract surgery. Mr AA was 
initially offered right ECCE and PCIOL, 
because combined SICS and trabecu-
lectomy can be more diffi cult to perform. 
However, the fi nal decision was to offer 
SICS with PCIOL at a temporal site, and 
simultaneous trabeculectomy with MMC at 
a more nasal position. The decision to use 
MMC was to prevent bleb scarring.
Mr AA’s immediate post-operative 
unaided visual acuity in the operated eye 
was 4/60. He was also informed about the 
importance of adherence to prescribed 
medication and follow-up after the operation. 
Mr AA returned for his 1-month 
follow-up appointment and had a post-
operative review of the right eye. His 
unaided visual acuity was 6/60; the bleb 
was draining and was not cystic; the IOP 
was 12 mmHg and he was pleased with 
his improved visual function. 
 There was some discussion about 
what to do about the left eye and he was 
asked to bring his fi rst-degree relatives to 
the next appointment, so that they could 
be screened for glaucoma. 
Mr AA underwent refraction of the left 
eye and had a corrected visual acuity of 
6/18. IOP was controlled with timolol and 
xalatan (which Mr AA was able to buy 
using some of the funds he had set aside 
for the operation). However, because he 
expressed concern about not being able 
to afford life-long medication, left eye 
trabeculectomy with MMC was subse-
quently performed.
We are grateful to our reviewers, Clare 
Gilbert, Richard Wormald, and Nick 
Astbury for their contributions. 
???????????Continued
‘The uptake of 
glaucoma surgery 
still seems very 
low in Africa’
“An interesting case and very real in our 
setting. Mr AA highlights the problem 
that we all experience: non-compliance 
with topical medication and failure to 
return for regular follow-up.”
“The ophthalmologist made very 
reasonable decisions in the light of the 
prevailing circumstances.”
“Even challenging situations can lead 
to success, as seen in this case, at 
least in the short term.”
“Surgery is definitely the right approach 
in the management of this patient; 
otherwise the next time he returns his 
visual acuity may be further reduced.”
“The uptake of glaucoma surgery still 
seems very low in Africa. However, we 
should realise that, for many of our 
patients, surgery should be the first line 
of treatment. Nevertheless, there will still 
be patients who would adamantly refuse 
surgery, and for whom we would need 
to consider laser treatment, if available.”
“This case underscores the role of 
advocacy for universal health care to 
cover potentially blinding conditions 
such as glaucoma, as well as the need 
for greater public education and 
awareness. These are issues which the 
ophthalmologist cannot handle alone 
but which require engagement with 
government and other community 
development sectors.”
Final comments by the panellists
© The author/s and Community Eye Health Journal 2012. This is an Open Access article distributed under the Creative Commons Attribution Non-Commercial License.
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So let me find my way, whatever it will cost me,
rather than leaving myself in darkness: experiences
of glaucoma in Nigeria
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Background: Blindness from glaucoma is associated with socio-economic deprivation, presumed to reflect
poor access to care and poor adherence to treatment.
Objectives: To determine why people with glaucoma are presenting late for treatment and to understand
access to glaucoma care. Additionally, we sought to identify what patients and the community know, do and
think about the condition and why the poor are the most affected with glaucoma blindness.
Design: Study participants were from four communities and two hospitals in Abuja-FCT and Kaduna State,
Nigeria. A total of 120 participants were involved, including 8 focus group discussions, 7 in-depth interviews
with blind/visually impaired glaucoma patients, 5 rapid direct observation visits with these patients and 13 exit
interviews of glaucoma patients in the hospital. The data were analysed using content analysis, interpreting
participant experiences in terms of three key steps conceptualised as important in the care pathway: what it
takes to know glaucoma, to reach a diagnosis and to access continued care.
Results: This article presents multiple narratives of accessing and maintaining glaucoma care and how people
manage and cope with the disease. People may be presenting late due to structural barriers, which include lack
of knowledge and awareness about glaucoma and not finding an appropriately equipped health care facility.
What keeps glaucoma patients within the care pathway are a good hospital experience; a support structure
involving family, counselling and shared patients’ experiences; and an informed choice of treatment, as well as
agency. The high cost of purchasing care is a major factor for patients dropping out of treatment.
Conclusion: The findings suggest the need to address economic and social structural drivers as glaucoma
presents another case study to demonstrate that poverty is a strong driver for blindness. There is also a need for
clear glaucoma care pathways with early case finding in the community, two-way referral/feedback systems,
well-equipped glaucoma care hospitals and better eye health care financing.
Keywords: glaucoma; blindness; vision loss; late diagnosis; early detection; care pathway; Nigeria
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Introduction
Glaucoma is the leading cause of avoidable irreversible
blindness globally (1). In Nigeria, the recent national
survey of blindness showed the prevalence of glaucoma to
be high (5%) among adults aged 40 years and above, 94%
of those with glaucoma were undiagnosed and untreated
and one in five were blind (2). Poverty and socio-economic
deprivation are significant risk factors for blindness from
glaucoma (35). In a recent study of glaucoma patients in
north-eastern Nigeria, 76% were already blind when they
presented to the hospital with older age, poor knowledge
of glaucoma, rural residence and living more than 10 km
from the hospital being associated with blindness at pre-
sentation (6). Glaucoma blindness, therefore, reflects dispa-
rity in access to care. Additionally, there is a correlation
between worsening quality of life and increasing severity of
disease (7, 8).
Recent advances in technology for early diagnosis
of glaucoma, greater therapeutic options and possibili-
ties for treatment monitoring reduce the probability of
Global Health Action
Global Health Action 2016. # 2016 Fatima Kyari et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to
remix, transform, and build upon the material for any purpose, even commercially, provided the original work is properly cited and states its license.
1
Citation: Glob Health Action 2016, 9: 31886 - http://dx.doi.org/10.3402/gha.v9.31886
(page number not for citation purpose)Fatima Kyari PhD Thesis Page 212
blindness among patients in the care system in industria-
lised countries (9). Hence, blindness from glaucoma and
the negative impact on quality of life are avoidable. The
biomedical description of glaucoma is based on a known
set of symptoms and signs including loss of sight, loss
of visual field and raised intraocular pressure. Once the
diagnosis has been made and the disease named, treat-
ment is recommended to prevent further vision loss and
maintain quality of life. Late presentation is when a per-
son presents with biomedically severe/advanced disease in
the worse-affected eye where visual acuity is B3/60, cup:
disc ratio is 0.8 and central visual field is B10 degrees.
In this qualitative study, our main question was why
are people with glaucoma presenting late for treatment,
with severe/advanced disease, rather than presenting with
moderate disease at a point when progression to blindness
can be slowed with biomedical intervention. We also sought
to identify what patients and the community know, do and
think about the condition and why the poor are the most
affectedwith glaucoma blindness. We studied sociocultural
contexts that impinge on the delivery of interventions for
glaucoma. Providing a critical perspective on services
for glaucoma would enable strategies to be developed to
deliver more responsive and, hence, effective interventions
and care, both for individuals and communities most
affected in Nigeria and other sub-Saharan countries with
similar high prevalence of glaucoma who also share similar
socio-economic and socio-demographic characteristics.
Methods
This study employed qualitative methods to assess parti-
cipants’ knowledge and treatment of glaucoma using our
clinical perspective as the benchmark.
Conceptual framework
We conceptualised a framework for an optimal glaucoma
care pathway (see the central flow in Fig. 1) and imagined
that patients should take those steps to avoid blindness.
The pathway involved getting to know glaucoma, having
a diagnosis, accepting the treatment offered, compliance
with treatment and maintaining monitoring and follow-
up. In order to obtain data from multiple perspectives,
the study employed a number of methods: focus group
discussions (FGDs) held in the community, in-depth
one-to-one interviews (IDIs) with blind/visually impaired
glaucoma patients and their direct observation (DOs),
and exit interviews (EIs) of glaucoma patients in the
hospital. This range was selected in order to have a wide
range of respondents at different sites so as to corroborate
findings between people in the community and patients
that have accessed care.
Study area
The study areas were Abuja, Federal Capital territory, the
capital city of Nigeria situated in the central part of the
country; and Kaduna State in the north-west geo-political
zone. Abuja comprises six local councils, two of which
were included in our study: Bwari and Gwagwalada,
in which we included one urban location (Kubwa) and
one rural location (Sheda), respectively. In Kaduna, we
included one urban location, Tudun Wada, and one rural
location, Sabon Birni. Both areas have government and
mission hospitals that provide eye care. We selected two
hospitals that provide glaucoma services, one in each of
the two areas. Hospital 1, located in Gwagwalada, Abuja,
is mission-run, and Hospital 2, located in Kaduna, is
government-owned.
Natural history
Current situation
Not known Earlydetection Diagnosis
Start
treatment
Accept/
continue
treatment
Follow-up and
monitor
Optimal care pathway Knowing, access to care, accepting treatment, maintaining treatment
How people get into the care pathway
Why patients drop out of the care pathway
What keeps patients in the care pathway
Poor vision-advanced/severe
Fear of the effect of vision loss
Referred from outreach
Invited for examination by FDR
Unpleasant experience with TEM
Knowing glaucoma
Not knowing the disease
Not understanding the possibility
      of further vision loss
Offered alternate nonmedical therapy
No one word for “glaucoma”
Reaching a diagnosis
Not getting a diagnosis
Not knowing where to find care
Far distance from hospital
Lack of access to information
Hospitals not adequately equipped
Late diagnosis
Accessing on-going care
High cost of care
Not understanding the treatment
Unrealistic medical instructions
Multiple opinions in different hospitals
Loss of economic productivity
Pleasant hospital experience
Treatment is explained
Surgery outcomes are explained
Accept treatment
GPA-support and
   shared experiences 
Agency; and can take decisions
Can afford treatment
Maintain follow up
Adequately monitored
Accepting possibility of further vision
    loss without treatment
Late diagnosis; treatment noncompliance; failed follow-up
Gradual visual loss and progression to blindness
B
lin
dn
es
s
Po
o
r 
tr
ea
tm
en
t
o
u
tc
om
es
M
ak
in
g 
th
ei
r w
ay
 th
ro
u
gh
 to
‘
n
o
n
-b
lin
dn
es
s’
FDR = first degree relative; TEM = traditional eye medication; GPA = glaucoma patient association
Fig. 1. A conceptual framework for the glaucoma care pathway.
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Participant selection and sample size
The study was based on eight FGDs held in the commu-
nity, seven one-to-one IDIs with blind/visually impaired
glaucoma patients, five of whom were directly observed
in the community, and 13 EIs of glaucoma patients in
the two selected hospitals (Fig. 2), consisting of a total of
120 participants. The fieldwork was conducted between
January and March 2012.
The study team consisted of the researcher who is also
the first author (FK) of this article, research assistant,
also a co-author (MM), and the note-taker/field assis-
tant. The two assistants were trained for data collection
in health care research. Training of the assistants by the
researcher included a discussion on the overview of the
study aim and objectives, procedures, participant recruit-
ment and interview/discussion techniques, and possible
challenges and how to overcome them.
Purposive sampling was used to select hospitals
and participants. Community-based research facilitators
(HR, CO, FE and ES) were involved in selecting the four
communities outlined above. The research assistant to-
gether with the community-based facilitators, who were
involved in community-based rehabilitation of patients
with disability or had been on outreach, identified and
recruited the participants in the community for the FGDs
and the IDIs (and DOs). There were two local ophthal-
mologists (FA and TN) who facilitated the selection of
participants for the EIs in their hospitals. No incentives
were provided to participate, but all were offered free eye
examination and referral where necessary and refresh-
ments were provided.
Discussions and interviews were conducted in English,
Hausa or Pidgin English by FK or MM accompanied by
the note-taker, with little need for an interpreter as both
interviewers were multilingual in the languages of discus-
sion. However, one FGD and one EI were conducted in
Gbagyi where a translator was required. All interviews/
discussions were recorded with a digital recording device,
and notes were taken.
Focus group discussions
Two FGDs with members of the community were held
in each of the four communities, that is, total of eight
FGDs, conducting separate discussions for female and
male groups in order to have a relaxed atmosphere and
foster openness. Participants were aged 30 years and above
and included a community leader, visually impaired/blind,
and normal-sighted community members. The FGDs
were held in a convenient private meeting area within the
community. Written informed consent was obtained from
participants after explanation of what would take place
and their basic demographic data were recorded.
A topic guide was followed in order to stimulate dis-
cussion and bring out potential factors exploring the
knowledge and practices in relation to eye diseases and
blindness in general, and glaucoma in particular, their
perception of risks and concept and understanding of
blindness. We also explored their health-seeking processes.
After each FGD, the study team reviewed the audio
recording, and challenges and need to include more pro-
bing questions were discussed.
In-depth interviews
IDIs were conducted with glaucoma patients in the
community who were visually impaired or blind and had
not accessed treatment or had had treatment whether
successful or not. The IDIs were conducted in the
participant’s home in a place which provided privacy. We
carried out IDIs using a narrative approach: ‘tell me about
your eye problem/disease . . .’ and with a topic guide
for prompt questions in order to explore participants’
knowledge about their disease, what symptoms triggered
them to seek care, difficulties in seeking care, their
perception of glaucoma as a cause of blindness and the
cost of finding care.
Direct observation
DO involved shadowing the participants to observe how
their everyday lives were affected, particularly with regard
Hospital 1 Hospital 2
Tudun Wada (U)
n = 16 n = 6 n = 8 n = 14    
IDI+DO blind IDI+DO blind IDI blind IDI+DO blind IDI blind
8 FGDs in the community total
participants n = 101
Total - 28 interviews
7 IDIs in the community of which
5 also had DO
IDI+DO blind IDI+DO blind
Summary
Total participants = 120*
*one participant had IDI+DO and
Exit Interview
U = urban; R = rural; FGD = focus group discussion; IDI = in-depth interview; DO = direct observation.
Sabon Birni (R)
Kaduna StateAbuja-FCT
Exit interviews
with 8 patients
Kubwa (U)
FGD1 females FGD2  males FGD3 females
Sheda (R)
FGD4  males FGD5 females FGD6 males
n = 15 n = 15
FGD7 females FGD8 males
n = 1 n = 16
13 Exit Interviews in the hospital
Hospital 1, Gwagwalada, Abuja
Hospital 2, Kaduna
Exit interviews
with 5 patients
 
Fig. 2. Sampling strategy and sample size for the patient and community perception study.
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to their home environment and interactions within the
community. We selected IDI participants who gave us
the opportunity to observe them in their homes. We
had a checklist of observations, which included how they
interacted with their family members and how members
of the community approached and related with them. We
also observed how independent they were in terms of
mobility, use of everyday gadgets such as mobile phones
and telling the time.
Exit interviews
One-to-one EIs were conducted, and participants were
asked to narrate their experience of the hospital visit and
what they felt about the diagnosis and treatment. This also
included their positive experiences, rather than only
barriers to accessing health care. They were also asked
about triggers that led them to seek care, whether their
condition was explained to them and what they under-
stood about glaucoma and the effects of their sight loss on
their everyday lives, and how much money they had spent
on eye care. They were also asked about their know-
ledge and use of traditional (non-medical) eye medication
(TEM) and what they would tell new patients who had
been diagnosed with glaucoma. Participants ranged in age
from 29 to 74 years.
Data handling and analysis
The audio recordings were transcribed in the language of
discussion. Hausa transcripts were translated into English.
English translations were crosschecked and finalised by
FK. English transcripts of FGDs, IDIs (and DOs) and EIs
were imported into NVivo 10 (QSR International Pty Ltd.,
Victoria, Australia). The data were accessible to only the
researcher and co-authors.
Data immersion
The researcher became familiar with the data through
conducting, transcribing and translating most of the inter-
views. Transcripts were read carefully and coded line by line.
The data were analysed using content analysis, inter-
preting participant experiences in terms of three key
steps conceptualised as important in the care pathway:
‘knowing glaucoma’ which gave a perspective of people’s
experience and not compared to what they should know;
‘reaching a diagnosis’ which stems from knowing glauco-
ma and as a prerequisite for treatment; and ‘accessing on-
going glaucoma care’ which includes issues of cost of care,
decisions on treatment and non-medical alternatives that
people might be offered. Within each step, we identified
explanatory themes. The themes were developed based on
initial reading through the transcripts. A coding template
was set up for the three themes that emerged from the
data and agreement of categorisation reached through
discussion and review by the co-authors (CC and CG). We
remained open to additional codes and new themes that
emerged during analysis. Additional codes were applied in
order to identify what it really meant to people to have
glaucoma and how debilitating it was. Initial coding was
done by hand, and subsequent categorisation and archiv-
ing were done using NVivo 10 (QSR International).
Ethics
Ethical approval was obtained from the Ethics Committee
of the London School of Hygiene and Tropical Medicine,
UK, and the Nigeria National Health Research and Ethics
Committee. Written informed consent was obtained from
the participants. We specifically asked to record interviews,
take photos and use anonymous quotes. Confidentiality
and anonymity were maintained. The study did not
interfere with any treatment that patients were receiving.
Participants in need of further management for their eye
condition were attended to and referred to the appropriate
facility if necessary.
Results
Study participants
All participants in the FGDs (n101) were aged 30 years
and above (Table 1). Basic demographic characteristics of
the IDI and EI participants (n19) are shown in Table 2.
The findings represent narratives of accessing and
maintaining glaucoma care and how people managed
and coped with the disease. It is important to know that
from many people’s perspective, there is no care pathway;
it is just life, the lived reality. Thus, other aspects we
explored were the coping mechanisms of patients with
glaucoma and the consequences of fear of the effect of
sight loss, feelings of isolation, abandonment, stigmatisa-
tion and loss of autonomy as well as financial stress and
loss of economic/social productivity. The coping mechan-
isms were within sociocultural constructs of faith in God
and support from family, friends and community. It was
not only about coping with the disease, but also about
coping with the social situation they were in.
Some quotes have been paraphrased to ease reading
without losing the context and meaning captured in the
discussion. Furthermore, four cases are presented to
illustrate the different themes.
Knowing glaucoma
Blindness is generally considered a serious problem.
However, participants avoided use of the term ‘blindness’
or ‘makanta’ (Hausa), rather they would say ‘eye problem’
or ‘matsalar ido’ (Hausa). Participants’ description of
blindness often indicated a total loss of vision, attaching a
morbid reality to it, while those with poor vision did not
always define themselves as blind.
There was generally poor knowledge of eye diseases as
understood in biomedicine and lack of access to informa-
tion. Most participants got information about health
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issues from the radio. Other sources are places of worship
(church and mosque), through reading and interaction
with neighbours or health workers. They, however, would
rely on information given them by the doctor or at the
hospital during health talks. They described symptoms
without giving specific names for eye disease except for
cataract (yana) and corneal opacity (hakiya), though
sometimes they interchanged description of the two.
Most participants had not heard about glaucoma, and
they recognised that self-medication with inappropriate
medicines would cause delay in seeking treatment.
None of the patients had heard of the term ‘glaucoma’
before their diagnosis. They did not bundle their symptoms
and experiences as a disease entity, and there was no
reference to any biomedical category. Some of their
symptoms such as redness and tearing were often con-
sidered to be common and less sight-threatening eye
conditions. Different things happened over time, such
that by the time they sought treatment, there was severe
vision loss in at least one eye. Participant EI-8 said
‘I cannot see very well. Like I am in the dark’, and EI-4
felt indeed glaucoma is a silent thief of sight.
People’s experiences differed, and some participants
came to know things were not quite right with their
vision, some of which may indicate visual field loss. For
example, not being able to see the right underarm while
shaving was illuminating for EI-1, whereas EI-13 could
only see clearly through the corner of the eye, and IDI-7
could not see people’s body completely.
Factors related to not knowing glaucoma included
stigma around blindness and poor vision so that they
would not talk about it; misconceptions on causations of
eye diseases; and general lack of awareness, knowledge
and access to information about glaucoma and eye
diseases. These factors led many participants in the care
system to present with late disease and to access multiple
opinions in different hospitals, hopping and hoping.
Reaching a diagnosis
Knowing glaucoma is part of reaching a diagnosis. Even
when they got to know they have glaucoma, some have no
information on what to do about it. In health care centres
where there are no trained health-workers or appropriate
equipment, then one cannot make a diagnosis of glaucoma.
Participants did not have a designated entry point
into clinical care, and there was no system of referral.
Participants did not know where to find care or what
treatment to expect nor did they appreciate the possibility
of future sight loss without treatment, which led some to
visit multiple providers  going from one health facility
to another. As IDI-5 experienced: ‘I kept going (to the
hospital). Then, the hospital was moved to Shika. Then
I started going to Eye centre. Thereafter I went to Dan
Tsoho. I was n’t satisfied, so I went to Zaria. Then I was
told that there was a hospital in Kano. I started going there.
I was not comfortable so I changed to another hospital,
right there at Kano’.
The high cost of finding care contributed to these
difficulties, but EI-11 had agency and was determined to
find and maintain care (Box 1). On the contrary, inability
to make autonomous decisions for one’s own benefit
contributed to delays in making a diagnosis (see Box 2:
IDI-2). Some participants mentioned distance to hospital
was a reason for their poor access to care and felt they
had no bargaining power and could not request for
services to be brought closer to them.
Thus, the contributory factors for late diagnosis include
poor knowledge about the disease, not finding an appro-
priately equipped hospital and inability to afford care.
Table 1. Demographic characteristics of participants of
focus group discussions in the community
Number of participants (%)
Rural
(Sheda and
Sabon-Birni)
Urban
(Kubwa and
Tudun-Wada) Total
Gender
Female 19 (39) 31 (60) 50 (50)
Male 30 (61) 21 (40) 51 (50)
Age (years)
3045 6 (12) 11 (21) 17 (17)
4660 17 (35) 17 (33) 34 (34)
61 and older 4 (8) 22 (42) 26 (26)
Not indicated 22 (45) 2 (4) 24 (24)
Occupation
(current/retired)
Civil service
officer
 6 (12) 6 (6)
Driver  2 (4) 2 (2)
Farmer 9 (18) 1 (2) 10 (10)
Housewife 6 (12) 16 (31) 22 (22)
Military  1 (2) 1 (1)
Office assistant/
cleaner
1 (2) 3 (6) 4 (4)
Student  1 (2) 1 (1)
Teacher/lecturer 2 (4) 3 (6) 5 (5)
Trader/business 3 (6) 16 (31) 19 (19)
Not indicated 28 (57) 3 (6) 31 (31)
Total participants 49 (100) 52 (100) 101 (100)
Language of
discussion
English  2 (50) 2 (25)
Gbagyia 1 (25)  1 (12.5)
Hausa 3 (75) 2 (50) 5 (62.5)
Total FGDs 4 (100) 4 (100) 8 (100)
FGD, focus group discussion.
aAn interpreter was used in this FGD.
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Accessing and maintaining glaucoma care
Hospital experiences varied considerably. However, a
good hospital experience and obtaining appropriate
information made a difference in patients’ understanding
of their disease and gave them hope.
Family members are cardinal in decision-making for
choice of treatment options, and participants would often
discuss with them before taking decisions. Thus, patients
and their carers/family need to fully understand the dis-
ease and the implications of choices of treatment. Once a
diagnosis of glaucoma is made and choice of treatment is
considered, physicians need to discuss treatment options
with the patient and family. This is also helpful for
identifying first-degree relatives with glaucoma. IDI-4’s
older brother was already blind at the time of diagnosis.
IDI-4 also had late diagnosis and could not sustain
medical treatment, and he gradually became blind. His
younger brother was also diagnosed late but had surgery in
the only seeing eye and this helped to maintain his vision.
Some participants had unpleasant experience with TEM
(see Box 3: IDI-6).
Hospital charges and cost of medicines were a great
concern, and in some cases, these contributed to poor
compliance with medical therapy. IDI-4 could not keep up
with buying medicines due to cost, and IDI-7 lamented
that all he had spent was to no avail. Inability to afford
hospital costs precluded patients from getting and main-
taining treatment. FGD/4/P6 mentioned ‘Actually, in the
hospital, they asked me to pay about N60,000 (£240). But
with that amount of money requested, I just put the paper
in my pocket and went back home. One who has not even
N100 (£0.40p) at home, they ask for N60,000 (£240); how
can you even begin to get that?’ On the contrary, EI-4
alluded to the availability of health insurance as being
beneficial for enabling access.
In terms of getting information about their disease,
some perceived a hierarchical doctorpatient relationship
characterised by one-way communication, with the patient
Table 2. Basic demographic information for the participants who had in-depth interviews in the community and exit interviews
in the two selected hospitals
No. Code Gender
Agea
(years) Occupation Available clinical description
1 IDI-1; EI-2 F 62 Housewife (military) VA: RE 6/9, LE HM; BE CDR 0.9
2 IDI-2 M 60 Retired as military nurse VA: NPL BE; BE CDR 1.0
3 IDI-3 M 59 Stopped driving VA: NPL BE
4 IDI-4 M 45 Trader VA: RE PL, LE NPL
5 IDI-5 M 75 Butcher VA: RE CF, LE 6/9; RE CDR 1.0, LE CDR 0.9; LE
trabeculectomy 12 years
6 IDI-6 F 67 Housewife BE not seeing. Sees some shadows
7 IDI-7 M 43 Teacher VA: RE NPL, LE NPL; Diagnosed glaucoma and had RE
trabeculectomy 9 years ago; then had RE vitrectomy for
endophthalmitis 6 years later
8 EI-1 M 29 Works with a trading company RE not seeing
9 EI-3 M 56 Stopped work RE cloudy; LE not seeing
10 EI-4 M 52 Senior civil servant (Intelligence
department)
Diagnosed glaucoma 8 years ago; Had triple procedure in
first eye and trabeculectomy only in second eye
11 EI-5 M 40 Farmer LE not seeing
12 EI-6 M 74 Lecturer at college of education One eye blind since early adulthood. Had cataract surgery
and diagnosed glaucoma in the only eye
13 EI-7 M 58 Electrician, works with contractor firm One is bad. Diagnosed glaucoma more than 5 years ago
14 EI-8 M 60 Farmer RE not seeing clearly; had RE trabeculectomy
15 EI-9 F 53 Theatre nurse RE worse; had RE trabeculectomy
16 EI-10 M 53 Worked in telecommunications. Made
redundant due to company closure
BE seeing ok
17 EI-11 M 42 Vehicle insurance officer (civil servant) LE not seeing  had surgery in LE prior to diagnosis of
glaucoma in BE
18 EI-12 M 70 Dependent on children RE not seeing
19 EI-13 M 62 Mechanic, contractor One sees well, other not much
IDI, in-depth interview; EI, exit interview; VA, visual acuity; RE, right eye; LE, left eye; HM, hand motions; BE, both eyes; CDR, cup-to-disc
ratio; NPL, no perception of light; PL, perception of light; CF, counting fingers.
aSome ages were estimates.
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not having courage to ask for explanations. Some partici-
pants felt this was because clinicians have enormous social
responsibilities despite their busy work schedule and much
is expected from them. Rather, they were satisfied with a
one-to-one guidance and counselling on their disease.
Having a forum such as a glaucoma patient association
would promote interaction between patients, with repre-
sentation for actively addressing challenges in accessing
care and treatment and obtaining social support. Parti-
cipants believed that shared experiences would enhance
ability to make informed choices and staying in treatment.
What keeps glaucoma patients within the care pathway
are a good hospital experience; a support structure in-
volving family, counselling and shared patients’ experi-
ences; and an informed choice of treatment, as well as
agency  knowing about glaucoma and being able to do
something about it. The cost of treatment is a major
factor for patients dropping out of treatment.
Having glaucoma and coping mechanisms
IDI-2 expressed feelings of isolation and abandonment
and loss of value to his children and friends (see Box 2),
while some participants note that their visual impairment
should not define who they are. IDI-5 felt awful for being
called ‘blind-man’ (makaho). Likewise, IDI-7 who had
been active in the community for about 40 years disliked
being addressed as ‘blind-man’ (makaho): ‘why would
people address me as such and alienate me?’
A diagnosis of glaucoma triggered anxiety: EI-1 said,
‘I had a breakdown. A shock went through my spine’; or
Box 1. EI-11 illustrates late presentation, getting to know
glaucoma, agency, accepting the possibility of further vision
loss without treatment and maintaining continued care
EI-11 is a 42-year-old senior civil servant:
When I discovered that I had eye problem . . . one eye
was seeing, one eye was not seeing, I said I cannot
continue like this, let me find my way to FMC but
I was stopped by a friend who recommended a private
clinic. I did not know it was run by a nurse. There,
I was told I had glaucoma. He did not give much
guidelines and explanation. Had I got guidelines and
explanation, it would have not reached up to this
stage at which I am in now. Later, after one year plus,
I changed to a private doctor. He also said I had
glaucoma and one of my eyes was severely affected.
That is the left eye. Then he explained glaucoma. And
ah, that’s how I started to know about glaucoma.
Because at the private hospital, . . . you will spend
much and much and much and much. I asked him to
give me a referral letter to NEC. He said ‘why refer if
it’s what I can do?’ Though he’s a qualified doctor,
he’s a doctor. Then I later thought it over . . . I said
kai . . . (sigh) I’m educated so let me find my way.
Whatever it will cost me, let it cost me rather than
leaving myself in darkness. And I don’t want to be in
the dark!
Here, they explained ALL (his emphasis) things to
me. And they said ANY (!) nerves, or ANY (!) eye
sight that glaucoma destroys, it is destroyed for life.
So that’s why I said I cannot stay and continue
looking at it . . . then leaving myself in darkness.
Because I am still young, I don’t know how long
I will live in the world and my eye . . . Then that I’m
finished. So that’s why I normally maintain the
period I’m given for appointment. I don’t fail it.
I don’t fail it. Yes.
Box 2. IDI-2 illustrates lack of autonomy to take
decisions, not understanding the treatment and feeling
of abandonment but accepting the situation he is in
IDI-2 retired as a staff sergeant after 35 years in the
military as a nurse. He is blind in both eyes from
glaucoma. He is a widower and lives with 3 of his
5 children, the youngest being 11 years old. The
oldest son is away on military service, and the oldest
daughter is at University. Interviewing him was my
second IDI of a blind person in the community.
‘When I was diagnosed with glaucoma in 2004’, the
doctors suggested surgery. However, my preparation
for retirement from the military stopped the discus-
sion of surgery. Then things happened so quickly 
I was retired, had to leave the barracks official
accommodation to my uncompleted house which
was yet to be roofed. ‘At the time I moved to this
place I could see and move around everywhere’. That
was 2007.
‘At the hospital, I had been receiving treatment
but there was no improvement. I went to another
hospital’. I continued treatment until I got fed up . . .
‘Anywhere I went, they would say timolol, timolol . . . ’
When asked about how he copes being blind 
‘It is not easy . . . The children would just go away.
Not that we don’t have . . . I have television, DVD,
radio, anything that can make them happy to stay
here. I don’t shout at them  there’s food, everything.
I don’t know why . . . I’m not having peace of mind
again. As I cannot see anything at all how can I go out
myself? There is nothing I can do . . . The challenge is
too much but there is nothing I can do. What can I do?
Do I cry? If I cry, am I the first person to go blind?
So there is nothing I can do than to accept it like that.
So I have to thank God very well. ‘It is said in the
Bible that in any situation you see yourself, accept it’.
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perhaps regarded as a fate worse than death because ‘some
people prefer to die instead of living with blindness’ (EI-4).
There was also an emotional component as IDI-1 kept
sobbing during the interview while saying ‘God, you know
better, you will make it better’. Participants who had lost
vision expressed their dismay in their inability to do certain
tasks especially driving, writing and keeping their jobs.
Some also had feelings of being a burden on those who
assist them in their everyday activities.
Within the sociocultural framework of faith in God,
some glaucoma participants did not see themselves as
being blind and now suffering. Rather, they found ways
to manage the situation. FGD/4/P3 said ‘I put my trust in
God’ (see also Box 4: IDI-7). IDI-4 remains an important
member of his community as the Imam who leads the
congregation prayers in the local mosque. He finds
strength in faith and accepts that everything in life would
be left behind anyway.
Discussion
This study found that most people do not know about
glaucoma, they are not aware when they have it, they do
not know where to find care and they are faced with
challenges in accessing and maintaining treatment because
of poor infrastructure and high cost of care. A major
trigger of seeking care was advanced loss of sight resulting
in late diagnosis. Indeed, a person with glaucoma may
frequently be unaware of the gradual loss of sight (10, 11).
Loss of sight was often not discussed, and participants did
not use the word ‘blind’ (‘makanta’ in Hausa) to describe
Box 3. IDI-6 illustrates lack of access to medical care,
use of traditional eye medication and not understanding
treatment
IDI-6 is a 67-year-old housewife. Her husband is
the District Head. She is blind in both eyes from
glaucoma. She has never been to a hospital/clinic nor
been on biomedical treatment:
‘My eyes kept hurting and hurting and then they
brought me some perfume which I sprayed on the
eyes. But they got worse. Then they said I should take
a frog and rub it on the eyes. I said I couldn’t do that.
Then my husband picked up the frog and rubbed it on
my eyes and when he threw the frog, it died. The eyes
got better, there was no pain again. Then they gave me
kohl which I kept applying for months and years and
the vision continued dimming and getting worse.
Now, that is my story’.
Asked why she didn’t go to the hospital 
‘I have not been to hospital. The first time they came
(on outreach), I was told I needed operation. But
some people said to my husband that if I went, they
would sever my eye nerves (za’a tsinke jijiya) so
I refused to go since then’.
Box 4. IDI-7 illustrates late diagnosis, difficulties in main-
taining care, poorly equipped tertiary hospital, agency
and coping mechanisms
IDI-7 is a 43-year-old man, civil servant.
‘In 2003, the doctor said my left eye had end-stage
glaucoma. I never knew that it was not seeing before
I went to the hospital. It was when they tested me that
I knew. They recommended surgery for the right
eye. I had the first surgery in 2003 and continued to
see without any problem. I would go for check-up
regularly. Four years later in 2007, my seeing right eye
got reddish. I got worried and went to see the
ophthalmic nurse who recommended an eye drop.
It was not available in my town so I bought it about
30 miles away. I saw my vision diminish gradually . . .
The following day I went to NEC. I needed vitrect-
omy but they didn’t have the materials. Through a
cumbersome process of referral, appointment and
solicitation of funds, I had vitrectomy in Cairo,
Egypt, two weeks later’.
‘My work keeps me busy. Currently I am heading a
centre that teaches secondary school students English
and Mathematics. We recruited 12 lecturers and we
have about 6 classes with over 65 students’.
However, he expressed disturbing limitations as a
public speaker and teacher. ‘You know when I address
people, the only response I can hear from them is
laughter or their voices, but I cannot see their eyes . . .
That is one of my problems. Some people do not talk,
but you can read them from their faces. But I cannot
read those because I cannot see. It is only when
somebody talks that I begin to know his feelings
about me, so that is one of the disturbing things’.
‘It has stopped me from furthering my studies,
Masters. After the first surgery, I could not read . . .
But most importantly, I was not sacked from my job 
that is a happy thing. I earn my salary and maintain
my family’.
On his relationship with his family and community:
‘My family and friends have been very, very suppor-
tive. Especially my wife . . . The community too.
If people could remove this sickness from me, the
number of people that trooped into this house when
I came back from hospital, they would have removed
the sickness from me, on sympathy basis, I tell you . . .
I gave everything to God’.
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themselves. This silence can be seen to have allowed
glaucoma to thrive without being diagnosed. As in Ghana
(12), there was no specific name for glaucoma in the
communities we studied. Similarly, the knowledge of
glaucoma was low, as documented in previous hospital-
based (1316) and population-based (1720) studies. Even
in some developed economies, knowledge of glaucoma
varies (21, 22). The lack of knowledge might have con-
tributed to difficulty in appreciating the possibility of
future sight loss if left untreated even though patients
would live with future uncertainties (23). However, it was
not only the silent nature of loss of sight due to glaucoma
that precluded participants from finding or securing early
care but also additional factors such as not knowing
where to find care and not being able to afford or sustain
care. In a study, where care is available and accessible, every
patient followed up in a population-based survey had
sought eye care (24), but the understanding of glaucoma
was limited (25). In our study, those who had more agency,
that is, resources and ability to take autonomous decisions,
appeared to have found ways to access care.
In line with the United Nations resolution on Universal
Health Coverage (26), a Global Action Plan (GAP) was
developed for eye care (27). GAP aims to ensure that
the diseases that cause blindness and visual impairment
are addressed through universal standards of eye care,
tailored according to local contexts and benefits of modern
medicine. The GAP, inherently linked with vision 2020
‘The Right to Sight’ (28), recognises the need to address
problems of unequal access to eye care and to support
weaker nations/communities to achieve those standards.
This study provides information that will be useful to
developing strategies for locally relevant eye care tailored
towards optimal care.
In interpreting our findings, we identified the concept
of structural violence as a useful way to understand
and explain what could be causing people to be in the
situation of lack of knowledge, late presentation and drop
out from continued care. Structural violence originates
from the perspectives that there is a disease and that the
disease is disabling  for example, HIV/AIDS and there
are structures that make the disease worse in others and
structural inequalities that prevent access to care (29).
When there are constraints and inequalities in socio-
economic status and health systems structures, as we note
here, that preclude avoidable blindness from being
avoided, then there is structural violence (30). Put more
succinctly, ‘structural violence is one way of describing
social arrangements that put individuals and populations
in harm’s way. The arrangements are structural because
they are embedded in the political and economic
organization of our social world; they are violent because
they cause injury to people (typically, not to those res-
ponsible for perpetuating such inequalities) . . . neither
culture nor pure individual will is at fault; rather,
historically given, and often economically driven pro-
cesses and forces conspire to constrain individual agency.
Structural violence is visited upon all those whose social
status denies them access to the fruits of scientific and
social progress’  Paul Farmer (29, 31). The concept of
structural violence encourages us to reorient ourselves
towards finding solutions, to critically engage the realities
and recognise the situation due to structural inequalities
and structural barriers, which cause harm, rather than
passively accepting these as systemic inequalities (32).
These structures of inequalities are invisible and em-
bedded within the same political and economic systems
such that no one individual or institution can be held
accountable (31). For example, if a person goes irrever-
sibly blind from glaucoma, which is avoidable, one might
ask, who do we hold culpable?
In terms of agency, autonomy is related, partially, to
having the ability or the resources to act freely. From the
economic aspect, it could mean those who have a voice 
for example, EI-11: ‘this is what I want’, wherein the
socio-economic structure enables him. However, when
people are unable to demand, the only agency they may
have is to lament and leave  for example, IDI-2: ‘what
else can I do?’ For those who had relatively better agency,
for example, EI-11, they were able to seek care and
navigate the difficult care pathway ‘rather than remain
in the dark’. That was an active response. A somewhat
passive response is accepting the situation and not taking
a decision to go for a biomedical or traditional medicine
but manage the ‘misfortune’ (e.g. IDI-6) and readjusting
their social and family interactions (33, 34). This may not
necessarily be interpreted as social suffering in the way
people manage adverse situations, but takes into con-
sideration coping mechanisms. The way they cope and
the way they accept their situation might be because of
the absence of care or structures that mean they cannot
access care and they do not feel or know that getting
better care is their right. It appears that health choices
have been left to ordinary people to continue their own
therapies, be it traditional medicine or self-medication
from patent medicine stores or markets. This has been
described as ‘subsistence’ health  where people are left
to seek their own care (35), and traditional medicine
is often sought where there were no alternative sources
of treatment (36). In glaucoma, there is no system, no
diagnostic category and no way of well-established man-
agement of the disease within traditional medicine. In fact,
the more established practice of couching, which is the
traditional manual manipulation for cataract, is widely
practiced in Nigeria with very poor visual outcomes (37).
Furthermore, the narratives imply that whether one
goes to the hospital or gets treated was a matter of fate
and destiny, depending on the will of God. In a way, this
submission to the will of God breeds acceptance of the
situation. Some believe that loss of their sight is a test of
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their faith and perhaps an expiation of sins for a better
life after death. Of note, however, is that coping may be a
response to the absence of care or the structures that
mean they cannot access care. This makes the coping
mechanisms dynamic  people have resources and ability
to manage the situation but they would not turn down
the opportunity to have better care that is well explained,
accessible and affordable.
Limitations
There are limitations of this study. The analysis was
undertaken using the transcripts of translation to English
for three-quarters of the discussion. As such, some distinct
expressions might have been lost in translation. Another
limitation is that we conceptualised a care pathway and
saw people who are not accessing or who are falling out
of our imagined pathway. But from their perspective, there
is no care pathway; for them, it is just life, embodied as
lived realities. Additionally, a limitation of the structural
violence perspective is that it labels one with a defining
feature, for example, the glaucoma blind, whereas these
patients did not see themselves as such.
Recommendations
This population-based study provides a baseline and
deeper understanding of access to glaucoma care. How-
ever, we recommend conducting a similar study in different
settings for local content. A further recommendation is
that in addition to offering biomedical/clinical service,
providers need to collaborate and communicate effectively
with patients, family members and carers so that they
understand the disease, manage their expectations and be
effectively supported to gain insight into the disabling
consequences of blindness. Other needs are better eye
healthcare financing, visual rehabilitation and social
adaptations for people with visual impairment/blindness.
A social policy and disability benefits would also ease
some of the social suffering of blindness.
Conclusion
In Nigeria, the reasons for late presentation imply the
need for improving services for glaucoma. Availability
and affordability of treatment need to be addressed so
that hospitals are well equipped to manage glaucoma,
incorporating early case-detection strategies with clear
glaucoma care pathways and two-way referral/feedback
systems.
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Paper context
Blindness from glaucoma is associated with late presentation
and poor compliance to treatment. This study indicates that
late diagnosis may be explained by structural barriers to
accessing care: socio-economic deprivation, poor under-
standing of the disease and high cost of care. The findings
suggest the need to address socio-economic structural drivers
as glaucoma experiences demonstrate that poverty is a strong
driver for blindness. There is also a need for clear glaucoma
care pathways and better eye healthcare financing.
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This article proposes a ‘top-down’ approach 
to developing glaucoma services. To do 
this, good evidence, gathered through 
research, is needed about the following: 
• The prevalence of different types of
glaucoma in the population (as
open-angle and angle-closure glaucoma
are managed differently).
• The age and socio-economic status of
the local population, as well as any
biomedical/metabolic or genetic factors
that might predispose them to
glaucoma. This makes it possible to
identify the high-risk groups.
• The local community’s knowledge,
beliefs and health-seeking behaviour
with regards to eye disease.
• The expectations and perceptions of
patients and family members.
• The best treatment options (based on
randomised controlled clinical trials and
outcomes studies), which take into account
the local realities and patients’ preferences.
All of the above can be used to develop 
efficient, streamlined services that will 
encourage patients to come back for 
long-term care and follow-up, which is 
essential.
Suggested steps
The initial focus should be on developing 
good quality sub-speciality services at the 
tertiary level, followed by strengthening of 
secondary eye care (at district level) and 
then implementation of strategies for the 
early detection of glaucoma. There should 
be clear guidelines for referral (in both direc-
tions) between tertiary and secondary 
levels, and from the community to the 
secondary level once early detection strat-
egies are implemented.
If this approach is ignored, early 
detection and diagnosis will create false 
expectations – and eventually disap-
pointment – when patients are told 
nothing can be done about their diagnosis 
due to inadequate services at secondary 
or tertiary level. This will lead to a loss of 
faith in the eye care service.
The fives steps in this approach are 
described below. 
Step 1. Strengthen tertiary eye care 
units to provide a good standard of 
glaucoma services
It must be possible for patients to 
undergo all the necessary investigations 
during a single visit. This will reduce costs 
to patients and encourage them to come 
back for follow-up visits. The following are 
also needed at tertiary level: 
• Equipment. The hospital should be
equipped with the appropriate
diagnostic and therapeutic equipment.
• Skilled personnel. The glaucoma team
should consist of glaucoma
sub-specialists, general
ophthalmologists, optometrists,
ophthalmic nurses, counsellors,
equipment technicians and other allied
eye care providers. The team should be
trained to provide accurate diagnosis
and prompt, appropriate management
with a choice of medical, laser or
surgical treatment. Personnel should be
able to monitor disease progression and
institute treatment using clear clinical
guidelines. Task sharing may be
required, such as training nurses or
technicians to assess visual fields, to
take optic disc images or to counsel
patients so that clinicians have time to
focus on management decisions.
• Information management. There
should be robust health management
information systems and reliable
management of medical records to
ensure follow-up and monitoring of
disease progression.
Step 2. Strengthen secondary 
centres (at district level) to manage 
less complex cases
• There should be a robust referral and
feedback system between the tertiary
centre and the secondary centres.
• Protocols for ocular examination and
glaucoma diagnosis and management
should be in place.
• Non-complex glaucoma cases should
be managed at the secondary centres.
Additionally, patients that had surgery or
laser treatment at the tertiary centre 
can be referred back to the secondary 
centres for long-term care and 
follow-up.
Step 3. Develop glaucoma 
case-detection strategies at the 
secondary and primary levels
For example, everyone aged 30 (or 40) 
years and above who seeks eye care (e.g. 
with presbyopia or refractive errors) and 
for driving tests, could be offered a 
comprehensive eye examination, 
including optic disc assessment and 
intraocular pressure measurement, with 
confirmation of glaucoma diagnosis by 
visual field testing.
Step 4. Provide low vision and 
rehabilitation services
Glaucoma is the commonest cause of 
functional low vision in Nigeria.1 Providing 
low vision services for glaucoma patients 
could therefore enhance their functional 
vision and quality of life. 
If a high proportion of the glaucoma 
patients who come forward are already 
blind, community-based rehabilitation 
(CBR) should be an integral part of the 
glaucoma service provided.
Step 5. Increase awareness of 
glaucoma among policy makers and 
the public
Develop good working relationships with 
people responsible for health policy, 
whether at a local or national level. 
Emphasise that glaucoma is a major 
cause of irreversible blindness that could 
potentially be avoided. Encourage policy 
makers to create supportive policies: for 
example, to enhance the availability of 
affordable glaucoma medication and 
laser treatment at an affordable cost.
A public health awareness campaign 
for glaucoma should only be instituted 
when a good glaucoma service is in place. 
The campaign should be based on local 
beliefs, attitudes and behaviour, and 
should make use of suitable communi-
cation channels. For example: 
• placing posters in public areas
• giving talks and handing out leaflets in
hospital waiting rooms
• working with local organisations
• using the media (e.g. radio or television
programmes and newspaper articles).
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SUMMARY	  
	  
Glaucoma	  in	  Africa	  is	  sometimes	  referred	  to	  as	  the	  silent	  thief	  of	  sight.	  In	  Nigeria,	  
glaucoma	  is	  common,	  it	  is	  serious,	  ophthalmologists	  face	  many	  constraints	  in	  
managing	  it,	  people	  do	  not	  even	  know	  they	  have	  it	  until	  it	  is	  advanced,	  patients	  
do	  not	  understand	  or	  comply	  with	  treatment	  after	  they	  are	  diagnosed	  and	  the	  
poor	  are	  more	  likely	  to	  be	  glaucoma	  blind.	  Available	  evidence	  indicates	  that	  the	  
health	  system	  in	  Nigeria	  is	  failing	  to	  meet	  the	  needs	  of	  glaucoma	  patients.	  Based	  
on	  evidence,	  we	  propose	  future	  directions	  for	  improving	  services	  for	  glaucoma	  
care	  in	  Nigeria,	  and	  the	  implications	  for	  policy	  and	  programmes	  to	  control	  
glaucoma	  blindness,	  using	  a	  health	  systems-­‐oriented	  approach.	  Three	  
complementary	  strategies	  are	  required:	  (i)	  strengthening	  clinical	  services	  for	  
glaucoma	  –	  by	  developing	  models	  of	  glaucoma	  care,	  improving	  clinical	  treatment	  
options,	  making	  medicines	  and	  equipment	  available,	  financing	  glaucoma	  care	  
and	  training	  eye	  care	  workers;	  (ii)	  introducing	  initiatives	  for	  earlier	  detection	  of	  
glaucoma	  in	  the	  clinic	  and	  approaches	  in	  the	  community;	  and	  (iii)	  strengthening	  
health	  system	  governance.	  
Glaucoma	  is	  a	  complex	  disease	  to	  manage	  and	  addressing	  it	  as	  a	  public	  health	  
problem	  is	  challenging.	  However,	  we	  need	  to	  change	  the	  paradigm	  to	  recognise	  
that	  glaucoma	  is	  a	  potentially	  avoidable	  cause	  of	  blindness	  in	  Africa.	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INTRODUCTION	   	  
	  
The	  United	  Nations	  resolution	  on	  Universal	  Health	  Coverage	  (UHC)	  is	  
fundamental	  to	  achieving	  Sustainable	  Development	  Goal	  no.	  3	  -­‐	  equity	  in	  health	  
for	  everyone.	  This	  entails	  not	  only	  improving	  access	  to	  quality	  health	  services	  but	  
also	  protection	  against	  financial	  risks	  in	  accessing	  services.[1]	  In	  line	  with	  UHC,	  a	  
Global	  Action	  Plan	  2014-­‐2019	  was	  developed	  for	  eye	  care,[2]	  which	  aims	  to	  ensure	  
that	  eye	  diseases	  that	  cause	  blindness	  and	  visual	  impairment	  are	  addressed	  
through	  universal	  standards	  of	  eye	  care	  that	  address	  local	  priorities.	  	  
	  
Glaucoma	  is	  a	  group	  of	  eye	  diseases	  characterised	  by	  progressive	  optic	  
neuropathy	  with	  visual	  field	  loss	  which	  can	  lead	  to	  irreversible	  blindness.	  
Glaucoma	  affected	  more	  than	  64.3	  million	  globally	  in	  2013,	  and	  is	  projected	  to	  
increase	  to	  76	  million	  by	  2020.[3]	  Primary	  open	  angle	  glaucoma	  (POAG)	  is	  the	  
most	  common	  type,	  affecting	  57.5	  million	  people	  in	  2015,	  increasing	  to	  65.5	  
million	  by	  2020.[4]	  
	  
Glaucoma	  in	  Africa	  is	  sometimes	  referred	  to	  as	  the	  silent	  thief	  of	  sight,[5]	  and	  
available	  evidence	  indicates	  that	  the	  health	  system	  in	  Nigeria	  is	  failing	  to	  meet	  
the	  needs	  of	  glaucoma	  patients.	  Based	  on	  our	  findings[6-­‐10]	  (summarised	  in	  
Figure	  1),	  we	  propose	  future	  directions	  for	  improving	  services	  for	  glaucoma	  care	  
in	  Nigeria,	  and	  the	  implications	  for	  policy	  and	  programmes	  to	  control	  glaucoma	  
blindness,	  using	  a	  health	  systems-­‐oriented	  approach.	  Some	  of	  our	  
recommendations	  also	  derive	  from	  major	  meetings	  on	  glaucoma	  in	  Africa:	  The	  
Africa	  Glaucoma	  Summit	  in	  Accra,	  Ghana	  (2010)[11]	  and	  the	  Public	  Health	  
Control	  of	  Vision	  Loss	  from	  Glaucoma	  in	  Africa	  Workshop	  in	  Kampala,	  Uganda	  
(2012)[12]	  as	  well	  as	  relevant	  publications.[13,	  14]	  The	  strategy	  we	  recommend	  is	  
to	  target	  those	  in	  greatest	  need	  for	  glaucoma	  care	  to	  prevent	  them	  from	  going	  
blind,	  supported	  by	  policies	  and	  funding	  mechanisms	  for	  service	  delivery,	  and	  
clinical	  and	  operational	  research.	  At	  the	  same	  time,	  there	  is	  a	  need	  for	  health	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partnerships	  and	  social	  policies	  to	  address	  poverty	  through	  improved	  education	  
and	  literacy,	  entrepreneurship	  and	  wealth	  creation.	  	  
	  
	  
GLAUCOMA	  IN	  NIGERIA	  
	  
Data	  from	  the	  2009	  Nigeria	  national	  blindness	  and	  visual	  impairment	  survey	  
(thereafter	  referred	  to	  as	  the	  Nigeria	  Blindness	  Survey)	  indicated	  that	  4.2%	  of	  
adults	  aged	  40	  years	  and	  above	  were	  blind.[15]	  Glaucoma	  was	  the	  second	  
commonest	  cause	  of	  blindness	  (16.7%),[16]	  principally	  open	  angle	  glaucoma	  
(OAG)	  (86%	  of	  all	  glaucoma).[6]	  In	  2009,	  5%	  of	  survey	  participants	  had	  
glaucoma,	  affecting	  an	  estimated	  1.8	  million	  adults,	  and	  one	  in	  five	  were	  blind	  i.e.	  
had	  a	  presenting	  visual	  acuity	  (VA)	  of	  less	  than	  3/60	  in	  the	  better	  eye.	  Ninety-­‐
four	  per	  cent	  were	  not	  diagnosed	  and	  not	  receiving	  care.[6]	  Independent	  risk	  
factors	  for	  OAG	  were	  higher	  intraocular	  pressure	  (IOP),	  increasing	  age	  and	  Igbo	  
ethnicity.[7]	  People	  of	  low	  socio-­‐economic	  status	  were	  approximately	  four	  times	  
more	  likely	  to	  be	  blind	  from	  glaucoma,[8]	  reflecting	  limited	  awareness	  of	  
glaucoma	  and	  poor	  access	  to	  care.	  Additionally,	  ophthalmologists	  face	  many	  
constraints	  in	  managing	  it.[9]	  
	  
From	  the	  Nigeria	  Blindness	  Survey,	  it	  is	  estimated	  that	  per	  million	  population,	  
10,500	  adults	  (aged	  40	  years	  and	  above)	  have	  glaucoma.	  The	  following	  definitions	  
were	  used	  to	  estimate	  the	  number	  affected	  by	  level	  of	  severity,	  using	  the	  most	  
affected	  eye:	  severe/advanced	  glaucoma	  –	  VA<3/60,	  vertical	  cup:disc	  ratio	  
(VCDR)	  >0.8	  and	  central	  visual	  field	  (CVF)	  of	  <10o;	  moderate	  glaucoma	  –	  any	  
level	  of	  VA	  with	  VCDR>0.7	  and	  CVF	  of	  10-­‐20o;	  early/mild	  glaucoma	  –	  any	  
glaucomatous	  visual	  field	  defect	  and	  VCDR	  >0.7.	  Blind/end-­‐stage	  glaucoma	  was	  
defined	  as	  VA<3/60	  in	  the	  better	  eye	  with	  a	  VCDR	  of	  1.0.[17]	  There	  are	  estimated	  
to	  be	  5,900	  (56%)	  adults	  per	  million	  population	  with	  severe/advanced	  disease,	  
often	  blind	  in	  one	  eye	  and/or	  with	  severe	  visual	  impairment	  in	  the	  other	  eye,	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2,100	  (20%)	  moderate	  cases,	  400	  (4%)	  early	  cases	  and	  a	  further	  2,100	  (20%)	  are	  
blind	  in	  both	  eyes.	  	  
	  
Several	  factors	  contribute	  to	  the	  high	  prevalence	  of	  glaucoma	  blindness	  in	  
Nigeria.	  These	  include	  low	  rates	  of	  early	  detection	  and	  diagnosis,[17]	  lack	  of	  
specialist	  equipment	  and	  treatment	  options,	  lack	  of	  specialist	  glaucoma	  clinics	  
and	  care	  pathways,	  poor	  compliance	  with	  treatment	  and	  follow-­‐up,[9]	  the	  high	  
cost	  of	  accessing	  care	  and	  treatment	  costs,[18]	  and	  lack	  of	  awareness	  and	  public	  
knowledge	  about	  glaucoma	  compounded	  by	  socioeconomic	  deprivation.[10]	  The	  
number	  of	  eye	  health	  workers	  in	  Nigeria,	  including	  ophthalmologists	  and	  
optometrists,	  falls	  short	  of	  World	  Health	  Organization	  recommendations.[19,	  20]	  
In	  addition,	  Nigeria	  does	  not	  have	  an	  eye	  health	  policy	  and	  the	  national	  strategic	  
plan	  for	  eye	  care	  is	  not	  uniformly	  implemented.	  
	  
Considering	  these	  factors,	  three	  complementary	  strategies	  need	  to	  be	  put	  in	  place	  
to	  reduce	  glaucoma	  blindness:	  (i)	  strengthening	  clinical	  services	  for	  glaucoma;	  
(ii)	  introducing	  initiatives	  for	  earlier	  detection	  of	  glaucoma;	  and	  (iii)	  
strengthening	  health	  system	  governance.	  
	  
	  
STRENGTHENING	  CLINICAL	  SERVICES	  FOR	  GLAUCOMA	  
	  
Developing	  models	  of	  glaucoma	  care	  
There	  are	  currently	  no	  published	  articles	  on	  models	  of	  glaucoma	  care	  in	  Africa.	  A	  
conceptual	  framework	  and	  systems	  approach	  for	  improving	  services	  for	  glaucoma	  
in	  Nigeria	  are	  shown	  in	  Figure	  1.	  Clinical,	  operational	  and	  health	  system	  research	  
need	  to	  be	  embedded	  in	  care	  delivery	  models	  to	  determine	  optimal	  ways	  to	  
improve	  access	  and	  acceptance	  of	  cost-­‐effective	  treatment,	  to	  improve	  patients’	  
hospital	  experiences	  and	  compliance	  rates,	  to	  promote	  follow-­‐up	  of	  patients	  with	  
stable	  disease	  in	  district	  eye	  departments,	  and	  for	  the	  earlier	  detection	  of	  
glaucoma	  in	  the	  community.	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Improving	  clinical	  treatment	  options	  
The	  treatment	  recommended	  for	  glaucoma	  in	  Africa	  depends	  on	  several	  factors.	  
Medical	  therapy	  is	  often	  the	  first-­‐line	  of	  treatment,	  with	  β-­‐blockers	  being	  the	  
most	  commonly	  used	  in	  Nigeria.	  Prostaglandin	  analogues	  (PGAs)	  are	  effective	  in	  
preventing	  progression	  of	  visual	  field	  loss	  in	  the	  United	  Kingdom	  population,[21]	  
but	  their	  use	  in	  Nigeria	  is	  limited	  due	  to	  their	  high	  cost.	  Other	  constraints	  
include	  poor	  compliance	  with	  medicines	  and	  uncertain	  potency	  of	  topical	  
preparations,	  which	  are	  usually	  kept	  in	  high	  ambient	  temperatures.	  One-­‐off	  
interventions	  are	  recommended	  in	  Africa,	  one	  being	  primary	  trabeculectomy	  
with	  antimetabolites	  or	  β-­‐irradiation,	  with	  a	  suggested	  ‘glaucoma	  surgical	  rate’	  of	  
800	  glaucoma	  surgeries	  per	  million	  population	  per	  year.[22]	  Indeed,	  skilful	  
trabeculectomy	  with	  a	  joint	  care	  plan	  and	  adequate	  follow-­‐up	  may	  be	  a	  good	  
option	  but	  acceptance	  of	  surgery	  can	  be	  very	  low.[9,	  17]	  Laser	  therapy	  seems	  a	  
safe	  and	  acceptable	  alternative,	  which	  reduces	  costs	  to	  patients,	  as	  an	  inpatient	  
stay	  is	  not	  required.	  Although	  the	  initial	  capital	  outlay	  for	  lasers	  is	  high,	  they	  can	  
be	  used	  to	  treat	  other	  eye	  conditions,	  and	  can	  function	  for	  many	  years.	  An	  
effective,	  safe,	  affordable	  and	  acceptable	  one-­‐off	  treatment	  is	  the	  first	  essential	  
building	  block	  of	  glaucoma	  care	  in	  Africa,	  particularly	  for	  the	  poor	  and	  illiterate	  
and	  those	  who	  live	  far	  from	  eye	  care	  facilities.	  Treatment	  modalities	  need	  to	  be	  
assessed	  in	  randomised	  controlled	  trials	  (RCTs)	  to	  determine	  the	  most	  cost-­‐
effective	  and	  acceptable	  treatment	  for	  patients	  and	  providers	  in	  the	  African	  
context.	  
	  
Making	  medicines,	  surgery	  and	  laser	  treatment	  available	  
To	  improve	  access	  to	  treatment,	  institutions	  need	  to	  be	  strengthened	  with	  
equipment	  and	  training	  in	  surgical	  skills	  and	  laser	  procedures,	  with	  the	  
development	  of	  glaucoma	  care	  teams.	  Tertiary	  institutions	  should	  have	  specialist	  
glaucoma	  clinics	  which	  are	  adequately	  resourced	  so	  that	  a	  full	  assessment	  and	  
definitive	  diagnosis	  can	  be	  made	  at	  the	  first	  visit,	  with	  counselling	  of	  patients	  and	  
their	  carers	  about	  treatment	  and	  the	  need	  for	  long-­‐term	  follow-­‐up.	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Relevant	  government	  ministries/agencies	  are	  urged	  to	  improve	  the	  supply	  chain	  
of	  glaucoma	  medications	  and	  surgical	  consumables	  through	  tax	  and	  import	  duty	  
waivers,	  and	  by	  providing	  an	  enabling	  environment	  for	  local	  production	  of	  
glaucoma	  medication.	  Pharmaceutical	  companies	  could	  be	  called	  upon	  to	  
provide	  PGAs	  free	  of	  charge	  to	  the	  poorest,	  and	  global	  technology	  partners	  
should	  make	  lasers	  and	  accessories	  (lenses,	  probes,	  protective	  goggles,	  etc.)	  more	  
affordable	  for	  service	  providers	  in	  low/middle	  income	  countries.	  	  
	  
Financing	  glaucoma	  care	  
No	  patient	  should	  receive	  suboptimal	  care	  because	  they	  cannot	  afford	  treatment.	  
Strategies	  for	  healthcare	  financing	  for	  glaucoma	  to	  contain	  costs	  need	  to	  be	  
developed	  and	  evaluated.	  One	  approach	  could	  be	  to	  provide	  free	  treatment	  to	  
poor	  patients.	  Another	  is	  to	  advocate	  that	  more	  potent	  medications	  such	  as	  
PGAs,	  and	  trabeculectomy	  and	  laser	  procedures	  be	  covered	  by	  health	  insurance.	  
UHC	  through	  government	  budgetary	  allocations	  is	  probably	  the	  most	  sustainable	  
approach	  for	  such	  a	  chronic,	  serious	  and	  life-­‐long	  disease.	  	  
	  
Human	  resources	  for	  eye	  health	  
In	  order	  to	  improve	  services	  for	  glaucoma,	  multi-­‐tasking	  by	  health	  workers	  is	  
recommended	  with,	  for	  example,	  nurses	  being	  trained	  to	  perform	  optic	  nerve	  
head	  photography	  and	  visual	  field	  analysis.	  Early	  detection	  of	  significant	  
glaucoma	  through	  community-­‐based	  opportunistic	  case-­‐detection	  by	  
optometrists,	  follow-­‐up	  in	  the	  community	  and	  community-­‐based	  care	  especially	  
for	  post-­‐operative	  cases	  by	  ophthalmic	  nurses,	  and	  testing	  for	  vision	  loss	  by	  
primary	  healthcare	  workers	  are	  also	  strategies	  to	  explore.	  Agreement	  on	  
professional	  boundaries	  will	  be	  required,	  with	  clearly	  defined	  work	  areas	  for	  
allied	  eye	  care	  members	  of	  the	  glaucoma	  care	  team,	  and	  clearly	  defined	  roles	  for	  
glaucoma	  care	  in	  secondary	  centres.[23]	  
	  
Health	  information	  system	  
Health	  management	  information	  systems	  are	  essential	  for	  improving	  glaucoma	  
services	  in	  Nigeria	  to	  provide	  good	  medical	  records	  systems	  to	  track	  patients	  over	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time	  and	  monitor	  trends	  of	  treatment.	  We	  recommend	  that	  the	  number	  of	  
procedures	  for	  glaucoma,	  as	  well	  as	  the	  number	  of	  cataract	  operations,	  be	  
monitored	  and	  reported	  centrally.	  Good	  medical	  records	  are	  also	  important	  for	  
robust	  referral/feedback	  systems,	  to	  document	  clinical	  findings	  for	  follow-­‐up	  and	  
to	  develop	  a	  database	  of	  glaucoma	  patients.	  	  
	  
	  
APPROACHES	  FOR	  EARLIER	  DETECTION	  OF	  GLAUCOMA	  
	  
Before	  starting	  any	  intervention	  for	  case-­‐detection,	  adequate	  clinical	  services	  for	  
glaucoma	  must	  be	  in	  place.	  The	  challenge	  of	  a	  public	  health	  glaucoma	  care	  
programme	  would	  be	  to	  find	  people	  who	  already	  have	  significant	  glaucoma	  and	  
ensure	  they	  have	  access	  to	  services	  to	  reduce	  the	  risk	  of	  progression	  to	  bilateral	  
blindness.	  The	  poorest	  in	  the	  population	  need	  to	  be	  targeted	  because	  glaucoma	  
blindness	  affects	  them	  the	  most.	  	  
	  
In	  the	  clinic	  
Primary	  eye	  care,	  including	  that	  provided	  by	  optometrists	  who	  are	  few	  in	  number	  
and	  usually	  	  located	  in	  urban	  areas,	  	  is	  almost	  entirely	  lacking	  in	  Nigeria,	  as	  in	  
many	  countries	  in	  Africa,	  and	  so	  there	  are	  no	  mechanisms	  for	  early	  detection	  of	  
glaucoma.	  One	  solution	  to	  improve	  earlier	  detection	  of	  glaucoma	  is	  to	  ensure	  
that	  all	  adults	  aged	  40	  years	  and	  above	  who	  present	  to	  eye	  care	  services,	  
regardless	  of	  their	  presenting	  complaint,	  undergo	  routine	  optic	  disc	  assessment.	  
This	  approach	  was	  effective	  in	  the	  eye	  department	  in	  Bauchi,	  North-­‐eastern	  
Nigeria,	  where	  the	  optometrists	  referred	  anyone	  with	  a	  CDR	  >0.6	  to	  the	  
ophthalmologist	  for	  examination.[17]	  	  	  	  	  
	  
Identified	  high-­‐risk	  groups	  and	  first-­‐degree	  relatives	  (FDRs)	  of	  patients	  with	  
glaucoma	  should	  also	  be	  targeted.	  	  
	  
Community	  approaches	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We	  advocate	  that	  optic	  disc	  assessment	  of	  all	  those	  aged	  40	  years	  and	  above	  
become	  an	  integral	  component	  of	  outreach	  eye	  care	  activities	  with	  a	  referral	  of	  
those	  with	  VCDR>0.6	  to	  designated	  facilities	  for	  full	  assessment,	  definitive	  
diagnosis	  and	  treatment.	  Another	  assessment	  to	  consider	  at	  the	  community	  level	  
is	  a	  properly	  conducted	  swinging	  flashlight	  test	  to	  detect	  relative	  afferent	  
pupillary	  defects	  (RAPD)	  which	  has	  to	  the	  potential	  to	  find	  at	  least	  25%	  of	  
glaucoma,[24]	  and	  with	  strong	  specificity	  for	  glaucoma.[25]	  	  
	  
Figure	  2	  shows	  a	  possible	  algorithm	  for	  glaucoma	  case-­‐detection	  at	  community	  
and	  clinic	  levels.	  In	  a	  retrospective	  evaluation	  of	  outreach	  in	  Ibadan,	  people	  
referred	  from	  outreach	  were	  twice	  as	  likely	  to	  have	  mild/moderate	  glaucoma	  
than	  patients	  referred	  from	  other	  facilities	  who	  had	  more	  severe	  disease.[26]	  	  
	  
Another	  strategy	  is	  to	  integrate	  optic	  disc	  imaging	  using	  mobile	  phone	  apps	  into	  
screening	  activities	  for	  non-­‐communicable	  diseases,	  or	  into	  programmes	  for	  the	  
control	  of	  onchocerciasis	  (river	  blindness)	  and	  trachoma,	  which	  are	  reaching	  a	  
high	  proportion	  of	  the	  most	  vulnerable	  population	  in	  Nigeria.	  
	  
Informal	  providers	  of	  healthcare,	  who	  are	  ubiquitous	  and	  acceptable	  to	  
community	  members	  in	  Africa,	  could	  also	  be	  engaged	  in	  identifying	  individuals	  
suspected	  of	  having	  glaucoma.	  For	  example,	  in	  Nassarawa,	  spectacle	  vendors	  
were	  enrolled	  in	  a	  study	  to	  assess	  interventions	  for	  finding	  cases	  of	  glaucoma	  in	  
the	  community.	  About	  half	  of	  those	  referred	  by	  spectacle	  vendors	  subsequently	  
attended	  the	  eye	  clinic,	  15%	  of	  whom	  were	  newly	  diagnosed	  with	  glaucoma.	  
(Personal	  communication:	  HI,	  MSc	  PHEC	  dissertation,	  LSHTM	  2016).	  
	  	  
Other	  approaches	  for	  earlier	  detection	  may	  include	  designing	  and	  implementing	  
a	  community	  awareness	  strategy,	  using	  local	  terms	  such	  as	  those	  in	  Hausa	  that	  
describe	  behaviour	  associated	  with	  peripheral	  visual	  field	  loss	  (e.g.	  taka	  shanya),	  
through	  social	  and	  mass	  media	  platforms	  	  such	  as	  radio	  which	  has	  a	  wide	  reach,	  
television,	  and	  newspapers.	  For	  example,	  people	  could	  be	  encouraged	  to	  regularly	  
check	  the	  vision	  of	  each	  eye	  by	  covering	  the	  other	  eye.	  Community	  awareness	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strategies	  should	  be	  planned	  carefully	  to	  avoid	  creating	  a	  demand	  that	  cannot	  be	  
met.	  However,	  greater	  demand	  is	  needed	  to	  generate	  political	  pressure	  that	  may	  
drive	  the	  development	  of	  better	  services.	  	  
	  
	  
STRENGTHENING	  HEALTH	  SYSTEMS	  GOVERNANCE	  
	  
A	  strong	  health	  system	  requires	  leadership	  and	  governance	  to	  deliver	  improved	  
care,	  based	  on	  evidence	  of	  what	  works,	  as	  day-­‐to-­‐day	  monitoring	  and	  interval	  
evaluation	  can	  improve	  services.	  Additionally,	  it	  is	  important	  that	  team	  leaders	  
take	  part	  in	  developing	  policies	  to	  include	  glaucoma	  in	  national	  healthcare	  plans	  
and	  to	  integrate	  eye	  care	  into	  programmes	  for	  non-­‐communicable	  diseases.	  Data	  
and	  information	  are	  also	  required	  for	  advocacy	  with	  policy	  makers	  and	  for	  the	  
engagement	  of	  civil	  society	  to	  improve	  health	  education,	  knowledge	  and	  public	  
awareness.	  
	  
Glaucoma	  patients’	  associations	  can	  be	  strengthened	  to	  support	  vulnerable	  
groups	  through	  sharing	  experiences	  and	  resources	  by	  patients	  and	  family	  
advocates.	  	  
	  
	  
CONCLUSION	  
	  
Glaucoma	  is	  a	  complex	  disease	  to	  manage	  and	  addressing	  it	  as	  a	  public	  health	  
problem	  is	  a	  challenge.	  However,	  we	  need	  to	  change	  the	  paradigm	  to	  recognise	  
that	  glaucoma	  is	  a	  potentially	  avoidable	  cause	  of	  blindness	  in	  Africa.	  We	  have	  
discussed	  possible	  ways	  in	  which	  to	  improve	  services	  for	  glaucoma	  in	  Nigeria	  
with	  the	  aim	  of	  ensuring	  inclusion	  of	  those	  most	  at	  risk	  of	  blindness	  from	  
glaucoma	  i.e.	  the	  poor.	  Further	  clinical	  and	  operational	  research	  is	  required	  to	  
address	  the	  acknowledged	  evidence	  gaps.	  We	  also	  advocate	  for	  policies	  to	  make	  
glaucoma	  treatment	  available	  and	  affordable	  to	  all,	  and	  possibly	  free	  to	  the	  poor.	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Rather	  than	  remaining	  silent,	  let	  us	  give	  glaucoma	  patients	  a	  voice	  so	  that	  the	  
silent	  thief	  of	  sight	  does	  not	  lead	  them	  into	  darkness.	  
	  
	  
Acknowledgements	  
The	  authors	  acknowledge	  the	  advisory	  input	  of	  Ms	  Winifred	  Nolan	  (FRCOphth,	  
MD),	  Dr	  Paul	  Spry	  (MCOptom, PhD)	  and	  Dr	  Clare	  Chandler	  (PhD).	  
	  
Competing	  interests	  
No	  conflicting	  relationship	  exists	  for	  any	  other	  
	  
Funding	  
The	  writing	  of	  this	  article	  was	  supported	  by	  the	  Fred	  Hollows	  Foundation	  (Grant	  
code	  ITCRVW04)	  as	  part	  of	  research	  degree	  study	  for	  FK.	  
RW	  is	  funded	  in	  the	  UK	  by	  financial	  support	  from	  the	  Department	  of	  Health	  
through	  the	  award	  made	  by	  the	  National	  Institute	  for	  Health	  Research	  to	  
Moorfields	  Eye	  Hospital	  NHS	  Foundation	  Trust	  and	  UCL	  Institute	  of	  
Ophthalmology	  for	  a	  Specialist	  Biomedical	  Research	  Centre	  for	  Ophthalmology.	  
The	  funding	  organisations	  had	  no	  role	  in	  the	  design	  and	  conduct	  of	  the	  study.	  
	  
	  
	  
Contributorship	  statement	  
FK	  led	  the	  conception	  and	  design	  of	  the	  study	  and	  drafted	  the	  manuscript	  and	  
edited	  it	  with	  consideration	  of	  input	  from	  co-­‐authors.	  CG	  supervised	  the	  
conception	  and	  design	  of	  the	  study	  and	  revised	  the	  article	  for	  important	  
intellectual	  content.	  
	  KB	  and	  RW	  contributed	  to	  the	  design	  of	  the	  study	  and	  revised	  the	  article	  for	  
important	  intellectual	  content.	  	  
Fatima Kyari PhD Thesis Page 238
	   12	  
	  
References	  
	  
1. United	  Nations.	  General	  Assembly.	  Global	  health	  and	  foreign	  policy.	  2012.	  
A/67/L.36.	  Available	  at	  
http://www.un.org/ga/search/view_doc.asp?symbol=A/67/L.36&referer=h
ttp://www.un.org/en/ga/info/draft/index.shtml&Lang=E.	  Last	  accessed	  29	  
July	  2016.	  
2. World	  Health	  Organization.	  Universal	  eye	  health:	  a	  global	  action	  plan	  for	  
the	  prevention	  of	  avoidable	  blindness	  and	  visual	  impairment	  2014-­‐2019.	  
World	  Health	  Organization.	  2013.	  A66/11.	  Available	  at	  
http://www.who.int/entity/blindness/EyeHealthActionPlanWHA66.pdf?u
a=1.	  Last	  accessed	  29	  July	  2016.	  
3. Tham	  YC,	  Li	  X,	  Wong	  TY	  et	  al.	  Global	  prevalence	  of	  glaucoma	  and	  
projections	  of	  glaucoma	  burden	  through	  2040:	  a	  systematic	  review	  and	  
meta-­‐analysis.	  Ophthalmology.	  2014;121:2081-­‐90.	  
4. Kapetanakis	  VV,	  Chan	  MP,	  Foster	  PJ	  et	  al.	  Global	  variations	  and	  time	  
trends	  in	  the	  prevalence	  of	  primary	  open	  angle	  glaucoma	  (POAG):	  a	  
systematic	  review	  and	  meta-­‐analysis.	  Br	  J	  Ophthalmol.	  2016;100:86-­‐93.	  
5. Kyari	  F,	  Abdull	  MM,	  Bastawrous	  A	  et	  al.	  Epidemiology	  of	  glaucoma	  in	  
Sub-­‐Saharan	  Africa:	  Prevalence,	  incidence	  and	  risk	  factors.	  Middle	  East	  Afr	  
J	  Ophthalmol.	  2013;20:111-­‐125.	  	  
6. Kyari	  F,	  Entekume	  G,	  Rabiu	  M	  et	  al.	  A	  Population-­‐based	  survey	  of	  the	  
prevalence	  and	  types	  of	  glaucoma	  in	  Nigeria:	  results	  from	  the	  Nigeria	  
National	  Blindness	  and	  Visual	  Impairment	  Survey.	  BMC	  Ophthalmol.	  
2015;15:176.	  
7. Kyari	  F,	  Abdull	  MM,	  Wormald	  R	  et	  al.	  Risk	  factors	  for	  open-­‐angle	  
glaucoma	  in	  Nigeria:	  results	  from	  the	  Nigeria	  National	  Blindness	  and	  
Visual	  Impairment	  Survey.	  BMC	  Ophthalmol.	  2016;16:78.	  
8. Kyari	  F,	  Wormald	  R,	  Murthy	  GVS	  et	  al.	  Ethnicity	  and	  deprivation	  are	  
associated	  with	  blindness	  among	  adults	  with	  primary	  glaucoma	  in	  Nigeria.	  
Fatima Kyari PhD Thesis Page 239
	   13	  
Results	  from	  the	  Nigeria	  National	  Blindness	  and	  Visual	  Impairment	  
Survey.	  J	  Glaucoma.	  2016;25(10):e861-­‐e872.	  
9. Kyari	  F,	  Nolan	  W,	  Gilbert	  CE.	  Ophthalmologists'	  practice	  pattern	  and	  
challenges	  in	  achieving	  optimal	  management	  for	  glaucoma	  in	  Nigeria:	  
Results	  from	  a	  nationwide	  survey.	  BMJ	  Open.	  2016;6(10);e012230.	  
10. Kyari	  F,	  Chandler	  CI,	  Martin	  M	  et	  al.	  So	  let	  me	  find	  my	  way,	  whatever	  it	  
will	  cost	  me,	  rather	  than	  leaving	  myself	  in	  darkness:	  experiences	  of	  
glaucoma	  in	  Nigeria.	  Glob	  Health	  Action.	  2016;9:31886.	  
11. WGA	  African	  Glaucoma	  Summit.	  Accra,	  Ghana.	  2010.	  Available	  at	  
http://www.worldglaucoma.org/AfricaSummit/.	  Last	  accessed	  29	  July	  
2016.	  
12. Africa	  Glaucoma	  Control	  Meeting.	  Kampala,	  Uganda.	  Kampala	  Resolution.	  
2012.	  Available	  at	  
http://www.pbunion.org/files/Full%20Workshop%20report%202%20Mayf
inal2docx.pdf.	  Last	  accessed	  29	  July	  2016.	  
13. World	  Health	  Organization.	  Strategies	  for	  prevention	  of	  blindness	  from	  
primary	  glaucomas:	  outcome	  of	  a	  WHO	  informal	  consultation	  in	  WHO	  
Headquarters,	  Geneva,	  Switzerland,	  12-­‐14	  APRIL	  2009.	  Geneva:	  World	  
Health	  Organization.	  2009.	  
14. Thomas	  R.	  Glaucoma	  in	  developing	  countries.	  Indian	  J	  Ophthalmol.	  
2012;60:446-­‐50.	  
15. Kyari	  F,	  Gudlavalleti	  MV,	  Sivsubramaniam	  S	  et	  al.	  Prevalence	  of	  blindness	  
and	  visual	  impairment	  in	  Nigeria:	  the	  National	  Blindness	  and	  Visual	  
Impairment	  Study.	  Invest	  Ophthalmol	  Vis	  Sci.	  2009;50:2033-­‐9.	  
16. Abdull	  MM,	  Sivasubramaniam	  S,	  Murthy	  GV	  et	  al.	  Causes	  of	  blindness	  and	  
visual	  impairment	  in	  Nigeria:	  the	  Nigeria	  national	  blindness	  and	  visual	  
impairment	  survey.	  Invest	  Ophthalmol	  Vis	  Sci.	  2009;50:4114-­‐20.	  
17. Abdull	  MM,	  Gilbert	  CC,	  Evans	  J.	  Primary	  open	  angle	  glaucoma	  in	  northern	  
Nigeria:	  stage	  at	  presentation	  and	  acceptance	  of	  treatment.	  BMC	  
Ophthalmol.	  2015;15:111.	  
18. Anonymous.	  Glaucoma	  care	  in	  a	  tertiary	  facility	  in	  Benin	  City,	  Nigeria;	  
predictors	  of	  poor	  follow	  up	  and	  barriers	  to	  compliance	  with	  treatment.	  
Fatima Kyari PhD Thesis Page 240
	   14	  
Uncorrected	  MSc	  Project	  Report	  LSHTM	  2013-­‐2014.	  2014.	  Available	  at	  
https://intra.lshtm.ac.uk/library/MSc_CEH/2013-­‐2014/107717.pdf.	  Last	  
accessed	  24	  August	  2016.	  
19. Palmer	  JJ,	  Chinanayi	  F,	  Gilbert	  A	  et	  al.	  Trends	  and	  implications	  for	  
achieving	  VISION	  2020	  human	  resources	  for	  eye	  health	  targets	  in	  16	  
countries	  of	  sub-­‐Saharan	  Africa	  by	  the	  year	  2020.	  Hum	  Resource	  Health.	  
2014;12:45.	  
20. Palmer	  JJ,	  Chinanayi	  F,	  Gilbert	  A	  et	  al.	  Mapping	  human	  resources	  for	  eye	  
health	  in	  21	  countries	  of	  sub-­‐Saharan	  Africa:	  current	  progress	  towards	  
VISION	  2020.	  Hum	  Resour	  Health.	  2014;12:44.	  
21. Garway-­‐Heath	  DF,	  Crabb	  DP,	  Bunce	  C	  et	  al.	  Latanoprost	  for	  open-­‐angle	  
glaucoma	  (UKGTS):	  a	  randomised,	  multicentre,	  placebo-­‐controlled	  trial.	  
Lancet.	  2015;385:1295-­‐304.	  
22. Cook	  C.	  Glaucoma	  in	  Africa:	  size	  of	  the	  problem	  and	  possible	  solutions.	  J	  
Glaucoma.	  2009;18:124-­‐8.	  
23. Holtzer-­‐Goor	  KM,	  Plochg	  T,	  Lemij	  HG	  et	  al.	  Why	  a	  successful	  task	  
substitution	  in	  glaucoma	  care	  could	  not	  be	  transferred	  from	  a	  hospital	  
setting	  to	  a	  primary	  care	  setting:	  a	  qualitative	  study.	  Implement	  Sci.	  
2013;8:14.	  	  
24. Skorkovska	  K,	  Wilhelm	  H,	  Ludtke	  H	  et	  al.	  [Relative	  afferent	  pupillary	  
defect	  in	  glaucoma].	  Klin	  Monbl	  Augenheilkd.	  2011:228(11);979-­‐83.	  
25. Charalel	  RA,	  Lin	  HS,	  	  Singh	  K.	  Glaucoma	  screening	  using	  relative	  afferent	  
pupillary	  defect.	  J	  Glaucoma.	  2014:23(3);169-­‐73.	  
26. Olawoye	  O,	  Fawole	  OI,	  Teng	  CC	  et	  al.	  Evaluation	  of	  community	  eye	  
outreach	  programs	  for	  early	  glaucoma	  detection	  in	  Nigeria.	  Clin	  
Ophthalmol.	  2013;7:1753-­‐9.	  
	  
	  
Fatima Kyari PhD Thesis Page 241
	   15	  
	  
	  FIGURES	  
	  
Figure	  1.	  Conceptual	  framework	  for	  improving	  services	  for	  glaucoma	  in	  Nigeria	  
	  
Figure	  2.	  Algorithm	  for	  glaucoma	  case-­‐detection	  at	  community	  and	  clinic	  levels	  
by	  assessment	  of	  cup:disc	  ratio	  and	  relative	  afferent	  pupillary	  defect	  	  
	  	  	  	  
Fatima Kyari PhD Thesis Page 242
Figure'1.'Conceptual+framework+for+improving+services+for+glaucoma+in+Nigeria!
!
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Figure 2. Algorithm for glaucoma case-detection at community and clinic levels by assessment of cup:disc ratio and relative afferent pupillary defect
In the community
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Refer for assessment and diagnosis
Glaucoma
Community-based 
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CDR - cup:disc ratio; VA - visual acuity; IOP - intraocular pressure; RAPD - relative afferent pupillary defect; FDRs - first degree relatives; CVF - central visual fields.
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Chapter(15!
Implications,for,research!
!
!
Diode&laser&micropulse&trabeculoplasty!
!
!
!
Implications,for,research!and$future$work$drawn!from%all%the%
contributing*work!
!
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! !!
Implications,for,research!
!
Glaucoma(is"a"major"public"health"problem"and"a"leading"blinding&eye&disease&in&
Africa;"and"up"to"!"%!remains!undiagnosed.!!The$aim$of$this$work$was$to!
determine(ways(in(which(to(improve(service(delivery(for(glaucoma(care(in(Nigeria(
in#order#to#control#glaucoma#blindness.#The#study#demonstrated"a"high"
prevalence)of)glaucoma,)a"high"proportion"of"glaucoma"blindness!and$many$
challenges)for)glaucoma)care)in)Nigeria.)The)findings!imply!the$need$for$public$
health&control&strategies&with&high&quality&integrated&glaucoma&care&services&to&
improve(quality(of(life,(and(reduce(morbidity(and!blindness.!!
!
Define&treatment&modality!
There%is%a%need%to%provide%evidence"based&optimal&clinical&care;!and$our$top$
priority'for'research'is'to'define'appropriate'choice!of#a"one"off#treatment#
modality)that)is!effective,(acceptable,(affordable(and(sustainable.(This#can$be$
determined(by(multi"centre&randomised#controlled#trials#(RCTs)#comparing#
treatment'outcomes!and$economic$advantages!of#intraocular#pressure#(IOP)#
lowering)therapies."For"example,"a"study"of"topical!medication*versus*selective*
laser&trabeculoplasty&(SLT)&or&diode&laser&micropulse+trabeculoplasty-(DLT),"
trabeculectomy,with,antimetabolites,versus#laser#therapy,#transcleral)diode%laser%
cyclophotocoagulation-versus-trabeculectomy,-etc.-There-are-currently-no-such-
RCTs%being%undertaken%in%Nigeria.%Initial&results&of&transcleral)diode)laser)
cyclophotocoagulation-in-refractory!glaucoma(showed&unsustained&lowering&of&
IOP.!!However,(more$recently,$the$results'of'a"prospective*monitoring*of#
transcleral)diode%laser%cyclophotocoagulation-in#seeing#glaucoma#eyes#are#being#
analysed!and$the$therapy$seems$promising.!!If#the#results#are#acceptable,#then#
ways%to"make"the"treatment"scalable"will"be"the"next"step."Although"the"diode"
laser&machine&has&an&initial&high&capital&outlay,&it&is&versatile&and&can&be&used&for&
many%other%treatments%and%it%can%be%used%repeatedly%for%a%long%time.%Prospective+
monitoring(of(outcomes&of&trabeculectomy&with&2"flourouracil)has)shown)
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! !!
significant)benefits)in)lowering)IOP)beyond)three)months!!and$complete(success(
with%IOP<*+mmHg!at#one#year.!!However,(there(have(been(no(studies(comparing(
different(surgical(methods(or(adjunctive(therapy.!
Acceptance(of(surgical(treatment'and$continuation$of$medical$treatment$is$
usually&low.&Motivational&interviewing&for&glaucoma&(MIG)&was&designed&to&
strengthen(patients’(personal(motivation(and(their(exploration(of(reasons(for(
change'in!an#atmosphere#of#understanding,#acceptance'and'compassion.!!An#RCT#
for$MIG!compared)with)standard)care)and)regular)glaucoma)information)to)
patients(is(being(undertaken(to(assess(whether(MIG(will(increase(the(uptake(of(
treatment.!!This%approach%is%potentially"scalable!and$may$be$included$in!
improved!glaucoma(care(guidelines)to#enhance!treatment'acceptability.!
!
Clinical'guidelines)and)protocols)of#management!
Clinical'care'may'also'be'improved'if'we'develop'an'algorithm'for'choice'of'
therapy(and(continued(management(using"weighted(scores(for(patient,(facility(
and$community)characteristics;"taking"into"account"local"realities"and"informed"
patients’)preferences."For"example,"a"young"patient"with"moderate"glaucoma"may"
be#advised#to#have#trabeculectomy#with#adjunctive+antimetabolite;+or#an#elderly#
man$with$access$to$a$glaucoma$clinic$may$be$treated!with!topical(latanoprost.(
With%appropriate%choice%of%therapy,%clinical%guidelines%and%protocols%of%
management'can'then'be'defined'and'care'teams'developed'to'provide'optimal'
glaucoma(management.(These%steps%may%be%undertaken%by#the#Nigerian!
Glaucoma'Society!within&the&context&of&operational&research&and&involving&
monitoring(of(outcomes(tools.!Additionally,+another(implication(is(an#evaluation#
research'to'assess'whether!use$of!clinical&guidelines)and)protocols)improve)
practice(patterns.!
!
!
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! !!
Determine(approaches(to(earlier(detection(of(cases!
The$second$priority$for$research$is$to$determine$approaches$to$earlier$detection$
of#glaucoma#cases.#This"will"involve"case"detection(of!patients#in#healthcare#
facilities)and)approaches)to!case"finding&in&the&community&with&a&clear&care&
pathway.!
The$envisaged$outcome$of$these$research'priorities(is(institutional)strengthening)
for$high$quality$optimal$glaucoma$service$in$the$hospitals!with%&"way$
referral/feedback+systems.!!
!
In#this#regard,#we#are#in#the#process#of#developing#online#forums!for$discussion$
on#“tertiary'institutional'strengthening$for$high$quality$optimal(glaucoma(care(in(
Africa”(and$on$“glaucoma$treatment”$on#the#platform#of#the#World!Glaucoma(
Association(Africa'project,"which"I"will"lead."This%strategy!is#the#first#step#in#our#
glaucoma(care(development(ladder.!I"am"part"of"the"team"that"developed"the"
International*Agency*for*the*Prevention*of*Blindness*(IAPB)*essential*list*of*
equipment#for#glaucoma,#which#will#be#launched#at#the#IAPB#89th!general'
assembly((*+GA)(in(October(6+*7.(I"am"also"a"convener"of!a"glaucoma"course"at"
the!!"GA."This%course%will%describe%the%challenges%and%solutions%of%glaucoma%care%
in#Africa.#Challenges#from#the#patients’)perspectives)as)well)as)from)the)service)
provider(perspectives(will(be(discussed.(On"going%glaucoma%sub"specialty*
training'initiatives'and'intervention'trials'will'be'presented,'with'opportunities'
for$discussion.$The$development$of$a$model$of$high"quality(glaucoma(service(in(
sub"!Saharan&Africa&will&be&described.&This&includes&programme!planning'and'
implementation,+clinical+care+and+public+health+interventions+for+the+control+of+
glaucoma(blindness.(Recommendations(at(the(last(‘Glaucoma(in(Africa’(meeting'
in#Kampala!!will$be$discussed$with$a$focus$on$targets$achieved$and$determining$
next%priorities!and$strategies.!!
!
! !
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Nigeria National Blindness and Low Vision Survey 
Demographic Information 
Subject Serial Number Household Serial Number Personal Identification Number (PIN)        Study Code 
Day     Month    Geo-political Zone  State LGA  Village / Town  Street Block Rural / Urban 
1=Single   3=Widowed 1=Female    1=Yes, 2=No 
Name  __________________________ Marital status  2=Married  4=Separated/Divorced Sex 2=Male Age (years) Special Case (1:7 =40)  Ethnic group ________________        
1 = Your own land or your family’s land 1 = Islam
What kind of work, if any, do you mainly do? 1) __________________________________ If you work in agriculture,  2 = Rented land What is your religion? 2 = Christianity 
do you work on: 3 = Someone else’s land 9=No agriculture work 3 = Other ________________________
2) _________________________________
   1=Yes  1=Primary (1-6)          4=University/Polytechnic  1=Easily  
Have you ever attended school? 2=No Highest level of school attended? 2= Jr Secondary (7-8)  5= Koranic school  Highest class / grade completed at that level?           Are you able to read or write? 2=With difficulty    
3= Sr Secondary (9-11)  3=Not at all 
1 =House ta p   3 = House well
Age at start of school 99= Never went to school Age at leaving school Main language _________ Other languages __________   __________  Water  2 = Street tap 4 = Village Well
5 = Surface wate r (stream, lake ) 
1 = Flush toilet
Latrine 2 = Pit latrine BP: Systolic / Diastolic 888=Refused, 999=Machine failed/Not available / Height . Wt(Kg) . 
3 = Bush (BP to be taken in adults only) 
Presenting Visual Acuity (D = distance glasses) 
Has no D-Glasses         Arrives with D-Glasses          Forgot D-Glasses          Given Glasses 
But not using 
At what age did you start wearing glasses? (99 = Never has worn glasses)  
Wears glasses for reading?  1 = Yes  2=No
Vision WITHOUT glasses              R       L 
Number letters seen at 4m:
Misses at least 1 E on top line at 4m, move to 1m. 
Number letters seen at 1m: 
Cannot see at 1m (Note: To be completed by Ophthalmologist) 
(Please tick correct box )  R L 
Counting fingers (at 1m): 
Hand movements: 
Perception of light:  
No perception light (test in dark): 
If RED CARD, test both eyes without wearing glasses at 4m and / or 1m, as 
needed. Remember to change the version of the ‘E’ chart.     
4m 
1m  
If wearing habitual distance spectacles, repeat VA WEARING GLASSES: 
R L  BE 
Number letters seen at 4m: 
Misses at least 1 E on top line at 4m, move to 1m. 
R L  BE 
Number letters seen at 1m: 
__________________________________________________________________ 
GREEN CARD / RED CARD 
Green / Red card G = Green, R = Red  YELLOW 
Interviewer will mark specials (1:7 = 40 years) with YELLOW tag
Note: Red card for those 24 letters or less in one or both eyes
Cannot be tested 
R                L 
1= Believed blind 
2= Believed not blind 
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Refraction (staple printout on sheet) 
Right Eye: 
Average Refractive Error and Keratometry:   
mm 
Sphere ±    .  R1 .  . 
Cylinder ±  . . R2 . 
Axis
Deg  R1 
Auto / Manual 
R2 
1=A 2=M 9=Subject did not understand Av K (mm) . 
(Record as 999 if no result)  
_________________________________________________________________________________ 
Left Eye: 
Average Refractive Error & Keratometry: mm 
Sphere ±  . R1  . 
Cylinder ±  . R2 . 
Axis
Deg  R1 
Auto / Manual 
R2 
1=A 2=M 9=Subject did not understand Av K (mm) . 
(Record as 999 if no result)  
For Red Cards 
If no automated refraction result obtainable and subject is a Red 
Card: do objective refraction and write result above.
R        L 
Was manual refraction impossible? 1 = Yes,  2 = No 
Best Corrected Visual Acuity (Wearing the refraction result) 
For Red Card & Special ONLY         R             L  BE 
Number letters seen at 4m: 
If misses at least 1 E on top line at 4m, move 1m: 
Number letters seen at 1m: 
Visual field analysis  1= Yes 2= No   R         L 
Screening test for all =40 years only 
Threshold test, if clinically indicated 
Ultrasound  only if = 40 years
Right Eye:        1 = Successful, 2 = Not possible, 3 = Not understand 
Axial Length: .  
ACD: .   
Lens: .   (Record as 999 if no result)
Left Eye:           1 = Successful, 2 = Not possible 3 = Not understand
Axial Length: . 
ACD: .  
Lens: . . (Record as 999 if no result)
EXAMINERS INTIALS 
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Previous Eye History and Examination for ALL subjects 
History of   1) diabetes 2) hypertension 1 = Yes   2= No
3) glaucoma 4) trachoma
Clinical evidence of trachoma                                    R              L 
       TT      1 =  Yes 2 = No 9 = no view 
       CO     1 =  Yes 2 = No 9 = no view  
       None – now do not need this 
Comment _____________________________________________ 
History of onchocerciasis  1 = Yes   2 = No
Evidence of Onchocerciasis (Photo clue test)   1 = Yes  2 = No
Ivermectin in last 12 months?    
1 = Yes   2 = No 3= Does not apply - non-oncho area
History of eye injury 1 = Yes 2 = No
Cataract Grade  (Mehra - Minassian): R  L 
(0, 1, 2A, 2B, 3, 4, 5)  
Evidence of surgery: 
Eyelid: 1A = Yes (Trachoma) 1B = Yes (Other)  2 = No
Cataract: 1 = Yes  2 = No
Other surgery:   1 = Yes 2 = No
Give details if ‘Other surgery’ : _______________________________________________________
Cataract surgery only R L 
Time (in months) since cataract surgery / couching: 
Location:
1 = Hospital  2 = Eye Camp   3 = Home   4 = Other
Actual name of the place of operation (city/town / village) and location, e.g. Kaduna NEC 
R_______________________________________________________________________________ 
L _______________________________________________________________________________
Technique: 1 = ICCE, 2 = ECCE, 3 = Couching, 4 = Phaco
IOL position : 1 = A/C IOL, 2 =P/C IOL, 3 = None 
Using aphakic spectacles: 1 = Yes  2 = No
Pterygium R L 
1A = Yes (visual axis)  1B = Yes (off axis) 2 = No
Other Conjunctival disease 1 = Yes, 2 = No 
Details: __________________________________________ 
Other Corneal disease/scar 1 = Yes, 2 = No 
Details: __________________________________________ 
Anterior chamber / Iris disease 
1 = Yes, 2 = No, 3 = No view  
(Note: Specify if onchocerciasis is queried.)  
Details: __________________________________________ 
Green Cards Only: Eye Examination 
Un-dilated Optic Disc Cup / Disc Ratio (CDR): 
R L 
CDR 99 cannot assess . .  
CDR asymmetry = 0.2        1 = Yes    2 =No  9 = Cannot assess 
Optic disc haemorrhage?   1 = Yes   2 = No 9 = Cannot assess 
(Undilated, direct ophthalmoscopy) 
R  L 
Vascular Retinopathy:          1 = Yes 2 = No 9 = Cannot assess
Retinitis Pigmentosa:  1 = Yes 2 = No 9 = Cannot assess
ARMD: 1 = Yes   2 = No  9 = Cannot assess
Other disease:                       1 = Yes    2 = No   9 = Cannot assess
(Details)_______________________________________________ 
Comment: _____________________________________________ 
Red cards :  
Green cards with abnormal disc findings:  
Yellows (Specials) for normative database 
CONTINUE WITH FULL EXAMINATION. 
EXAMINERS INTIALS 
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FULL EXAMINATION 
Reason for full examination: (tick correct box/es) 
1 = Red card 
2 = Special (1:7=40 years) 
3 = Green card with detected abnormality 
4 = Persons with known visual / eye problems  
(Extensive examination as clinically indicated)                    R L 
Iris Colour 1=Brown, 2=Hazel, 2=Blue, 3=Green, 9 = Not seen 
Van Herick’s Grade  0 - 4, 9 = Not possible  
Applanation IOP 99 = Not possible
Gonioscopy 1 = Open, 2 = Closed, 9 = Not possible
(Indications for gonioscopy: IOP = 20 mmHg; CDR > 0.6; 
CDR difference > 0.2; Van Herick’s grades 0, 1, 2) 
RAPD 1 = Yes, 2 = No, 9 = Not possible
* DILATE*
WHO grading:    R L                 
    Nuclear (0-3) or  7 = Aphakia;   8 = IOL; 9 = Cannot grade  
Cortical (0-3 +/ - CEN) or 7 = Aphakia;  8 = IOL; 9 = Cannot grade 
    PSCLO (0-3) or  7 = Aphakia;   8 = IOL; 9 = Cannot grade 
   Hypermature 1 = Yes, 2 = No;  7 = Aphakia;  8 = IOL; 9 = Cannot grade
Posterior capsular opacification (PCO) with IOL(s) 
1 = Yes PCO,  2 = Clear capsule ,  3 = Not sure ,  9 = Not applicable  
Disc Pathology 1 = Yes,  2 = No,  9 = No view   
Excluding myopia, large CDR, PPA.  
Details:____________________________________________________ 
R  L 
Quality of view: 1= Good 2 = Poor 3 =  None 
CDR .      .
CDR asymmetry (RCDR - LCDR)   
Abnormal is >0.2      1 = Abnormal, 2 = Not
 Notch  1 = Yes, 2 = No      
 Disc Haemorrhage  1 = Yes, 2 = No
Diabetic retinopathy 1 = Yes 2 = No 9 = Not seen  R L 
Non-proliferative  
Proliferative and end-stage    
Maculopathy   
Take blood glucose: if:      
Query Diabetic retinopathy (if subject reports no History) 
1 = Yes, 2 = No
Special (1:7 =40 years)
Blood glucose (mmol/L) . 
Age-Related Macular Disease  1 = Yes  2 = No   9 = Not seen   
ARM (drusen, hypo / hyper - pig. of RPE)   
ARMD a) dry / geographic atrophy    
b) wet / neovascular / disciform scar
Other Vitreous / Retinal Pathology  
1 = Yes, 2 = No 9 = No view  
Excluding diabetic retinopathy, Age-related macular degeneration  
Details: 
Digital Photos taken 1 = Yes, 2 = No
 (Red and Yellow cards) 
Comments: ___________________________________________________ 
EXAMINERS INTIALS 
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MACHINE FAILURE 
1 = Autorefractometer, 2 = Slitlamp, 3 = VF, 4= Camera 5= U/S 
SUBJECT FAILURE 
Subject refused 1=All tests 2=Dilation 3=Equipment  
___________________________________________________________________
All Disorders that reduce vision in each eye 
(Completed for all eyes ≤24 letters before refraction) 
Disorders                                                   R               L  
Phthisical, disorganised or absent globe 
Refractive error 
Cataract 
Post Capsule opacification 
Uncorrected aphakia 
Corneal opacity* (Explain) 
Anterior uveitis 
Glaucoma* (Explain) 
Optic atrophy  
Diabetic retinopathy  
Other vascular retinopathy* (Explain) 
Chorioretinitis 
Macular degeneration 
Amblyopia (Refer to definition) 
Other / un-explained cause _____________________________ 
* Details___________________________________________
Underlying causes
Unknown
Trauma 
Congenital / Neonatal factor 
Measles/vitamin A deficiency/TEM  
Surgical procedure 
Onchocerciasis 
Trachoma  
Other, specify______________________ 
Principle cause of low vision 
or blindness in each eye  
Mark only 1 cause per < 6/12 
eye(s) (VA: =24 letters)
R L           
Principle cause of 
low vision or 
blindness in this 
subject (see note*) 
Full diagnosis: 
R eye: ____________________________________________________ 
L eye: ____________________________________________________ 
Current Action needed R eye         L eye      
• No current action needed
Action needed (tick all of which apply) 
• Eyelid surgery
• Cataract surgery
• Glaucoma treatment
• Spectacles
• Medication
• Other Action Right Eye _______________________________
• Other Action Left Eye_ _______________________________
Barriers to Up-take of Eye Care Services 
(Indications: VA < 6/60; M-M cataract grades 2B or 3; TT grading) 
Please rank numerically the first three responses given by the subject. 
Cannot afford 
No one to accompany 
No time 
Did not know about his / her eye disease 
Fear of treatment / surgery 
Waiting for cataract to mature 
Need not felt 
Does not know where to go for treatment 
Other _______________________________________________________ 
Candidate for Vision Function / Quality of Life questionnaire  
(Indications: VA < 6/60 (<2 Letters); M-M cataract grades 2B or 3; 1 
in  every 20 Green cards) 
TO THE INTERVIEWER ? ?  
* Note: In cases of 'Cataract + Refractive Error', if the Best Corrected Visual Acuity is 6/18 or better (>18 letters), mark 'Refractive Error' as the cause. If not, mark 'Cataract'.
EXAMINERS INTIALS 
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1Physicians'*Prac,ce*Pa.ern*for*Glaucoma*in*Nigeria
Serial(Number Zone State PIN
Study(code((zone/state/PIN(x/xx/xxx)
(Put*an*"x"*for*the*appropriate*response*boxes*and*numbers*where*applicable)(e.g. x 1 9
1 Personal/Demographic*details (Please(provide(all(details)
First(Name Surname
Sex Female( Age((years)
Male
Address Hospital
Town
State
2 Professional*Background
Ophthalmology(qualiﬁcaKon Fellowship Number(of(years(since(ophthalmology(qualiﬁcaKon
Diplomate
Other((specify)
Are(you(a(pracKsing(ophthalmologist? Yes How(many(years(have(you(been(pracKsing(for?
No
Have(you(had(clinical(subspecialty(training? Yes If(yes,(which(subspecialty?
No
Number(of(years(since(subspecialty(qualiﬁcaKon
Have(you(been(pracKsing(as(a(subspecialist? Yes Yes
No No
Yes
No
If(yes,
AQendance(at(courses Yes .RRR> Number(of(courses(aQended(in(the(last(3(years
No
AQendance(at(conferences Yes .RRR> Number(of(conferences(aQended(in(the(last(3(years
No
Use(of(online(CPD(resources Yes .RRR> If(yes,(name(2(top(websites/programmes(you(use
No 1 2
Use(of(journal(CPD(resources Yes .RRR> If(yes,(name(3(journals(that(you(regularly(read
No 1 2 3
3 Place*of*prac,ce
Type*of*facility (mark("x"(in(ALL(that(apply) General(hospital 1
Government 1 General(specialist(hospital 2
Private 2 Specialist(eye(hospital 3
NGO/Missionary 3 University(teaching(hospital 4
Military 4 Specialist(eye(teaching(hospital 5
Other((specify) 6
Do(you(parKcipate(in(conKnuous(professional(development((CPD)/(conKnuous(medical(educaKon((CME)?
FOR*OFFICIAL*USE*ONLY
Do(you(restrict(your(pracKce(to(your(
subspecialty?
3.1
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2Do(you(have(subspecialty*clinics(in(your(hospital? .RRRR> If(yes,(which(subspeciality(clincis(are(taking(place?
Yes Glaucoma 1
No PlasKc(and(reconstrucKve(surgery 2
Cornea(and(anterior(segment 3
VitreoRreKna 4
Paediatric( 5
NeuroRophthalmology 6
Other((specify) 7
Yes .TTTTT> If(yes,(Kck(the(services(available(in(your(hospital
No PaKent(counselling 1
Mobility(training 2
EducaKonal(placement 3
VocaKonal(placement 4
Other((specify) 5
CareTpathway*(Mark("x"(to(all(that(apply)
How(do(paKents(access(the(services(in(your(hospital? How(do(paKents(speciﬁcally(get(to(you(as(a(Consultant?
WalkRin 1 First(screened(and(selected(by(nurses 1
Referral(from(other(hospitals 2 Screened(and(selected(by(optometrists 2
Referral(from(community(screening 3 Seen(and(selected(by(residents 3
Emergency 4 Seen(directly(by(you 4
Other((specify) 5 Other((specify) 5
Is(there(a(wriQen/outlined(protocol(for(management(of(glaucoma(paKents(in(your(hospital? Yes
No
Equipment
What(equipment(is(available(for(your(use(for(glaucoma(diagnosis(and(treatment?((mark("x"(to(ALL(that(apply)
Available(in(the(hospital FuncKoning YOU(use(regularly
Ophthalmoscope
ApplanaKon(tonometer
Schiotz(tonometer
Other(tonometer((specify)
Gonioscope
SlitRlamp(with(60(R(90D(lens
Binocular(indirect(ophthalmoscope
Visual(ﬁeld(analyzer((specify(type)
Fundus(camera
Ultrasound(scan
OpKcal(coherent(tomogram((OCT)
Scanning(laser(ophthalmoscope((SLO)
Laser(machine(for(glaucoma(treatment
Other((specify)
4 Care*for*glaucoma
Diagnosis On(average,(how(many(NEW(glaucoma(paKents(do(you(see(in(3(months?
Do(you(have(visual(rehabilitaKon(services(
in(your(hospital?
Do(you(have(disease(counselling(services(
in(your(hospital?
Yes
No
3.2
3.3
4.1
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3What(is(the(SINGLE(most(important(feature(that(prompts(you(to(workRup(for(glaucoma(diagnosis?((mark("x"(in(ONE(only)
History AC(angle(morphology((gonio)
Visual(Acuity Corneal(thickness
Visual(ﬁeld Colour(vision(defect
IntraRocular(pressure Night(vision(defect
Disc(morphology Other((specify)
Which(of(the(following(tests/examinaKon(do(you(ACTUALLY(do(on(ALL(your(paKents(with(glaucoma?
Cup:Disc(RaKo(assessment Yes Visual(ﬁeld(examinaKon Yes
No No
Gonioscopy IOP(measurement Yes
No
OpKc(nerve(head(imaging Pachymetry Yes
No
When(examining(the(disc(to(make(a(glaucoma(diagnosis,(if(viewable,(which(of(the(following(do(you(ACTUALLY(use?
Direct(fundoscopy BIO(with(condensing(lens
StereoRfundoscopy(with(+60/78/90D Fundus(camera(images Yes
StereoRfundoscopy(with(contact(lens OCT Yes
Treatment
(mark(x(in(ONE(only)
Medical((specify) 1
Surgical((specify) 2
Laser((specify) 3
ObservaKon(and(followRup 4
Other((specify) 5
What(parameters(do(you(use(to(make(a(choice(of(treatment? For(the(last(10(glaucoma(cases(you(have(seen:
(Mark("x"(in(all(that(apply)
Severity(of(disease 1 How(many(were(oﬀered(surgery?
Availability(of(treatment 2
PaKent(acceptance(of(treatment 3 How(many(accepted(surgery?
Cost(of(treatment 4
Other((specify) 5 How(many(actually(had(surgery?
Glaucoma*Surgery
What(type(of(glaucoma(surgery(do(you(most(frequently(perform?
4.2
Yes
No
No
Yes
No
Yes
No
Yes
Most(of(our(glaucoma(paKents(present(with(late(disease.(Assuming(all(necessary(equipment(and(treatment(opKons(are(
available(and(cost(not(a(barrier,(what(is(the(best(opKon(of(treatment(that(you(WILL(oﬀer(your(glaucoma(paKent?
4.3
No
Yes
No
No
No
On(average,(how(many(glaucoma(surgeries(
do(you(perform(in(3(months?
On(average,(how(many(cataract(surgeries(
do(you(perform(in(3(months?
Yes
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4Yes Which(anKmetabolites(do(you(use?
5(ﬂuoroRuracil((5RFU)
MitomycinRC((MMC)
Other((specify)
If(yes, for(how(many(paKents(out(of(10(would(you(use(anKRmetabolites?
Where(do(you(get(the(anKmetabolites(from? Do(you(have(any(diﬃculKes(in(obtaining(a(supply?
The(hospital's(pharmacy Yes
Outside(retail(pharmacy No
PaKents(buy If(yes,(what(are(the(diﬃculKes?
Doctor's(supply(by(private(arrangement
Nurses(supply(by(private(arrangement
Yes
1 No
2
3
5 FollowTup*arrangement
Yes
No
How(do(you(encourage/ensure(followRup?
You(give(an(appointment(date(and(hope(the(paKent(turns(up
No(eﬀorts(are(made(to(contact(those(who(have(missed(their(appointments
PaKent(communicaKon/reminders(are(sent by(email
by(phone
by(text
by(community/home(visit
Do(you(ask(for(the(glaucoma(paKent(to(bring(1st(degree(relaKves(for(examinaKon?(
All(the(Kme
Some(of(the(Kme
Occassionally
Never
6 Costs
(Naira)
(Naira)
Is(there(a(wriQen/outlined(followRup(
arrangement(for(glaucoma(paKents(in(your(
hospital?
What(medicaKons(for(glaucoma(are(
available(for(you(to(prescribe?(MenKon(all
Do(you(know(the(costs(of(the(diﬀerent(
treatment(opKons(available(for(glaucoma?
Yes
What(is(the(cost(of(glaucoma(surgery(in(
your(hospital,(including(standard(hospital(
stay(charges?
What(3(main(complicaKons(related(to(use(of(
anKmetabolites(have(you(encountered(in(the(last(10(
Do(you(have(an(audit(of(outcome(of(
surgery(for(the(last(10(to(50(glaucoma(
surgeries(you(have(performed?
What(is(the(average(cost(of(a(course(of(
medical(therapy(for(one(month?
No
No
Do(you(use(anKRmetabolites(for(glaucoma(
surgery?
Fatima Kyari PhD Thesis Page 263
57 Challenges*in*glaucoma*care
What(are(your(perceived(challenges(in(glaucoma(care?(((Mark("x"(to(ALL(that(apply)
Fear(of(making(a(wrong(diagnosis Uncertain(postRop(outcome
Fear(of(surgical(complicaKons PaKent(compliance(with(medical(treatment
Need(for(more(training(in(glaucoma(diagnosis PaKent(acceptance(of(surgical(treatment
Need(for(more(training(in(glaucoma(surgery Other((specify)
Diﬃculty(of(postRop(care
How(would(you(assess(the(training(you(received(in(glaucoma? Excellent 1
Good 2
Fair 3
Poor 4
Very(poor 5
Please(write(any(addiKonal(comments(in(the(box(below
Thank*you*very*much*for*taking*,me*out*to*ﬁll*out*this*ques,onnaire
All*respondents*will*be*entered*for*a*prizeTdraw Mark("x"(if(you(do(NOT(want(to(be(entered(for(the(draw
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Information*Sheet*–!Physicians)practice)pattern"
!
Greetings!
!
Principal)investigator)and)researchers"
!
I"am"Fatima"Kyari,"an"ophthalmologist"working"on"a"research"project"at"the"
London%School%of%Hygiene%and%Tropical%Medicine%(LSHTM),%under%the%
supervision*of*Professor*Clare*Gilbert.*Working*together*with*research*assistants*
and$fieldworkers,$we$are$looking$for$more$information$on$glaucoma.$!
!
The$research$is$funded$by$Fred$Hollows$Foundation,$an$independent,$non"profit,(
politically)unaligned)and)secular)NGO)involved)in)eye)care.!
!
!
Ethical(permission"
!
We#have#obtained#ethical#permission#to#conduct#this#study#from$the$LSHTM$and$
the$Federal$Ministry$of$Health.!
!
Background"
!
Accounting)for),-%)of)world)blindness)(excluding)refractive)errors),)glaucoma)is)
the$second$leading$cause$of$blindness$(Resnikoff,$5667).$It$is$projected$that$
glaucoma(will(affect(./(million(people%worldwide%by%,-.-,%of%which%34%million%
will$have$OAG,$with$the$highest$percentage$of$6.89%$of$6;$year"olds%and%older%in%
Africa'(Quigley'and'Broman,'5667).'The'Nigerian'national'survey'of'blindness'
and$low$vision$(NBS),$which$included$56,788$people$aged"#$"years"and"above"
showed'the'prevalence'of'blindness'to'be'3.5%.'Glaucoma'was'the'second'leading'
cause&(().+%)&with&over&(56,666&Nigerians&being&blind&from&glaucoma&(Kyari&et&
al,$%&&').!
!!
Interventions*to*prevent*blindness*from*glaucoma*aim*at*lowering*IOP$and$
include(surgical((mostly(trabeculectomy),(laser(and(medical(therapies.(While(
highlighting'acceptable'surgical'outcomes'for'trabeculectomy'in'Africa,'
difficulties*and*challenges*of*glaucoma*management*in*west*Africa*have*been*
documented)(Egbert,)011!).$The$cost$of$glaucoma$medication$and$the$economic$
burden'of'disease'in'the'United'States'have'been'demonstrated'using'the'life"
table&model&(Quigley,&1223).!
!
Study&objectives&and&relevance"
!
We#want#to#find#out#how#glaucoma#is#currently#being#managed#in#Nigeria;'in'
terms&of&service&delivery&to&patients;&what&glaucoma&treatment&is&available&and&
how$much$they$cost.$We$seek$your$cooperation$because$the$information$is$
relevant(for(hospitals(and(government(to(improve(the(quality(and(extent(of(
services'provided'in#order#to#prevent#the#glaucoma#patient#from#losing#vision.!
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!
Participation*"
!
You$are$asked$to$take$part$in$the$study$because$you$are$an$ophthalmologist$
providing)eye)care)services.)It)is)voluntary)for)you)to)participate.)If)you)agree)to)
participate,)we)will"ask"you"to"complete"a"questionnaire,"which"will"take"about"67"
minutes.)The)questions)are)about)your)pattern)of)practice)for)eye)care,)
infrastructure+and+equipment+available+to+you+for+glaucoma+care+and+information+
on#the#types#of#glaucoma#patients#you#see.#If#you#agree#to#participate#now,#you#
still%have%the%right%to%withdraw%at%anytime.!
!
Confidentiality,and,use,of,the,data"
!
The$information$obtained$will$not$be$linked$to$you$(anonymity)$and$all$data$will$
be#kept#secured#and#used#only#by#those#involved#in#the#study.#No#quotes#or#other#
results'arising'from'your'participation'in'this'study'will'be'included'in'any'
reports,(even(anonymously,)without)your)agreement.)The)analysed)results)will)be)
disseminated)to)World)Health)Organization,!government,*health*care*workers*
and$through$publications.!
!
Consent"
!
If#you#have#agreed#to#participate#please#complete#and#sign#the#questionnaire#
attached.&!
!
Thank&you&for&your&time&and&for&the&information.!
!
Further'information"
!
Should'you'have'any'questions'after'we'leave,'or'you'seek'further'information'or'
explanation,+please+contact+Fatima+Kyari+at+the+address+below.!
!
Dr#Fatima#Kyari!
International*Centre%for%Eye%Health!
London%School%of%Hygiene%and%Tropical%Medicine!
Keppel%Street!
WC#E%&HT!
!
Tel:%+''%()*%+,-%-...!
Tel:%+'()%*+(%,*-%-.-'!
Tel:%+''%()*(%*+(%+',!
!
Email:'Fatima.Kyari@lshtm.ac.uk!
! fatimaygk@gmail.com!
!
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Information*Sheet*–!Community!Perception!"!Interviews#
!
This%will%be%read%out%to%potential%participants."A"translated"version"in"the"local"
language'will'also%be#used.!
!
Greetings!
!
Principal)investigator)and)researchers#
!
I"am"Fatima"Kyari,"an"eye"doctor"and"I"am!working(on(a(research(project(with(
staff!at#the#London#School#of#Hygiene#and#Tropical#Medicine#(LSHTM),#under#
the$supervision$of$Professor$Clare$Gilbert."We#are#aware#that#eye#conditions#are#
quite&common&in&the&community&and&we&want&to&find&out&what&community(
members&know&about&conditions&of&the&eye&so&that&services&for&eye&conditions&can&
be#better#planned."!
!
The$research$is$funded$by$Fred$Hollows$Foundation,$an$independent,$non"profit,(
politically)unaligned)and)secular)NGO)involved)in)eye)care.!
!
Ethical#permission#
!
We!have%obtained%ethical%permission%to%conduct%this%study%from%the%LSHTM%and%
the$Federal$Ministry$of$Health.!
!
Background#
!
The$Nigerian$national$survey$on$blindness$and$low$vision$conducted$in$6778$to$
!""#$showed#that#some#eye#conditions#are#important)causes&of&poor&vision&in&our&
communities.!
!
Study&objective&and&relevance#
!
We#want#to#find%out!what%you%know,%think%and%do%about%some%eye%diseases."In#
particular)we)want)to)find)out)what)you)know)about)a)condition)called)glaucoma.)
We#want#to#find#out$if$you$know!what%treatment%is%possible,%and%how%much%
money&is#spent!on#treating#it.#We#seek#your#cooperation#because#the!information)
is#relevant#for!clinics,'hospitals)and)government)to)improve)the)quality)and)
extent%of%services%provided.!
!
Participation"#
!
You$are$asked$to$take$part$in$the$study$because$your%community%was%selected%for%
the$study!and$you$have$visual$impairment."It#is#voluntary#for#you#to#participate.#If#
you$agree$to$participate,$we$will$interview(you(for(-.(to(-/(minutes."The"interview(
will"be"in"a"private"room"and"it!will$be$recorded$and$transcribed$to$aid$our$
analysis.(Photographs(will(also(be(taken(which%may%be%used%for%publication%or%
electronically+in+a+manner+of+which+you+may+or+may+not+be+identified.+However,+
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you$may$decide$not$to$participate'in'the'interview!or#not#agree#to#be#recorded#or#
have%your%photo%taken.%And$if!you$agree$now,%you%still%have%the%right%to%withdraw%
at#anytime#during#the#interview.!
!
!
Confidentiality,and,use,of,the,data#
!
The$interview!will$not$affect$any$treatment$you$are$receiving$for$any$health$
condition'that'you'may'have.'But#if#we#feel#there#is#a#need#to#improve#the#
treatment'or'address'other'health'issues,'we'will'indicate'that."We"will"also"give"
you$a$referral$to$the$hospital$and$take$the$necessary$steps$to$make#sure#you#
receive&the&necessary&services.&!
!
The$information$obtained$will$not$be$linked$to$you$(anonymity)$and$all$data$will$
be#kept#secured#and#used#only#by#those#involved#in#the#study.#No#quotes#or#other#
results'arising'from'your'participation'in'this'study&will&be&included&in&any&
reports,(even(anonymously,(without(your(agreement.(The$analysed$results$will$be$
disseminated)to)World%Health%Organization,!government,*health*care*workers*
and$through$publications.!
!
Consent#
!
If#you#have#agreed#to#participate#please%read!(or#will#be#read)!and$sign!(or#thumb#
print)!the$consent$form$attached.$!
!
Thank&you&for&your&time&and&for&the&information.!
!
Further'information#
!
Should'you'have'any'questions'after'we'leave,'or'you'seek'further'information'or'
explanation,+please+contact&Fatima&Kyari&at&the&address&below.!
!
Dr#Fatima#Kyari!
International*Centre*for*Eye*Health!
London%School%of%Hygiene%and%Tropical%Medicine!
Keppel%Street!
WC#E%&HT!
!
Tel:%+''%()*%+,-%-.'!!
!
Email:'Fatima.Kyari@lshtm.ac.uk!
!
!
!
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Information*Sheet*–!Community!Perception!–!Observation,studies"
!
This%will%be%read%out%to%potential%participants."A"translated"version"in"the"local"
language'will'also%be#used.!
!
Greetings!
!
Principal)investigator)and)researchers"
!
I"am"Fatima"Kyari,"an"eye"doctor&and&I&am!working(on(a(research(project(with(
staff!at#the#London#School#of#Hygiene#and#Tropical#Medicine#(LSHTM),#under#
the$supervision$of$Professor$Clare$Gilbert."We#are#aware#that#eye#conditions#are#
quite&common&in&the&community&and&we&want&to&find!out$what$community$
members&know&about&conditions&of&the&eye&so&that&services&for&eye&conditions&can&
be#better#planned."!
!
The$research$is$funded$by$Fred$Hollows$Foundation,$an$independent,$non"profit,(
politically)unaligned)and)secular)NGO)involved)in)eye)care.!
!
Ethical(permission"
!
We!have%obtained%ethical%permission%to%conduct%this%study%from%the%LSHTM%and%
the$Federal$Ministry$of$Health.!
!
Background"
!
The$Nigerian$national$survey$on$blindness$and$low$vision$conducted$in$6778$to$
!""#$showed#that#some#eye#conditions&are&important)causes&of&poor&vision&in&our&
communities.!
!
Study&objective&and&relevance"
!
We#want#to#find%out!how$you$are$coping$with$your$eye$condition$and$how$it$
affects'your'day"to"day$living."We#also!want%to%find%out%what%you%know%about%a%
condition'called'glaucoma.'We'want'to'find'out'if'you'have!it;$if#you#know#what%
treatment'is!possible,)and)how)much)money)you)spend!on#treating#it.#We#seek#
your%cooperation%because%the!information)is)relevant)for!clinics,&hospitals)and)
government)to)improve)the)quality)and)extent)of)services)provided.!
!
Participation*"
!
You$are$asked$to$take$part$in$the$study$because$your%community%was%selected%for%
the$study$and$you$have$been$identified$to$have$poor$eye$sight."It#is#voluntary'for'
you$to$participate.$If$you$agree$to$participate,$we$will$spend&'&to&*&hours&with&you&
while&you&carry&out&your&normal&day"to"day$activities."We#will#also#interview#you.#
The$interview!will$be$recorded$and$transcribed$to$aid$our$analysis.$Photographs#
will$also$be$taken$which%may%be%used%for%publication%or%electronically%in%a%
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manner&of&which&you&may&or&may&not&be&identified.&However,&you&may&decide&not&
to#participate#in#the#interview(or#not#agree#to#be#recorded#or#have#your#photo#
taken!or#to#be#observed."And$if!you$agree$now,%you%still%have%the%right%to%
withdraw(at(anytime(during(the(interview/observation.!
!
Confidentiality,and,use,of,the,data"
!
The$discussions$will$not$affect$any$treatment$you$are$receiving$for$any$health$
condition'that'you'may'have.'But#if#we#feel#there#is#a#need#to#improve#the#
treatment'or'address'other'health'issues,'we'will'indicate'that'and$give$you$a$
referral&to&the&hospital&and$take$the$necessary$steps$to$make$sure$you$receive$the$
necessary(services.!
!
The$information$obtained$will"not"be"linked"to"you"(anonymity)"and"all"data"will"
be#kept#secured#and#used#only#by#those#involved#in#the#study."No#quotes#or#other#
results'arising'from'your!participation)in)this)study)will)be)included)in)any)
reports,(even(anonymously,(without(your(agreement.(The$analysed$results$will$be$
disseminated)to)World%Health%Organization,!government,*health*care*workers*
and$through$publications.!
!
Consent"
!
If#you#have#agreed&to&participate&please&read!(or#will#be#read)!and$sign!(or#thumb#
print)!the$consent$form$attached.$!
!
Thank&you&for&your&time&and&for&the&information.!
!
Further'information"
!
Should'you'have'any'questions'after'we'leave,'or'you'seek'further'information'or#
explanation,+please+contact+Fatima+Kyari+at+the+address+below.!
!
Dr#Fatima#Kyari!
International*Centre*for*Eye*Health!
London%School%of%Hygiene%and%Tropical%Medicine!
Keppel%Street!
WC#E%&HT!
!
Tel:%+''%()*%+,-%-...!
!
Email:'Fatima.Kyari@lshtm.ac.uk!
!
!
!
!
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Information*Sheet*–!Patient!Perception"
!
This%will%be%read%out%to%potential%participants.%A%translated%version%in%the%local%
language'will'also%be#used.!
!
Greetings!
!
Principal)investigator)and)researchers"
!
I"am"Fatima"Kyari,"an"eye"doctor!working(on(a(research(project(with(staff!at#the#
London%School%of%Hygiene%and%Tropical%Medicine%(LSHTM),%under%the%
supervision*of*Professor*Clare*Gilbert.*Working*together*with*research*assistants*
and$fieldworkers,$we$are$looking$for$more$information$on$eye"conditions"and"
what%you%may%know%about%them.!
!
The$research$is$funded$by$Fred$Hollows$Foundation,$an$independent,(non"profit,(
politically)unaligned)and)secular!NGO$involved$in$eye$care.!
!
Ethical(permission"
!
We!have%obtained%ethical%permission%to%conduct%this$study$from$the$LSHTM$and$
the$Federal$Ministry$of$Health.!
!
Background"
!
The$Nigerian$national$survey$on$blindness$and$low$vision$conducted$in$6778$to$
!""#$showed$that$some$eye$conditions$are$important$causes$of$poor$vision$in$our$
communities.!
!
Study&objectives!and$relevance"
!
We#want#to#find#out#what#you#know,#think#and#do#about#some#eye#diseases.#In#
particular)we)want)to)find)out)what)you)know)about)your%condition'called'
glaucoma.)We)want)to)find)what)you)know)about)treatment)of)the)condition)and)
how$much!money&you!spend!on#treating#it.#We#seek#your#cooperation#because#
the$information$is$relevant$for$clinics,$hospitals$and$government$to$improve$the$
quality(and(extent(of(services(provided.!
!
Participation*"
!
You$are$asked$to$take$part$in$the$study$because$you!are$a$glaucoma$patient$
receiving(treatment(in(the(hospital.(It#is#voluntary#for#you#to#participate.#If#you#
agree%to%participate,%we%will%be#interviewed#for#-.#to#-/#minutes."The"interview(
will$be$in$a$private$room$and$it#will$be$recorded$and$transcribed$to$aid$our$
analysis.(Photographs(will(also(be(taken(which%may%be%used%for%publication%or%
electronically+in+a+manner+of+which+you+may+or+may+not+be+identified.+However,+
you$may$decide$not$to$participate$in$the$interview(or#not#agree#to#be#recorded#or#
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have%your%photo%taken.%And$if!you$agree$now,%you%still%have%the%right%to%withdraw%
at#anytime#during!the$interview.!
!
Confidentiality,and,use,of,the,data"
!
The$interview(will$not$affect$your$current$treatment$in$the$hospital$but$if$we#feel#
there%is%a%need%to%improve%the%treatment%or%address%other%health%issues,%we%will%
indicate(that(to(your(attending(physician.!
!
The$information$obtained$will$not$be$linked$to$you$(anonymity)$and$all$data$will$
be#kept#secured#and#used#only#by#those#involved&in&the&study.&No#quotes#or#other#
results'arising'from'your!participation)in)this)study)will)be)included)in)any)
reports,(even(anonymously,(without(your(agreement.(The$analysed$results$will$be$
disseminated)to)World%Health%Organization,!government,*health#care#workers#
and$through$publications.!
!
Consent"
!
If#you#have#agreed#to#participate#please#read#(or#will#be#read)"and$sign!(or#thumb#
print)!the$consent$form$attached.$!
!
Thank&you&for&your&time&and&for&the&information.!
!
Further'information"
!
Should'you'have"any"questions"after"we"leave,"or"you"seek"further"information"or"
explanation,+please+contact+Fatima+Kyari+at+the+address+below.!
!
Dr#Fatima#Kyari!
International*Centre*for*Eye*Health!
London%School%of%Hygiene%and%Tropical%Medicine!
Keppel%Street!
WC#E%&HT!
!
Tel:#+%%#&'(#)*+#+!"!!
!
Email:'Fatima.Kyari@lshtm.ac.uk!
!
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Informed)Consent)Form!
!
Glaucoma(in(Nigeria:(!
A"study"about"glaucoma"treatment"and"service"delivery;"and"patients"and"
community)perception)of)the)condition!
!
Investigator’s-name-and-contact-details!
!
Dr#Fatima#Kyari!
International*Centre*for*Eye*Health!
London%School&of&Hygiene&and&Tropical&Medicine!
Keppel%Street!
WC!E"!HT!
!
Tel:%+""!!"#!!"#!!"""!
Email:'Fatima.Kyari@lshtm.ac.uk!
!
To#be#completed#by#participant!(Please'tick'as'appropriate)!
! ! Yes$ No$
1! I!have!read!the!information!sheet!concerning!this!study!(or!have!
understood!the!verbal!explanation),!and!I!understand!what!is!required!of!
me!and!what!will!happen!to!me!if!I!take!part!
! !
2! My!questions!concerning!this!study!have!been!answered!by!the!researchers! ! !
3! I!understand!that!at!anytime!I!may!decide!not!to!participate!without!giving!
any!reason.!
! !
4! I!agree!that!you!record!what!we!talk!about! ! !
5! *I!agree!that!you!take!photos!during!our!discussions!for!the!study! ! !
6! *I!agree!that!you!use!quotes!of!things!I!say!in!the!discussions!in!any!reports!
about!the!study!
! !
7! *I!agree!that!you!use!quotes!of!things!I!say!in!the!discussions!only!
anonymously,!in!any!reports!about!the!study.!
! !
8! I!agree!that!results!arising!from!my!participation!in!the!study!can!be!
included!in!any!reports!about!the!study!
! !
9! I!agree!that!any!discussions!and!results!arising!from!any!general!analyses!
(rather!than!individual!quotes)!that!deal!with!the!data!can!be!included!in!
any!reports!about!the!study!
! !
10! I!agree!to!take!part!in!the!study! ! !
*Participants+may+decide+not+agree+for+their+photos+to+be+taken+and+use+of+quotes.+!
All#other#fields#must#be#agreed#by#the#participant#in#order#to#take#part#in#the#study.!
!
Participant)(name)in)BLOCK)LETTERS)!!!!!_______________________________!
!
Signed'! _______________________________!
!
Date! ! ____________!
!
Witness'(name'in'BLOCK'LETTERS)!!!!!!!________________________________!
!
Signed! ________________________________!
!
Date%! ! _____________!
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Editorial Commentary
Department of Ophthalmology, University of Alberta, Canada
Corresponding Author: Dr. Karim F. Damji, Department of Ophthalmology, University of Alberta, Canada. E-mail: kdamji@ualberta.ca
Strengthening Institutional Capacity for Glaucoma 
Care in Sub-Saharan Africa
Karim F. Damji
‘An enabling environment’ -A setting in which additional developmentinitiatives can take root and thrive.
His Highness the Aga Khan, Maputo, Mozambique, December 
16, 2010.1
Sub-Saharan Africa (SSA) is advancing economically, and these 
are exciting times to invest in improvement of vision related 
quality of life for the people in this region.2 In SSA, a leading 
cause of blindness is glaucoma, a group of diseases that have 
in common a characteristic progressive optic neuropathy and 
visual field deterioration, which can generally be arrested 
or mitigated with lowering of intraocular pressure (IOP). 
Glaucoma is a disease with a significant public health burden 
that warrants a commensurate, targeted response. This is a 
conclusion emphasized at two major meetings on the subject 
in recent years: The Africa Glaucoma Summit in Accra, Ghana 
hosted by the World Glaucoma Association (August 2010)3 
and a Workshop on Public Health Control of Vision Loss from 
Glaucoma in Africa hosted by the Prevention of Blindness Union 
in collaboration with International Agency for the Prevention of 
Blindness Africa in Kampala, Uganda (April 2012).4 This clarion 
call is also evident when we examine the data presented by Kyari 
et al.5 in their outstanding article, which leads this theme issue 
“Glaucoma in SSA”. A challenging picture of glaucoma emerges 
from the above sources:
• Glaucoma	is	the	second	leading	cause	of	blindness	worldwide
with Africa disproportionately affected.
• There	are	an	estimated	6	million	people	with	potentially
blinding or disabling glaucoma in Africa while 0.5 million
are already blind from the disease.
• The	estimated	prevalence	of	glaucoma	is	approximately	4%
among people 40 years and older. This figure is likely an
underestimate as it is often difficult to diagnose glaucoma
when there is coexistent media opacity such as cataract/
corneal opacity, and many studies to date do not include
visual field data as part of the diagnosis.
• The	most	 common form of glaucoma is primary open
angle glaucoma, which is approximately six times more
common than angle closure; however, there is a paucity of 
good epidemiological data, particularly with regard to other 
types of glaucoma such as exfoliation related glaucoma.
• The	awareness	of	glaucoma	is	very	low,	and	a	large	majority
of	patients	are	untreated.	In	fact,	90%	or	more	of	those	with
glaucoma remain undiagnosed. The article by Komolafe
et al.6 examines the level of awareness amongst non-
ophthalmic health-care personnel and how these individuals
can be empowered to play a more active role in raising
patient awareness. The articles on “teleglaucoma” by
Kassam et al.7 and Kiage et al.8 propose a creative response,
that needs to be studied further, to promote access based
on the provision of expert care from a distance.
• When	patients	do	present,	at	least	half	do	so	with	advanced
disease and of these, over half are blind in one eye. The
article by Josephine et al.9 reports on important barriers
to glaucoma surgery in Nigeria including fear of blindness.
The article on advanced glaucoma by Gessesse and Damji10
provides practical tips for managing these challenging
patients, including, approaching patients through an
integrated “biopsychosociospiritual” frame-work, and
pearls to optimize trabeculectomy technique so as to protect
vision and prevent/minimize chances of visual field “wipe
out.”
• Risk	 factors	 for	developing	open-angle	glaucoma	 in	SSA
include increasing age, higher IOP, lower systolic blood
pressure (BP) to IOP ratio (BP/IOP), lower mean diastolic
ocular perfusion pressure (diastolic BP minus IOP), thinner
central corneal thickness, and a positive family history of
glaucoma. Can future programs aimed at detecting glaucoma
leverage these and any other high risk characteristics?
• There	is	much	that	needs	to	be	studied	in	order	to	arrive	at
better ways of managing glaucomas in various SSA contexts.
One technique that may be of value in challenging cases
is an aqueous drainage device, and the article by Aminlari
et al.11 offers insight in this regard.
There are many barriers, which prevent patients from 
receiving appropriate care including geographic, educational, 
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socioeconomic, cultural/spiritual, and political considerations, as 
well as lack of adequate facilities, human resources, equipment, 
medication, laser, and surgical treatment options. Although, 
this is a daunting list, progress is being made in terms of 
acknowledging the magnitude and importance of the problem 
and	taking	steps	toward	addressing	these	challenges.	Recently,	a	
very practical guide to diagnosis and management of glaucoma 
in the SSA context was published, and I would recommend 
all involved with such efforts to read the special issue of the 
Community Eye Health Journal Vol. 25 Issues 79 and 80, 
2012.12 The value of eliminating avoidable blindness and visual 
impairment in developing countries is underscored in a recent 
report by price water house Coopers commissioned by The 
Fred Hollows Foundation and other key non-governmental 
organizations. Using a conservative estimate, they illustrate 
that for every dollar invested in preventing someone from 
going blind, more than four dollars in economic benefits are 
generated.13 This estimate does not factor in further gains to 
quality of life that accrue from improved vision health.
An important question to ask is what can be carried out to 
strengthen detection and management of glaucoma at the 
primary, secondary and tertiary levels? Building solid tertiary 
institutional capacity can provide a hub for integration of 
primary, secondary and tertiary approaches to glaucoma care. 
Outstanding institutions, networked with other like-minded and 
like-hearted Institutions and eye care partners, can catalyze and 
propel advances in patient centered care, education, research, 
and health-care policy. Whether or not an institution achieves 
excellence and success in these endeavors is predicated on solid 
leadership and governance that nurtures a culture of respect, 
continuous learning and collaboration, as well as excellence in 
clinical, educational and research environments.
LEADERSHIP AND GOVERNANCE
The quality of institutions is directly dependent on the quality 
of leadership that is provided, nurtured, and sustained and how 
this leadership utilizes the institutional framework to deliver its 
services. This includes setting international standards of care 
and effectively leading a team of eye care professionals such 
as ophthalmologists, nurses, optometrists, pharmacists, and 
counselors. Creating a learning organization that continuously 
transforms itself is also a key to success.14 In my view, greater 
thought is required so that over the next 5 years, programs 
and processes are in place to ensure a continuous pipeline of 
physicians as well as other leadership talent is being developed 
that will serve SSA in the short term and for the long term in 
a sustainable manner.
Leadership in institutions is exercised through good governance, 
i.e., how an organization can utilize structure and process
to exercise power effectively. Good governance includes the
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following elements: Clear structure and organization, an 
understanding of vision, mandate, and responsibilities, an 
organizational culture that promotes continuous learning and 
collaboration, transparency and probity as well as team spirit 
and high performance, robust processes and information, and 
performance assessment and accountability. The quality of 
various institutional processes as well the physical environment 
(i.e., the spaces in which one works and learns) will be critical to 
ensuring high quality clinical outcomes and patient satisfaction, 
which ultimately form part of the raison d’être for service 
institutions.15
INSTITUTIONAL MODELS, SUSTAINABLE 
HUMAN, FINANCIAL AND INFORMATION 
TECHNOLOGY RESOURCES AND 
IMPORTANCE OF MEASURING RESULTS
There are many models of eye care institutions in SSA. These 
include public, private, civil society, as well as emerging models 
of social entrepreneurship and public private partnership. 
These institutions also need to be viewed in the context of 
health care systems. Hence, consideration thus needs to be 
given to pragmatic issues such ensuring a stable supply chain 
of medications and equipment.15 Structuring institutions for 
long term success will also require optimal utilization of finite 
human, financial, and information technology related resources. 
Developing strong professional managers who can lead various 
operations teams (clinical, operating, biomedical engineering, 
community outreach etc.) is a key ingredient in this regard.16 
On the financial front, sustainable sources of income are 
required, developing high efficiency, appropriate budget and 
price for various services, and effective cost-control measures.16 
Standard protocols, processes for continuous improvement, 
monitoring and empowering staff, and succession planning are 
methods by which the other dimensions of sustainability can 
be addressed.16 Developing key metrics to track efficiency and 
effectiveness as well as a culture of accountability is also key to 
achieving excellence in institutional performance. The balanced 
scorecard is one approach, which can provide a framework for 
developing and tracking key performance measures, including 
in developing national academic hospitals.17,18
T E A C H I N G  A N D  L E A R N I N G 
ENVIRONMENT AND MULTIPLIER 
EFFECT
Developing an outstanding teaching and learning environment 
is essential to developing outstanding human resources. These 
individuals can then have a powerful ripple or multiplier effect, 
empowering various members of the eye care team, as well 
as student learners with knowledge and skills to detect and 
manage glaucoma at various levels. Over the past 6 years, I have 
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been fortunate to work with several tertiary care institutions in 
Kenya and Ethiopia in order to assist in institutional capacity 
development utilizing the “sandwich” educational model.19 
The essence of this model has been to gradually strengthen 
institutional capacity through international standard subspecialty 
training while simultaneously enhancing the patient care, 
teaching/learning and research environments. The model helps 
provide an “enabling environment” for professional growth, 
which we hope fosters retention of individuals and provides 
a gateway into long term, mutually beneficial collaborative 
partnerships.
“Sandwich” fellowship graduates to date have been successful 
in helping to modify curricula for residency training, improve 
standards of care for patients with glaucoma, and develop 
models for raising awareness of glaucoma in communities. 
They have also helped in detecting/managing earlier stages of 
disease, including via creative “teleglaucoma” approaches, as 
well as contributing to the development of national guidelines 
for glaucoma, such as those being developed in Kenya (personal 
communication Drs. Dan Kiage and Sheila Marco).
R E S E A R C H  A N D  K N O W L E D G E 
TRANSLATION
A number of centers in SSA are now well positioned to 
conduct research at various levels, i.e., population, clinical, 
and basic science as well as a partner with other regional and 
international institutions/entities. Conducting and publishing 
high-quality research will not only lead to a better understanding 
of how to advance patient care specific to SSA, but can also 
uplift the educational environment attracting bright minds 
and entrepreneurial investment long-term. Several interesting 
questions need to be addressed (the Kampala workshop4 and 
the Kyari article5 contains some excellent ideas in this regard):
• What	is	the	prevalence	of	various	types	of	glaucoma	types
in the various countries and subpopulations? Are subtypes
such as neovascular glaucoma on the rise given the rapid
increase in the prevalence of diabetes and if so, what steps
can be taken to mitigate this trend?
• What	is	the	level	of	awareness	of	glaucoma,	what	are	barriers
to awareness, and what can be carried out to improve the
level of awareness?
• What	are	the	specific	barriers	in	SSA	for	access	to	glaucoma
care, as well as for compliance and adherence to treatment
and how can these be overcome?
• How	 can	 glaucoma	 best	 be	 detected	 and	 managed?
Randomized	 controlled	 trials	 are	 needed,	 cost	 and
comparative effectiveness studies, quality of life studies.
Program level research is needed so as to learn from pilot
studies and then replicate and scale up successful projects.
• What	are	underlying	genetic	and	environmental	factors	that
play a role in the pathogenesis of various glaucomas in SSA?
• Clinical	guidelines	are	needed	to	offer	best	practice	and
thinking on detection of various glaucomas, identification
of the stage of disease, and appropriate medical, laser,
and surgical management options. Guidelines also need
to consider treatment options for absolute glaucoma (a
blind eye, which is often painful as well) and for vision
rehabilitation/support.
• What	 tools	 and	metrics	 can	 be	 utilized	 to	monitor	 and
study the impact of various activities/interventions on vision
related quality of life?
• Health	 systems	 research	 is	 also	 required	 that	 includes
the development of innovative health delivery models, in
particular to be able to provide glaucoma care to those who
are unable to afford it.
RELEVANCE TO ENHANCING GLAUCOMA 
CARE
Glaucoma is an enormous problem in SSA and given the 
demographic trends, will be an even greater challenge in the 
decades ahead. Hence, it is essential that glaucoma be widely 
recognized as a serious public health concern and creative 
steps taken to eliminate avoidable blindness from this group 
of diseases. One of the key steps, in my view, is to strengthen 
institutional capacity for glaucoma care. A year ago I had 
proposed the idea of a special issue of MEAJO dedicated to 
glaucoma in SSA in order to better inform readers of the current 
landscape and encourage a call to action for the benefit of current 
and future generations in SSA. I am very pleased that this issue 
has now reached fruition and I would like to thank the editors 
of the journal for the privilege of having served as guest editor 
and for the opportunity to write this editorial. I would also like 
to thank all peer reviewers for their enormous contribution of 
knowledge, time and energy.
I hope that over the next decade, we are able to build solid 
capacity for integrated glaucoma care at the primary, secondary 
and tertiary levels in SSA and that glaucoma centers of excellence 
can partner with and continue to learn from the best that local 
and global stakeholders have to offer so that they can advance to 
better serve their patients and communities. This will necessitate 
continued development of a new generation of subspecialists 
with leadership/management skills that can entrench good 
governance and develop other members of the eye care team, 
partnerships with a variety of public and civil society players, and 
the creation of enabling environments for patient care, education 
and research where “new initiatives can take root and thrive” 
and patients with or at risk for glaucoma receive international 
standard care to protect visual function and maintain or enhance 
their overall health related quality of life.
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